Freedom of Information (FOI)

The Freedom of Information Act 2000 (FOI) came fully into force in January 2005. All bodies must have in place a Publication Scheme (a list of classes of information available to the public).

The act also gave individuals and corporate bodies the right of access to all types of recorded information held by public sector bodies, with the exception of certain specified exemptions (for instance, personal information and commercially sensitive information). For more information about the act please visit the Information Commissioner’s website: www.ico.org.uk/for-the-public/official-information

Our Publication Scheme has most of the information frequently asked for by members of the public.

Before making a formal request to the Trust, please check our website to make sure that the information you require isn’t already available by clicking here.  This data will be updated on a six monthly basis and FOI requests for this information will be exempt under Section 22 – Information intended for future publication.

You can also search this site below for information disclosed by the Trust following requests made under the Freedom of Information Act 2000 since 1 April 2015.

It is important that the public realises that the provision of recorded information from the Trust, requires busy Trust staff to spend time away from the core business of clinical, management and clerical functions that support patient care, in order to retrieve this information from complex data sources.

If the information you require is not held on our website, you can contact us either by emailing us at: mtw-tr.foiadmin@nhs.net or writing to us at Freedom of Information Officer, Trust Headquarters, Maidstone and Tunbridge Wells NHS Trust, Hermitage Lane, Maidstone ME16 9QQ.

Once we have received your request, we will send you an acknowledgement letter. We are required to give you a response within 20 working days of our acknowledgement letter. We will try to respond as quickly as possible. Sometimes, some or all of the information cannot be provided. If this is the case, we will explain the reasons why.

We are able to charge fees for requests, outlined in the Freedom of Information Guide. We will generally only charge you for hard copies or copying onto media eg CD. The charges will vary according to how information is made available. Legally, if the cost of obtaining and sending you the information is more than £450, we do not have to provide you with the information you requested. This amount is based on the DCA’s (Department of Constitutional Affairs) regulations of a national cost of 18 hours work at £25 per hour.

In the first instance you should appeal to us directly, in line with our FOI appeal process. Download a copy of the appeals process document, or email us at mtw-tr.foiadmin@nhs.net for a copy to be sent to you. If you are still dissatisfied after the appeals process, you have the right, under section 50 of the Act, to apply to the Information Commissioner to seek resolution to the matter.

You can search our FOI database below, or alternatively you can look through our recent responses here or by clicking on the right hand column.

Cyber Security

MTW have enlisted the support of a 3rd party security specialist and have purchased and installed many different solutions to help protect us against cyber threats. However, will not be publicising or sharing the details of these products, solutions or vendors because we believe that in doing so, we put our self at risk.

We will also not be publishing details around any system be it hardware or software that is either end of life or is coming to end of life as we believe that publishing this information also puts the trust as risk. This would include but is not limited to items such as ‘does the trust have any machines running an out of date operating system or unsupported hardware.

The contract for our cyber solution started in August 2018 and runs for 5 years.

You can view our IT Department staff structure here.

Search our FOI database

Choose a category:

Agency staff

Agency Staff

1) Total spend on agency staff split by each of the following staffing groups:
2) Total spend on internal bank staff (split by the following categories)
3) Total number of staff employed on the bank, and of which, the number that also hold substantive contracts with the trust.
4) Does the trust outsource bank staff to NHSP? If so, how much was spent on outsourced bank staff?
5) Does the trust use rostering software, if so which provider (Allocate, SMART, DRS, SMI etc.)?
6) Does the trust directly engage locum staff? If so, how much of the trust’s medical locum spend was put through direct engagement in the last financial year?

Download response Agency Staff 170815

A&E agency staff 2016. 290317

1. The amount spent on employing agency/temporary/locum doctors in A&E departments in each month in 2016.
2. The number of FTE roles covered by agency/temporary/locum doctors in each month in 2016
3. The total number of FTE doctors working in the A&E department in each month in 2016.

Download response A&E agency staff 2016. 290317

A&E staffing. 080519

1. The amount spent on employing agency, temporary and/or locum doctors in A&E departments in each month in 2017 and 2018
2. The number of FTE roles in A&E departments covered by agency, temporary and/or locum doctors in each month in 2017 and 2018
3. The total number of FTE doctors (including agency, temporary and/or locum and permanent staff) working in A&E departments in each month in 2017 and 2018

Download response A&E staffing. 080519

Agency and Bank Doctors. 051218

You asked:
1) The total amount you spend on Agency Locum Doctors for 2017-2018: – £
2) For the above information to be broken down by grade and specialty (example provided below)
Specialty FY1/2 ST1/2 ST3-6 Staff Grade Consultant
A&E
Medicine
Anaesthetics
Medicine
Surgery
Paeds
Pathology
O & G
Ophthalmology
3) Your Bank spend on Doctors for 2017-2018 broken down as question (2): – £
4) The total number of hours filled and unfilled each month for Agency medical locums for 2017-2018.
5) The highest bank rate paid in 2017-2018, providing confirmation of the grade and speciality.
6) Your current Bank rates for each grade and speciality, including any specialities or sub specialities which have an escalated Bank rate.
7) The Trusts average rates for Agency medical locums from September, October, November and December collectively broken down by grade and specialty (example provided below).
Specialty FY1/2 ST1/2 ST3-6 Staff Grade Consultant
A&E
Medicine
Anaesthetics
Medicine
Surgery
Paeds
Pathology
O & G
Ophthalmology
(8) The spend for medical locums through off-framework agencies for 2017-2018 and confirmation of the off-framework agencies used.
(9) Please confirm any contracts you have in place for medical locums and please confirm the list of suppliers used for medical locums.

Download response Agency and Bank Doctors. 051218

Agency and bank staff. 021019

Sourced Staffing Arrangements
1a. Do you have a master vendor or neutral vendor arrangement in place for sourcing agency staff? If so, please state which arrangement is in place
1b. Please state the name of the appointed supplier for the above arrangement
1c. Please state the start date of the contract with this supplier
1d. Please state the end date of the contract with this supplier
1e. Annual cost of your supplier in 18/19?

Agency Spend and Supply
2a. Please state the organisations total expenditure on agency (non-contract) staff for the financial year 18/19 (April 2018 – March 2019). Split by the following staffing groups
2b. Please state the name of the framework(s) you source your agency staff under, for each of the following staffing groups

Direct Engagement
3a. Does the organisation use a third party to provide a Direct Engagement/Outsourced Employment Solution? (This is where the NHS organisation sources agency staff via a recruitment agency but hold a direct contract between the organisation and the worker – there is often VAT savings associated to this employment model)
3b. Please state the name of the Direct Engagement/Outsourced Employment supplier (e.g. 247Time/Allocate, PlusUs, Retinue, Liaison etc.)
3c. Please state all staffing groups that are managed via your direct engagement provider; for example; Medical, Admin, Scientific staff
3d. Please state the start date of the contract with the DE supplier
3e. Please state the end date of the contract with the DE supplier
3f. What was the annual cost to the organisation for the provision of the direct engagement service in 18/19?
3g. Did the organisation procure these services via a framework? If so, please provide the full name of the framework

Internal Bank Spend
4. Please state the organisations total expenditure on internal bank staff for the financial year 18/19 (April 2018 – March 2019). Split by the following staffing groups

Medical Bank Supplier
5a. Please state the name of the technology provider used to manage the supply of your medical bank staff, inclusive of any outsourced or managed arrangements (i.e. NHSP, Patchwork, Allocate, Liaison, PlusUs, Locum’s Nest etc., please state if in-house)
5b. Please state the start date of the contract with your medical bank provider
5c. Please state the end date of the contract with your medical bank provider
5d. What was the annual cost to the organisations for the provision of bank provider services/software in 18/19
5e. Did the organisation procure these services via a framework? If so, please provide the full name of the framework

Download response Agency and bank staff. 021019

Agency and Bank Staff. 120320

1. Please quantify Agency recruitment splits (total spending and total WTE numbers) for medical, nursing and other employees (Forecasts 2019/20 and 2018/2019, and actuals 2018/19, 2017/2018, and 2016/2017)
2. Please quantify Bank recruitment splits (total spending and total WTE numbers) for medical, nursing and other employees (Forecasts 2019/20 and 2018/2019, and actuals 2018/19, 2017/2018, and 2016/2017)

Download response Agency and Bank Staff. 120320

Agency costs 2014/2015

1. Staff Numbers (Average over the whole year or the count on Tuesday, March 31st 2015)
2. Staff Cost
3. Agency Hours
4. Agency Spend
I would greatly appreciate it if you could supply this information for the year 2014/15 (April ’14 to March ‘15).

Download response Agency costs 2014/2015 040216

Agency doctors and nurses 2016-2017. 231117

• The total amount you spend on Agency Doctors & Nurses for the financial year 16/17 (April – March)

• For the above information to be broken down by Banding / Grade and also specialty

Download response Agency doctors and nurses 2016-2017. 231117

Agency expenditure 2016-2017. 050717

1. The trust’s completed ‘Detailed agency collection” for month 12 of 2016-17, showing the year to date figures. (Example attached)
If for any reason the trust is minded not to provide this document, please list the five specialties for which the trust had the highest agency staff costs – as a % of total pay costs for the specialty – in 2016-17 in the table below. Please also fill in the cells detailing expenditure. If the trust’s accounts have not yet been audited, please use the unaudited figures.
2. Please state the total number of shifts for which the trust breached the national pay cap for medical agency staff in 2016-17 (55% above basic rates), and break this total down for each specialty where the breach occurred (its fine to only detail the top five specialties).
3. Please state the total number of shifts for the trust breached the national pay cap for agency nursing staff in 2016-17 (55% above basic rates), and break this total down for each specialty where the breach occurred. (It’s fine to only detail the top five specialties).
4. Please state the total number of shifts which required CEO sign off, and break these down for each specialty.
5. Please state the ten shifts for agency medical staff for which the highest hourly rate was paid. Please state the rate paid and the specialty.
6. For individual medical locums who have incurred the greatest total expenditure for the trust in 2016-17, please state the total amounts paid by the trust in the year in relation to these individuals’ work. Please also state their specialty. E.g. Medical locum 1, emergency medicine, total expenditure by the trust in 2016-17; £196,000

Download response Agency expenditure 2016-2017. 050717

Agency Locum Doctor spend for 2015-2016.

• The total amount you spend on Agency Locum Doctors for the financial year 15/16 (April – March)
• For the above information to be broken down by grade and specialty (example provided below)

Download response Agency Locum Doctor spend for 2015-2016 270616

Agency locum doctor supply. 151118

You asked:
1. What percentage fill rates (doctors) were reached between January and present?
2. Does your organisation use a Direct Engagement scheme? If so, who provides it and when does their contract expire?
3. What percentage of bookings are made outside of the DE model (non-DE)?
4. Do you outsource any of the following services to external companies:
• Provision of Residential Medical Officers
• Gastroenterology/Endoscopy
• Dermatology
• Radiology
5. Do you use agencies for national and international permanent doctor and/or nursing recruitment? If so, do you employ nurses from the Philippines?

Download response Agency locum doctor supply. 151118

Agency locum doctors and consultants spend for 2015-2016.

Please can you let us know what the Trust as a whole (including hospitals that are run by you) spent on employing agency locum Doctors and Consultants last year.

Download response Agency locum doctors and consultants spend for 2015-2016 010716

Agency, locum or bank staff. 181019

1. Over the last 5 years, broken down by year, the total number of hours of work provided to the trust by non-substantive doctors, either via a locum agency or a bank staffing system, and the total cost to the trust of those hours.
2. The above information broken down by staff sourced through agency and those sourced through your bank staffing arrangement.
3. The figures (hours and spend for each of locum and bank) provided in answer to 2. broken down first by specialty and then grade of doctor.
4. The standard hospital hourly rate of pay for each of the specialties and grades listed in answer to 3.
5. The hospital and NHS capped rates for each of the specialties and grades listed in 3. if different to the rate listed in 4.
6. For each category created in response to 3. (i.e bank haematology registrars), the percentage of hours worked at standard rate, above the standard rate, and above the capped rate if different from the standard rate.
7. What penalties, if any, are levied against the trust if it exceeds the ‘capped’ rate.
8. What penalties were levied against the trust for breaking the cap in each of the years for which data has been provided.
9. If the trust utilises a Bank Partner, what is the cost of said Partner and how does this cost manifest e.g. lump sum, fee per position filled etc.

Download response Agency, locum or bank staff. 181019

Agency locum spend. 010818

How much did the trust spend on agency locums last year? Broken down into SHO, Middle Grade and Consultants

If I could please have this information on the following specialities: A&E, Acute Medicine, General Medicine, Radiology and Paediatrics I would be appreciative.

Download response Agency locum spend. 010818

Agency locum spend 2015-2016.

Please could you send me the agency locum spend for the trust for the last financial year. I would like the spend for doctors only.

Please include the agency spend in each specialty breaking it down into the different grades (SHO, Middle Grade, Consultant).

Please could you also provide the spend on introductory fees for doctors for each specialty based on Doctors taken onto NHS contracts.

Download response Agency locum spend 2015-2016 050816

Agency locum spend in Cardiology. 040717

Could you please let me know the locum agency spend from May 2016 – Present? This refers directly to the cardiology department only; the staff will be Cardiographers, Cardiac Physiologists, Echo cardiographers, please note this is not referring to locum doctors or specialists.

These staff will fall under AHP/HSS or healthcare.

Download response Agency locum spend in Cardiology. 040717

Agency midwives and pay 2015.

1. What was the total cost for your trust, including fees and any other on-costs, for midwives supplied by an agency, broken down by the months in the table below?

2. What was the cost for your trust for the fees and any other on-costs, for midwives supplied by an agency, broken down by the months in the table below?

3. What was the total number of hours worked by midwives supplied by an agency, broken down by the months in the table below?

4. What was the total cost for your trust for midwives working overtime, broken down by the months in the table below?

5. What was the total number of hours worked by midwives working overtime, broken down by the months in the table below?

6. What was the total cost for your trust, for midwives supplied by the bank, broken down by the months in the table below?

7. What was the total number of hours worked by midwives supplied by the bank, broken down by the months in the table below?

8. Does your trust pay bank rates at the individual’s actual pay point or higher or lower than their pay point?

Download response Agency midwives and pay 2015 140316

Agency Midwives and pay 2016. 300117

1. What was the total cost for your trust, including fees and any other on-costs, for midwives supplied by an agency, broken down by the months in the table below?
2. What was the total number of hours worked by midwives supplied by an agency, broken down by the months in the table below?
3. What was the total cost for your trust for midwives working overtime, broken down by the months in the table below?
4. What was the total number of hours worked by midwives working overtime, broken down by the months in the table below?
5. What was the total cost for your trust, for midwives supplied by the bank, broken down by the months in the table below?
6. What was the total number of hours worked by midwives supplied by the bank, broken down by the months in the table below?

Download response Agency Midwives and pay 2016. 300117

Agency nurse cover November 2015 – April 2016. 061216

1. Are off frame work agencies used to cover nurse shifts?
2. On a month by month basis, what was your spend on agencies supplying off frame work nurses from 1st November 2015 to date? Please break down this information by RGN, ITU, CRITICAL, ODP’S, SCRUBS, PAEDS, HDU, A&E, AMU, ADVANCED NURSE PRACTITIONER, HCA’S ETC. If this is not possible then please break down by nurse bands.
3. Which agencies supply off frame work nurses?
4. On a month by month basis, how many times was the break glass clause used from 1st November 2015 to date?
5. Please pick 10 random shifts which were filled via off frame work agencies between 1st November 2015 to date and provide the following for each of the 10 shifts picked at random (it is not essential to name the specific agencies which relate to the chosen shifts):
• Amount that was paid to the agency to fill each shift or the hourly rate paid to the agency
• Number of hours in the shift
• Date shift filled
• The type of nurse used to fill the shift e.g. RGN, ITU, HDU, CRITICAL, A&E, PAEDS etc.
• The type of shift or shift start time e.g. Long Day or Long Night or alternatively shift start time e.g. 08:00 etc.

Download response Agency nurse cover November 2015 – April 2016. 061216

Agency nurse expenditure for 2015-2016.

• The total amount you spend on Agency Nurses for the financial year 15/16 (April – March)
• For the above information to be broken down by banding and specialty (example provided below)

Download response Agency nurse expenditure for 2015-2016 010716

Agency nurses. 041019

Could the trust please provide information on how much has been spent on agency nurses?

1) This financial year to date
2) 2018/19 financial year
3) 2017/18 financial year

Are these amounts higher, lower or within the budgets allocated for agency staff?

Are there any measures being implemented to lower the reliance or use of agency staff?

Download response Agency nurses. 041019

Agency nursing costs – January and February and July to December 2015?

Please could you tell me what the cost was in wages to the trust for agency nursing during the months of January and February and July to December 2015? (Could the cost per month be separated, please?)

Please include the wage bill for the two sites, and, if at all possible, please can you break them down into departments and sites?

However, if this is not possible, please still provide me with the overall cost.

Please could you tell me what the cost was in wages to the trust for all agency staff during the months of January to December 2015? (Could the cost per month be separated, please?)

Please include the wage bill for the two sites, and, if at all possible, please can you break them down into departments and sites?

However, if this is not possible, please still provide me with the overall cost.

Download response Agency nursing costs – January and February and July to December 2015 080116

Agency nursing shifts. 260919

1) How many agency nursing shifts have your Trust used Thornbury nursing services for between 1st July 2019 and 31st July 2019?

2) How many agency nursing shifts have your Trust used Thornbury nursing services for between the dates of 1/8/2019 and 18/8/2019?

3) Please provide a breakdown of the amount of shifts per ward or department where Thornbury were used in July 2019 and 1/8/19- 18/8/19/.

4) Please provide a breakdown for July 2019 of the amount of shifts filled at your Trust by other off contract nursing providers (ie non-framework). Please break this down in the same format (i.e. by ward or department) as question 3.

Download response Agency nursing shifts. 260919

Agency Nursing shifts. 2609192

1. Which agency filled the most nursing shifts at your Trust in the last 30 days and how many hours or shifts did they fill?
2. How many of the shifts filled by agency nurses in the last 30 days were above cap?
3. Which wards or departments and sites within your Trust utilised agency nurses in the last 30 days and how many shifts were booked on each?
4. How many nursing shifts were filled by Framework agencies above the 50% NHS Improvement increased caps in the last 30 days?
5. Please list the nursing agencies utilised in the last 30 days above the 50% increased NHS Improvement capped rates by your Trust.

Download response Agency Nursing shifts. 2609192

Agency nursing shifts. 2609193

1. How many agency nursing shifts have your Trust used Thornbury nursing services for in the last 30 days?
2. Please provide a breakdown of the amount of shifts per ward or Departments that Thornbury filled for agency nurses in the last 30 days.
3. What other nursing agencies do you use off contract/off framework?
4. How many nursing shifts did other off contract agencies fill in the last 30 days?
5. Are there any other services linked to your Trust that utilise TNS or any other off contract supplier re Prisons, or community based services? If so please provide a list of these services and the amount of nursing shifts filled in each over the last 30 days

Download response Agency nursing shifts. 2609193

 

Agency nursing spending rules from October 01 2015

Questions on the trust’s ceiling for agency nurse spend, as per the rules introduced from October 1, 2015:

1) How many applications has your trust made to increase its ceiling for agency nurse spend?
2) How many of these applications were successful?
Questions on the agency pay caps – specifically regarding nurses – as per the rules introduced on November 23, 2015:
3) On how many shifts has your trust overridden the rules for hourly rate agency caps – specifically for nurses – since the rules were introduced?
4) Across how many weeks have these breaches (in question 3 above) occurred? .
5) How many band five nurses has your trust overridden the rules for?
6) How many band six nurses has your trust overridden the rules for?
7) How many band seven nurses has your trust overridden the rules for?
8) How many band eight nurses has your trust overridden the rules for?

Download response Agency nursing spending rules from October 01 2015 150216

Agency Payments. 090419

1. Please provide the 10 largest individual agency payments for core hours your trust has authorised above the agency worker price caps set by NHS Improvement for each of the following medical grades for (a) 2017-18 and (b) 2018-19 (to date).
• Foundation Year 1
• Foundation Year 2
• Registrar ST1-2
• Registrar ST3
• Speciality staff/staff grade
• Associate specialist
• Consultant

Please provide the figures excluding VAT, as a rate per hour, what the cap was at that particular point in time, the month it was paid and the type of shift being filled.

2. Please provide the 10 largest individual agency payments for unsocial hours your trust has authorised above the agency worker price caps set by NHS Improvement for each of the following medical grades for (a) 2017-18 and (b) 2018-19 (to date).
• Foundation Year 1
• Foundation Year 2
• Registrar ST1-2
• Registrar ST3
• Speciality staff/staff grade
• Associate specialist
• Consultant

Download response Agency Payments. 090419

Agency Pharmacists and Pharmacy Technicians. 240119

I would like you to send me the locum agency spend in the AHP/HSS division of the hospital for Pharmacists and Pharmacy Technicians. I would like to know the spend for 2018 with each agency- if this is not possible then I’d like to know overall spend for the year for both Pharmacists and Pharmacy Technicians.

Download response Agency Pharmacists and Pharmacy Technicians. 240119

Agency Recruitment. 051218

You asked:
1. How many doctors have been booked outside of IR35 since April 2017?
2. What is your yearly trust spend on agency locum doctors via framework agencies, broken down into grade and specialty?
3. What is your yearly trust spend on agency locum doctors via OFF-framework agencies, broken down into grade and specialty?
4. What is your average total charge rate for a locum consultant doctor?
5. Who is the highest paid locum Consultant, what is the hourly rate and in what specialty do they practice?
6. Please can you outline your spend per agency, broken down by grade and specialty of doctor over the past 12 months?

Download response Agency Recruitment. 051218

Agency Shift Cost

1. What was the highest amount you paid (including any agency commission/charges) for a single shift filled by each of the following a. a doctor b. a GP (if employed) c. a registered nurse and d. a non-registered support worker/healthcare assistant in the period March 28th to April 19th 2015? Please include date and length of shift and grade of doctor/nurse involved, the department they were needed for (e.g. A&E) and the agency which supplied the doctor/nurse in each case.
2. What percentage of shifts covered by agency staff during this time period were paid in accordance with either an NHS wide or a local framework, and what proportion were off framework?
3. What was your total spend on temporary (locum, agency and bank) clinical staff for 2014-15? Please include doctors, nurses and healthcare assistants/support workers in your answer. What were the comparable figures for 2013-14 and 2012-13?

Download response Agency Shift Cost 050515

Agency shifts. 250817

I am making a Freedom of Information Request to gain information on the volume of shifts that have been filled by agencies within nursing and medical locums (Doctors) at your organisation.

Further to this what is the percentage of shifts filled for Medical and for Nursing above the NHSi Cap.

Download response Agency shifts. 250817

Agency spend.260219

Please can you outline your agency spend into each 52 weeks or 12 months for the year 2018 (I understand the year has not finished yet so up to OCTOBER 2018) would be sufficient.
1. How many agencies did your trust use in the year of 2018?
2. How much was spent on agency nurses in 2018?
3. On December 25th 2017, how many shifts went nursing shifts went unfilled?
4. What is the highest hourly rate paid to a locum agency in 2018 and what band was this nurse i.e. band 5 general.
5. Please list the names of agencies that we used in year 2018 and list the total amount of spend for each used.
6. What is the total number of different nurse locums did the trust use in 2018.
7. What was the highest hourly rate paid to an agency for a nurse in 2018 – Please state what agency this was and what band they were.
8. Of all agencies used, were any off framework? If so, what are the agencies called?
9. Who is the head of procurement at your Trust who approves agency use?
10. Who approves above-cap and/or off-framework usage?
11. Who are your tier 1 and tier 2 agencies?

Download response Agency spend.260219

Agency spend for doctors. 240119

I would like you to send me the locum agency spend for Doctors for the hospital in acute settings as well as the community for each specialism.

I would like to know the spend from January 2018 – present, also including the amount of locums that this refers to per month, broken down on a monthly basis. In the breakdown if you could please include the agencies that provide the locums also broken down numerically.

Download response Agency spend for doctors. 240119

Agency spend for Radiology locum doctors December 2015 to May 2016.

Can you please assist me with retrieving the total Agency spend for Locum Doctors only within Radiology over the following months, within your Trust or Health Board?

Download response Agency spend for Radiology locum doctors December 2015 to May 2016 060916

Agency spend in Radiology August 2016 – January 2017. 240317

Can you please assist me with retrieving the total Agency spend for Medical Locum Doctors within Radiology over the following months, within your Trust or Health Board?
August 2016
September 2016
October 2016
November 2016
December 2016
January 2017

Download response Agency spend in Radiology August 2016 – January 2017. 240317

Agency spend and substantive vacancies. 091117

1. The total amount of agency spend on medical locums in the 2016/2017 tax year
2. The total amount of spend on agency nurses in the 2016/2017 tax year
3. The total amount of spend on agency AHPs in the 2016/2017 tax year
4. The percentage of substantive Doctor positions that are currently unfilled
5. The percentage of substantive Nurse positions that are currently unfilled
6. Do you have a managed service or master vendor arrangement, or an outsourced staff bank for any clinical staff groups and if so, who is/are the supplier(s)?
7. Do you have a Direct Engagement supplier and if so, who?

Download response Agency spend and substantive vacancies. 091117

Agency spend within Gastroenterology.

Can you please assist me with retrieving the total Agency spend within Gastroenterology over the following months, within your Trust or Health Board?

Download response Agency spend within Gastroenterology

Agency staff. 010818

1. Since January 2018, have you allowed an Agency to fill a shift or booking above the April Cap (implemented in 2016) via the CPP Framework (otherwise known as the National Clinical Staffing Framework Agreement (Reference CPP2015/01))? For reference the term ‘shift’ can include any general nursing or critical nursing role.

2. If the answer is yes to the above question, please inform us of how many such shifts have been filled above cap via the CPP Framework.

3. What was the total value of charges paid under all of the call-off agreements identified in response to request 1 (above)?

4. Any information relating to the decision(s) of the Trust to enter into call-off agreements that include pay rates that exceed the maximum pay rates allowed under the Framework Agreement.

Download response Agency staff. 010818

Agency staff.01118

1. In relation to the value of the contracts in your previous response of 1 August 2018, the value of which was £514,072.20, please state the total costs that the Trust paid in excess of the rates allowed under the fee caps (those fee caps being the April Caps (implemented in 2016) for the National Clinical Staffing Framework Agreement (Reference CPP20 15/011) (otherwise known as CPP Framework) (the “Framework Agreement”).
2. In relation to your answer to point 1, please state how much of this sum was attributed to shifts for Nursing & Midwifery staff.
3. In the event that the anticipated costs of providing all of the information requested under points 1 and 2 above are likely to exceed the appropriate limit specified in Regulation 3 of the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004, please provide instead the total costs that the Trust paid in excess of the rates allowed under the fee caps in June 2018.
4. In the event that you provided a substantive response to point 3, please provide us with how many such shifts have been filled above cap via the Framework Agreement in June 2018.
5. In the event that the anticipated costs of providing all of the information requested under point 3 above is likely to exceed the appropriate limit specified in Regulation 3 of the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004, please provide instead the total costs that the Trust paid in excess of the rates allowed under the fee caps for the period Monday 4 June 2018 to Sunday 10 June 2018.
6. In the event that you provided a substantive response to point 5, please provide us with how many such shifts have been filled above cap via the Framework Agreement, for the period Monday 4 June 2018 to Sunday 10 June 2018.
7. In your response of 1 August 2018, you stated that 16,754 shifts were for Medical & Dental staff. Please provide a breakdown of this figure and categorise the shifts into grades of staff.

Download response Agency staff.01118

Agency Staff. 210917

I am looking at the other positions supplied, starting with AHP and HSS staff.
Namely:
Allied Health Professionals Health Science Services
Dieticians Biomedical Scientists
Occupational Therapists Cytologists
Orthoptists Dental Service Staff (excluding dental nurses)
Physiotherapists Genetic Counsellors
Podiatrists Healthcare Scientists
Psychologists Medical Technologists
Radiographers Optometrists
Speech and Language Therapists Pathologists
Pharmacy Services Staff

Please could you provide me with the following information:
1. Names of Agencies used to provide AHP or HSS staff over the last 12 months
2. Monthly spend, on Agency Staff, per job role over the last 12 months
3. Hours, per job role, filled each month by Agency over the last 12 months
4. Number of shifts offered to Agencies for each role, monthly for the last 12 months.
5. Number of shifts filled by Agency for each role, monthly for the last 12 months.

Download response letter Agency Staff. 210917

Agency staff. 260919

Please could you advise the number of hours or shifts filled from 01th April 2018 – 31st March 2019 with qualified nursing staff within the Trust with agency staff?

Download response Agency staff. 260919

Agency Staff Cost

Under the freedom of information act 2000, I am writing to formally request the following information:
1. Staff Numbers
2. Staff Cost
3. Agency Hours
4. Agency Spend
I would greatly appreciate it if you could supply this information for the year 2013/14 (April ’13 to March ‘14).

Download response Agency Staff Cost 040815

Agency staff spend 2013-2016. 221116

Please can you confirm your monthly Hospital and/or Trust spend on agency staff during the last three financial years (FYE Mar-14, Mar-15, & Mar-16). Ideally, this should be broken down into spend by Hospitals/Trusts, the agency supplying the staff and by month.

Download response letter Agency staff spend 2013-2016. 221116

Agency Staffing. 050718

1. Agency spend on Medical Locums/Doctors
2. Agency spend on AHP’s (Allied Health Professionals) and HSS (Health and Social Sciences)
3. Agency spend on Nursing
4. Agency spend on NMNC (Non-Medical, Non Clinical)
5. Do you use a Direct Engagement model to engage locum staff?
6. If so, please state the name of the company used
7. What is the expiry date for this contract?

Download response Agency Staffing. 050718

Agency Staffing. 260919

1. (a) Who is the head of procurement at your trust responsible for approving Nursing agency usage?
(b)Secondly, who is the temporary / flexible staffing lead responsible for the management of this service?
2. Please can you provide the contact information in relation to both question 1 (a) and (b)
3. Please can you outline your Off-Framework agency spend for each of the following staff groups between April 2019 – June 2019: (a) RGN’s (b) RCN’s (c) RN’s and (d) HealthCare Assistants (e) RMN (f) Specialist RN (ITU) (g) Medical Locums
4. Following the same breakdown of staff groups in Question 3, how many Off-framework shifts have been unfilled between April 2019 – June 2019
5. Since the start of January 2019 – present, please provide the current charge rates from your Off Framework, Nursing providers, providing a clear breakdown between the workers pay rate and agency commission
6. Based on the above information, who are your current Nursing Off-Framework agencies and how many shifts have been booked for each month from January 2019 – June 2019

Download response Agency Staffing. 260919

Agency staffing and vacancies. 061119

1. Please can you confirm how and how regularly you confirm you and your suppliers are IR35 compliant?
2. Please can you confirm the percentage of agency shifts in the past financial year that were NHSI cap compliant? Please could you break this down by staff group?
a. Nursing
b. Doctors
c. AHP/HSS
d. Other clinical
3. Please can you confirm the number of permanent vacancies you have in the following staff groups?
a. Nursing
b. AHP/HSS

Download response Agency staffing and vacancies. 061119

Agency usage. 240418

1. How many agencies do you engage with for your recruitment of temporary nurses and health care assistants and can you please list them?
2. How many agencies do you engage with for your recruitment of permanent nurses and can you please list them?
3. What has your spend been on temporary nurses?
4. What has your spend been on permanent nurses in 2017?
5. How many temporary shifts have been released to agencies for mental health nurses?
6. How many temporary shifts have been released to agencies for general nurses?
7. How many temporary shifts have been released to agencies for theaters nurses?
8. How many temporary shifts have been released to agencies for A&E nurses?
9. How many temporary shifts have been released to agencies for Community nurses?
10. How many temporary shifts that have been released to agencies for mental health nurses go unfilled?
11. How many temporary shifts that have been released to agencies for general nurses go unfilled?
12. How many temporary shifts that have been released to agencies for theaters nurses go unfilled?
13. How many temporary shifts that have been released to agencies for A&E nurses go unfilled?
14. How many temporary shifts that have been released to agencies for Community nurses go unfilled?
15. Are all temporary shifts released to all agencies at the same time or is there a tiering system?
16. Do you have any off framework spend for temporary agency staff?

Download response Agency usage. 240418

Agency use. 010818

1) Which Frameworks do you use for the supply of;
a) Locum Doctors
b) Locum Nurses
2) Do you operate a master vend arrangement or preferred supplier list?
3) Please list the agencies on your preferred supplier list for a and b. Please provide the supply list in tearing order or PSL if applicable.
a) Locum Doctors
b) Locum Nurses
4) Please provide contact details for the member of staff in charge of this process.

Download response Agency use. 010818

AHP agency staff spend 2015-2016

Question 1
Please can you confirm what your total spend on Allied Health Professional (AHP) agency staff was during the financial year April 2015-January 2016?
Can you please break this financial information down by AHP specialism:
• Arts Therapists,
• Chiropodist/Podiatrist,
• Dietician,
• Occupational Therapist,
• Physiotherapist,
• Prosthetist / Orthotist,
• Imaging Professionals,
• Speech / Language Professionals.
Question 2
Please can you confirm the names of the organisation/s you procure temporary Allied Health Professionals (AHP) from and the total spend for each organisation/s. To provide additional clarity on my request, ‘temporary Allied Health Professionals’ is to mean all persons who are AHPs and are not on permanent contracts of employment with the Board, but are supplied via employment agencies.

Download response AHP agency staff spend 2015-2016 150316

Altrix and agency spend. 240919

For the last 12 months can you provide me details on the Trusts agreement with Altrix.

Specifically:
The monthly spend for the last 12 months.
The number of hours covered monthly for the last 12 months.
Agreed rates for shifts covered.
Clarification on workers under this models Tax/IR35 status and if they are paid in line with the NHS Frameworks expectations.

Download response Altrix and agency spend. 240919

Amount spent on employing agency/temporary/locum doctors in A&E departments 2014 and 2015

Under the Freedom of Information Act, please can you provide me with the amount spent on employing agency/temporary/locum doctors in A&E departments, and the number of FTE roles covered by agency doctors, if possible for each month in 2014 and 2015, or for 2014 and for 2015 as whole years.

Please can you provide me with the number of FTE doctors working in the A&E department, if possible for each month in 2014 and 2015, or for 2014 and for 2015 as whole years?

If possible, please provide a breakdown between junior doctors and consultants.

Download response Amount spent on employing agency/temporary/locum doctors in A&E departments 2014 and 2015 140316

Annual spend on agency nursing staff. 070417

1) What is your annual spend on Agency Nurses?
2) How is this spend on agency Nurses broken down by individual supplier and what status are they? (i.e. PSL, Tier 1, Tier 2, Master Vendor, or Managed Service Provider?
3) What is the end / renewal date of the current contract you have in place for agency nursing?
4) Which framework do you currently use? (CCS, HTE, LPP, other)
5) Who is your senior procurement contact?
6) Who is your senior medical staffing/ nurse bank contact?

Download response Annual spend on agency nursing staff. 070417

Bank and Agency spend 2016. 070417

1. The number of hours filled by agency for all categories of Allied Health Professionals and Health Science Services for calendar year 2016 – broken down by month, Job Title and Job Band

2. The number of hours filled by bank for all categories of Allied Health Professionals and Health Science Services for calendar year 2016 – broken down by month, Job Title and Job Band

3. The Trusts total spend on agency staff for all categories of Allied Health professionals and Health Science Services for calendar year 2016 – broken down by month, Job Title and Job Band

4. The Trusts total spend on bank staff for all categories of Allied Health professionals and Health Science Services for calendar year 2016 – broken down by month, Job Title and Job Band

5. The number of hours filled by agency for all Nursing Staff for calendar year 2016 – broken down by month, Job Title and Job Band

6. The number of hours filled by bank for all Nursing Staff for calendar year 2016 – broken down by month, Job Title and Job Band

7. The Trusts total spend on agency staff for all Nursing Staff for calendar year 2016 – broken down by month, Job Title and Job Band
8. The Trusts total spend on bank staff for all Nursing Staff for calendar year 2016 – broken down by month, Job Title and Job Band

Download response Bank and Agency spend 2016. 070417

Bank and Agency Midwife spend. 110319

How much did the Trust spend on a) agency midwives b) bank midwives in each calendar month in 2018 (calendar year)?

Download response Bank and Agency Midwife spend. 110319

Bank and Agency Staff 221116

Staff Bank
1. Do you use a nurse bank?
2. Is it outsourced?
a. If yes, who is the provider?
b. Is your outsourced bank used via a framework, e.g., CCS, HTE, LPP?
c. Do you use the bank for other staff groups?
d. What was the spend on your staff bank in 2015/2016?
3. Do you use Agency Nurses?
a. What was your spend on agency nurses during 2015/2016?
b. Which framework do you use for agency nursing staff? E.g.: CCS, HTE, LPP, NOECPP
4. Are you meeting the NHS Improvement price caps on?
a. Band 5 general nurses
b. Band 5 specialist nurses
c. HCAs

Download response letter Bank and Agency Staff 221116

Bank and Agency Staffing. 181019

1. Please could you confirm your current bank spend (FY 18/19), broken down by the following staff groups:
a. Nursing staff
b. Medical locums (Doctors)
c. AHP/HSS
d. Other clinical
e. Non-clinical
2. Please confirm your current bank fill rate (FY 18/19), broken down by the following staff groups:
a. Nursing staff
b. Medical locums (Doctors)
c. AHP/HSS
d. Other clinical
e. Non-clinical
3. Please could you confirm your current agency spend (FY 18/19), broken down by the following staff groups:
a. Nursing staff
b. Medical locums (Doctors)
c. AHP/HSS
d. Other clinical
e. Non-clinical
4. Please could you confirm your current agency engagement procedure (i.e. MV, PSL etc) and which agencies you are currently working with, broken down by the following staff groups:
a. Nursing staff
b. Medical locums (Doctors)
c. AHP/HSS
d. Other clinical
e. Non-clinical
5. Do you have DE supplier, if so who, broken down by staff group? When is the expiry date for this contract?
6. Do you have an MV supplier, if so who, broken down by staff group? When is the expiry date for this contract?
7. Do you have an external Bank supplier, if so who, broken down by staff group? When is the expiry date for this contract?
8. Please could you confirm what your agency spend is for permanent staff in the past 24 months, broken down by the following staff groups. How much of this is international recruitment?
a. Nursing staff
b. Medical locums (Doctors)
c. AHP/HSS
d. Other clinical
e. Non-clinical
9. How many permanent vacancies do you have as per the below table. Do you have a current supplier for these roles?

Download response Bank and Agency Staffing. 181019

Bank staff. 310320

1. The total internal bank spend broken down by Dr, Nurses and AHP for period Jan 19 – Dec 19
2. Is this contracted to a third party or ran by the Trust (e.g. NHSP, Bank Partners etc.)
a. If contracted to a third party the expiry date of the agreement

Download response Bank staff. 310320

Bank Staff (Medical Locums) Maidstone Hospital

Please complete the attached table with the relevant information regarding Bank Staff (Medical Locums) at your Trust.

Grade Core Hours Pay rate Unsocial Pay Rates
FY1
+FY2
Sp1-2
Sp3+
Dental Core Training
Specialty Doctor/staff grade
Associate Specialist
Consultant

Download response Bank Staff (Medical Locums) Maidstone Hospital 010216

Bank Staff (Medical Locums) Tunbridge Wells Hospital

Please complete the attached table with the relevant information regarding Bank Staff (Medical Locums) at your Trust.

Grade Core Hours Pay rate Unsocial Pay Rates
FY1
FY2
Sp1-2
Sp3+
Dental Core Training
Specialty Doctor/staff grade
Associate Specialist
Consultant

Download response Bank Staff (Medical Locums) Tunbridge Wells Hospital 010216

Break glass and escalated agency rates. 171218

1. Could you please provide me with a breakdown of all the healthcare staffing disciplines provided by agencies in which the trust are breaking glass / being charged escalated rates?
2. Could you please state how many agency workers, per discipline, the break glass / escalated rates applies to re question 1?
3. Could you please state how many healthcare agency workers, per discipline, the Trust are being charged the maximum capped rate as stipulated by their governed framework?

Download response Break glass and escalated agency rates. 171218

Clinical Coding staff. 060220

1. How many staff do you have in your clinical coding department?
2. How many vacancies do you currently have in your clinical coding department?
3. Do you have any 3rd party’s providing you with clinical coding service?
A. If yes, which external organisations (3rd parties or other NHS) provide you with clinical coding services?
B. When did you start these contracts, how long are they for and what procurement framework did you use?
4. How much did the Trust spend last year on bank staff for clinical coding?
5. How much did the Trust spend on consultancy relating to clinical coding last year?

Download response Clinical Coding staff. 060220

Community Nursing. 010618

1. What was your trust spend for temporary community agency nursing in 2017?
2. How many rgn shifts are released to temporary agencies?
3. How many rgn shifts released to agency go unfilled?
4. How many hca shifts are released to temporary agencies?
5. How many hca shifts released to agency go unfilled?
6. How many agencies are on your proffered suppliers list for these requirements?

Download response Community Nursing. 010618

Dermatology locum doctors 060317

Can you please assist me with retrieving the total Agency spend for Medical Locum Doctors within Dermatology over the following months, within your Trust or Health Board?

Download response Dermatology locum doctors 060317

Diagnostic radiology staff details. 260919

1. How many permanent staff are employed by the Radiography/Imaging department (Radiographers & Sonographers, not Radiologists)?
2. How many permanent vacancies are currently open/unfilled within the Radiography/Imaging department (Radiographers & Sonographers, not Radiologists)?
3. How many agency staff/locums are currently being used across the Radiography/Imaging department (Radiographers & Sonographers, not Radiologists)?
4. For agency staff/locums, what is the split in numbers between radiographers and sonographers?
5. How many bank temps are being used across the Radiography/Imaging department?
6. During the 2017-2018 financial year, how much did the Radiography/Imaging department spend on temporary agency staff?
7. During the 2018-2019 financial year, how much did the Radiography/Imaging department spend on temporary agency staff?
8. During the 2018-2019 financial year, how much did the Radiography/Imaging department spend on temporary bank staff?
9. During the 2018-2019 financial year, how much did the Radiography/Imaging department spend on permanent finders/introduction fees through recruitment agencies?
10. Does the Radiography/Imaging department have a dedicated breast screening unit?
11. Please provide me with the following contact names within the authority:
a) The name of the senior manager (Radiology Services Manager / Imaging Services Manager) with overall responsibility for the Radiography/Imaging department.
b) The name of the head of temporary staffing.

Download response Diagnostic radiology staff details. 260919

Engagement of locum staff using third parties. 181718

1. Does your organization use a Direct Engagement scheme?
2. If so, who provides it? And when did you start using it?
3. Did you take external legal advice before entering into it and, if so, from whom did you take external legal advice?
4. What has your total locum/temporary staffing spend since you started using the scheme? If you started using the scheme before April 2017 please also state the total locum/temporary staffing spend since April 2017.
5. How does the third party direct engagement facilitator save you money on the agency spend? Please answer in short point form
6. How much has been paid to the third party direct engagement facilitator thus far?
7. Was this payment calculated as a percentage of the savings generated by employing the services of the third party direct engagement facilitator? If so, what percentage is this?

Download response Engagement of locum staff using third parties. 181718

Flexible staffing 071216

1. Does your Trust currently utilise a Direct Engagement (DE) model? – YES / NO
2. If Yes, who currently provides the service;
a. Brookson
b. Liaison/ PWC (StafFlow)
c. Liaison (TEMPre)
d. 24/7 Time
e. Other (please specify here)………………………..
3. What proportion (in percentage) of your agency workers for the following staff groups are directly engaged:
a. Medical Locums/Doctors (e.g. Acute, Emergency, General Surgery, Paediatrics, Gynaecology, Neurosurgery, Dermatology, Cardiology)
b. Allied Health Professionals/Health Science Staff (e.g. Biomedical Science, Clinical Physiology (Cardiology), Dietician, Occupational Therapy, Pharmacy, Physiotherapy, Radiography, Talking Therapy, Speech & Language Therapy, Psychology, Anatomical Pathology)
4. What percentage are you charged for the management of these services?
5. When was the DE contract awarded?
6. What is the contract duration?
7. What was the motivation with engaging with these services?

Download response Flexible staffing 071216

Framework and non-framework locum agencies

What framework and non-framework locum agencies you use for:
Doctors
Nursing staff
Doctors and nursing staff

I also want to know do you have a staff bank. Do you with any particular agencies as a rule and others when simply in need?

Download response Framework and non-framework locum agencies 260116

Full contact details for the HR staff member responsible for locum appointments

Please can you give me the contact details for the HR person that deals with Locum appointments?

Please can I have their full name, job title, email address and direct dial telephone number.

Download response Full contact details for the HR staff member responsible for locum appointments 180516

Interim Appointments. 100120

1) How many interim appointments were made at your organisation in the (i) 2017-18 and (ii) 2018-19 financial years where the daily rate you paid to the supplier was £500-per-day or more?
Please note that by ‘interim appointment’ I’m referring to an individual on a fixed-term contract, hired to work in management.
2) For each such appointment, please provide me with (i) whether the appointment started in either the 2017-18 financial year or the 2018-19 financial year, (ii) the job title, (iii) whether the position was full or part-time, (iv) the name of the supplier, (v) the daily rate paid to the supplier, (vi) the total amount budgeted for and (vii) the length of the fixed-term contract on which they were hired.

Download response Interim Appointments. 100120

International recruitment and agency spend. 091019

1. In the last 12 months, how many visa applications did the hospital process for medical staff?
Please break down into specialties where possible (e.g. medicine, surgery, anaesthetics etc.)
2. If this information is not readily available could you tell me how many were processed for medicine only?
3. How many permanent vacancies in medicines has the trust had unfilled in the last 12 months?
4. From these vacancies how many were SHO’s? (this includes FY1, FY2, ST1, ST2, CT1, CT2, StR Lower, Clinical fellow, Trust grade, RMO)
5. From these vacancies how many were Specialty Doctors? (Staff Grade)
6. From these vacancies how many were Consultants?
7. How many permanent vacancies do you currently have in medicine?
8. In the last 12 months through which agencies have you recruited doctors across any speciality on either a permanent or fixed term contract?
9. Which agencies were successful in recruiting doctors from overseas for the trust on any type of contract?
10. Across all grades what number of medical agency locum staff did the trust employ across the dates 31/03/2018 to 31/06/2018?
11. How much did the trust spend on medical agency locum staff over the 2017/2018 financial year?
12. Does the trust utilize a medical recruitment framework for international doctors?
13. Who is the dedicated contact in your organisation who liaises with agencies for the purposes of international medical recruitment?
14. Please provide names and contact details for the following posts within the trust:
– Medical Director
– All Clinical Directors within Mental Health
– Head of HR
– Head of Medical Staffing
– Head of Procurement

Download response International recruitment and agency spend. 091019

Legal and HR consultants. 030919

A) 2017/18
B) 2018/19
1. Did your organisation use an external consultant for any of the following functions?
a. Human Resources
b. Legal Services
c. Leadership and organisational development
d. Board reviews
e. Mediation
f. Regulatory body inspection support
2. What were the names of the consultants used?
3. What was the expenditure with each consultant?

Download response Legal and HR consultants. 030919

locum agency ahp and hss staff.

Please provide the spend on locum agency ahp and hss staff broken down by the below disciplines and, if applicable whether the spend is in an acute or community setting for the period 1st October 2014 – 30th September 2015.

Occupational Therapists

Physiotherapists

Speech & Language Therapists

Dietitians

Pharmacists

Radiography to include Diagnostic, CT, MRI, Nuc Med

Radiotherapists

Sonographers

Download response locum agency ahp and hss staff 161215

Locum agency Doctors. 270619

1. Please could you provide me a breakdown of the locum agency doctor spend for the last financial year? Please break this down in to specialty and grades
2. Please could you provide me a breakdown of the permanent doctor vacancies across the trust? Please break this down into specialty and grades
3. Please could you confirm how many agency locums are currently in post on long term agency contracts? In the last 6 months and year
4. Please could you provide how much the trust has paid to agencies for introductory fees?
5. Please provide details of any overseas recruitment campaigns that the trust has taken part in for the recruitment of doctors?

Download response Locum agency Doctors. 270619

Locum-agency spend. 300518

1) The total amount the trust spent on agency/locum doctors for the following years: 2012/13, 2013/14, 2014/15, 2015/16, 2016/17 – breaking this information down by speciality and grade.
2) What is the highest hourly/shift rate paid to an agency or locum doctor at any point in the following years: 2012/13, 2013/14, 2014/15, 2015/16, 2016/17 – please include job title and date.

Download response Locum-agency spend. 300518

Locum agency spend within Dermatology.

Can you please assist me with retrieving the total Locum Agency spend for Locum Doctors only within Dermatology over the following months, within your Trust or Health Board?

Download response Locum agency spend within Dermatology 060916

Locum Audiologists. 210917

1. Are the Locum Audiologists that are selected by the trust registered with a regulatory body? If not, why not and when will this become a mandatory trust requirement?
2. Does the trust believe in regulated professionals raising the quality of care given to patients as per other trusts where mandatory registration with the RCCP is a precursor?
3. When does the trust envision the newly recruited Audiologists taking up their posts? Will the locum cover cease or continue after this date?
4. Has the trust sought to recruit band 5 locum’s? When was the last time this was attempted to reduce costs? Is this something the trust would consider now to save taxpayer’s money?
5. What is the present weekly spend on locum’s excluding agency fees per full time (2) and part time locum?
6. What is the process in place for the trust in “increasing hourly rates” as per previous FOI – who makes the final decision on the rate given to a locum Audiologist and how is this audited?
7. Within the trust recruitment checks are immediate prior employers (locum) sought for a reference or does MTW NHS trust allow for references from any sources? How does the trust ensure competency with the locums used?

Download response Locum Audiologists. 210917

Locum doctor costs 2015

1. How many permanent positions for doctors did the trust undertake recruitment to fill in 2015?
2. What was the trust’s total spend on recruiting doctors in 2015?
3. What was the average length of time taken to fill vacant doctor posts in 2015?
4. What was the trust’s total spend on employing locum doctors in 2015?
5. What was the trust’s total spend on employing locum doctors to cover unfilled permanent posts in 2015?
6. What was the trust’s total spend on locum agency fees, for the recruitment of doctors, in 2015?

In your response, please confirm the official name of the trust or trusts that the information relates to.

Download response Locum doctor costs 2015 110316

Locum doctors and agency nurses. 210519

How much has your trust spent on locum doctors each year from 2014-15, 2015-16, 2016-17, 2017-18, 2018-19, respectively?

How much has your trust spent on agency nurses, during the years listed above?

What was the highest amount the trust had to pay a locum doctor for a shift during the years stated above?

What was the highest amount the trust had to pay an agency nurse for a shift during the years stated above?

Download response Locum doctors and agency nurses. 210519

Locum doctors in Radiology. 201117

Can you please assist me with retrieving the total Agency spend for Medical Locum Doctors within Radiology over the following months, within your Trust or Health Board?

Download response Locum doctors in Radiology. 201117

Locum doctors in Stroke Medicine. 061217

Can you please assist me with retrieving the total Agency spend for Medical Locum Doctors within Stroke Medicine over the following months, within your Trust or Health Board?

Download response Locum doctors in Stroke Medicine. 061217

Locum doctors within Gastroenterology. 011217

Can you please assist me with retrieving the total Agency spend for Medical Locum Doctors within Gastroenterology over the following months, within your Trust or Health Board?

Download response Locum doctors within Gastroenterology. 011217

Locum doctors within Haematology.

Can you please assist me with retrieving the total Agency spend on Locum Doctors within Haematology over the following months, within your Trust or Health Board?

December 2015
January 2016
February 2016
March 2016
April 2016
May 2016

Download response Locum doctors within Haematology 060916

locum staff.010318

1. What was the total spend on locum Physiotherapists in the last financial year 01/04/2016 to 01/04/2017?
2. What was the spend on locum Occupational Therapists in the last financial year 01/04/2016 to 01/04/2017?
3. What was the spend on locum Podiatrists in the last financial year 01/04/2016 to 01/04/2017?
4. What was the spend on locum Radiographers in the last financial year 01/04/2016 to 01/04/2017?
5. What job roles have the Trust broken glass (Paid outside the framework rates) for in the last financial year within the Allied Health Professionals area 01/04/2016 to 01/04/2017?

Download response Locum staff.010318

locum staff 2013 – 2015 161116

Please could you provide me with the information mentioned below for 2013, 2014 and 2015?
1. Doctors: Annually how many posts are covered by locum staff in your Trust?
2. Nurses: Annually how many posts are covered by locum staff in your Trust?
3. How many posts as a percentage was covered by locum agency staff in your Trust (doctors and nurses separately for the years mentioned above)?

Download response locum staff 2013 – 2015 161116

Locum staff and job vacancies 2010/2011 & 2014/2015

1. (a) In the Financial Year 2014/15, how many hours in total were worked by locum staff for the Trust?

(b) In the Financial Year 2014/15, how many days in total were permanent job positions left vacant for? (I.e. the number of days that positions were left unfilled by permanent staff)

2. (a) In the Financial Year 2010/11, how many hours in total were worked by locum staff for the Trust?

(b) In the Financial Year 2010/11, how many days in total were permanent job positions left vacant for? (I.e. the number of days that positions were left unfilled by permanent staff)

NB: I would prefer the figures to be for financial years, as stated. However, if it is only possible to supply the figures in terms of calendar years, please supply them for 2014 (in Q1), and 2010 (in Q2).

Download response Locum staff and job vacancies 2010/2011 & 2014/2015 260116

Medical locum agencies. 070417

1. A list of all agencies the trust uses for temporary workers (Med Locums).

2. A breakdown of monetary spend per agency for the last 12 months.

Download response Medical locum agencies. 070417

Medical locum and bank shifts. 181019

1. What was the highest amount you spent on a single medical locum shift (regardless of length) in the following? Please state specialty and grade involved, length of shift and date/dates worked in each case. Please include any agency commission.
a. 2019-20 to date
b. 2018-19
c. 2017-18?
2. With regard to the highest amount spent in the current financial year, was this shift offered to doctors at your trust? Did their reasons for refusal relate to concerns over the tax treatment of pension contributions?
3.
a. How much did you spend on locum medics each month in the following periods?
Financial year 2017-18
Financial year 2018-19
So far this financial year (please state end date)
b. How many shifts were involved in each period?

Please give figures broken down by month e.g. April 2017 £75,000 (150 shifts) May 2017 £100,000 (29 shifts) etc.

Download response Medical locum and bank shifts. 181019

Medical Locum doctors and Agency Nurses. 221116

Please clarify for the supply of both medical locum doctors and agency nurses:
1. What was your total spend for the last financial year (2015/16) for agency medical locums?
2. What was that spend broken by specialty, for example Accident and Emergency, Anaesthetics, Medicine, Mental Health, Obstetrics and Gynaecology, and Surgery?
3. What was that spend broken down by agency?
4. What was your total spend for the last financial year (2015/16) for agency nurses?
5. What was that spend broken by specialty, for example Accident and Emergency, Community, Critical, General, Mental Health, Midwifery, and Theatres?
6. What was that spend broken down by agency?

Download response Medical Locum doctors and Agency Nurses. 221116

Medical locum spend 2016. 130417

I would like to request the Trusts Medical Agency Locum Spend for the year 2016.

Can you please break these figures down accordingly?
1. Agency Locum spend for A&E Doctors in 2016
2. Agency Locum spend for General and Acute medicine Doctors in 2016
3. Agency Locum spend for Radiology Doctors in 2016
4. Agency Locum spend for Paediatric Doctors in 2016
5. Agency Locum spend for Obs and Gynae Doctors in 2016
6. Total Medical Agency Locum Spend in 2016

Please also break them down into the grade accordingly (SHO, Middle and Consultant).

Download response Medical locum spend 2016. 130417

Medical locums. 070318

1. Please confirm the Trust’s total annual spend on agency Medical Locums
2. Please confirm what delivery model the Trust currently uses to engage agency Medical Locums:
a. Managed Service
b. PSL
3. If the Trust uses a managed service, please can you confirm the name of the provider and when this contract is due to expire
4. If the Trust uses a PSL, is this a third party PSL i.e. CCS framework, H T E Framework etc. or the Trusts own PSL?
5. Please confirm whether the Trust currently uses any form of e-rostering platform in relation to engaging Medical Locums. Yes / No, if Yes please can you confirm the name of this technology.
6. Does the Trust operate a Medical Locum staff bank Yes / No?
7. In relation to the above, does the Trust currently utilise any technology for running this staff bank – if yes, what is the name of this technology?
8. Is the trust participating in the DHSC / NHSI 2018 Bank Pilots?
9. Who is / are the person(s) responsible at trust level for leading the DHSC / NHSI Bank Pilots project? Please provide name(s) and job title(s).

Download response Medical locums. 070318  

NHS Direct Engagement Schemes. 270619

1. Have you used a Direct Engagement firm?
2. If so please list all you have used with dates.
3. For the purposes of IR35 assessments, do you claim to supervise direct and control (SDC) your temporary workforce (temporary staffing/finance will know) – and have policy relating to this?
4. If you have outsourced this IR35 assessment function, did you claim to supervise, direct and control your temporary workforce prior to doing so?
5. What are the job titles of the designated points of contact in your organisation with any direct engagement firms you may use, or have used?
6. Having reviewed the attached communication from one of the direct engagement firms (prior to answering the questions), the public interest articles linked and parliamentary select committee evidence at the end of this FOI – could you please confirm:
a. Have board-members, and/or, if different, the points of contact within your trust for your Direct Engagement firm received this email?
b. If so please disclose a copy (please search only as far back as 30th January 2019 –likely received on 5th February 2019).
c. Please disclose all correspondence with any direct engagement firms since 30th January 2019 to these points of contact and the board until the date of response to this FOI.
d. Please disclose all minutes discussing Direct Engagement/VAT on locums since 30th January 2019 until the date of response to this FOI (by the board, finance team, temporary staffing, or other committee likely to discuss this matter).
e. Please disclose a copy of the letter sent by IHPA to your CEO at the beginning of May 2018 regarding Direct Engagement schemes. (link to notice of permission from the IHPA/commercial interest waiver – https://ihpa.org.uk/uncategorized/ihpa-a…
f. Please disclose any due diligence pursuant to the Criminal Finance Act 2017, you may have conducted as a result of the letter from IHPA, and the subsequent email reproduced above from a direct engagement provider if you received it.
g. For the avoidance of doubt, all communications/discussion with alternative direct engagement providers are to be considered within the scope of this request.
h. Please disclose all email or written discussion of this matter with any frameworks you may use, and identify the framework in question.
For clarification, Questions a-h are a continuation of question 6. They relate to the attached email from PlusUs and any subsequent and/or previous actions in connection to this and direct engage models. Please may you also answer questions a-h and provide any evidence in recorded format.

Download response NHS Direct Engagement Schemes. 270619

NHS Improvement Agency Rules (20 November 2015). 040117

1. Since the introduction of NHS improvement Agency Rules (20 November 2015) how many times have you reported service closure of elective pathway?
2. Since the introduction of NHS Improvement Agency Rules (20 November 2015) how many times have you reported an effect on the patient experience?
3. Since the introduction of NHS Improvement Agency Rules (20 November 2015) how many times has there been occurrence of serious harm due to staffing levels?
4. How many times have you fallen below your safer staffing target since the introduction of the NHS Improvement Agency rules (20 November 2015)?
5. How many of the below have been reported due to insufficient staffing numbers since the introduction of NHSI Agency Rules in November 2015?
a). Patient falls
b). Pressure Ulcers

Download response NHS Improvement Agency Rules (20 November 2015). 040117

Nursing agency information. 210417

1. A list of all agencies the trust uses to fill Nursing requirements in tearing order (If the trust uses any tearing systems).
2. A breakdown of spend per agency the trust uses for nursing in the last 12 months.
3. A breakdown of hours filled per agency for nurses in the last 12 months.
4. The highest charge rate agreed to pay an agency nurse per hour for each speciality.
5. The highest margin an agency has declared per hour, for each speciality for nursing.
6. Any agency which has been blacklisted from supplying nurses to the trust.
7. If the trust uses any 3rd party payment systems and/or master venders in place who cascade shifts out to agencies, if so what are they called?

Download response Nursing agency information. 210417

Nursing shifts. 011118

You asked:
Please answer all questions with the relevant data for the month of August 2018 (1st August 2018 – 31st August 2018).
1. The total number of nursing shifts sent to agencies to fill.
2. The total number of nursing shifts filled by agencies.
3. The total number of critical banded nursing shifts sent to agencies to fill.
4. The total number of critical banded nursing shifts filled by agencies.
5. The total number of ‘breaches’ for filling a shift with agency nurses (Registered Nurses) not within the NHSI capped charge rates.
6. Please provide a list of all agencies which supply the trust with nursing staff.
7. Please provide a list of off framework agencies which currently supply the trust with nursing staff

Download response Nursing shifts. 011118

Nursing shifts September 2018.011118

You asked:
Please answer all questions with the relevant data for the month of September 2018 (1st September 2018 – 30th September 2018).
1. The total number of nursing shifts sent to agencies to fill.
2. The total number of nursing shifts filled by agencies.
3. The total number of critical banded nursing shifts sent to agencies to fill.
4. The total number of critical banded nursing shifts filled by agencies.
5. The total number of ‘breaches’ for filling a shift with agency nurses (Registered Nurses) not within the NHSI capped charge rates.
6. Please provide a list of all agencies which supply the trust with nursing staff.
7. Please provide a list of off framework agencies which currently supply the trust with nursing staff

Download response Nursing shifts September 2018.011118

Nursing usage. 091219

1. Please provide name and contact details (email address and telephone number where possible) of any Lead Cancer Nurses and Cancer Managers you have within your Trust, broken down by site, and then department and speciality of cancer.
2. How much cancer related agency usage from January 2018 to November 2019 has the Trust used? This is a request for Nursing only. I request for this information to be broken down into the following:
a) unit/site and ward/department
b) grade/title (i.e. Band 5/6/7 Nurse etc.)
c) amount of hours and/or full time equivalent (FTE) broken down per month during the requested time period above
d) total cost of agency usage (in £) per month during the requested time period above
e) what agencies were used, along with total amount in £ per agency on a monthly basis during the requested time period above
3. How does the Trust source any cancer-related Nurse agency requirements? I request your answer include any frameworks that you use along with the number of SLAs you have in place with providers.
4. Based on your answer above, can you confirm the number of incidences whereby your agency need has been charged above NHSi cap, broken down per shift on a monthly basis i.e. April 2018 = 25 shifts.
5. Who is responsible for making the decision on which agency/recruitment business to use to fulfill your agency nursing requirements. Please include name and contact details (email and telephone number where possible).
6. What are the Trusts current full-time and part-time vacancies for:
a) Cancer Clinical Nurse Specialists
b) Lead Cancer Nurse
c) Cancer Manager
d) Chemotherapy Nurses
e) Radiology Nurses
f) Oncology Nurses

Download response Nursing usage. 091219

Off framework and off payroll agency spend. 200220

For the months of 2019 between Jan – November could you please break down your off framework/ off payroll agency spend by cost (highest to lowest) by recruitment company.
Could this be completed separately for doctors and nurses?

Download response Off framework and off payroll agency spend. 200220

Out of Hours GP Service.130619

I wish to know whether your Trust uses agency GPs to staff your Out of Hours rotas.
Please provide the following information:
1. Name of provider or corporate body holding the contract
2. Name and contact details of the contract provider’s principal contact or local decision-maker
3. Whether the main contractor has sub-contracted all or part of the GP provision

Download response Out of Hours GP Service.130619 

Permanently employed and supplemental nurses. 241016

1. The number of nurses permanently employed and the number of supplemental nurses:
By each of those two categories, supplemental vs. permanently employed, we would like to know:
a. The average experience, measured in number of years as registered nurse.
b. The average age.
c. How many of them are i) British ii) EU-citizen (with exclusion of the UK) iii) Extra-EU citizen.
d. How many of them are certified.
e. How many of them are male.

Download response Permanently employed and supplemental nurses. 241016

Physiotherapy Services. 280917

VACANCIES
Request 1
a) Please confirm how many whole time equivalent physiotherapist and physiotherapy support worker vacancies were held in Maidstone and Tunbridge Wells NHS Trust as at 31 March 2017.
b) Please confirm how many of the posts in Request 1a had been vacant for 3 months or more as at 31 March 2017.

POSTS
Request 2:
Please confirm how many whole time equivalent (WTE) physiotherapists and physiotherapy support workers were employed by Maidstone and Tunbridge Wells NHS Trust on the 31 March 2017. (This should include any generic assistant or technical instructor posts that support physiotherapy service provision).

PATIENT DEMAND
Request 3:
Please confirm the number of new referrals (including patient self-referral) to physiotherapy services in Maidstone and Tunbridge Wells NHS Trust, in the following financial years:
• 1 April 2016 to end of 31 March 2017
• 1 April 2015 to end of 31 March 2016
• 1 April 2014 to end of 31 March 2015

SPENDING
Request 4:
Please confirm how much was spent on physiotherapy agency/locum/temp staff in Maidstone and Tunbridge Wells NHS Trust, in the following financial years:
• 1 April 2016 to end of 31 March 2017
• 1 April 2015 to end of 31 March 2016
• 1 April 2014 to end of 31 March 2015

PRACTICE BASED LEARNING
Request 5:
Please identify the clinical areas within your physiotherapy services that provide placements for physiotherapy undergraduates in the last financial year (1 April 2016 to end of 31 March 2017).

MUSCULOSKELETAL (MSK) PATHWAY
Request 6:
a) Please confirm/deny whether Maidstone and Tunbridge Wells NHS Trust provides MSK services that include first contact physiotherapists in General Practice
b) Please confirm/deny whether patients can self-refer to physiotherapy services within the MSK services provided by Maidstone and Tunbridge Wells NHS Trust

Download response Physiotherapy Services. 280917

Public sector spending on contingent staff. 221217

Questions
Is the organisation part of any regional Workforce networks, forums or collaborations? If so please provide name(s) and description(s)
Is there a named person responsible for leading HR / workforce / agency for the STP region that you are a part of?
Named individual
Organisation
Job title
Please state the organisation’s total expenditure on agency (non-contract) staff (16/17)
TOTAL
Nursing & HCAs
Medical & Dental
AHPs
Admin & Clerical
Estates & Facilities
Scientific
Other
Please state the organisation’s total expenditure on internal bank staff (16/17)
TOTAL
Nursing & HCAs
Medical & Dental
AHPs
Admin & Clerical
Estates & Facilities
Scientific
Other
Does the organisation use a third party to provide a Direct Engagement / Outsourced Employment Solution to recover VAT?
Please state the name of the Direct Engagement / Outsourced Employment supplier (e.g. Liaison, 247 Time, Brookson, Retinue etc.)
Contract start date
Contract end date
How much did the organisation spend on these services in total? (16/17)
Please state the organisation’s expenditure on staff directly engaged via these employment solutions (16/17) Please note this figure should be the proportion of your agency expenditure engaged directly
Medical & Dental
AHPs
Please state what rostering systems have been successfully implemented at the organisation, split by the following staffing types:
Nursing & HCAs
Medical & Dental
AHPs
Admin & Clerical
Estates & Facilities
Scientific
Other
Does the organisation use a third party systems to assist with job planning, appraisals or revalidation for medical staff? Please provide the following information:
Supplier name
Service description
Staffing types
Contract start date
Contract end date
Name of framwork used to procure services
How much did the organisation spend on these services in total? (16/17)
Does the trust use any third party systems / services to manage the supply of temporary staff? Please provide the following information for each supplier. Please copy cells down for each supplier as necessary:
Supplier name
Service description
Staffing types
Contract start date
Contract end date
Name of framework used to procure services
How much did the organisation spend on these services in total? (16/17)

Download response Public sector spending on contingent staff. 221217

Shifts covered by any doctor level for which the Trust has paid in excess of £150 per hour. 170517

1) In the past 6 months, have many shifts covered by any doctor level have you paid in excess of £150 per hour

2) In the past 3 months, have many shifts covered by any doctor level have you paid in excess of £150 per hour

3) In the past 1 months, have many shifts covered by any doctor level have you paid in excess of £150 per hour

Download response Shifts covered by any doctor level for which the Trust has paid in excess of £150 per hour. 170517

Staff and agency information

1. Staff Numbers – Average headcount of permanent and non-permanent staff over the entire 2015/16 financial year or just the headcount as at Thursday, March 31st 2016. Can you please split this into the major speciality/grades used by the trust?
2. Staff Cost – Total staff cost during the 2015/16 financial year split into permanent and non-permanent staff.
3. Agency Hours – Hours worked by agency staff in the 2015/16 financial year split by speciality/grade depending on how you report this within your trust.
4. Agency Spend – Total amount spent on agency staff in the 2015/16 financial year split into the categories or speciality/grade used by the trust.
5. Do you use a direct engagement model within your trust? Direct engagement model means the Trust pays agency staff directly and then pays the agency commission separately. The alternative to this is to pay the agency a lump sum for any work done by agency staff and the Agency in turn pays their own staff.

Download response Staff and agency information 060916

Staff Bank. 200320

Please answer the below questions in relation to your organisations staff bank utilisation for each staffing group.
1a. Does your organisation have staff bank? (an entity of staff managed by either the organisation or a third-party, who are temporarily contracted to take on shifts)
“1b. If yes, what type of bank is in place:
i) Internal bank supported by third-party technology
ii) Managed bank
iii) Outsourced bank
iv) In-house (no third-party involved, possibly managed on Excel) ”
2a. What is the monthly average number of workers (headcount) on the bank in the last 12 months?
2b. What is the monthly average utilisation rate for your bank in the last 12 months? (calculated based on the % of vacant shifts filled by bank workers)
2c. What is the average utilisation rate for your bank in November 2019?
2d. What is the average utilisation rate for your bank in December 2019?
2e. What is the average utilisation rate for your bank in January 2020?
Please answer the below questions in relation to the organisations staff bank supplier for each staffing group
3a. Please state the name of the third-party supplier(s) used to manage the supply of your bank staff, inclusive of any outsourced or managed arrangements (i.e. NHSP, Patchwork, Allocate, Liaison, PlusUs, Locum’s Nest etc.)
3b. Please state the name of the software used to book and manage your bank staff (i.e. NHSP:Connect, TempRE Bank, Allocate BankStaff etc.)
3c. Do your bank workers book shifts via a mobile app? If yes, please state the name of the app being used
3d. Do your bank workers submit electronic timesheets using the software?
3e. Does your organisation make use of an API (Application Programming Interface) i.e. allows for interaction/communication with other software.
3ei. If yes to the above, please state the software integrations that are currently being utilised e.g. Ryalto with NHSP, Reed with Patchwork etc.
4a. What framework was used to procure the supplier?
4b. What is the contract start date? (dd/mm/yy)
4c. What is the contract end date? (dd/mm/yy)
4d. What was the average monthly fee paid to the supplier in the last 12 months?
4e. What is the pricing structure of the fees paid to the supplier? I.e. % of costs processed, fixed transactional fee, license fee etc.

Download response Staff Bank. 200320

Staff recruitment and agency spend. 300518

1. Spend on agency recruitment fees for permanent staff (not including salaries) – medical staff
2. Spend on agency recruitment fees for permanent staff (not including salaries) – nursing staff
3. Spend on agency recruitment fees for permanent staff (not including salaries) – allied health professionals (AHPs) and health science services (HSS) staff
4. Spend on agency recruitment fees for permanent staff (not including salaries) – non medical, non-clinical (NMNC) staff
5. Internal spend bank staff management
6. Outsourced spend on bank staff management
7. Please provide your spend on recruitment process outsourcing in the last available full financial year (please note the year in your response).

Download response Staff recruitment and agency spend. 300518

Staff recruitment and agency spend. 120919

1. The average time taken to fill permanent roles advertised on NHS jobs. Please break down into grades such as SHO, Middle Grade, and Consultant
2. The average time taken to fill permanent roles via an agency. Please break down into grades such as SHO, Middle Grade, and Consultant
3. What is your locum spend for the last financial year? Please break down into grades such as SHO, Middle Grade, and Consultant
4. How many total hours does your locum spend relate to in the financial year? Please break down into grades such as SHO, Middle Grade, and Consultant
5. How many permanent doctors were hired by your Trust in the last financial year? Please break down into grades such as SHO, Middle Grade, and Consultant
6. Please could you provide how much the trust have paid to agencies for introductory fees in the last financial year? Please break down into grades such as SHO, Middle Grade, and Consultant
7. What is your average retention for your permanent doctor hires in this last financial year? Please break down into grades such as SHO, Middle Grade, and Consultant

Download response Staff recruitment and agency spend. 120919

Staffing and locum data 2013 – 2016. 250417

Rota Data: (Please complete separate tables for each month for which data exists, for the last three years).
Consultant
Trainee (Specialist Registrar)
Trainee (Core Trainee)
Trainee (Foundation Year 2 Trainee)
Trainee (Foundation Year 1 Trainee)
Band 5 and 6 Registered Nursing Staff
Other Registered nurses
Nursing assistant
Phlebotomists
Occupational Therapists
Physiotherapists
Other allied Healthcare Professionals (please specify)
Ward Clerks
Other staff (please specify)

Locum Data: (Please provide separate tables for each year, for the last three years, that there is data available from).
Consultant
Non-training grades (excluding consultants)
Trainee (Specialist Registrar)
Trainee (Core Trainee)
Trainee (Foundation Year 2 Trainee)
Trainee (Foundation Year 1 Trainee)
Band 5 and 6 Registered Nursing Staff
Other Registered nurses
Nursing assistant
Phlebotomists
Occupational Therapists
Physiotherapists
Other allied Healthcare Professionals (please specify)
Ward Clerks
Other staff (please specify)

Download response Staffing and locum data 2013 – 2016. 250417

Temporary agency workers 211116

1. Please advise the total staff headcount that are employed directly by Maidstone and Tunbridge Wells NHS Trust, with each part-time employee counted as one employee. Please exclude all temporary agency workers from this figure.
2. Please identify each supplier that Maidstone and Tunbridge Wells NHS Trust has a contract with to supply temporary agency workers.
3. Please identify: a. the type of contract that Maidstone and Tunbridge Wells NHS Trust has with each of these suppliers (preferred supplier list/ framework/ etc. If framework, please indicate b. which – e.g. MSTAR/ YPO/ Panel London/ Pan London/ NPS All Wales/ Crown Commercial Services/ etc; and c. whether this is on a neutral/ master/ hybrid vender model, or the lot number.
4. Please advise for each contract identified within (2) above of: a. the current end date of the contract; b. the date(s) that any break clause(s) can be enabled; and c. the length of time of any extension that can be enabled.
5. Please advise of the full name of the main contact at Maidstone and Tunbridge Wells NHS Trust who is responsible for the main (or majority of the) contract(s) identified within (2) above, together with their:
a. job title;
b. group (either team, division or department, whichever is the smallest identifiable group);
c. telephone number;
d. email; and
e. full postal address, inc postcode.
6. Please identify all suppliers that Maidstone and Tunbridge Wells NHS Trust has sourced a temporary agency worker from – but does not have a contract with – from 1 April 2015 to 31 March 2016.
7. For each temporary agency supplier (either a. contracted as identified within (2) above; b. non-contracted as identified within (6) above; and c. all workers Maidstone and Tunbridge Wells NHS Trust has sourced directly), how much has been spent on each supplier (or directly), from 1 April 2015 to 31 March 2016?

Download response Temporary agency workers 211116

Temporary Nursing staff – Internal Bank and External Agency suppliers

1) Do you use temporary nurses? If yes, can we have a breakdown of how many have been used in the last three years?

2) What is the cost if using these nurses? Can we have a breakdown of how much one nurse costs and the total of cost in the last three years?

Download response Temporary Nursing staff – Internal Bank and External Agency suppliers 010216

Temporary staff. 050718

You asked:
1. Spend on temporary nursing staff through your staff bank, by band (1-9)
2. Spend on temporary nursing staff through agencies, by band (1-9)
3. Spend on temporary staff through the trust’s staff bank
4. Spend on temporary staff through agencies
a. Spend on temporary staff by agency (agency names can be anonymised if necessary)

Download response Temporary staff. 050718

Temporary staff. 090718

You asked:
1. Do you have an outsourced payroll for temporary staff?
• If yes can you confirm if this is a weekly payroll?
• Can you confirm the name of the payroll provider?
• Can you confirm agreed contract start and End dates of this provider?
2. Is your temporary staff Bank in-house or outsourced?
• If the bank is outsourced, can you confirm the name of the supplier?
• Can you confirm agreed contract start and End dates?
3. Are you currently using Direct engagement? (DE / VAT saving model for Locums)
• If yes, can you confirm the name of the supplier?
• Can you confirm agreed contract start and End dates?
4. Do you have a Master or Neutral vendor contract in place for the following staff groups Nursing & Midwifery, Doctors, AHP’s and Admin and clerical?
• If yes, please can you confirm the name of the supplier?
• Can you confirm agreed contract start and End dates?
• Does the Master or Neutral vendor contract include any other Trusts in addition to yourself?
5. Please can you confirm if you are using a mobile application-based or web-based booking platform for booking bank / agency with the following staff groups: Nursing & Midwifery, Doctors, AHP’s and Admin and clerical?
• If yes, please can you confirm the name of the supplier?
• Can you confirm agreed contract start and End dates?
• Is Direct engagement for Doctors included with the application?

Download response Temporary staff. 090718

Temporary staff. 211118

You asked:
1. Does your trust have a centralised temporary staff booking team?
2. Does your trust have a centralised temporary staff booking team specifically for Non-Medical Non-Clinical Staffing?
3. If Yes, which categories does it book for?
• Admin & Clerical
– Staff Lead Name & Position
– Contact telephone DD
– Contact email
• Corporate Functions
– Staff Lead Name & Position
– Contact telephone DD
– Contact email
• Ancillary Functions
– Staff Lead Name & Position
– Contact telephone DD
– Contact email
• IT Professionals
– Staff Lead Name & Position
– Contact telephone DD
– Contact email
• Legal Supply
– Staff Lead Name & Position
– Contact telephone DD
– Contact email
Some (Please specify which)
4. If No, please provide a list of all departmental heads responsible for booking temporary staff.
5. Who is your Head of Procurement and who is your Senior Buyer/Category Manager responsible for overseeing HR/Agency procurement in your trust?
Please also provide their contact telephone DD and email addresses.
6. Please can you provide your annual agency spend for 2017/18 for Non-Medical Non-Clinical Staffing?
7. Please can you provide your annual agency spend for 2017/18 for each of the Non-Medical Non-Clinical staffing categories?:
• Admin & Clerical
• Corporate Functions
• Ancillary Functions
• IT Professionals
• Legal Supply
8. Which procurement frameworks does the trust currently use for Non-Medical Non-Clinical Staffing?
9. Do you use a Master Vendor model for your agency Non-Medical Non-Clinical staffing requirements?
10. If Yes, can you confirm the following details:
• Name of Master Vendor
• Agency Contact Name
• Agency Contact Email
• Agency Contact Number

Download response Temporary staff. 211118

Temporary staff provisions 2015-2016 221116

Medical Locums
1. What was your agency spend on medical locums during 2015/2016?
2. Do you source your locums via:
o Mastervend
o Managed service
o Preferred supplier list
o Other (please state)
3. Which framework do you use to source your medical locums?
4. Are you working to the NHS Improvement rate caps?
5. Do you use direct engagement (VAT mitigation)?
AHP/HSS Staff Groups
6. What was your spend on agency AHP and HSS during 2015/2016?
7. Which framework do you use to source your agency workers in this area?
8. Are you working to the NHS Improvement rate caps?
Other staff groups
9. What was your agency spend on non clinical staff (not doctors, nurses, HSS or AHP staff) during 2015/2016?
10. Which framework do you use to source these staff?
11. Which staff groups do you use (eg, admin and clerical, ancillary, IT staff, senior manager interim staff, VSM interims)
12. Are you working to the NHS Improvement rate caps?

Download response Temporary staff provisions 2015-2016 221116

Temporary staffing processes

1) Do you have a master vendor (MV) arrangement in place for the supply of medical locums? If so please state the name of the provider used (Medacs, Holt, A&E Agency etc.)
2) Please state the utilisation rate that has been achieved through the master vendor in the last 12 months. This is the total value of locum spend supplied by the master vendor itself in the last 12 months as a percentage of total locum spend in the same period.
3) Does the trust use a direct engagement model to engage locum staff? If so please state the name of the company used (Liaison PwC, 247 Time, Brookson, HB Retinue, Medacs etc.)?
4) Do you run a weekly payroll for medical bank?
5) Does the trust use rostering software (Allocate, Smart etc.)? If so please state the name of the company used, and the total amount that the trust has spent on rostering in 2014/15.
Please provide all subsequent information split by the following staffing categories. Please include all spend outside of the specified categories as “other”.
– Nursing & HCA’s
– Medical & Dental
– AHP’s
– Other
6) Please state the trusts expenditure on agency staff in 2014/15 split by the above staff categories.
7) Please state the total spent on internal bank staff in 2014/15, split by the above staff categories. This is the total paid to workers completing shifts via the trust bank, excluding any costs to 3rd parties. Please do not include any spend on outsourced bank staff
8) Please state the total number of staff signed up to the trust’s internal bank, split by the above categories.
9)Of the above figure, please state the total number of staff signed up to the bank who also work as substantive staff at the trust. I.e. Staff that hold substantive contracts but have also completed shifts via the internal bank.
10) Does the trust outsource the supply of any bank staff to third parties such as NHS Professionals, Bank Partners, etc.? If so please specify the name of the company used and the staffing categories supplied by the 3rd party. 11)Does the trust use any third party tech solutions to manage internal bank staff (de Poel, HB Retinue, Liaison, Holt, 247 Time etc.)? If so please specify the name of the company used and the staffing categories managed through the tech solution.
12)Do you use any suppliers or systems to manage the release of vacancies to agencies and bank workers? If so please state the name of the company used and the staffing categories managed. If you use different suppliers/systems for different staffing categories, please specify.

Download response Temporary staffing processes 150416

Total spend on bank and agency admin and clerical staff. 030719

For the last financial year (2018-19) what was your total spend on bank and Agency for the admin and clerical staff group? (Please specify total spend for bank and agency separately, if you do not have a bank for this staff group please specify agency spend only)

Do you have a master or neutral vend supplier in place for admin and clerical agency?

• If you do have a master or neutral vend in place for admin and clerical, what is the name of the supplier and when does your existing contract with the supplier end?

Download response Total spend on bank and agency admin and clerical staff. 030719

Trust’s expenditure on Interim Managers 2014/2015

By interim managers we mean any manager who is referred to as “interim” or “temporary” in the trust Annual Reports for the five previous financial years up to 2014/2015.

For each individual interim manager, please provide:
1. The name, position within the trust, and the recruitment firm associated with the interim manager.
2. The total amount paid for the services of the interim manager, and for how many months’ work.
3. Out of the money paid for the individual’s services, how much of that money went to the recruitment firm (i.e. was not part of the interim manager’s salary).
4. Please could you provide the information from the five previous financial years up to 2014/2015 in Excel Format?
5. In a separate data set, please could you provide how much has been spent this year up to the present date (4/2/16) in Excel format?

Download response Trust’s expenditure on Interim Managers 2014/2015 290316

Use of Staff Banks. 020519

1a) – please can you confirm whether your Trust has either
a) an in-house staff bank or
b) outsourced staff bank or
c) other service provision or
d) not applicable, i.e. staff not required by the Trust, for the following staff groups:
– administrative services staff
– allied health professionals
– emergency services staff
– health science services staff
– ‘registered’ nursing and midwifery staff
– ‘unregistered’ nursing and midwifery staff
– medical and dental staff
– personal social services staff
– support services staff.

If would be helpful to me if you could please reply in the following format: administrative services staff = c; allied health professionals = a; emergency services staff = d and so on.
1b) – where you have not answered a) (an in house staff bank) to question 1a), please elaborate as follows:
i) if any staffing category has received an answer of b) (an outsourced staff bank), please confirm the name of the outsourced staff bank service provider. For example, this could be either NHS Professionals or Pulse Healthcare Ltd. trading as Bank Partners or Reed Specialist Recruitment Ltd. or other service provider.
ii) if any staffing category has received an answer of c) (other service provision), please confirm the nature of the other service provision. For example, this could be full, or in part, reliance on agency staff.
It would be helpful to me if you could please reply in the following format: administrative services staff = c, reliance on agencies; nursing and midwifery staff = b, name of outsourced staff bank service provider and so on
2a) – where you have answered b) (an outsourced staff bank) to question no. 1a), please confirm whether – in line with the Public Contract Regulations 2015 – you have entered a contract with that service provider under either:
a) a locally procured contract; or
b) called-off from an NHS accessible framework agreement, such as Crown Commercial Services RM1072 Workforce management services or Healthtrust Europe Total workforce solutions framework; or
c) other
Where you have not entered a contract, please confirm accordingly.
2b) – where you have answered b) (called-off from an NHS accessible framework) to question no. 2a), please confirm the framework, for example, Crown Commercial Services RM1072 Workforce management services framework.
2c) – where you have answered c) (other) to question no. 2a), please elaborate.
2d) – where you have entered into a contract, for the most recent 12 month period, i.e financial year 2018/19, please confirm the contract’s :
a) overall annual value (£/pence excl. VAT). For example, £1 million excl. VAT.
Please note that this request is in relation to the provision of outsourced staff bank services only and should include any annual management fees, operational (transaction) costs, i.e.volume related hourly fees for the provision of bank workers and/or agency workers. Please do not include any other agency related spend.
b) overall annual value by staffing type (£/pence excl. VAT), for example, ‘qualified’ nursing and midwifery staff = £250,000 excl. VAT; ‘unregistered’ nursing and midwifery staff = £150,000 excl. VAT and so on.
Please note that this request is in relation to the provision of outsourced staff bank services only and should include operational (transaction) costs, i.e.volume related hourly fees for the provision of bank workers and/or agency workers. Please do not include any other agency related spend.
2e) – where you have entered into a contract, please confirm the contract’s:
a) commencement date;
b) expiry date of any initial term; and
c) expiry date of any applicable extension periods if taken.
For example, if the contract entered commenced on 1st April 2018 for an initial period of 2 years with an option to extend by up to 2 years, then I would be looking for your reply to be as follows:
a) 01/04/2018;
b) 31/03/2020;
c) 31/03/2022.
2f) – where your contract’s initial or extended term is due to expire in the next 12 months, i.e. during financial year 2019/20, please confirm whether your Trust intends to:
a) bring the outsourced managed staff bank service back in-house; or
b) establish another local procured contract, advertising the business opportunity in line Public Contract Regulations 2015; or
c) call-off again from an NHS accessible framework agreement, such as Crown Commercial Services or Healthtrust Europe.
2g) – where you have answered c) (call-off again from an NHS accessible framework) to question no. 2f), please confirm the framework the Trust is likely to use, for example, Healthtrust Europe Total workforce solutions framework. If not yet known, please confirm accordingly.
2h) – where you have answered c) (call-off from an NHS accessible framework) to question no. 2f), please confirm whether this outsourced staff bank contract shall be:
a) relevant to the Trust only; or
b) a collaborative contract including other trusts from across your and/or neighbouring STP’s footprint?
3 – for the most recent 12 month period, i.e. financial year 2018/19, please confirm the effectiveness of the Trust’s staff bank as follows:
a) monthly bank filled rate, broken down by staff type. For example, registered nursing and midwifery staff = 40%; and
b) monthly agency filled rate, broken down by staff type. For example, registered nursing and midwifery staff = 40%; and
c) monthly unfilled rate, broken down by staff type. For example, registered nursing and midwifery staff = 20%.
Where this monthly information is not readily available, please provide an annual average percentage rate instead.
4a) – please can you confirm either ‘Yes’ or ‘No’ whether:
i) there is a member, or members, of your Trust’s Board who is accountable for the effective management of temporary staffing and in turn the reduction of agency spend? making effective use of staff banks overseeing the use of temporary staff; and
ii) temporary staff usage is regularly discussed at Board meetings?
4b) – where you have answered yes to question 4a)i) (there is an accountable member, or members, of your Trust’s Board), can you please tell me whether the relevant persons concerned are either:
a) a non-executive; or
b) an employee of the Trust? If a Trust employee, please elaborate by confirming the role (not their name) of that person within the Trust.

Download response Use of Staff Banks. 020519

Utilisation of nursing recruitment agencies. 030518

Shifts filled a week via Nursing Recruitment Agencies
How many Nursing Recruitment Agencies you source from
For the following departments that you have within your Hospital:
Paediatrics
Oncology
NICU
Cath Labs
HDU
Interventional Radiology

Download response Utilisation of nursing recruitment agencies. 030518

Vacancies and agency cover. 010818

Q1: Bank cover:
How many FTE equivalent posts at your trust were covered by bank staff on Tuesday 3 April 2018 for each of the following groups:
1. All staff (including below groups)
2. Hospital & Community Health Service Doctors
3. Registered nurses
Q2: Agency cover:
How many FTE equivalent posts were covered by agency staff on Tuesday 3 April 2018 for each of the following groups:
1. All staff (including below groups)
2. Hospital & Community Health Service Doctors
3. Registered nurses

Download response Vacancies and agency cover. 010818

Weekly or monthly data collection to NHS Improvement. 210918

You asked:
From March 2017 until July 2018 inclusive:
1) Please disclose your weekly collection sheets of data sent to NHS Improvement relating to temporary staffing. The full sheet is sought but to aid you in locating the correct information these include number of vacancies, agency fill rate, number of workers on more than £120 per hour, and since October 2017, this also includes the same data for bank staff . Please disclose both the Agency and Bank information.
2) How is this information sent to NHS Improvement? If by email to which email address is it sent?
3) Do you use a Direct Engagement Company, if so please confirm the name of the company used, who handled the negotiation.
4) What is your Trust’s individual agency expenditure ceiling from NHS Improvement?
5) Does the trust have concerns that this ceiling is unachievable?

Download response Weekly or monthly data collection to NHS Improvement. 210918

Workforce spend and suppliers. 210918

You asked:
1. Please state the organisation’s total expenditure on agency (non-contract) staff for 17/18
2. Please state the organisation’s total expenditure on internal bank staff for 17/18
3. Does the organisation use a third party to provide a Direct Engagement/Outsourced Employment Solution to recover VAT?
4. Please name the technology provider used to manage the supply of your medical bank staff, inclusive of any outsources or managed arrangements (i.e. NHSP, Bank Partners, Allocate, Liaison, Brookson, and Locum’s Nest etc.)
5. Does the organisation utilise any temporary staffing apps (i.e. locums nest, locumtap, Rightstaff, Allocate etc.) If so, please state which apps are used split by the below staffing groups:

Download response Workforce spend and suppliers. 210918

 

Cancelled operations

Cancelled children’s operations – 01.07.16. 050517

1. How many children’s operations have been cancelled each month since 1st July 2016? Please give additional details as to what the main reasons for the cancellations were, how many were urgent operations or elective operations, and what type of illness did they involve, e.g. cancer, breathing problems, broken limbs etc.

2. How many children’s operations have been cancelled over the last four financial years to date?

Kindly note a child is anyone up to the age of 18.

Download response Cancelled children’s operations – 01.07.16. 050517

Cancelled elective admissions and outpatient attendances. 150118

1) In the months of October, November and December, how many elective admissions and outpatient attendances had to be cancelled due to non-clinical reasons?
2) How many of these were able to be rescheduled within 28 days (please give actual figure)?
3) And how many were not able to be rescheduled within 28 days?

Download response Cancelled elective admissions and outpatient attendances. 150118

Cancelled elective operations 2010-2016. 200417

1. Since 1st April 2010 what has been the maximum cost to the Trust of an elective operation being cancelled last-minute for non-clinical reasons? Please give additional detail as to what the operation was and how many members of staff were supposed to be working on the operation.
2. Please provide the total number of elective operations cancelled last-minute for non-clinical reasons for each quarter going back to 2010.
3. Please provide the total quarterly cost of elective operations being cancelled last-minute for non-clinical reasons for each quarter going back to 2010.

Download response Cancelled elective operations 2010-2016. 200417

Cancelled elective operations for December 2015 and January 2016.

I would like to ask for each day over the past two months how many elective operations have had to be cancelled and what reasons were given?

And for each of those days, how many elective operations had been originally planned?

Download response Cancelled elective operations for December 2015 and January 2016 190416

Cancelled operations. 011018

I would like to request the total number of operations cancelled for non-clinical reasons, broken down by the cause of the cancellation, for example due to lack of beds, operating theatre capacity, staffing issues, and equipment failures.

Please provide this information for each of the past five financial years (i.e. years running from April to March – 2013/14, 2014/15, 2015/16, 2016/17, 2017/18).

In the total number of operations, broken down by cancellation reason, please include:
1. Elective operations cancelled at the last minute. For the purposes of this request, last minute means on the day the patient was due to arrive, after the patient has arrived in hospital or on the day of the operation or surgery.
2. Cancelled urgent operations.
If the data is collected by the trust, please also provide a separate total for each year for all operations cancelled for non-clinical reasons, regardless of how soon before the scheduled operation time the cancellation occurred.

Download response Cancelled operations. 011018

Cancelled operations 2011 – 2016. 141216

1. Over the past five financial years (2011-12, 2012-13, 2013-14, 2014-15, 2015-16) please state the number of last minute elective surgery cancellations there have been for non-clinical reasons for the following branches of surgery: trauma and orthopaedics, neurology, cancer, and ophthalmology. Please break down by year and surgery type.
2. Over the past five financial years (2011-12, 2012-13, 2013-14, 2014-15, 2015-16) please state how many patients were not treated within 28 days of last minute elective cancellation of an operation for the following branches of surgery: trauma and orthopaedics, neurology, cancer, and ophthalmology. Please break down by year and surgery type.

Download response Cancelled operations 2011 – 2016. 141216

Cancelled operations 2012-2017. 200917

1. The number of elective operations carried out by the Trust in the following financial years:
2012/13
2013/14
2014/15
2015/16
2016/17

2. The number of elective operations cancelled at the last minute* due to non-clinical reasons, in the following financial years:
2012/13
2013/14
2014/15
2015/16
2016/17
NOTE: Please use NHS England’s standard definition of last minute cancellations, “Last minute means on the day the patient was due to arrive, after the patient has arrived in hospital or on the day of the operation or surgery.” See: https://www.england.nhs.uk/statistics/statistical-work-areas/cancelled-elective-operations/

3. The number of elective operations cancelled at the last minute due to non-clinical reasons per financial year (2012/13 to 2016/17 inclusive), split into the following categories:
– Staff unavailable or sick (either anaesthetist, surgeon, theatre staff or other)
– Lack of available bed (either general or HDU, critical, or intensive care)
– Theatre list over-ran or no space on it (e.g. due to emergency case(s) coming in)
– Equipment missing / failure
– Any other reason

Download response Cancelled operations 2012-2017. 200917

Cancelled operations 2013 to 2016.

1. In relation to (i) 2013/14, (ii) 2014/15 and (iii) 2015/16 financial year please provide me with the number of operations cancelled at your Trust on the day of operation or admission where the reason is recorded as there being no post-operative bed available for the patient.
2. For each year please state if possible how many of these cancellations were due to the fact that there was no critical care bed or intensive care bed available rather than the unavailability of a general ward bed?

Download response Cancelled operations 2013 to 2016 250716

Cancelled operations 2014 – April 2017. 050517

How many operations have been cancelled for non-clinical reasons IN THE 3 DAYS BEFORE a patient was due to be admitted?
Out of those cancellations, how many were rescheduled within 1 month?
How many operations have been cancelled for non-clinical reasons ON THE DAY a patient was due to be admitted?
Out of those cancellations, how many were rescheduled within the statutory time limit – e.g. 28 days?
Please provide this data by month for 2014, 2015, 2016 and 2017 – up to and including April 2017.
The following should be included in the figures for ‘operations’:
All planned or elective operations and day surgery
For ‘non-clinical reasons’ please include a break-down of the following:
· Bed-ward not available
· Staff unavailable
· Emergency operations taking priority
· Maintenance needed on equipment
· Patient unavailable
· Admin error

Download response Cancelled operations 2014 – April 2017. 050517

Cancelled operations and appointments. 210218

The National Emergency Preparedness Panel warned on 22 December that non-urgent operations should be cancelled, with a further update on 2 January advising that “day case and outpatient procedures” should also be put on hold to preserve emergency care.

Could the trust please provide the following details about cancellations for non-clinical reasons, and last minute (on the scheduled day of arrival at hospital or later) non-clinical cancellations.

Download response Cancelled operations and appointments. 210218

Cancelled operations for non-clinical reasons. 050919

The total number of operations cancelled for non-clinical reasons, broken down by the cause of the cancellation, for example due to lack of beds, operating theatre capacity, staffing issues, and equipment failures. Please provide this information for each of the past three financial years (2016/17, 2017/18, 2018/19). In the total number of operations, broken down by cancellation reason, please include:
• Elective operations cancelled at the last minute. For the purposes of this request, last minute means on the day the patient was due to arrive, after the patient has arrived in hospital or on the day of the operation or surgery.
• Cancelled urgent operations.

Download response Cancelled operations for non-clinical reasons. 050919

Cancelled operations for non-clinical reasons.2 050919

I would like to request the total number of operations cancelled for non-clinical reasons, broken down by the cause of the cancellation, for example due to lack of beds, operating theatre capacity, staffing issues, and equipment failures, in 2018/19 (financial year, April to March).

In the total number of operations, broken down by cancellation reason, please include:
• Elective operations cancelled at the last minute. For the purposes of this request, last minute means on the day the patient was due to arrive, after the patient has arrived in hospital or on the day of the operation or surgery.
• Cancelled urgent operations.
If the data is collected by the trust, please also provide a separate total for each year for all operations cancelled for non-clinical reasons, regardless of how soon before the scheduled operation time the cancellation occurred.

Download response Cancelled operations for non-clinical reasons.2 050919

Cancelled operations for non-clinical reasons 2013 to March 2016. 170516

How many operations have been cancelled for non-clinical reasons IN THE 3 DAY BEFORE a patient was due to be admitted?
Out of those cancellations, how many were rescheduled within 1 month?
How many operations have been cancelled for non-clinical reasons ON THE DAY a patient was due to be admitted?
Out of those cancellations, how many were rescheduled within the statutory time limit – e.g. 28 days?
Please provide this data by month for 2013, 2014, 2015 and 2016 – up to and including March 2016.
The following should be included in the figures for ‘operations’:
• All planned or elective operations and day surgery
For ‘non-clinical reasons’ please include a break-down of the following:
Bed-ward not available
Staff unavailable
Emergency operations taking priority
Maintenance needed on equipment
Patient unavailable
Admin error

Download response Cancelled operations for non-clinical reasons 2013 to March 2016. 170516

Cancelled planned operations. 210318

How many planned operations were cancelled in January 2018 due to winter pressures? If possible, please provide a specific reason for each case.

Download response Cancelled planned operations. 210318

Loss of income due to cancelled operations. 080119

Please could you provide me with your trust’s loss of income as a result of the cancelled elective or non-urgent surgeries this year? I understand that there are tariffs assigned for every procedure undertaken and that cancelling an operation results in the loss of that revenue.

I would like this data on a monthly basis from January 2018 to the last date for which the data is held.

If you have comparative data for Jan-Dec 2017 (on the monthly basis also), I would also like this. If there is any breakdown of this data (for example, tariffs lost, cost of surgeons not working and so on), could you provide that too?

Download response Loss of income due to cancelled operations. 080119

Missing medical records 2013-2016.100217

• Over the last four years how many medical records went missing? Can I have that data broken down by year?
• How many incidents was this? Can I have that data broken down by year?
• As a result of these lost records how many procedures were a) delayed/postponed b) cancelled. Can I have that data broken down by year?
• What procedures were a) delayed/postponed b) cancelled. Can I have that data broken down by year?
I would like all this data by calendar years please.

Download response Missing medical records 2013-2016.100217

Theatre cancellation 2015-2017. 070317

1. Total number of theatre cancellations at your Trust on the day of surgery by month, site and surgical specialty from the 1st January 2015 to 31st January 2017 (inclusive).

2. Total number of theatre cancellations at your Trust within three (<3) days of surgery by month, site, surgical specialty and cancellation reason from the 1st January 2015 to 31st January 2017 (inclusive).

3. Total number of theatre cancellations at your Trust whether on or before the day of surgery due to no ward beds or no HDU / ITU beds being available by month, site and surgical specialty from the 1st January 2015 to 31st January 2017 (inclusive).

4. Total number of operations actually performed at your Trust by month, site, admission type (elective or non-elective) and surgical specialty from the 1st January 2015 to 31st January 2017 (inclusive).

Download response Theatre cancellation 2015-2017. 070317

Unfilled vacancies and cancelled procedures and operations. 070219

1. Your current number of current unfilled vacancies/positions across all departments
2. How long each of those positions has been unfilled
3. Number of urgent operations and procedures cancelled per month for the past five years

Download response Unfilled vacancies and cancelled procedures and operations. 070219

Winter funding and postponed non-urgent surgery. 130220

1. In November 2019, Northampton General Hospital Trust announced it was postponing ‘some’ non-urgent inpatient surgery procedures until the end of March 2020 to free up capacity for emergency care.
1A. In November or December 2019, did your Trust also postpone non-urgent inpatient surgery procedures until March 2020 (or later)?
1B. How many procedures were postponed?
2. In November 2019, NHS sources reportedly said that extra funding was being offered this winter to Trusts. Trusts were asked to put forward suggestions and make the case to NHS England for this supplementary money.
2A. Did your Trust put forward a case to NHS England to receive extra funding for the winter period?
2B. What quantity of funding did you ask for?
2C. What purpose did you propose for the funding?
2D. What quantity of winter funding did you receive from NHS England?

Download response Winter funding and postponed non-urgent surgery. 130220

 

Cancer and Haematology & Radiology

Active surveillance for prostate cancer. 260717

Please outline details of the active surveillance protocol below (or attach the protocol document when replying to our request email):

Download response Active surveillance for prostate cancer. 260717

Advanced Breast Cancer. 221019

1a. Does your trust treat advanced breast cancer?
1b. If none, where are your patients referred?
2. In the past 3 months, how many advanced breast cancer patients [Stage IV] have the status of;
HR+ and HER2+ [Hormone receptor-positive and human epidermal growth factor 2-positive]
HR+ and HER2- [Hormone receptor-positive and human epidermal growth factor 2-negative]
HR- and HER2+ [Hormone receptor-negative and human epidermal growth factor 2-positive]
HR- and HER2- [Hormone receptor-negative and human epidermal growth factor 2-negative] – Triple negative disease
Not Known
3. In the past 3 months, how many breast cancer patients were treated with:
Abemaciclib (Verzenios) + aromatase inhibitor *
Abemaciclib (Verzenios) + Fulvestrant (Faslodex)
Alpelisib (Piqray) + Fulvestrant (Faslodex)
Atezolizumab (Tecentriq)**
Bevacizumab (Avastin)
Eribulin (Halaven)
Everolimus (Afinitor) + Exemestane
Fulvestrant (Faslodex) as a single agent
Gemcitabine + paclitaxel
Lapatinib (Tyverb)
Neratinib (Nerlynx)
Olaparib (Lynparza)
Palbociclib (Ibrance) + aromatase inhibitor*
Pertuzumab (Perjeta) + trastuzumab + docetaxel
Ribociclib (Kisqali) + aromatase inhibitor*
Ribociclib (Kisqali) + Fulvestrant (Faslodex)
Talazoparib (Talzenna)
Trastuzumab + paclitaxel
Trastuzumab as a single agent
Trastuzumab emtansine (Kadcyla)
Other active systemic anti-cancer therapy **
*aromatase inhibitor e.g. Anastrozole, Exemestane or Letrozole
**e.g. docetaxel, vinorelbine or capecitabine as a single agent

Download response Advanced Breast Cancer. 221019

Advanced Prostate Cancer 070317

1. Within your trust how many unique patients with Advanced Prostate Cancer have been treated in the past 12 months?

2. How many patients with Advanced Prostate Cancer have received:
Abiraterone (Zytiga)
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
Enzalutamide (Xtandi)
Radium-223 (Xofigo)
Bicalutamide (Casodex)

Download response Advanced Prostate Cancer 070317

Advanced prostate cancer June 2016 to May 2017. 090617

Within your trust how many unique patients with Advanced Prostate Cancer have been treated in the past 12 months?

How many patients with Advanced Prostate Cancer have received;
Abiraterone (Zytiga)
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
Enzalutamide (Xtandi)
Radium-223 (Xofigo)
Bicalutamide (Casodex)
Advanced prostate cancer is cancer that has spread outside the prostate to other parts of the body such as the bones

Download response Advanced prostate cancer June 2016 to May 2017. 090617

Average and longest waiting times for cancer treatment. 141217

Firstly, in days what is the a) average and b) longest a single patient has waited to receive a First Consultant Appointment following a GP Urgent Referral (two week target) in calendar year 2017 (Year to Date), 2016, 2015, 2010 and 2009.
Secondly, in days what is the a) average and b) longest a single patient has waited for a First Treatment for Cancer following a Decision to Treat (31 days target) in calendar year 2017 (Year to Date), 2016, 2015, 2010 and 2009.
Thirdly, in days what is the a) average and b) longest a single patient has waited for a First Treatment for Cancer following a GP Urgent Referral (62 days target) in calendar year 2017 (Year to Date), 2016, 2015, 2010 and 2009.

Download response Average and longest waiting times for cancer treatment. 141217

Bisphosphonates. 160818

1. Does your Trust routinely provide bisphosphonates to postmenopausal women with primary breast cancer to reduce the risk of their cancer spreading to other parts of the body?
2. If your Trust does routinely provide bisphosphonates to reduce the risk of primary breast cancer spreading to other parts of the body, but is not providing them for all postmenopausal women, how is eligibility defined? For example, women at increased risk of recurrence.
3. If your Trust does routinely provide bisphosphonates for postmenopausal women to reduce the risk of primary breast cancer spreading to other parts of the body, which bisphosphonates do you prescribe? For example, zoledronic acid, ibandronic acid, sodium clodronate.
4. If your Trust does not routinely provide bisphosphonates for postmenopausal women to reduce the risk of primary breast cancer spreading to other parts of the body, what are your reasons for not doing so?

Download response Bisphosphonates. 160818

Bone Metastases. 240919

1. Within your health trust how many metastatic breast cancer patients are currently [within the past 6 months] being treated, with any therapy, surgery or palliative care.
2. Within your health trust how many breast cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;
a. disodium pamidronate (Arcadia)
b. ibandronic acid or ibandronate (Bondronat)
c. sodium clodronate (Bonefos, Clasteon, Loron)
d. zoledronic acid or zoledronate (Zometa)
e. denosumab (Xgeva)
3. Within your health trust how many breast cancer patients are currently [within the past 6 months] being treated with adjuvant therapy with the following treatments;
a. disodium pamidronate (Aredia)
b. ibandronic acid or ibandronate (Bondronat)
c. sodium clodronate (Bonefos, Clasteon, Loron)
d. zoledronic acid or zoledronate (Zometa)
4. Within your health trust how many metastatic lung cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care.
5. Within your health trust how many lung cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;
a. disodium pamidronate (Aredia)
b. ibandronic acid or ibandronate (Bondronat)
c. sodium clodronate (Bonefos, Clasteon, Loron)
d. zoledronic acid or zoledronate (Zometa)
e. denosumab (Xgeva)
6. Within your health trust how many metastatic renal cell cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care.
7. Within your health trust how many renal cell carcinoma [RCC] patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;
a. disodium pamidronate (Aredia)
b. ibandronic acid or ibandronate (Bondronat)
c. sodium clodronate (Bonefos, Clasteon, Loron)
d. zoledronic acid or zoledronate (Zometa)
e. denosumab (Xgeva)

Download response Bone Metastases. 240919

Breast Biopsy. 280317

Under the Freedom of Information Act, please could you provide the following information for your Trust?
1. How many benign breast lesions has your Trust diagnosed per annum in the last three years?
2. How many benign breast lesions have been removed surgically per annum within your Trust in the last three years?
a. Of this total number, how many of these are classified as B2?
b. Of this total number, how many of these are classified as B3?
3. How many benign breast lesions have not been removed per annum in the last three years?
4. How many benign breast lesions have been removed by vacuum assisted excision (VEA) per annum in the last three years?
a. Of this total number, how many of these are classified as B2 (definition below)?
b. Of this total number, how many of these are classified as B3 (definition below)?
5. Is the Trust aware of NICE guidance promoting the use of VAE for removal of benign lesions?
6. Does the Trust have a referral pathway in place for vacuum assisted percutaneous excision of benign breast lesions?

With regards to this request, please note the following:

B3 Breast Lesion – Lesion of Uncertain Malignant Potential
Findings typical of this category include:
1. Clusters of tiny calcifications – round or oval
2. Non-calcified solid nodules (no size limitation but non palpable on physical examination), round, ovoid and well-defined.
3. Selected focal asymmetrical areas of fibroglandular densities (not palpable): This might include concave-outward defined margins, interspersed with fat and without central increased fibular density on two projections.
4. Miscellaneous focal findings, such as a dilated duct or post biopsy architectural distortion without central density
5. Generalized distribution in both breasts. For example, multiple similar lesions with tiny calcifications or nodules distributed randomly

B2 Breast Lesion – Benign Lesion
A definitive benign finding indicating something abnormal on a mammogram but not something that is breast cancer or malignant in any way. Findings often include:
1. Round opacities with macrocalcifications (typical calcified fibroadenoma or cyst)
2. Round opacities corresponding to a typical cyst at ultrasonography
3. Oval opacities with a radiolucent center
4. Fatty densities or partially fatty images (lipoma, galactocele, oil cyst, hamartoma )
5. Surgical scar
6. Scattered macrocalcifications (fibroadenoma, cyst, cytosteatonecrosis, secretory ductal ectasia);
7. Vascular calcifications
8. Breast implants, silicone granuloma

Download response Breast Biopsy. 280317

Breast cancer. 181019

1. Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust holds information on the number of people diagnosed in Maidstone and Tunbridge Wells NHS Trust with early breast cancer in each year from 2013 to 2018.
If confirm, please release this data.
2. Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust holds information on the number of people diagnosed in Maidstone and Tunbridge Wells NHS Trust with early breast cancer that were offered tumour profiling tests to guide adjuvant chemotherapy decisions, in each year from 2013 to 2018. If confirm, please release this data.
3. Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust holds information on the number of people diagnosed in Maidstone and Tunbridge Wells NHS Trust with early breast cancer that were tested with tumour profiling tests to guide adjuvant chemotherapy decisions, in each year from 2013 to 2018. If confirm, please release this data.
4. Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust holds information on the number of people diagnosed in Maidstone and Tunbridge Wells NHS Trust with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative and lymph node (LN)-negative (including micrometastatic disease) early breast cancer in each year from 2013 to 2018. If confirm, please release this data.
5. Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust holds information on the numbers of people diagnosed in Maidstone and Tunbridge Wells NHS Trust with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative and lymph node (LN)-negative (including micrometastatic disease) early breast cancer that were offered tumour profiling tests to guide adjuvant chemotherapy decisions in each year from 2013 to 2018. If confirm, please release this data.
6. Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust holds information on the number of people diagnosed in Maidstone and Tunbridge Wells NHS Trust with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative and lymph node (LN)-negative (including micrometastatic disease) early breast cancer that were tested with tumour profiling tests to guide adjuvant chemotherapy decisions in each year from 2013 to 2018. If confirm, please release this data.

Download response Breast cancer. 181019

Breast Cancer Services. 070417

Can you please tell me how many women were diagnosed and received treatment between the years 2014 – 2015 and 2015 – 2016. How many women in each year were treated by breast conserving surgery (lumpectomy) and how many by mastectomy. Of the women who underwent mastectomy how many received an immediate reconstruction.

Download response Breast Cancer Services. 070417

Breast Cancer Surgery. 051017

Do you have data showing the outcome of breast cancer surgery at your trust in relation to?

1. Survival rates for patients five years after surgery?
1a. Can you tell me what the figure is?
1b. Do you have results for individual surgeons?

2. Survival rates for patients ten years after surgery?
2a. Can you tell me what the figure is?
2b. Do you have results for individual surgeons?

Do you have data showing the outcome of breast cancer surgery at your trust in relation to:

3. Local Recurrence rates for patients five years after mastectomy and breast conserving surgery.
3a. Can you tell me what the figures are.
3b. Do you have figures for individual surgeons?

Download response Breast Cancer Surgery. 051017

Breast Cancer treatments.241219

1. Within your health trust how many patients are currently [within the past 3 months] being treated with the following for breast cancer?
Abemaciclib + aromatase inhibitor *
Abemaciclib + Fulvestrant
Alpelisib + Fulvestrant
Atezolizumab
Bevacizumab
Eribulin
Everolimus + Exemestane
Fulvestrant as a single agent
Gemcitabine + paclitaxel
Lapatinib
Neratinib
Olaparib
Palbociclib + aromatase inhibitor*
Pertuzumab + trastuzumab + docetaxel
Ribociclib + aromatase inhibitor*
Ribociclib + Fulvestrant
Talazoparib
Herceptin SC
Herceptin IV
Transtuzumab biosimilar SC
Transtuzumab biosimilar IV
Trastuzumab emtansine
Other active systemic anti-cancer therapy **
*aromatase inhibitor e.g. Anastrozole, Exemestane or Letrozole
**e.g. docetaxel, vinorelbine or capecitabine as a single agent

2. How many patients are being treated for
2a Neo-adjuvant breast cancer;
Transtuzumab total SC
Transtuzumab total IV
2.b Adjuvant breast cancer;
Transtuzumab total SC
Transtuzumab total IV

Download response Breast Cancer treatments.241219

Breast radiotherapy access. 170120

1. In November and December 2019 how many requests/bookings for radical radiotherapy to the breast or chestwall were received by the radiotherapy department?
2. For those patients requested/booked in November and December 2019, how many commenced treatment?
3. Of those who received treatment what was the average length of time between the request/booking being made and the patient receiving treatment?
4. What is your average length of time for all radical radiotherapy requests/bookings to starting treatment?

Download response Breast radiotherapy access. 170120

Breast Screening & Breast Clinics. 031219

Breast Screening – (Asymptomatic)
1. Does the trust have a dedicated breast screening service/unit (Asymptomatic mammograms) – This could be separate from the main x-ray department?
2. If so, what is the name of the service?
3. Is this run in a static unit or on breast screening vans (Or Both)? How many vans does the service run? How many static sites does the service run?
4. How many ladies are scanned/screened on average, per day on each van/static unit?
5. Does the service scan on a 5 day or 7 day week?
6. Who has the overall responsibility for the breast screening service?
7. Please provide an organisational chart for the team/department with overall responsibility for the breast screening service

Symptomatic Mammography & Breast Clinics
1. Which department has the responsibility for symptomatic mammograms / Symptomatic Breast Lists/Clinics? Does this come under the breast screening unit or the main radiography department of the trust?
2. How many ladies are assessed on average per day in the symptomatic breast clinic?
3. Does the service scan on a 5 day or 7 day week?
4. Who has the overall responsibility for the symptomatic breast clinics?
5. Please provide an organisational chart for the team/department with overall responsibility for the symptomatic breast clinics

Download response Breast Screening & Breast Clinics. 031219

C-Arm provision. 250220

Please can you answer the following questions regarding the Mobile C-arm medical imaging equipment used within the Trust?
Please can you provide the following information for each piece of Mobile C-arm medical imaging equipment? (Please complete the attached spreadsheet)
a. Manufacturer
b. Model
c. Type (Image Intensifier, Flat Panel Detector)
d. Generator Power
e. Location – Hospital Name
f. Location – Department
g. Method of Finance at Procurement
h. Initial cost of Equipment
i. Annual Maintenance cost
j. Acquisition Date
k. Planned Replacement Date

Download response C-Arm provision. 250220

Cancer care or treatment 2015-2016. 020317

1. In the years 2015 & 2016 of the patients that became resident for Cancer care/treatment with inside a hospital managed by your trust, please list the annual total for the patients as described?

2. Further to the above please also provide the annual total for those patients’ families who received a pass entitling free parking during the patients stay to reduce the financial burden on the family visiting?

Download response Cancer care or treatment 2015-2016. 020317

Cancer care or treatment 2015-2016. 020317

1. In the years 2015 & 2016 of the patients that became resident for Cancer care/treatment with inside a hospital managed by your trust, please list the annual total for the patients as described?

2. Further to the above please also provide the annual total for those patients’ families who received a pass entitling free parking during the patients stay to reduce the financial burden on the family visiting?

Download response Cancer care or treatment 2015-2016. 020317

Cancer operations – Annual cancellations. 310117

In the years 2015, 2016 & 2017 from January 1st until the current date could you please provide me with the total number per month of cancer operations cancelled by Hospitals under the umbrella of your Acute NHS Trust?

Download response Cancer operations – Annual cancellations. 310117

Cancer treatment. 040817

Please provide the following information:

-The number of patients who have received NHS-funded treatment for cancer (including surgery, radiotherapy and medicines) at your trust who have also received cancer treatment privately at your trust (including directly and through private patient units located on trust premises), providing an annual total for each of the last five financial years.

-Where cancer treatment was provided privately for patients at your trust in addition to NHS-funded cancer treatment, the total value of treatments received, providing an annual total for each of the last five financial years.

-Where cancer treatment was provided privately for patients at your trust in addition to NHS-funded cancer treatment, the five cancer treatments that were most commonly provided privately, providing an annual total for each of the last five financial years.

-Where cancer treatment was provided privately for patients at your trust in addition to NHS-funded cancer treatment, please include a breakdown of patient numbers and value of treatment by type of cancer.

-The number of patients who have received NHS-funded treatment for cancer (including surgery, radiotherapy and medicines) at your trust who have also received cancer treatment from any private provider, providing an annual total for each of the last five financial years.

Download response Cancer treatment. 040817

Cancer treatment. 081117

Please provide the following information:

-The number of patients who have received NHS-funded treatment for cancer (including surgery, radiotherapy and medicines) at your trust who have also received cancer treatment privately at your trust (including directly and through private patient units located on trust premises), providing an annual total for each of the last five financial years.

-Where cancer treatment was provided privately for patients at your trust in addition to NHS-funded cancer treatment, the total value of treatments received, providing an annual total for each of the last five financial years.

-Where cancer treatment was provided privately for patients at your trust in addition to NHS-funded cancer treatment, the five cancer treatments that were most commonly provided privately, providing an annual total for each of the last five financial years.

-Where cancer treatment was provided privately for patients at your trust in addition to NHS-funded cancer treatment, please include a breakdown of patient numbers and value of treatment by type of cancer.

-The number of patients who have received NHS-funded treatment for cancer (including surgery, radiotherapy and medicines) at your trust who have also received cancer treatment from any private provider, providing an annual total for each of the last five financial years.

Download response Cancer treatment. 081117

Cancer treatment. 181019

1 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Non-small cell Lung Cancer (NSCLC) with the following
Paclitaxel
Gemcitabine
Osimertinib
Carboplatin and Pemetrexed
Cisplatin and Pemetrexed
Pembrolizumab monotherapy
Pembrolizumab in combination
Atezolizumab
Nivolumab
Other active systemic anti-cancer therapy
2a – Does your Health Trust participate in any ongoing clinical trails for the treatment of Metastatic Non Small Cell Lung cancer patients ?
2b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?
3 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Colorectal Cancer (CRC) with the following:
Cetuximab not in combination with FOLFIRIE or FOLOX
Cetuximab in combination with FOLFIRI
Cetuximab in combination with FOLFOX
Panitumumab not in combination with FOLFIRI or FOLFOX
Panitumumab in combination with FOLFIRI
Panitumumab in combination with FOLFOX
Nivolumab
Aflibercept
Bevacizumab
Ramucirumab
Regorafenib
Sorafenib
Other active systemic anti-cancer therapy (eg 5FU, CAPIRI, CAPOX, FOLFIRI, FOLFOX, Oxaliplatin, Irinotecan, Tegafur or Uracil + 5FU)
3a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Colorectal cancer patients ?
3b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?
4 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Head and Neck Cancer (Squamous Cell Carcinoma) ?
4a – If your Trust is able to split these patients, how many are locally advanced and how many are recurrent and or metastatic Head and Neck Cancer patients ?
Locally advanced
Recurrent metastatic
Unable to split
4b – Of the Head and Neck cancer patients please split by their current drug treatment (if you are unable to split by locally advanced and recurrent please state the total)
Carboplatin (only or in combination with 5-FU)
Cisplatin (only or in combination with 5-FU)
Cetuximab with / without chemotherapy
Cetuximab with radiotherapy
Pembrolizumab monotherapy
Pembrolizumab with chemotherapy
Nivolumab
Docetaxel (only or in combination with 5-FU)
Fluorouracil (5-FU)
Radiotherapy only
Other
4c – Does your Health Trust participate in any ongoing clinical trials for the treatment of Head and Neck cancer patients ?
4d – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?
5 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Urothelial Carcinoma UCC) with the following:
Cisplatin single agent
Cisplatin in combination with another agent
Carboplatin single agent
Carboplatin in combination with another agent
Nivolumab
Pembrolizumab
Atezolizumab
Other active systemic anti-cancer therapy
5a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Metastatic Urothelial Carcinoma patients ?
5b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?

Download response Cancer treatment. 181019

Cancer treatment. 181019

1 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Non-small cell Lung Cancer (NSCLC) with the following
Paclitaxel
Gemcitabine
Osimertinib
Carboplatin and Pemetrexed
Cisplatin and Pemetrexed
Pembrolizumab monotherapy
Pembrolizumab in combination
Atezolizumab
Nivolumab
Other active systemic anti-cancer therapy
2a – Does your Health Trust participate in any ongoing clinical trails for the treatment of Metastatic Non Small Cell Lung cancer patients ?
2b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?
3 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Colorectal Cancer (CRC) with the following:
Cetuximab not in combination with FOLFIRIE or FOLOX
Cetuximab in combination with FOLFIRI
Cetuximab in combination with FOLFOX
Panitumumab not in combination with FOLFIRI or FOLFOX
Panitumumab in combination with FOLFIRI
Panitumumab in combination with FOLFOX
Nivolumab
Aflibercept
Bevacizumab
Ramucirumab
Regorafenib
Sorafenib
Other active systemic anti-cancer therapy (e.g. 5FU, CAPIRI, CAPOX, FOLFIRI, FOLFOX, Oxaliplatin, Irinotecan, Tegafur or Uracil + 5FU)
3a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Colorectal cancer patients ?
3b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?
4 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Head and Neck Cancer (Squamous Cell Carcinoma) ?
4a – If your Trust is able to split these patients, how many are locally advanced and how many are recurrent and or metastatic Head and Neck Cancer patients ?
Locally advanced
Recurrent metastatic
Unable to split
4b – Of the Head and Neck cancer patients please split by their current drug treatment (if you are unable to split by locally advanced and recurrent please state the total)
Carboplatin (only or in combination with 5-FU)
Cisplatin (only or in combination with 5-FU)
Cetuximab with / without chemotherapy
Cetuximab with radiotherapy
Pembrolizumab monotherapy
Pembrolizumab with chemotherapy
Nivolumab
Docetaxel (only or in combination with 5-FU)
Fluorouracil (5-FU)
Radiotherapy only
Other
4c – Does your Health Trust participate in any ongoing clinical trials for the treatment of Head and Neck cancer patients ?
4d – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?
5 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Urothelial Carcinoma UCC) with the following:
Cisplatin single agent
Cisplatin in combination with another agent
Carboplatin single agent
Carboplatin in combination with another agent
Nivolumab
Pembrolizumab
Atezolizumab
Other active systemic anti-cancer therapy
5a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Metastatic Urothelial Carcinoma patients ?
5b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?

Download response Cancer treatment. 181019

Cancer treatment 2010 – 2016. 250917

How many patients were treated for cancer by your trust each year since 2010?

How many of these patients in each year were ‘self-funders’ or paid the trust for their treatment, either personally or through an insurer and other third party?

What was the total amount of money raised in this way for each year?

How many patients for each year were ordinary NHS patients, ie patients whose care was free at the point of delivery?

How many designated cancer wards does your trust have for each year since 2010?

How many wards, if any, were for ‘self-funders’ and how many were for ordinary NHS patients for each year since 2010?

Download response Cancer treatment 2010 – 2016. 250917

Cancer treatment. 291118

You asked:
1. In the past 3 months, how many mNSCLC patients were treated with?
Afatinib
Atezolizumab
Becacizumab
Ceritinib
Crizotinib
Erlotinib
Gefitinib
Nitendaninb
Nivolumab
Pembrolizumab
Pemetrexed
Ramucirumab
Metastatic hepatocellular carcinoma
2. In the past three months, how many patients were treated with?
Bevacizumab
Cisplatin
Doxorubicin
Everolimus
Lapatinib
Levantinib
Regorafenib
Sorafenib
Sunitinib
TACE
Other active systemic anti-cancer therapy
Metastatic Thyroid Cancer
3. In the past three months, how many patients were treated with?
Axitinib
Cabozantinib
Levantinib
Pazopanib
Sorafenib
Sunitinib
Vandetanib
Others

Download response Cancer treatment. 291118

Cancer Treatments. 040320

1a – How many melanoma patients undergoing treatment are BRAF+?
1b – In the past 3 months, how many melanoma patients were treated with the following:
Bevacizumab
Cobimetinib
Dabrafenib
Dabrafenib AND trametinib
Dacarbazine
Encorafenib AND binimetinib
Ipilimumab
Ipilimumab AND Nivolumab
Nivolumab
Pembrolizumab
Trametinib
Vemurafenib
Vemurafenib AND Cobimetinib
Other active systemic anti-cancer therapy
Palliative care
1c – In the past 3 months how many patients were seen who had stage III resectable melanoma
1d – Of all stage III patients seen, how many received a complete resection?
2 – In the past 3 months, how many Squamous Cell Non-small cell lung cancer (SqNSCLC) patients were treated with:
Afatinib
Atezolizumab monotherapy
Bevacizumab
Docetaxel monotherapy
Durvalumab
Erlotinib
Gemcitabine
Necitumumab
Nivolumab
Paclitaxel
Pembrolizumab monotherapy
Pembrolizumab chemo in combination
Pemetrexed
Ramucirumab
Vinorelbine and cisplatin / carboplatin
Other active systemic anti-cancer therapy [please state]
Palliative care only
3 – In the past 3 months, how many Non Squamous Cell Non-small cell lung cancer (Non SqNSCLC) patients were treated with:
Afatinib
Alectinib
Atezolizumab mono
Atezolizumab + bevacizumab + carboplatin + paclitaxel
Bevacizumab
Brigatinib
Ceritinib
Crizotinib
Dacomitinib
Docetaxel monotherapy
Erlotinib
Gefitinib
Nintedanib with docetaxel
Nivolumab
Osimertinib
Paclitaxel
Pembrolizumab monotherapy
Pembrolizumab chemo in combination
Pemetrexed with carboplatin
Pemetrexed with cisplatin
Ramucirumab
Other active systemic anti-cancer therapy [please state]
Palliative care only

Download response Cancer Treatments. 040320

Cancer treatments. 220120

1. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma)?
2. Of these patients how many are locally advanced and how many are recurrent and/or metastatic head and neck cancer patients?
Locally advanced
Recurrent metastatic
Unknown
3. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma) with the following agents?
Carboplatin (only or in combination with 5-FU)
Cisplatin (only or in combination with 5-FU)
Cetuximab with/without chemotherapy
Cetuximab with radiotherapy
Pembrolizumab monotherapy
Pembrolizumab with chemotherapy
Nivolumab
Docetaxel (only or in combination with 5-FU)
Fluorouracil (5FU)
Radiotherapy only
Other
Does your health trust participate in any ongoing clinical trials for the treatment of head and neck cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?
4. Within your health trust how many patients have been treated in the past 6 months with the following agent for colorectal cancer [CRC];
Aflibercept
Bevacizumab
Capecitabine
CAPIRI
CAPOX
Cetuximab not in combination with FOLFIRI or FOLFOX
Cetuximab in combination with FOLFIRI
Cetuximab in combination with FOLFOX
Irinotecan
FOLFIRI
FOLFOX
Oxaliplatin
Panitumumab not in combination with FOLFIRI or FOLFOX
Panitumumab in combination with FOLFIRI
Panitumumab in combination with FOLFOX
Nivolumab
Raltitrexed
Ramucirumab
Regorafenib
Sorafenib
5FU only
Tegafur Uracil + 5FU
Trifluridine–tipiracil
XELOX
Other
5. Within your health trust how many patients have been treated in the past 6 months with the following agent for Renal Cell Carcinoma :
Sunitinib
Avelumab + Axitinib
Axinitib
Cabozantinib
Everolimus
Lenvantinib + Everolimus
Nivolumab
Nivolumab + Ipilimumab
Pazopanib
Pembrolizumab + Axitinib
Sunitinib
Temsirolimus
Tivozanib
6. Does your health trust participate in any ongoing clinical trials for the treatment of renal cell cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?

Download response Cancer treatments. 220120

Cancer treatments. 241019

1 – Within your Health Trust how many patients are currently (within the past 3 months) being treated with the following treatments for Kidney Carcinoma (Renal Cell – RCC);
If you do not treat, where do you refer these patients?
2 – Within your Health Trust how many patients are currently (within the past 3 months) being treated with the following treatments for Melanoma?
If you do not treat, where do you refer these patients?
2a – In the past 3 months, how many Melanoma patients were BRAF+?
3 – Within your Health Trust how many patients are currently (within the past 3 months) being treated with the following treatments for Liver Cancer (Hepatic Cell – HCC);
If you do not treat, where do you refer these patients?
4 – Within your Health Trust how many patients are currently (within the past 3 months) being treated with the following treatments for Thyroid Cancer;
If you do not treat, where do you refer these patients?

Download response Cancer treatments. 241019

Cancers. 050718

1. How many individuals diagnosed in the last 5 years with prostate cancer?
2. How many deaths attributable to prostate cancer in the last 5 years?
3. How many individuals diagnosed in the last 5 years with breast cancer?
4. How many deaths attributable to breast cancer in the last 5 years?
5. How many individuals diagnosed with brain cancer in the last 5 years?
6. Of those diagnosed with brain cancer how many with GBM4?
7. How many deaths attributable to brain cancer in the last 5 years?
8. Of those deaths how many due to GBM4?
9. How many children diagnosed with brain cancer in the last 5 years?
10. How many child deaths attributable to brain cancer in the last 5 years?
Download response Cancers. 050718

Carcinoma and melanoma

1. The number of patients with NON SMALL CELL LUNG CARCINOMA (Stage IIIB/Stage IV) treated in the last 6 months with the following:
Afatinib (Giotrif)
Ceritinib (Zykadia)
Crizotinib (Xalkori)
Erlotinib (Tarceva)
Gefitinib (Iressa)
Pemetrexed (Alimta)
Nivolumab (Opdivo)
Nintedanib (Vargatef)

2. The number of patients with METASTATIC MELANOMA Stage IV (advanced or metastatic), treated in the last 6 months with the following:
Ipilimumab (Yervoy)
Nivolumab (Opdivo)
Ipilimumab AND Nivolumab
Pembrolizumab (Keytruda)
Vemurafenib (Zelboraf)
Vemurafenib AND Cobimetinib
Dabrafenib (Taflinar)
Trametinib (Mekinist)
Dabrafenib AND trametinib
Dacarbazine (DTIC)
For the period 1/1/2016-30/06/2016

Download response Carcinoma and melanoma 230916

Chronic Myeloid Leukaemia (CML) 2015.

1. In your organisation, how many patients diagnosed with Chronic Myeloid Leukaemia (CML) have been treated in calendar year 2015?

2. Of these patients, how many are currently being treated with each of the following tyrosine kinase inhibitors (TKIs)?
· Dasatinib (Sprycel)
· Imatinib (Glivec)
· Nilotinib (Tasigna)
· Ponatinib (Iclusig)
· Bosutinib (Bosulif)

3. If possible, of these patients on a TKI, how many have had treatment with a previous TKI?

4. In your organisation, how many patients diagnosed with Philadelphia positive (Ph+) Acute Lymphoblastic Leukaemia (ALL) have been treated in calendar year 2015?

5. Of these patients how many are currently being treated with each of the following TKIs?
· Dasatinib (Sprycel)
· Imatinib (Glivec)
· Nilotinib (Tasigna)
· Ponatinib (Iclusig)
· Bosutinib (Bosulif)
· Other (i.e. not on a TKI)

Download response Chronic Myeloid Leukaemia (CML) 2015 190416

Coronary CT angiography scans. 270918

1) How many Coronary CT angiography scans were performed in the trust in the financial year 2011-12?
2) How many Coronary CT angiography scans were performed in the trust in the financial year 2012-13?
3) How many Coronary CT angiography scans were performed in the trust in the financial year 2013-14?
4) How many Coronary CT angiography scans were performed in the trust in the financial year 2014-15?
5) How many Coronary CT angiography scans were performed in the trust in the financial year 2015-16?

Download response Coronary CT angiography scans. 270918

Cutaneous Squamous Cell Carcinoma. 270220

1. How many patients with cutaneous squamous cell carcinoma have you treated?
2. How many adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma have you treated?
3. Of these how many are not candidates for curative surgery or curative radiation?
4. In the past 3 months, how many adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation have you treated with the following;
Libtayo (cemiplimab)
Non curative surgery only
Non curative surgery + chemotherapy*
Non curative surgery + radiotherapy
Non curative surgery + chemotherapy* + radiotherapy
Chemotherapy* only
Chemotherapy* + radiotherapy
Non curative radiotherapy only
No treatment
Palliative Care / Best Supportive care
Other [please state]
*chemotherapy such as cisplatin, doxorubicin, 5-fluorouracil (5-FU), capecitabine, topotecan, or etoposide
5. Does your trust treat adult multiple myeloma [MM]? – if you refer your multiple myeloma patients to another centre, please state which.
6. If yes, then how many multiple myeloma patients, have been treated in the past 6 months with the following;
Bortezomib [Velcade]
Carfilzomib [Kyprolis]
Ixazomib [Ninlaro]
Lenalidomide [Revlimid]
Daratumumab [Darzalex]
Melphalan, prednisolone and thalidomide (known as MPT)
Cyclophosphamide, thalidomide and dexamethasone (known as CTD)
Pomalidomide [Imnovid]
7. Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?
If possible how many CLL patients treated were new to therapy in the past 3 months?
8 How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following;
Fludarabine (Fludara), cyclophosphamide (Cytoxan), and rituximab (known as FCR)
Bendamustine and rituximab (known as BR)
Ibrutinib [Imbruvica]
Chlorambucil
Venetoclax
Obinutuzumab
Idelalisib
Fludarabine and rituximab (known as FR)
High-dose prednisone and rituximab
Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR)
Alemtuzumab (Campath) with rituximab

Download response Cutaneous Squamous Cell Carcinoma. 270220

Cutaneous Squamous Cell Carcinoma. 271119

Question 1 – How many adult patients with Cutaneous Squamous Cell Carcinoma have you seen / treated (example Surgery, Radiotherapy, Chemotherapy or combinations of these) in the last 6 months?
Question 2 – How many adult patients with locally advanced (patients with Perineural invasion and local Lymphovascular or Bone involvement) or Metastatic Cutaneous Squamous Cell Carcinoma (patients with both local and distant Nodal involvement, as well as any other organ involvement) have you seen / treated (example Surgery, Radiotherapy, Chemotherapy or combinations of these) in the last 6 months?
Question 3 – Of these how many are not candidates for Curative surgery or Curative Radiation? *
Question 4 – In the past 6 months, how many adult patients with locally advanced or metastatic Cutaneous Squamous Cell Carcinoma have you treated with the following:
Question 5 – Are you participating in any clinical trials for Cutaneous Squamous Cell Carcinoma (CSCC)?
If yes, please state which?
*Example of factors to consider when deciding if locally advanced patients are suitable candidates for surgery: Disease recurrence after two or more surgical procedures and the treating clinicians expected that curative resection would be unlikely
CSCC in a anatomically challenging location where surgery would result in substantial complications or deformity or dysfunction significant local invasion that precludes complete resection
* Example of factors to consider when deciding if locally advanced patients are suitable candidates for radiation:
CSCC in a anatomically challenging location where radiation would be associated with unacceptable toxicity risk in context of the patients overall condition
Clinical judgement that tumour might not respond to RT
Factors / conditions contradicting for RT
Prior treatment with RT for CSCC, and further RT would exceed the threshold of acceptable cumulative does
** Chemotherapy such as Cisplatin, Doxorubicin, 5-Fluorouracil (5-FU), Capecitabine, Topotecan, Methotrexate or Etoposide

Download response Cutaneous Squamous Cell Carcinoma. 271119

Da vinchi surgical robots. 100419

1. The number of da Vinci surgical robots in use throughout your trust and the number of each model (e.g. Si, X, Xi, SP)
2. The number of yearly procedures carried out using da Vinci systems with a breakdown by procedure type for the last 5 years
3. A breakdown of the cost per procedure using da Vinci systems including instrumentation, servicing, disposable accessories, sterilisation costs, depreciation and other costs incurred
4. The upfront cost of da Vinci system instruments per surgery or on a per instrument basis
5. Historical number/rate of occurrence of incidences where cross infection has resulted from improper sterilisation and the number of associated adverse events
6. The rate of surgical site infections associated with procedures where a da Vinci system has been used.

Download response Da vinchi surgical robots. 100419

Dental X-Ray equipment. 210519

Please can you answer the following questions regarding the Dental X-Ray equipment used within the Trust?
1. Please can you provide the following information for each piece of Dental X-Ray equipment within the Trust or associated sites? (Please complete the attached spreadsheet)
a. Manufacturer
b. Model
c. Location – Hospital Name or Site Name
d. Department equipment is primarily used in
e. Method of Finance at Procurement (Trust/Lease/MES/Charity/PFI)
f. Initial cost of Equipment
g. Annual Maintenance cost
h. Acquisition Date
i. Planned Replacement Date

2. Please can you provide the following information for each Cone Beam CT Imaging equipment within the Trust or associated sites? (Please complete the attached spreadsheet)
a. Manufacturer
b. Model
c. Location – Hospital Name or Site Name
d. Department equipment is primarily used in
e. Method of Finance at Procurement (Trust/Lease/MES/Charity/PFI)
f. Initial cost of Equipment
g. Annual Maintenance cost
h. Acquisition Date
i. Planned Replacement Date

Download response Dental X-Ray equipment. 210519

Diagnostic data on an MRI technique for men with suspected prostate cancer.270318

1. Please tell us which Trust, Health Board or Health and Social Care Trust you are responding on behalf of?
2. What percentage of men receive mpMRI before biopsy as part of the initial diagnostic process using T2-weighted, diffusion-weighted (multi-b ADC and high/long b) and dynamic contrast enhanced (DCE) sequences?
3. What are your eligibility criteria/exclusion criteria for men to receive pre-biopsy mpMRI?
4. Are you using mpMRI before biopsy to rule some men out of biopsy as part of the initial diagnostic process?
5. What mpMRI scores and/or other clinical factors are used to rule men out of biopsy?
6. Do you intend to use mpMRI to rule men out of biopsy in the future?
7. How many men annually are referred?
8. If you are unable to provide numbers for question 6, please estimate the percentage of all men referred for b, c and d.
9. Do you carry out targeted biopsies in men with mpMRI lesions in addition to systematic biopsies?
(Please indicate with a X below)
If No, what are the reasons for not carrying this out? (e.g. expertise, equipment, don’t believe it makes a difference)
10. If you do not currently carry out targeted biopsies, but wish to in the future, what are the current barriers to doing so?
(Please indicate with a X below)
11. Please indicate the number of uroradiologists undertaking prostate MRI
12. How many scanners do you have available for mpMRI before biopsy?
Has this increased in the last 12 months?
13. What percentage of scanner time is dedicated to mpMRI before biopsy?

Download response Diagnostic data on an MRI technique for men with suspected prostate cancer.270318

Elastomeric Infusion Devices (E.I.D) 020320

Information request in respect to Elastomeric Infusion Devices

Please could you kindly advise which departments and healthcare professionals within your Trust use elastomeric infusion devices?

Information request in respect of Elastomeric Infusion Devices

1. Please could you also advise if you purchase E.I.D and if so:
a. What brand(s) do you purchase?
b. What quantities do you purchase on an annual basis?
c. Who are the main clinicians responsible within your Trust for the prescribing and administration of elastomeric devices?
d. What medicines do you fill the devices with?
e. Do you fill elastomeric devices in your pharmacy aseptic unit if you have one?
2. Please could you also advise if you purchase pre-filled elastomeric devices from a commercial compounder and if so:
a. What drugs are provided pre-filled?
b. What quantities do you purchase on an annual basis?

Download response Elastomeric Infusion Devices (E.I.D) 020320

EMB Biopsy 060317

Do any hospitals in the trust perform Endomyocardial Biopsy?
– Yes
– No
a) If so how many were performed in 2014-15 financial year?
b) How many were performed for investigation of Myocarditis?
2) How many patients in 2014-15 were diagnosed with Myocarditis in the trust?
3) Does the Trust refer patients to other centres or trusts for Endomyocardial Biopsy?
4) If so which centres or trusts do you refer to?
5) Does your trust receive referrals from other centres or trusts for Endomyocardial biopsy?

Download response EMB Biopsy 060317

Extravasation Incidents. 310118

Name of person completing request:
Hospital Trust/Health Board:
Telephone No:
E-mail Address:
1. Does your organisation provide a chemotherapy service – this may include inpatient, outpatient or a community service? 0 Yes 0 No
2. In the past financial year, how many doses of chemotherapy did you deliver? (April 2016 – March 2017)
3. In the past financial year, how many doses of anthracyclines did you administer? (April 2016 – March 2017)
4. In the past financial year, how many anthracycline extravasations have been reported due to chemotherapy? (April 2016 – March 2017)
5. In the past 3 financial years, how many patients have submitted a claim for medical negligence and/or damages against the Trust/Health Board due to an anthracycline extravasation injury?
6. In the past 3 financial years, how much compensation has the Trust/Health Board had to pay to those claimants who have suffered an anthracycline extravasation injury and have been successful in their medical negligence and/or damages case?
7. Does your Trust/Health Board have in place guidelines as to how to recognise and manage an extravasation injury? If not, is this available via your Cancer Alliance/Network or another source? If other, please state source ………………………………………………….
Trust/Health Board Guidelines 0 Yes 0 No If yes, when were they last updated?…………………………………………
8. Does your Trust/Health Board stock or have readily available any of the following extravasation treatments for chemotherapy?
a. Sodium Thiosulfate 0 Yes 0 No If yes, how often used in the past financial year? (April 2016 – March 2017)……………………
b. Hyaluronidase 0 Yes 0 No If yes, how often used in the past financial year? (April 2016 – March 2017)……………………
c. DMSO 0 Yes 0 No If yes, how often used in the past financial year? (April 2016 – March 2017)……………………
d. Dexrazoxane (Savene) 0 Yes 0 No If yes, how often used in the past financial year? (April 2016 – March 2017)……………………
9. In the past 3 financial years, how many annual reconstruction operations have been carried out by the Trust/Health Board due to an extravasation injury?
10. Does your Trust/Health Board’s plastics and/or nursing team have the expertise/core competency to undertake the wash-out/flush-out technique if an extravasation occurs?
0 Yes 0 No
11. If you answered yes to question 10, in the past 3 financial years, how many wash-out/flush-out procedures have been carried out by the Trust/Health Board due to an extravasation incident?

Download response Extravasation Incidents. 310118

General Anaesthetics. 180319

1. How many general anaesthetics were administered by your NHS Trust in 2018, 2017, 2016 and 2015?
2. How many patients died as a result of general anaesthesia in 2018, 2017, 2016 and 2015?
3. How many patients were given a general anaesthetic for the purpose of carrying out a diagnostic scan/test (MRI, CT etc.) in 2018, 2017, 2016 and 2015?
4. How many patients died as a result of being given a general anaesthetic for the purpose of carrying out a diagnostic scan/test (MRI, CT etc.) in 2018, 2017, 2016 and 2015?
5. How many patients were given a general anaesthetic for the purpose of carrying out an MRI scan in 2018, 2017, 2016 and 2015?
6. How many patients died as a result of being given a general anaesthetic for the purpose of carrying out an MRI scan in 2018, 2017, 2016 and 2015?
7. How many patients were given any other form of sedation for the purpose of carrying out a diagnostic scan/test (MRI, CT etc.) in 2018, 2017, 2016 and 2015?
8. How many patients were given any other form of sedation for the purpose of carrying out an MRI scan in 2018, 2017, 2016 and 2015?
9. How many diagnostic scans/tests (MRI, CT etc.) were aborted at your NHS Trust in 2018, 2017, 2016 and 2015 as a result of patients failing to attend the appointment or the process being stopped mid-way.
10. How many MRI scans were aborted at your NHS Trust in 2018, 2017, 2016 and 2015 as a result of patients failing to attend the appointment or the process being stopped mid-way.

Download response General Anaesthetics. 180319

Genesiscare. 270919

1. Please can you tell me if the Trust sends NHS Patients to GenesisCare for Cancer treatment?
2. Does the Trust send private patients to GenesisCare for cancer treatment?
3. How many Maidstone & Tunbridge Wells NHS Trust patients were treated by GenesisCare in 2018 and 2019? Please break the numbers down into NHS and private.
4. How long is the Trusts contract with GenesisCare?

Download response Genesiscare. 270919

Gonadorelin (GnRH) Analogues.

1 Within your organisation, which healthcare professional (role) clinically recommends the LHRH that is prescribed?
2 Which healthcare professional (role) within your organisation usually administers the first injection?
3 Where is the first injection usually given (hospital or primary care)?
4 Which healthcare professional (role) within your organisation usually administers subsequent injections?
5 Where are subsequent injections usually given (hospital or primary care)?
6 For subsequent injections, does the patient still remain under the care of the hospital (e.g. attends hospital clinics although injections are given in primary care), and if so, for how long?
7 If injections are administered in primary care, what recommendation/advice comes from the hospital?

Download response Gonadorelin (GnRH) Analogues 300316

Haemonetics. 311019

1. Please can you tell me how many of the following two devices – MCS+ 9000 Mobile Platelet Collection System and/or MCS+ 8150 Multicomponent Collection System both from a company called Haemonetics – the trust has used over the last 10 years and how many of these devices are currently in operation.

2. Please provide a figure for each device and each year over the last 10 years. If possible, please also state how many patients have had this device used on them.

Download response Haemonetics. 311019

Haemonetics plasma device. 220120

Please can you tell me how many deaths have been reviewed by the trust or reported to a coroner in the past 10 calendar years where the hospital used a Haemonetics plasma device (any model number) on the patient before they died.

Where the death was investigated please can you send me the report (redacted to remove personal details if necessary) and include the age, gender and diagnosis of the patient. If the death was reported to the coroner please include a copy of their report.

Download response Haemonetics plasma device. 220120

Head and Neck Cancer

Within your health trust how many patients are currently [within the past 6 months] being treated for head and neck cancer (Squamous cell carcinoma)?
April to September 2015 – 26 patients
Of these how many are treated with the following therapies;
Carboplatin
Cetuximab
Cisplatin
Docetaxel
5-Fluorouracil (5FU)
Radiotherapy Only
Please see the table below:
If your health trust has a protocol or pathway for the treatment of head and neck cancer patients [including referral pathway to other trusts], please could you provide details?
Please see the attached document.
Within your health trust how many patients are currently [within the past 6 months] being treated for Colorectal Cancer?
April to September 2015 – 136 patients
Of these how many are treated with the following therapies;
Bevacizumab
Cetuximab
Panitumumab
Aflibercept
Oxaliplatin
Irinotecan
5-Fluorouracil
Irinotecan with 5-fluorouracil (5FU) and folinic acid [FOLFIRI]
Oxaliplatin with 5-fluorouracil (5FU) and folinic acid [FOLFOX]
Capecitabine and oxalipatin (CAPOX / XELOX)
Capecitabine and irinitecan (CAPIRI)

Download response letter Head and Neck Cancer 201115

Head and Neck Cancer (Squamous cell carcinoma).

1. Within your health trust how many patients are currently [within the past 6 months] being treated for head and neck cancer (Squamous cell carcinoma)?
2. Of these patients how many are locally advanced and how many are recurrent and/or metastatic head and neck cancer patients?
A. Locally advanced
B. Recurrent and/or metastatic
Of the these patients please split by their current drug treatment;
Carboplatin (Only or in combination with 5-FU)
Cetuximab (Erbitux) and chemotherapy or radiotherapy
Cetuximab (Erbitux) Only
Cisplatin (Only or in combination with 5-FU)
Docetaxel (Taxotere), (Only or in combination with 5-FU)
Fluorouracil (5FU)
Radiotherapy Only
Other – Specify
3. Does your health trust participate in any ongoing clinical trials for the treatment of head and neck cancer patients, if so please could you provide details?
4. Within your health trust how many patients are currently [within the past 6 months] being treated for metastatic Colorectal Cancer?
Of those patients please split by their current drug treatment;

Bevacizumab
Cetuximab
Panitumumab
Aflibercept
Oxaliplatin
Irinotecan
5-Fluorouracil
Irinotecan with 5-fluorouracil (5FU) and folinic acid [FOLFIRI]
Oxaliplatin with 5-fluorouracil (5FU) and folinic acid [FOLFOX]
Capecitabine and oxalipatin (CAPOX / XELOX)
Capecitabine and irinitecan (CAPIRI)
Other – Specify

Download response Head and Neck Cancer (Squamous cell carcinoma) 270616

Head and Neck Cancer (Squamous Cell Carcinoma). 081116

1. Within your health trust how many patients are currently [within the past 6 months] being treated for head and neck cancer (Squamous cell carcinoma)?
Of these patients how many are locally advanced and how many are recurrent and/or metastatic head and neck cancer patients?
A. Locally advanced
B. Recurrent and/or metastatic
Of these patients please split by their current drug treatment;
Carboplatin (Only or in combination with 5-FU)
Cetuximab (Erbitux) and chemotherapy or radiotherapy
Cetuximab (Erbitux) Only
Cisplatin (Only or in combination with 5-FU)
Docetaxel (Taxotere), (Only or in combination with 5-FU)
Fluorouracil (5FU)
Radiotherapy Only
Other – Specify
2. Within your health trust how many patients are currently [within the past 6 months] being treated for metastatic Colorectal Cancer?
Of those patients please split by their current drug treatment;
Bevacizumab
Cetuximab
Panitumumab
Aflibercept
Oxaliplatin
Irinotecan
5-Fluorouracil
Irinotecan with 5-fluorouracil (5FU) and folinic acid [FOLFIRI]
Oxaliplatin with 5-fluorouracil (5FU) and folinic acid [FOLFOX]
Capecitabine and oxalipatin (CAPOX / XELOX)
Capecitabine and irinitecan (CAPIRI)
Other – Specify

Download response Head and Neck Cancer (Squamous Cell Carcinoma). 081116

Head and Neck Cancer (Squamous cell carcinoma). 260418

1. Within your health trust how many patients are currently [within the past 6 months available] being treated for head and neck cancer (Squamous cell carcinoma)?
2. Of these patients how many are locally advanced and how many are recurrent and/or metastatic head and neck cancer patients?
a. Locally advanced
b. Recurrent metastatic
3. Of the locally advanced/ recurrent or metastatic head and neck cancer patients how many are currently [within the past 6 months available]
Carboplatin (only or in combination with 5-FU)
Cisplatin (only or in combination with 5-FU)
Cetuximab (Erbitux) with/without chemotherapy
Cetuximab (Erbitux) with radiotherapy
Docetaxel (Taxotere) -only or in combination with 5-FU
Fluorouracil (5FU)
Radiotherapy only
Other
4. Does your health trust participate in any ongoing clinical trials for the treatment of head and neck cancer patients, if so how many patients are currently taking part in clinical trials?
5. Within your health trust how many patients are currently [within the past 6 months available] being drug treated for metastatic colorectal cancer?
Of those patients please split by their drug treatment;
Cetuximab (Erbitux) with/without chemotherapy
Panitumumab (Vectibix) with/without chemotherapy
Nivolumab (Opdivo) with/without chemotherapy
Chemotherapy + other mAb
Chemotherapy alone
Other
6. Does your health trust participate in any ongoing clinical trials for the treatment of colorectal cancer patients, if so how many patients are currently taking part in clinical trials?
Download response Head and Neck Cancer (Squamous cell carcinoma). 260418

HER2 Breast Cancer. 080517

In your trust, how many patients with HER2 breast cancer are currently being treated (in the past 3 months available) with the following products;

Herceptin IV (trastuzumab IV) only
Herceptin SC (trastuzumab SC) only
Perjeta (pertuzumab) combined with Herceptin/Docatexel
Kadcyla (trastuzumab emtansine)
Tyverb (lapatinib)

Download response HER2 Breast Cancer. 080517

Imaging. 270918

1. How many CDs does your department produce per annum for the distribution of patient images?*
2. How many CDs does your department produce per annum for interested 3rd parties such as insurance companies or solicitors?*
3. What is the cost of CD production for patient images, e.g. materials for your department per annum?*
4. What are the time/resource costs associated with CD production for patient images for your department per annum?*
5. What are the costs of postage/couriering of CDs of patient images for your department, per annum?*
6. Please provide a breakdown of total costs of CDs for patient images to other hospitals for your department, per annum?*
7. Please provide a breakdown of total costs of CDs to patients for your department, per annum?*
8. Please provide a breakdown of total costs of CDs to interested 3rd parties for your department such as insurance companies or solicitors, per annum?*
9. Are the CDs dispatched from your department that contain patient data consistently encrypted / password protected?*
10. Can you provide information on the number of CDs that are lost or misplaced before they reach the intended recipient?*

*If you use a centralised administration team to administer imaging for your department please include this information to the above questions.
Please provide these answers for the following departments:
• Radiology
• Cardiology
• Medical illustration
• Theatres
• Endoscopy
• Colposcopy
• Diabetic Retinopathy
• Medical Photography
• Dermatology
• Podiatary

Download response Imaging. 270918

IMRT Radiotherapy Machines. 121119

IMRT Radiotherapy Machines
Could you please advise whether we are using the above modern machines in the Kent and Canterbury Hospital (K&C) and Maidstone?

Download response IMRT Radiotherapy Machines. 121119

Intravenous cancer drug therapies 081116

On average how many patients receive intravenous cancer drug therapies (includes monoclonal antibodies (mAbs)) on a daily basis across all hospital chemotherapy day units in your organisation/Trust?

Download response Intravenous cancer drug therapies 081116

Kawasaki Disease. 300819

For your Trust, please provide, per calendar year for the period January 2006 to December 2018 inclusive, the following information for each admission of Kawasaki Disease – ICD10 diagnosis (primary or secondary) of M303 Mucocutaneous lymph node syndrome:
• Year of each admission
• Month of each admission
• Patient gender
• Patient ethnicity
• Age of patient at diagnosis
• First four items of patient postcode (partial postcode which is non-identifiable)

Download response Kawasaki Disease. 300819

Leukaemia care. 111217

1. What haematological (blood) cancers are treated at the trust?
2. In May 2015 how many blood cancer patients were under the care of your trust?
3. In May 2015 how many leukaemia patients were under the care of your trust?
• How many of these are chronic lymphocytic leukaemia (CLL) patients?
• How many of these are chronic myeloid leukaemia (CML) patients?
• How many of these are Acute Lymphoblastic leukaemia (ALL) patients?
• How many of these are Acute Myeloid leukaemia (AML) patients?
4. As of September 2017 how many blood cancer patients are under the care of your trust?
5. As of September 2017 how many leukaemia patients are under the care of your trust?
• How many of these are chronic lymphocytic leukaemia (CLL) patients?
• How many of these are chronic myeloid leukaemia (CML) patients?
• How many of these are Acute Lymphoblastic leukaemia (ALL) patients?
• How many of these are Acute Myeloid leukaemia (AML) patients?
6. The total number of haematology clinical nurse specialists in your trust in May 2015.
7. The total number of haematology clinical nurse specialists in your trust in September 2017.
8. The total number of blood cancer specific clinical nurse specialists in your trust in May 2015.
9. The total number of blood cancer specific clinical nurse specialists in your trust in September 2017.
10. The total number of leukaemia specific clinical nurse specialists in your trust in May 2015.
11. The total number of leukaemia specific clinical nurse specialists in your trust in September 2017.
12. Are haematology/blood cancer clinical nurse specialists at your trust required to undertake normal ward duties?
13. Have you measured patient access to a clinical nurse specialist within your trust? If so what was the outcome of this.
14. Have you measured the cost value or savings relating to haematology/blood cancer clinical nurse specialists in the trust? If so what were your findings?
15. Do you have or plan to have any funding in place for training more haematology or blood cancer specific clinical nurse specialists?
If you do not have any specialised leukaemia clinical nurse specialists please answer:
16. As of September 2017 how many patients are there per haematology clinical nurse specialist in your trust?
17. As of September 2017 how many blood cancer patients are there per haematology clinical nurse specialist in your trust?
18. As of September 2017 how many leukaemia patients are there per haematology clinical nurse specialist in your trust?
If you have specialised leukaemia clinical nurse specialists please answer:
19. As of September 2017 how many leukaemia patients are there per leukaemia clinical nurse specialist in your trust?

Download response Leukaemia care. 111217

LINAC machines and SBRT or SABR for oligometastatic disease. 020919

1. The year of purchase of every LINAC machine in operation at your trust?

2. How many patients received lung SBRT or SABR for oligometastatic disease at your Trust in the most recent year for which data is available? How many of those had been referred from other Trusts?

3. If your Trust does not offer SABR or SBRT for lung or oligometastatic disease, how many patients were referred to another NHS Trust for SBRT or SABR in the most recent year for which data is available? How many of those patients completed their SBRT or SABR treatment at the Trust they had been referred to?

Download response LINAC machines and SBRT or SABR for oligometastatic disease. 020919

LINAC machines and SBRT or SABR for oligometastatic disease. 020919

1. The year of purchase of every LINAC machine in operation at your trust?

2. How many patients received lung SBRT or SABR for oligometastatic disease at your Trust in the most recent year for which data is available? How many of those had been referred from other Trusts?

3. If your Trust does not offer SABR or SBRT for lung or oligometastatic disease, how many patients were referred to another NHS Trust for SBRT or SABR in the most recent year for which data is available? How many of those patients completed their SBRT or SABR treatment at the Trust they had been referred to?

Download response LINAC machines and SBRT or SABR for oligometastatic disease. 020919

Locum doctors in Oncology. 111217

Can you please assist me with retrieving the total Agency spend for Medical Locum Doctors within Oncology over the following months, within your Trust or Health Board?

Month Total Agency Spend in Oncology
April 2017
May 2017
June 2017
July 2017
August 2017
September 2017

Download response Locum doctors in Oncology. 111217

Lung cancer cases in Vigo. 121018

It has come to my attention that there is a disproportionately high number of patients are presenting to Maidstone Respiratory Clinic from people living in Vigo, Gravesend.

I would be grateful if you could provide me with any information you hold on the number of recorded patients you have from Vigo over the past ten years with lung cancer. That would include both incidence and prevalence figures.

Before we commenced extracting any data the Trust highlighted the following to you and asked if you were happy for us to proceed with your request with the following limitations.
• Data will only be as long as the data system has been used, (since 2009)
• Postcodes used have been identified as those listed below, as this is a not an area we can identify any other way from our system.

DA13 0RL
DA13 0SB
DA13 0RR
DA13 0UU
DA13 0SR
DA13 0UT
DA13 0TG
DA13 0ST
DA13 0TD
DA13 0SH
DA13 0TA
DA13 0SF
DA13 0TQ
DA13 0SX
DA13 0RY
DA13 0SP
DA13 0SU
DA13 0SQ
DA13 0RZ
DA13 0SJ
DA13 0TE
DA13 0SY
DA13 0SG
DA13 0SN
DA13 0SL
DA13 0SW

• We cannot give prevalence, and not even incidence really since this is new cases, rather we can give just numbers in those postcodes specified that are on our system, I.e. being treated by the Trust.
• This will be for patients under Maidstone and Tunbridge Wells NHS Trust (MTW) with lung cancer in that postcode area each year, so if they moved in or out, they will appear or disappear (i.e. diagnosis may or may not have been made by MTW depending if they first presented with suspected cancer to us or whether they moved into the area after diagnosis was already made elsewhere).

You confirmed that you were happy to proceed with the listed limitations.

Download response Lung cancer cases in Vigo. 121018

Lynch Syndrome testing. 111018

1. Do you test newly diagnosed bowel cancer patients in your trust (either contracted or referred) for molecular features of Lynch syndrome using either immunohistochemistry or microsatellite instability testing?
2. If yes, at what stage does this testing take place?
3. Is this test carried out as a reflex test i.e. automatically or upon referral?
4. In their published adoption support resource NICE suggest identifying a named ‘clinical champion’ within each colorectal multidisciplinary team to effectively implement testing people for molecular features for Lynch syndrome. Is this established in your trust?
5. Do you audit diagnostic outcomes within your trust to ensure that every patient is tested for molecular features for Lynch syndrome?
6. Have you had to submit a business case for funding in order to effectively implement this new guidance?
7. If no such testing is in place, do you have information on whether there are any plans to introduce molecular testing for Lynch syndrome as per NICE guidance?
8. What are the main barriers you have faced if no molecular testing or only selected testing is performed? Please specify.

Download response Lynch Syndrome testing. 111018

Maintenance services for flexible endoscopy inventory . 211118

You asked:
• When does the existing maintenance contract(s) expire for the Trust’s flexible endoscope inventory?
• I.e. please provide the expiry date for any contract(s) that cover the maintenance and repair of the Trust’s flexible endoscope inventory.

Download response Maintenance services for flexible endoscopy inventory . 211118

Melanoma patients and treatments. 240317

1. Within your health trust how many patients are currently [within the past 6 months] being treated for Melanoma?

2. Of these Melanoma patients how many are being treated for stage IV (advanced or metastatic) melanoma?

3. Of these how many are being treated for (advanced or metastatic) melanoma with the following;
Ipilimumab (Yervoy) single agent
Ipilimumab (Yervoy) in combination
Nivolumab (Opdivo)
Pembrolizumab (Keytruda)
vemurafenib (Zelboraf) single agent
vemurafenib (Zelboraf) in combination
dabrafenib (Taflinar)
trametinib (Mekinist)
dabrafenib AND trametinib
dacarbazine (DTIC)

4. How many patients are currently [within the past 6 months] being treated for Non Squamous Cell Lung Cancer with the following;
Afatinib (Giotrif)
Ceritinib (Zykadia)
Crizotinib (Xalkori)
Erlotinib (Tarceva)
Gefitinib (Iressa)
Pemetrexed (Alimta)
Nivolumab (Opdivo)
Pembrolizumab (Keytruda)

5. How many patients are currently [within the past 6 months] being treated for Renal Cell Carcinoma (RCC) with the following;
Interferon (Intron A)
Bevacizumab (Avastin)
Sunitinib (Sutent)
Pazopanib (Votrient)
Aldesleukin (IL-2, Proleukin or interleukin 2)
Sorafenib (Nexavar)
Everolimus (Afinitor)
Temsirolimus (Torisel)
Cabozantinib (Cometriq)

Download response Melanoma patients and treatments. 240317

Mental health and cancer patients. 130220

1) The total number of cancer patients who have been referred by you to mental health services during their treatment cancer under your services, in each year since 2010.
2) A breakdown of that total figure into categories for the reason given for the cancer patients’ referral, in each year since 2010.
3) A breakdown of that total figure into categories for the kinds of cancer that referred patients are suffering.
4) Details on average waiting time that cancer patients have faced while waiting for referral to mental health services each year over the past 10 years.

Download response Mental health and cancer patients. 130220

Metal and missile incidents in MRI. 110220

1. Name of Trust
2. How many MRI scanners are in your trust?
3. Number of missile/metal incidents in your trust?
a. 2014-2015
b. 2015-2016
c. 2016-2017
d. 2017-2018
e. 2018-2019
4. Any recorded patient or staff harm?
5. Any financial implications to your trust in respect of:
a. Patient costs (£)
b. Equipment costs (£)

Download response Metal and missile incidents in MRI. 110220

Metastatic Breast Cancer. 070119

1. Within your health trust how many metastatic breast cancer patients are currently [within the past 6 months] being treated, with any therapy, surgery or palliative care.
2. Within your health trust how many breast cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;
3. Within your health trust how many breast cancer patients are currently [within the past 6 months] being treated with adjuvant therapy with the following treatments;
4. Within your health trust how many metastatic lung cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care.
5. Within your health trust how many lung cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;
6. Within your health trust how many metastatic renal cell cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care.
7. Within your health trust how many renal cell carcinoma [RCC] patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;

Download response Metastatic Breast Cancer. 070119

Metastatic hepatocellular carcinoma patients. 260418

1 – In the past three months, how many metastatic hepatocellular carcinoma patients were treated with?
Sorafenib (Nexavar)
Other active systemic anti-cancer therapy
Other including palliative care
2 – In the past three months, how many metastatic renal cell carcinoma patients were treated with?
Sunitinib (Sutent)
Pazopanib (Votrient)
Everolimus (Afinitor)
Temsirolimus (Torisel)
Cabozantinib (Cometriq)
Nivolumab (Opdivo)
Axinitib (Inlyta)
Nivolumab + Ipilimumab (Opdivo + Yervoy)
Levantinib (Lenvima) + Everolimus (Afinitor)
Tivozanib (Fotivda)
Other active systemic anti-cancer therapy
Other including palliative care
3 – In the past 3 months, how many metastatic melanoma patients were treated with?
Pembrolizumab (Keytruda)
Nivolumab (Opdivo)
Ipilumumb (Yervoy)
Nivolumab + Ipilumumb (Opdivo + Yervoy)
Dabrafenib + Trametinib (Tafinlar + Mekinist)
Dabrafenib (Tafinlar)
Vemurafenib (Zelboraf)
Vemurafenib + cobimetinib (Zelboraf _ Cotellic)
Other active systemic anti-cancer therapy
Other including palliative care

Download response Metastatic hepatocellular carcinoma patients. 260418

Metastatic Squamous Cell Non-Small cell lung cancer. 070618

Metastatic Squamous Cell Non-small cell lung cancer (NSCLC):
1. In the past 3 months, how many patients were treated with?
Atezolizumab (Tecentriq)
Pembrolizumab (Keytruda)
Nivolumab (Opdivo)
Other active systemic anti-cancer therapy
Palliative care only

Metastatic Non Squamous Cell Non-small cell lung cancer (NSCLC):
2. In the past 3 months, how many patients were treated with?
Atezolizumab (Tecentriq)
Pembrolizumab (Keytruda)
Nivolumab (Opdivo)
Other active systemic anti-cancer therapy
Palliative care only

Adjuvant Melanoma
3. In the past three months how many patients were seen who had stage III resectable melanoma?
4. Of all stage III patients seen, how many received a complete resection?
5. Of all stage III patients seen, how many were stage III a?

Download response Metastatic Squamous Cell Non-Small cell lung cancer. 070618

Mobile Healthcare facilities. 030420

1. Please specify the number of mobile healthcare facilities that are currently deployed i.e. in use by your trust (a. mobile operating theatres, b. mobile endoscopy suites and c. mobile imaging units are mobile (relocatable) units that are temporarily brought to a trust by a third party provider): FY 19/20, Past 5 years
a. Mobile operating theatre
b. Mobile endoscopy suites
c. Mobile imaging units
2. Please specify the average mobile healthcare facility deployment and fee (Please specify weekly or monthly) for the listed types (a,b,c), please leave blank if not applicable (a. mobile operating theatres, b. mobile endoscopy suites and c. mobile imaging units are mobile (relocatable) units that are temporarily brought to a trust by a third party provider):
a. Mobile operating theatre
b. Mobile endoscopy suites
c. Mobile imaging units
FY 19/20 (£)
Deployment fee (£)
Weekly
Monthly
3. Please specify the number of imaging units you have currently in use in your trust?
a. MRI
b. CT Scanner
c. PET CT Scanner
FY 19/20 (£)
Deployment fee (£)
Weekly
Monthly

Mobile Healthcare facilities. 030420

Molecular testing for mismatch repair (MMR) deficiency.

1. Do all patients, who are diagnosed with bowel cancer under the age of 50 years in your trust, have a molecular screening test for Lynch Syndrome, such as immunohistochemistry or microsatellite instability testing, carried out on tumour tissue?
2. If yes, at what stage does this testing take place? Does it take place:
3. Is this test carried out as a reflex test i.e. automatically or upon referral?
4. Which of the following molecular tests does your trust use to identify people who could have Lynch syndrome:
5. Are the results of this reflex test communicated to the patient?
6. If no such reflex test is in place, do you have information on whether there are any plans to introduce molecular testing for Lynch syndrome?

Download response Molecular testing for mismatch repair (MMR) deficiency 100616

Mouthwash product for oral mucositis treatment or prevention. 270317

1. Please advise the estimated number of beds at your hospital(s)
2. Please advise the estimated number of patients treated annually at your hospital(s)
3. Please advise the estimated number of patients receiving chemotherapy at your hospital(s) each year
4. What is the preferred mouthwash product prescribed to patients for oral mucositis treatment or prevention?
5. What is the estimated annual spend on mouthwash?
6. What is the estimated annual number units of mouthwash prescribed?

Download response Mouthwash product for oral mucositis treatment or prevention. 270317

MRI scans and obesity. 270918

a) How many MRI scans were aborted for reasons related to the patient being too large or heavy to use the scanner for each of the last three financial years (April 1 2015 – March 31 2016, April 1 2016 – March 31 2017, April 1 2017 – March 31 2018) and between April 2018 and the current date if recorded.

b) i) Has your you trust purchased extra-large scanners (if information held) ? (The hole size of standard scanner measures 68cm (26in) and some hospitals put a 25-stone (158kg) limit on patients using them.)

ii) How much money was spent purchasing these extra-large scanners (if information held)?

Download response MRI scans and obesity. 270918

Multiple Myeloma

Section 1 – Treatment and Management
1. How many patients has your Trust diagnosed with multiple myeloma in the calendar year 2014?
2. How many multiple myeloma patients in your Trust received systemic anti-cancer treatment in the calendar year 2014?
3. How many patients aged 75 years and over has your Trust diagnosed with multiple myeloma in the calendar year 2014?
4. How many multiple myeloma patients aged 75 years and over in your Trust received systemic anti-cancer treatment in the calendar year 2014?
5. Does your Trust produce local guidelines to support the management of elderly cancer patients?
6. Does your Trust produce local guidelines to support the management of elderly multiple myeloma patients?
(Note: Multiple Myeloma is defined by the ICD-10 code as C90.0 – C90.3)
Section 2 – Specialist Geriatric Input
7. Does your Trust’s multiple myeloma multidisciplinary team (MM MDT) include input from a geriatrician?
a. If so, does a geriatrician routinely attend all MM MDT meetings?
b. How often does the MM MDT meet?
8. Do multiple myeloma patients aged 75 and over at diagnosis routinely receive a consultation with a geriatrician?
a. If so, does this happen prior to making a decision as to whether a patient is suitable for systemic anticancer therapy?
b. If, so does information from this consultation feed into clinical decision making?
9. How frequently do all multiple myeloma patients aged 75 years and over receive a consultation with a geriatrician?
a. How is this information used in these consultations fed into clinical management and decision making?
Section 3 – Specific Tools and Metrics
10. Does your Trust use Comprehensive Geriatric Assessment to assess if a patient with cancer is suitable for treatment?
a. If so, what proportion of multiple myeloma patients aged 75 and over received the assessment in 2014?
b. Who routinely carries out this assessment (i.e. a nurse or a consultant – and what type of consultant (haematologist or geriatric))?
11. Does your Trust routinely assess patients over the age of 75 according to a Comorbidity Score (either a standardised score such as the Charlson index or a local ‘in house’ score, please specify)?
a. If so, what proportion of multiple myeloma patients aged 75 and over received the assessment in 2014?
b. Who routinely carries out this assessment (i.e. a nurse or a consultant – and what type of consultant (haematologist or geriatric))?
12. Does your Trust routinely assess patients over the age of 75 according to a Clinical Frailty Scale (either a standardised scale or a local ‘in house’ scale, please specify)?
a. If so, what proportion of multiple myeloma patients aged 75 and over received the assessment in 2014?
b. Who routinely carries out this assessment (i.e. a nurse or a consultant – and what type of consultant (haematologist or geriatric))?

Download response Multiple Myeloma 201115

Myocardial perfusion scans. 151118

You asked:
1) How many Myocardial perfusion scans were performed in the trust in the financial year 2011-12?
2) How many Myocardial perfusion scans were performed in the trust in the financial year 2012-13?
3) How many Myocardial perfusion scans were performed in the trust in the financial year 2013-14?
4) How many Myocardial perfusion scans were performed in the trust in the financial year 2014-15?
5) How many Myocardial perfusion scans were performed in the trust in the financial year 2015-16?
6) How many Myocardial perfusion scans were performed in the trust in the financial year 2016-17?

Download response Myocardial perfusion scans. 151118

Neuroendocrine Tumours. 070717

1. In your trust, please provide the number of patients treated in the last 12 months who have been diagnosed [any diagnosis position] with neuroendocrine tumours
2. Of these how many have carcinoid syndrome (E34.0)?
3. Of the patients with neuroendocrine tumours (NETs), how many received with the following treatments:
• Somatuline Autogel (lanreotide)
• Somatuline LA (lanreotide)
• Sandostatin LAR (octreotide LAR)
• Octreotide
• Afinitor (everolimus)
• Sutent (sunitinib)
4. Please provide the number of patients treated in the last 12 months who have been diagnosed [any diagnosis position] with acromegaly (ICD10 code E220 or ICD10 code D352), with the following treatments:
• Somatuline Autogel (lanreotide)
• Somatuline LA (lanreotide)
• Sandostatin LAR (octreotide LAR)
• Octreotide
• Somavert (pegvisomant)
• Signifor (pasireotide pamoate)

*To assist in sourcing the answer to my question specifically in respect of NETs, the below information may be of use.
In relation to patients with neuroendocrine tumours, these tumours are typically identified from pathology analysis, but may be coded using various ICD10 codes. The following may be commonly used:
• C787 – Secondary malignant neoplasm of liver
• C786 – Secondary malignant neoplasm of retroperitoneum and peritoneum
• C772 – Secondary and unspecified malignant neoplasm of Intra-abdominal lymph nodes
• C780 – Secondary malignant neoplasm of the lung
• Z850 – Personal history of malignant neoplasm of digestive organs
In any event, I am requesting information only in respect of those patients with neuroendocrine tumours who are being treated with the above treatments.

Download response Neuroendocrine Tumours. 070717

NHS wheelchair services. 130918

1. Is the Trust a provider of NHS Wheelchair Services?
If the answer to question 1 is “No”, the Trust need not respond to the remainder of this request. If the answer to question 1 is “Yes”, please respond to question 2.
For the remaining questions of this request, if the Trust provides NHS Wheelchair Services under different contracts, please list the requested information for each contract.
2. The name of the CCGs for which the Trust provides NHS Wheelchair Services; when it started providing this service; and when its current contract(s) ends
3. The current eligibility criteria for receiving NHS-funded wheelchairs via the NHS Wheelchair Services provided by the Trust
4. A list of all changes to the eligibility criteria for receiving NHS-funded wheelchairs via the NHS Wheelchair Services provided by the Trust, if those changes were implemented after April 1st 2015; please state not just the new criteria in each case, but also the old criteria that was altered by the change (e.g. ‘inability to walk 20m unaided’ replacing ‘inability to walk 40m unaided’)
5. For each change listed in response to question 4, please provide details of any public consultation that was carried out on the change; whether any measures to publicise the consultation were undertaken beyond posting it online; and what responses were received to any such consultation
6. A list of any changes to the eligibility criteria for receiving NHS-funded wheelchairs via the NHS Wheelchair Services provided by the Trust area that are currently being considered, proposed or consulted on.

Download response NHS wheelchair services. 130918

NICE guidelines. 310719

We are looking specifically at diagnostics – NICE Guidance – DG34 – tumour profiling for breast cancer, as a recent example. We would like to understand any procurement plans you have in place as a result of this? Including dates, procurement route (open, restricted), regime (whether light touch regime, standard OJEU), likely weightings (quality vs price), or via NHS Supply Chain or other framework provider?

Download response NICE guidelines. 310719

Non-Small Cell Lung Cancer. 050718

Please provide the following information relating to NSCLC patients treated by your Trust in the 3 months, December 2017 to February 2018 inclusive.
If data is not held in a sufficient way within your Trust systems, i.e. if for example you are unable to distinguish between cancer type and/or stage, please indicate accordingly within the tables below.
1. Total number treated Stage IIIB/IV NSCLC Patients
If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:
2. Of the Stage IIIB/IV NSCLC patients, please indicate the number of patients treated by your Trust in the 3 months December 2017 to February 2018 inclusive, with the following therapies.
Total number treated Stage IIIB/IV NSCLC Patients
If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:
Docetaxel (mono or combination therapy)
Atezolizumab (Tecentriq)
Nivolumab (Opdivo)
Pembrolizumab (Keytruda)
3. If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust(s) patients are referred:

Download response Non-Small Cell Lung Cancer. 050718

Non-Small Cell Lung Cancer. 291118

You asked:

Please provide the following information relating to NSCLC patients treated by your Trust in the 3 months, July 2018 to September 2018 inclusive.
If data is not held in a sufficient way within your Trust systems, i.e. if for example you are unable to distinguish between cancer type and/or stage, please indicate accordingly within the tables below.

1. Total number treated Stage IIIB/IV NSCLC Patients
Patients with NSCLC Stage IIIB/IV (Stage 3b/4)
Total number NSCLC patients
Other (please specify)
Data not held/accessible
Of the Stage IIIB/IV NSCLC patients, please indicate the number of patients treated by your Trust in the 3 months July 2018 to September 2018 inclusive, with the following therapies.

2. Total number treated Stage IIIB/IV NSCLC Patients. If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:
Docetaxel (mono or combination therapy)
Atezolizumab (Tecentriq)
Nivolumab (Opdivo)
Pembrolizumab (Keytruda)

3. If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust(s) patients are referred:

Download response Non-Small Cell Lung Cancer. 291118

Non-Small Cell Lung Cancer. 300317

1. Within your health trust how many patients are currently [within the past 6 months] being treated with a chemotherapy agent [not including surgery/radiotherapy only];

a. All Non-Small Cell Lung Cancer patients
b. Patients with Non-Small Cell Lung Cancer (NSCLC) Stage IIIB**/IV** (Stage 3b/4)

c. Of the NSCLC patients, please state the number of patients currently [within the past 6 months] being treated with the following therapies;
Afatinib (Giotrif)
Ceritinib (Zykadia)
Crizotinib (Xalkori)
Erlotinib (Tarceva)
Gefitinib (Iressa)
Nitendaninb + docetaxel
Nivolumab (Opdivo)
Pemetrexed (Alimta) mono or in combination with carboplatin / cisplatin
Pembrolizumab (Keytruda)
Gemcitabine mono or in combination with carboplatin / cisplatin
Paclitaxel mono or in combination with carboplatin / cisplatin
Doxetaxel mono or in combination with carboplatin / cisplatin
Vinorelbine [or other Vinka alkaloid] mono or in combination with carboplatin / Cisplatin

Download response Non-Small Cell Lung Cancer. 300317

Non-small Cell Lung Cancer. 301117

1. How many of the following patients (excluding clinical trial patients) are currently being managed by your Health Trust:
All Non-Small Cell Lung Cancer (NSCLC) patients
Patients with NSCLC Stage IIIB**/IV** (Stage 3b/4)
2. Of the Stage IIIB/IV NSCLC patients, please state the number of patients currently being treated with the following therapies:
Afatinib (Giotrif)
Ceritinib (Zykadia)
Crizotinib (Xalkori)
Erlotinib (Tarceva)
Gefitinib (Iressa)
Nintedanib + docetaxel
Pemetrexed (Alimta) mono or in combination with carboplatin / cisplatin
Gemcitabine mono or in combination with carboplatin / cisplatin
Atezolizumab (Tecentriq)
Nivolumab (Opdivo)
Pembrolizumab (Keytruda)
Paclitaxel mono or in combination with carboplatin / cisplatin
Doxetaxel mono or in combination with carboplatin / cisplatin
Vinorelbine [or other Vinka alkaloid] mono or in combination with carboplatin / Cisplatin
3. If your trust does not treat Stage IIIB/IV NSCLC patients and you refer your patients to another trust, please state to which trust patients are referred

Download response Non-small Cell Lung Cancer. 301117

Non-small cell lung carcinoma (NSCLC) pathology testing 111016

1) What is the volume of NSCLC pathology samples tested in house?
2) Does your laboratory process EGFR samples in house? (Yes/No)
• If yes, what is the number of samples being tested per year/month?
3) Does your laboratory process ALK samples in house? (Yes/No)
• If yes, what is the number of samples being tested per year/month?

Download response Non-small cell lung carcinoma (NSCLC) pathology testing 111016

Oncology clinical system. 010319

I contacted Freedomofinformation (MEDWAY NHS FOUNDATION TRUST) medwayft.foi@nhs.net regarding the Oncology system used by their trust. Please see details below. However, they responded that your trust hold the contract.

May I ask if the systems has a new contract expiration date and is it annually renewed?

Please let me know if it is still in use and if not, what supplier systems have replaced them.

Download response Oncology clinical system. 010319

Oral mucositis and barrier mouthwashes. 190717

1) Please advise the estimated number of patients receiving chemotherapy and radiotherapy at your hospital(s) each year.
2) What is the preferred ‘barrier’ mouthwash product prescribed to patients for oral mucositis treatment and/or prevention?
3) Which of the following ‘barrier’ mouthwash brands, if any, have previously been prescribed in your hospital(s):
– Caphosol
– Gelclair
– Mucodis
4) What is the estimated annual spend on mouthwash?
5) What is the estimated annual number of units of mouthwash prescribed annually?
6) How much Saline and Difflam mouthwash are prescribed for OM?
7) What are your current prescribing pathways for oral mucositis care?
8) Do you currently prescribe anything for the prevention and/or treatment of the following conditions:
– Vaginal mucositis (Vulvovaginitis)
– Rectal mucositis
– Radiation dermatitis

Download response Oral mucositis and barrier mouthwashes. 190717

Outsourced Tele-Radiology services. 190719

Q1 – Did your trust outsource the reporting of diagnostic images to any tele-radiology companies within the past 6 months listed in the table below?

Q2 – If so, for each company, please provide the name of the tele-radiology provider along with the information in the table below (where available).

Q3 – Please break down the amount(s) spent with each supplier over the following periods;

Download response Outsourced Tele-Radiology services. 190719

Ovarian cancer. 040118

Does your Trust manage/treat patients with Ovarian Cancer?
Number of patients diagnosed with Ovarian Cancer
Please indicate the number of unique NHS Ovarian Cancer patients managed by your Trust treated at initial diagnosis with the following:
• Avastin (Bevacizumab) +/- chemotherapy
• Chemotherapy alone
Does your Trust refer Ovarian Cancer patients to other Trusts or Centres for the treatment of ovarian cancer?

Download response Ovarian cancer. 040118

Ovarian Cancer. 200320

Question 1
How many patients have been diagnosed over the last 6 months with epithelial ovarian, fallopian tube or primary peritoneal cancer?
If none, do you refer ovarian cancer patients to another trust, if so which one?
Question 2
Of the ovarian patients, how many have been tested for BRCA mutation?
If unknown please state unknown and move to Question 4
Question 3
Of the ovarian patient BRCA mutation tests how many tested positive?
Question 4
Of the ovarian patients diagnosed over the last 6 months, how many have been treated with the below:
Paclitaxel in combination with a platinum-based compound
Platinum-based therapy alone (cisplatin or carboplatin)
Bevacizumab in combination with paclitaxel and carboplatin
Olaparib
Niraparib
Rucaparib
Pegylated liposomal doxorubicin hydrochloride (PLDH) as monotherapy or in combination with a platinum-based compound
Question 5
Of those who were positive for a BRCA mutation, how many received Olaparib for 1st line maintenance?
Question 6
Of those who were positive for a BRCA mutation, how many received Bevacizumab in combination with paclitaxel and carboplatin for 1st line maintenance?

Download response Ovarian Cancer. 200320

Ovarian and Prostate treatments. 010318

1 – How many Ovarian Carcinoma patients (any stage) have been diagnosed in the last 12 months?
2 – How many stage III or IV Ovarian Carcinoma patients have received Chemotherapy for the first time in the last 12 months?
Of these how many patients are on Platinum based therapy (Monotherapy or combination therapy)?
3 – How many stage III or IV Ovarian Carcinoma patients have been diagnosed as Platinum refractory (i.e. progression of disease whilst receiving Platinum therapy) or resistant (i.e. progression of disease within 6 months of last Platinum dose) in the last 12 months?
4 – How many patients with Stage III or IV Ovarian Carcinoma have been treated with the following treatments in the last 12 months?
5 – Within your Trust how many patients with Advanced Prostate Cancer have been treated in the past 12 months with the following treatments?
6 – How many patients being treated with Abiraterone or Enzalutamide and have been on this treatment for more than 1 year?

Download response Ovarian and Prostate treatments. 010318

PDL1 testing. 070417

1. Do you currently offer a clinical testing service for PD-L1 in non-small cell lung carcinoma (NSCLC) as off the beginning of 2017?
2. How is PD-L1 testing in NSCLC normally requested by the clinician? (please select all that apply)
3. If requested as part of a NSCLC panel of tests, how is PD-L1 testing performed in the lab
4. What sample types are processed by the lab for NSCLC testing (EGFR/ALK/PD-L1)? (please select all that apply)
5. What is the number of NSCLC samples being tested (or sent-out) are tested for:?
6. What proportion of PD-L1 NSCLC samples tested are cytology/ cytological cell block samples? (per month or per year or as a percentage of PD-L1 samples tested, whichever is easier to determine)
7. What proportion of PD-L1 NSCLC samples are NOT tested because the samples are EBUS/cytology samples? (per month or per year or as a percentage of PD-L1 samples tested, whichever is easier to determine)
8. What methods are used for PD-L1 testing in NSCLC and their associated clinical cut-off? (please select all that apply)
9. What is the clinical cut offs are used in relation to the antibodies selected above?
10. What IHC staining platform(s) are used in the laboratory that performs the PD-L1 testing e.g. Ventana, Dako, Leica, Menarini, Shandon, Labvision, etc? (If possible, please supply the model of the platform)
11. What percentage of samples tested have ≥1% PD-L1 expression?
12. What percentage of samples tested have ≥50% PD-L1 expression?
13. What is the average turnaround time from sample receipt to report being issued?
14. Are there bottlenecks that prevent this turnaround time from being quicker?
15. Who pays for DLBCL testing?

Download response PDL1 testing. 070417

Pet and CT scan two week wait. 210519

How many patients under the two-week rule waited more than two weeks for their PET/CT scans at the PET centres at the Maidstone and Tunbridge Wells NHS Trust in the last calendar year?By the two-week rule I refer to the suspected cancer cases referred for imaging. So, how many cases (number of cases and percentage of cases referred) have waited two weeks or more from the date of referral for imaging?How many PET-CT scans have been delayed and /or cancelled at this PET centre in the last year?What is the reason given for these scans being delayed?

Download response Pet and CT scan two week wait. 210519

Post-treatment support for breast cancer patients. 160518

1) Does your Trust offer a Health and Wellbeing event accessible to all breast cancer patients at the end of hospital-based treatment?
(A Health and Wellbeing event is defined as a group education and support event which helps people to manage their physical and psychological health after a cancer diagnosis.)

2) If the Trust does offer a Health and Wellbeing event for breast cancer patients, are these events:
A. solely for people with breast cancer
or
B. for people with all types of cancer

3) For breast cancer patients who have completed their hospital-based treatment, do the nurses in the breast care unit routinely make direct referrals, where appropriate, to the following?
(By ‘direct referral’ we mean gaining consent from a patient to pass on their details to a support service or arranging for someone from the service to contact the patient)

Services provided by charities

a. Support services provided by charities that support people with cancer (yes/no)
b. Support services provided by charities that support people with breast cancer only (yes/no)

NHS Services

c. Counselling / psychology services within the NHS (yes/no)
d. Physiotherapy services within the NHS (yes/no)
e. Fertility services within the NHS (yes/no)
f. Lymphoedema services within the NHS (yes/no)
g. Other support services – please specify below (yes/no)

4) If you do not refer to some/any of the services in question 3, is this due to any of the reasons below? Please indicate all that apply.
a. Support services provided by charities that support people with cancer
• Service not available (yes/no)
• Unaware of service (yes/no)
• Service is oversubscribed (yes/no)
• Service is unsuitable for breast cancer patients (yes/no)
• Patient is informed of the service but a direct referral is not made (yes/no)
• Workload capacity does not allow time for referrals (yes/no)
• Other (please give details)
b. Support services provided by charities that support people with breast cancer only
• Service not available (yes/no)
• Unaware of service (yes/no)
• Service is oversubscribed (yes/no)
• Patient is informed of the service but a direct referral is not made (yes/no)
• Workload capacity does not allow time for referrals (yes/no)
• Other (please give details)
c. Counselling / psychology services within the NHS
• Service not available (yes/no)
• Unaware of service (yes/no)
• Service is oversubscribed (yes/no)
• Patient is informed of the service but a direct referral is not made (yes/no)
• Workload capacity does not allow time for referrals (yes/no)
• Other (please give details)
d. Physiotherapy services within the NHS
• Service not available (yes/no)
• Unaware of service (yes/no)
• Service is oversubscribed (yes/no)
• Patient is informed of the service but a direct referral is not made (yes/no)
• Workload capacity does not allow time for referrals (yes/no)
• Other (please give details)
e. Fertility services within the NHS
• Service not available (yes/no)
• Unaware of service (yes/no)
• Service is oversubscribed (yes/no)
• Patient is informed of the service but a direct referral is not made (yes/no)
• Workload capacity does not allow time for referrals (yes/no)
• Other (please give details)
f. Lymphoedema services within the NHS
• Service not available (yes/no)
• Unaware of service (yes/no)
• Service is oversubscribed (yes/no)
• Patient is informed of the service but a direct referral is not made (yes/no)
• Workload capacity does not allow time for referrals (yes/no)
• Other (please give details)

Download response Post-treatment support for breast cancer patients. 160518

Prescribing data in Oncology 01.11.2015- 31.10.2016. 090617

I am writing to request hospital prescribing data for the attached list of chemical substances being used in Oncology.

The data is required for all generic and branded prescriptions of these and I would request to provide this in the attached format.

Download response Prescribing data in Oncology 01.11.2015- 31.10.2016. 090617

Prostate Cancer 160916

1. We understand the Trust has a Local Urology MDT and has representation on the Specialist Urological MDT for West Kent. Please can you confirm if these MDTs are still operational?
2. If yes, please confirm if the following individuals/roles are still members of the MDTs?
3. Please can you confirm whether the Trust still references the following document(s) in relation to the treatment of patients with Prostate Cancer:
Local Management of Urological Cancers 2015 – Review date June 2016 (Dartford and Gravesham NHS Trust, Medway NHS Foundation Trust, Maidstone and Tunbridge Wells NHS Trust)
4. Does the Trust reference any other Referral Pathways / Care Pathways in relation to the treatment of Prostate Cancer? If so, please provide a copy or website link.
5. If yes, when is/are the document(s) expected to be reviewed?
6. Please can you confirm whether we are permitted to reuse the above information under the Open Government Licence?
We (IMS Health) request permission to re-use as a part of an independent analysis into the treatment of patients with Prostate Cancer, which has been commissioned by one of our clients. The contents of the report will not be made available publically, but may be used by other IMS Health Group entities and service suppliers. The information in the report will be presented in a factual manner with all publication details staying true to the publisher.

We acknowledge that information provided may be protected by copyright and will include a copyright statement to this effect at the end of any information we publish if requested by you.

Download response Prostate Cancer 160916

Prostate cancer and psychological support. 151118

You asked:
1. How many prostate cancer patients (new and existing) were registered within your Trust/hospitals between 1st April 2017 – 31st March 2018?
a. Of those how many were offered specialist psychological support services in the last 12 months (1st April 2017- 31st March 2018)?
b. Of those how many were referred to specialist psychological support services in the last 12 months (1st April 2017- 31st March 2018)?
2. Do you offer psychological support services for families and or carers? (Yes or No)
a. If yes, how is this service offered? (e.g. everyone is proactively offered a referral as standard of care, or do families/carers request access to psychological support reactively)
b. What proportion of families/carers were referred to psychological support services in the last 12 months (1st April 2017- 31st March 2018)?
3. Do men have access to other psychological support services beyond active treatment (i.e. those that are under active surveillance and living beyond cancer)? (Yes or No)
4. Who provides other psychological support service for your prostate cancer patients? Choose from below:
a. NHS commissioned mental health service (funded by CCG/NHS England or Trust)
b. National charitable organisation (e.g. Macmillan, Prostate Cancer UK)
c. Local support group (volunteer-led)
d. Hospice
e. Other (please specify)

Download response Prostate cancer and psychological support. 151118

Prostate cancer and Hepatocellular Carcinoma. 160818

Within your trust how many patients with advanced Prostate cancer have been treated in the past 12 months with the following treatments?
Abiraterone (Zytiga)
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
Enzalutamide (Xtandi)
Radium-223 (Xofigo)
How many patients being treated with Abiraterone or Enzalutamide and have been on this treatment for more than 1 year?

Within your trust how many patients with Hepatocellular Carcinoma (HCC) have been treated in the past 12 months with the following treatments?
Patients who have undergone Transarterial chemoembolization (TACE)
Bevacizumab (Avastin)
Everolimus (Afinitor)
Lapatinib (Tyverb)
Sorafenib (Nexavar)
Sunitinib (Sutent)
Stivarga (Regorafenib)
Others

Download response Prostate cancer and Hepatocellular Carcinoma. 160818

Radiographer posts and vacancies. 030518

1. From the latest data, how many FTE radiographer posts in your trust are vacant?
2. How many FTE radiographer posts do you currently have funded?
3. How does this compare to the situation on 1st April 2013? For the sake of clarity: please can you provide answers on the same questions in Q1 and Q2 but for 1st April 2013 if possible.
4. How are you currently filling the shifts that should be covered by the vacant posts?
5. Have you had to offer fewer radiography services in any way as a result of this?

Download response Radiographer posts and vacancies. 030518

Radiology. 090320

1. How much money did your trust pay to outsourcing companies for diagnostic imaging (e.g. X-Rays, CT or MRI scans) in a) 2018-19 and 2019-20 to date?
2. If possible please state what the volume was of outsourcing for each year e.g. 2,000 X-Rays in 2018-19, 4,000 X-Rays in 2019-20
3. What are the names of the companies your trust uses and if they are read overseas, what countries are the scans sent to
4. How many radiographers does your trust have as of 25/02/20 and how many short of a full complement are you?

Download response Radiology. 090320

Radiology. 141118

You asked:
1. Does your Trust Outsource Radiology Reporting (Diagnosis)? If yes which Reporting Houses do they use?
2. In the last financial year what % of Radiology Reporting (Diagnosis) has been outsourced to companies such as 4ways, Medica, Everlight and Telemedicine?
3. What was the total spend in the last financial year for the outsourcing of Radiology Reporting (Diagnosis).
4. Has the Trust previously used the Health Trust Europe (HTE) Framework to purchase services within the Trust?

Download response Radiology. 141118

Radiology. 180718

You asked:
1. Does the Radiology department use Radiology Reporting Houses to outsource Radiology reporting /diagnosing outcomes?
2. If yes please could you provide me the Name/Names of the Reporting Houses you use?

Download response Radiology. 180718

Radiology and Ultrasound equipment. 270918

You asked:
1. For each individual Radiology and Ultrasound diagnostic imaging system within the Trust:
a. Site Location (Hospital Name)
b. Manufacturer Name
c. Model Name
d. Whether the equipment has been Purchased / Leased / MES
e. Age of equipment (years)
f. Current Service provider name
g. Current Service contract end date
h. Current Service contract type:
i. Preventative Maintenance
ii. Fully Comprehensive
i. Service cost per annum
j. Planned replacement date

Download response Radiology and Ultrasound equipment. 270918

Radiology Service Provision. 291118

You asked:
What is your radiologist whole time equivalent establishment?
How many whole time equivalent Radiologists do you currently have in post?
What is your reporting radiographer (excluding Ultrasound) whole time equivalent establishment?
How many whole time equivalent Reporting Radiographers (excluding Ultrasound) do you currently have in post?
What is your average reporting time (exam to report) for elective CT for the last 3 months?
What is your average reporting time (exam to report) for elective MRI for the last 3 months?
What is your average reporting time (exam to report) for elective CR for the last 3 months?
What is your average reporting time (exam to report) for acute CT overnight for the last 3 months?
What is your average reporting time (exam to report) for acute MRI overnight for the last 3 months?
Which types of Plain Film do you auto-report?

Please complete if you part of a regional network for radiology reporting

How many elective CT examinations have been reported by this route?
How many elective MR examinations have been reported by this route?
How many elective Plain Film examinations have been reported by this route?
How many urgent CT examinations have been reported by this route?
How many urgent MR examinations have been reported by this route?
Do you use them for anything else? (please detail)

Please complete if you pay your employees to provide additional radiology reporting outside their substantive hours

How many elective CT examinations have been reported by this route?
How many elective MR examinations have been reported by this route?
How many elective Plain Film examinations have been reported by this route?
How many urgent CT examinations have been reported by this route?
How many urgent MR examinations have been reported by this route?
Do you use them for anything else? (please detail)

Please complete if you use Teleradiology provider(s) for radiology reporting
(duplicate this section if you use more than 4 providers)

How many elective CT examinations have been reported by this route?
How many elective MR examinations have been reported by this route?
How many elective Plain Film examinations have been reported by this route?
How many urgent CT examinations have been reported by this route?
What is the average turnaround for urgent CT examinations reported by this route (in minutes)?
How many urgent CT exams reported by this route took longer than one hour to report?
How many urgent MR examinations have been reported by this route?
Do you use them for anything else? (please detail)
Does your provider send patient identifiable data outside the European Economic Area?
How was the contract established (e.g. Your own tender, Framework Call off, Quotation)?
Are you restricted to use only one provider for the type of work covered by the contract?
When is the next break point in the current contract?
What extension options are in the current contract?

Please complete if you use external companies to provide onsite radiology reporting

How many elective CT examinations have been reported by this route?
How many elective MR examinations have been reported by this route?
How many elective Plain Film examinations have been reported by this route?
How many urgent CT examinations have been reported by this route?
How many urgent MR examinations have been reported by this route?
Do you use them for anything else? (please detail)

Please provide any questions/responses the Trust has issued in response to any Freedom of Information request relating to Radiology Spend or activity since April 2017

Download response Radiology Service Provision. 291118

Radiology Services. 250220

1 What is your Radiologist whole time equivalent establishment?
2 How many whole time equivalent Radiologists do you currently have in post?
3 What is your Reporting Radiographer (excluding Ultrasound) whole time equivalent establishment?
4 How many whole time equivalent Reporting Radiographers (excluding Ultrasound) do you currently have in post?
5 What is your average reporting time (exam to report) for elective CT for October-December 2019 in days?
6 What is your average reporting time (exam to report) for elective MRI for October-December 2019 in days?
7 What is your average reporting time (exam to report) for elective CR for October-December 2019 in days?
8 What is your average reporting time (exam to report) for acute CT overnight for October-December 2019 in hours?
9 What is your average reporting time (exam to report) for acute MRI overnight for October-December 2019 in hours?
10 Which types of Plain Film do you auto-report? (please delete as appropriate)
Please complete if you have set up home reporting workstations
11 How many whole time equivalent Radiologists do you currently have set up with a home reporting workstation?
12 How many whole time equivalent Reporting Radiographers (excluding Ultrasound) do you currently have set up with a home reporting workstation?
13 What metric are you using to answer the below (number of body parts or examinations)?
14 How many elective CT examinations have been reported by this route?
15 How many elective MR examinations have been reported by this route?
16 How many elective Plain Film examinations have been reported by this route?
17 How many emergency (1 hour) CT examinations have been reported by this route?
18 How many emergency (1 hour) MR examinations have been reported by this route?
19 Do you use them for anything else? (please detail)
Please complete if you are part of a regional network for radiology reporting
20 What metric are you using to answer the below (number of body parts or examinations)?
21 How many elective CT examinations have been reported by this route?
22 How many elective MR examinations have been reported by this route?
23 How many elective Plain Film examinations have been reported by this route?
24 How many emergency (1 hour) CT examinations have been reported by this route?
25 How many emergency (1 hour) MR examinations have been reported by this route?
26 Do you use them for anything else? (please detail)
Please complete if you use Teleradiology provider(s) for radiology reporting
27 What metric are you using to answer the below (number of body parts or examinations)?
28 How many elective CT examinations have been reported by this route?
29 How many elective MR examinations have been reported by this route?
30 How many elective Plain Film examinations have been reported by this route?
31 How many emergency (1 hour) CT examinations have been reported by this route?
32 What is the average turnaround (exam to report) for emergency (1 hour) CT examinations reported by this route (in minutes)?
33 How many emergency (1 hour) CT examinations reported by this route took longer than one hour to report (exam to report)?
34 How many emergency (1 hour) MR examinations have been reported by this route?
35 What time does emergency (1 hour) CT/MR reporting cover start on weekdays?
36 What time does emergency (1 hour) CT/MR reporting cover end on weekdays?
37 What time does emergency (1 hour) CT/MR reporting cover start on weekends?
38 What time does emergency (1 hour) CT/MR reporting cover end on weekends?
39 Do you use them for any other sub-specialist streams of work (e.g. PET CT, Nuclear Medicine, Prostate)?
40 Does your provider send patient identifiable data outside the European Economic Area?
Please complete for all contracts in place with Teleradiology provider(s) for radiology reporting
41 “Do you have more than one contract in place with this Teleradiology provider (e.g. separate agreements for elective and emergency (1 hour) reporting)?
If yes, please duplicate this section with separate details”
42 Please outline the type of radiology reporting contracted (e.g. elective or emergency (1 hour) reporting)?
43 How was the contract established (e.g. Your own tender, Framework Call off, Quotation)?
44 Are you restricted to use only one provider for the type of work covered by the contract?
45 When is the next break point in the current contract?
46 What extension options are in the current contract?
47 Do you already have plans in place to change this provider and if so what is the expected change date and who is the replacement provider?
Please complete if you DO NOT use Teleradiology provider(s) for radiology reporting
48 How is your out of hours rota covered (e.g. Consultants, Registrars)?
49 What metric are you using to answer the below (number of body parts or examinations)?
50 What is your average number of emergency (1 hour) CT examinations per night (5pm – 9am)?
51 What is your average number of emergency (1 hour) MR examinations per night (5pm – 9am)?
Please complete if you use external companies to provide onsite radiology reporting
(duplicate this section if you use more than 4 providers)
52 What metric are you using to answer the below (number of body parts or examinations)?
53 How many elective CT examinations have been reported by this route?
54 How many elective MR examinations have been reported by this route?
55 How many elective Plain Film examinations have been reported by this route?
56 How many emergency (1 hour) CT examinations have been reported by this route?
57 How many emergency (1 hour) MR examinations have been reported by this route?
58 Do you use them for any other sub-specialist streams of work (e.g. PET CT, Nuclear Medicine, Prostate)?
Artificial Intelligence (AI)
59 Do you use (or have you trialled at any point) AI which analyses radiology images for possible clinical abnormalities and provides support to the reporter?
60 If yes, please detail the provider, the date(s) of use and the clinical findings the AI was looking for:
61 Please provide below (or by attachment) any FOI questions and corresponding responses the Organisation has processed relating to Radiology Spend or Activity since April 2018

Download response Radiology Services. 250220

Radiology staff details. 271118

You asked:
1. The name and email address of the Trust PACS manager
2. The name and email address of the Trust Radiology Manager
3. The name and email address of the Trust Radiology Service Manager
4. The name and email address of the Trust RIS Manager
5. The name and email address of the Trust Head of Imaging
6. The name and email address of the Radiology IT Manager

Download response Radiology staff details. 271118

Radiotherapy machines.241219

1. In the last calendar year to date 26/11/2019, for each radiotherapy machine(Linac) of the radiotherapy machines that were commissioned for service for the entire period, how many days was each machine out of service for more than half of the standard working day for repairs or maintenance;
2. And, for each machine of the radiotherapy machines that were commissioned for service for the entire period specified, what proportion did these days(in which the machine in question was out of service for repairs and maintenance for more than half of the standard working day) comprise of the total number of days the machine, had it not been being repaired or maintained, would have been able to treat patients if staffed(excluding days which were not staffed to provide radiotherapy – for instance, some Trusts won’t have staffing arrangement on weekends and bank holidays, so those days should be omitted when calculating this ratio).

Download response Radiotherapy machines.241219

Radiotherapy, Physics and Dosimetry agency staff. 210918

You asked:
1. What was your Trusts total spend on Radiotherapy Agency staff from 09/04/2018 to date?
2. How many Radiotherapy agency staff did you use at your Trust from 09/04/2018 to date?
3. How many Radiotherapy agency staff do you currently utilise at your Trust?
4. What were your Trusts total spend on Radiotherapy Physics/Dosimetry Agency staff from 09/04/2018 to date?
5. How many Radiotherapy Physics/Dosimetry agency staff did you use at your Trust from 09/04/2018 to date?
6. How many Radiotherapy Physics/Dosimetry agency staff do you currently utilise at your Trust?

Download response Radiotherapy, Physics and Dosimetry agency staff. 210918

Radiotherapy treatment sessions.241219

1. How many radiotherapy treatment sessions were rescheduled due to the linear accelerator(Linac) they were due to be treated in being out of service for repairs or maintenance.

Download response Radiotherapy treatment sessions.241219

Renal cell carcinoma specialist nurses

Please provide the number of a.) Renal cell carcinoma clinical nurse specialist b.) Uro-oncology clinical nurse specialists and c.) Urology clinical nurse specialists currently employed by your Trust

Download response Renal cell carcinoma specialist nurses 040116

Renal Multidisciplinary team (MDT)

1. Does your Trust employ one or more renal Multidisciplinary team (MDT)?
2. If yes, does this team include an Interventional Radiologist (IR)?
3. Does your Trust employ a Specialist to look into access problems with AV fistulas?

Download response Renal Multidisciplinary team (MDT) 270516

Rituximab. 180718

1. Do you have local clinical pathways or standard operating procedures (SOPs) for the use of MabThera? If so are you able to share these? For instance, is one cycle of MabThera intravenous (IV) always used before initiating the patients on MabThera subcutaneous (SC) in oncology indications?
2. Number of patients treated* using MabThera subcutaneous versus MabThera intravenous in oncology indications between 2016-2018, if only partial data is available please indicate the timeframe the data refers to.
3. Total number of patients treated* with MabThera (intravenous and subcutaneous) vs Rixathon vs Truxima in oncology and rheumatology indications between 2016-2018, if only partial data is available please indicate the timeframe the data refers to.
4. Do you have local clinical pathways or standard operating procedures (SOPs) for the initiation of new patient treatment regimens? If so are you able to share these?
5. Specifically, are new patients directly prescribed biosimilar rituximab (i.e. Truxima or Rixathon) instead of MabThera?
6. Are existing patients being switched from MabThera intravenous to biosimilar rituximab (i.e. Truxima or Rixathon)? If so is there a set point in their treatment pathway when patients are switched and how is this managed?
7. Are any existing patients being switched from MabThera subcutaneous to biosimilar rituximab (i.e. Truxima or Rixathon)? If so is there a set point in their treatment pathway when patients are switched and how is this managed?
8. Number of patients treated* using rituximab biosimilars (Truxima and Rixathon) instead of MabThera (intravenous and subcutaneous) between 2016-2018, if only partial data is available please indicate the timeframe the data refers to.
9. As an organisation, are you aware of any financial savings made by using biosimilar rituximab (i.e. Truxima or Rixathon) vs MabThera between 2017-2018, if only partial data is available please indicate the timeframe the data refers to and the methods used to calculate the financial savings.
10. Please provide information for the current contracts for Truxima, Rixathon, MabThera intravenous (IV) or subcutaneous (SC).
11. Related to question 10, if contracts are tiered by volume, could you please provide the thresholds for each tier and what is the price percentage difference between tiers?

Download response Rituximab. 180718

Secondary breast cancer

1. Is Maidstone and Tunbridge Wells NHS Trust (MTW) routinely collecting data on secondary breast cancer?

2. If so, how many people were diagnosed with the disease within the Trust in the last twelve months (or for the latest period available)? These should include (a) those who were diagnosed with secondary breast cancer at their first presentation; and (b) those for whom their primary breast cancer has progressed and spread to other parts of the body. Please also include the time period this data refers to.

Download response Secondary breast cancer 100516

Sickle cell and thalassaemia specialist nurses. 220118

1. How many sickle cell and thalassaemia specialist nurses are employed at your trust in the financial years 2013/14, 2014/2015 and 2015/2016?

2. How many sickle cell related deaths have there been in the years 2013/14, 2014/2015 and 2015/2016?

3. What is the age of deceased and cause of death?

Download response Sickle cell and thalassaemia specialist nurses. 220118

Specialist Skin MDT’s. 170119

There are two types of skin cancer MDTs; Local Skin MDTs and Specialist skin cancer multidisciplinary teams (SSMDT).
Specialist Skin MDTs will normally consider patients who:
• Have a rare skin cancer.
• Have SCC or melanoma that’s at higher risk of coming back or has come back.
• Have any type of skin cancer that’s spread to another part of the body.
• Need treatment that the Local Hospital Skin Cancer MDT doesn’t provide.
• May be offered to participate in a clinical trial.
If your Trust hosts a Specialist Skin MDT, we would be very grateful for the names of the MDT participants please.
Specialist Skin MDT members:
Dermatologists:
Plastic Surgeons:
Clinical Oncologists:
Medical Oncologists:
Radiologists
Histopathologists
Skin Cancer Nurse Specialists
Skin Cancer MDT/pathway coordinators
Other MDT attendees

Download response Specialist Skin MDT’s. 170119

Stress echocardiograms. 291118

You asked:
1) How many Stress echocardiograms (Dobutamine or exercise) were performed in the trust in the financial year 2011-12?
2) How many Stress echocardiograms (Dobutamine or exercise) were performed in the trust in the financial year 2012-13?
3) How many Stress echocardiograms (Dobutamine or exercise) were performed in the trust in the financial year 2013-14?
4) How many Stress echocardiograms (Dobutamine or exercise) were performed in the trust in the financial year 2014-15?
5) How many Stress echocardiograms (Dobutamine or exercise) were performed in the trust in the financial year 2015-16?
6) How many Stress echocardiograms (Dobutamine or exercise)were performed in the trust in the financial year 2016-17?

Download response Stress echocardiograms. 291118

Support for secondary breast cancer patients. 041018

You asked:
Holistic Needs Assessments (HNAs)
1) Do patients with secondary breast cancer have a Holistic Needs Assessment (HNA), used to plan their care, conducted at the point of diagnosis (of their secondary breast cancer) and/or as their treatment changes?
2) If yes, do the HNAs cover the following areas?
Access to a Clinical Nurse Specialist
3) How many people with secondary breast cancer are currently under the care of your Trust?
4) Do all patients with secondary breast cancer under the care of your Trust have access to a Clinical Nurse Specialist (CNS) with the appropriate skills, knowledge and experience of secondary breast cancer? (yes/no)
5) If yes, do these nurses:
a) Provide care to secondary breast cancer patients only? (yes/no)
b) Provide care to both primary and secondary breast cancer patients? (yes/no)
6) If yes, please provide the number of CNS posts that fall under each of these categories (as applicable):
a) CNSs that provide care to secondary breast cancer patients only
b) CNSs that provide care to both primary and secondary breast cancer patients
7) If there are CNS posts within your Trust that provide care to both primary and secondary breast cancer patients, please tell us if they:
a) Work in a combined role (where the care of both primary and secondary breast cancer patients is part of their formal job description) (yes/no)
b) Work across both areas but their formal job description only covers primary breast cancer patients (yes/no)
Information and referrals
8) At diagnosis and/or during the time they are under the care of your Trust, are patients with secondary breast cancer provided with the following information and/or referred to the following services?
Treatment Summaries
9) Do patients with secondary breast cancer receive a Treatment Summary* at the end of each significant phase of treatment? (yes/no)
Access to Health and Wellbeing Events
10) Does your Trust offer a Health and Wellbeing event* suitable for patients with secondary breast cancer? (yes/no)

Download response Support for secondary breast cancer patients. 041018

Surface contamination wipe tests. 161216

• Does your Trust conduct regular environmental monitoring, risk assessment and/or staff surveillance within cancer day units to detect possible chemical contamination from hazardous drugs being administered? E.g. Surface contamination wipes tests.
• If so, what assessments/tests are conducted and how often are they carried out?

Download response Surface contamination wipe tests. 161216

TARGeted Intraoperative Radiotherapy

For Maidstone and Tunbridge Wells NHS Trust (and any previous iterations of it) the number of early breast cancer cases treated at the Trust with TARGeted Intraoperative Radiotherapy (also known as Intrabeam or TARGIT IORT) for each year from January 2000 to the date of this request. Please identify the number of cases in each year which were delivered as part of a clinical trial and the number which were delivered as treatment which was not part of a clinical trial.

For the Trust, the date at which the Trust or Clinical Commissioning Group purchased equipment able to deliver TARGeted Intraoperative Radiotherapy, the price paid for that equipment and the name of the organisation from whom it was purchased.

Download response TARGeted Intraoperative Radiotherapy 220216

Tele-Radiology Reporting services. 270618

If your trust uses Tele-radiology services, please kindly outline which suppliers you utilise and the total number of images outsourced during the months of November 2017 – March 2018:

Download response Tele-Radiology Reporting services. 270618

Testing services for cancer indications and therapies.

Do you currently offer a companion diagnostic (stratified medicine) testing services for the following cancer indications and therapies? If so I would be grateful if you could please indicate which tests are offered, the charge per patient test (ideally a comment on what the overhead/kit breakdown of the test cost) and the number performed per year January-December (or month if easier – please specify in comments). The brand name of the test used or any information regarding commercial partnerships would also be appreciated to be included in the comments.

Test Types: IHC = Immunohistochemistry, FISH = Fluorescent In-Situ Hybridization, PCR = Polymerase Chain Reaction, Pyro= Pyrosequencing, NGS = Next Generation Sequencing. If the lab performs another test type or the test is linked to another oncological therapy not listed please check “Other” and include it in the comments section.

Download response Testing services for cancer indications and therapies 270616

Thyroid surgery. 160818

You asked:
1). Do any of the hospital (s) in your Trust admit as daycase or longer patients who are admitted to undergo thyroid surgery?
2a) How many consultant surgeon(s) in your trust undertake thyroid surgery operations?
2b) What are the parent specialties of each of the surgeons undertaking thyroid surgery operations e.g. general surgery, endocrine surgery, otolaryngology, OMFS etc.
2c) In 2017 (1st Jan to 31st Dec 2017) how many thyroid operations procedures did each consultant surgeon undertake (include number undertaken by other team members where the patients were under the care of the consultant). Please break down also by parent specialty
2c) i) How many of the consultant surgeons undertaking thyroid surgery in your trust submit all or most of their thyroid patient outcome data to the United Kingdom Register of Thyroid and Endocrine Surgery (UKRETS) provided by British Association of Thyroid and Endocrine Surgery?
ii) Of this group what is the breakdown of their parent speciality(ies)
2d) With regard to the local Thyroid cancer MDT how many of the consultant surgeons undertaking thyroid surgery in your trust or other health service organisation are:
i) Core members of the local thyroid cancer MDT.
ii) Extended members of the local thyroid cancer MDT.
iii) Not connected with the local thyroid cancer MDT.
2e) Which Trust or other health service organisation and which hospital site hosts the local thyroid Cancer MDT that connected surgeons attend?
3) This question only applies if your Trust or other Health Service Organisation Hosts the local Thyroid MDT.
3a) What is the frequency of the local thyroid cancer MDT meeting?
3b) Is the MDT:
i)‘Stand alone ‘
ii) Adjacent in time to the Head and Neck MDT but not within the Head and Neck MDT
iii) Within the Head and Neck MDT.
iv) Other – please give details:
v) What medical / surgical / diagnostic specialties are represented in the CORE membership of the MDT (doctors only)
vi) What medical / surgical / diagnostic specialties are represented in the EXTENDED membership of the MDT (doctors only)
3c) Does the MDT Routinely discuss the following groups of patients?
i) Patients who are being investigated but have not yet had surgery but where pre operative investigation has shown a high likelihood of
ii) Patients who are being investigated but have not yet had surgery but where pre operative investigation has shown an intermediate risk of cancer
iii) Patients who have had thyroid surgery and where histopathology has shown thyroid cancer in the resected specimen?

Download response Thyroid surgery. 160818

Ultrasound. 010719

1. How many hospitals make up your trust/Health Board?
2. Please could I know how many Ultrasound scanning machines your trust has along with their make and model, install, replacement dates and location within hospital?
3. Please may I have the contact details of the person/persons responsible for your existing Ultrasound systems?

Download response Ultrasound. 010719

Urgent cancer referrals

How many urgent cancer referrals did the Trust receive from GPs each year in 2011, 2012, 2013, 2014 and 2015?
How many of these referrals each year were deemed, by the consultant or referral management panel, to not meet the criteria for an urgent cancer referral?

Download response Urgent cancer referrals 090916

Urgent suspected cancer (USC) MRI. 090617

1. What is the trust target time for an urgent suspected cancer (USC) referral for an MRI scan?
2. If question 1 does not apply, what is the trust target time for a USC referral to have a diagnostic test/report?
3. How many of the referrals from questions 1 and 2 have failed to meet these targets in the year 1/4/16 – 1/4/17? If the data is available please may I have the amount who have not met the MRI waiting time? If that data is unavailable may I have the amount that have failed to meet the target time for a USC referral to a diagnostic test/report?
4. Is there a financial penalty if either above target is not met? If so what is this penalty?

Download response Urgent suspected cancer (USC) MRI. 090617

Urothelial Cancer. 270918

You asked:

Please indicate the number of metastatic or locally advanced Urothelial cancer patients treated by your Trust in the 3 months, April 2018 to June 2018 inclusive.
If data is not held in a sufficient way within your Trust systems, i.e. if for example you are unable to distinguish between cancer type and/or stage, please indicate accordingly within the tables below.
1. Total number of metastatic or locally advanced Urothelial cancer (UCC, transitional carcinoma, TCC) patients treated
2. Of the metastatic or locally advanced Urothelial cancer patients treated by your Trust in the 3 months, April 2018 to June 2018 inclusive, please indicate the number treated with the following therapies.
Cisplatin (mono or combination therapy)
Carboplatin (mono or combination therapy)
Pembrolizumab (Keytruda)
Atezolizumab (Tecentriq)
If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust(s) patients are referred:

Download response Urothelial Cancer. 270918

Urothelial Cell Cancer. 050718

You asked:
Please indicate the number of metastatic or locally advanced Urothelial cancer patients treated by your Trust in the 3 months, December 2017 to February 2018 inclusive.
If data is not held in a sufficient way within your Trust systems, i.e. if for example you are unable to distinguish between cancer type and/or stage, please indicate accordingly within the tables below.
1. Total number treated (Metastatic/locally advanced Urothelial patients)
If unable to provide number of metastatic/locally advanced Urothelial patients, please indicate the level at which data has been provided:
2. Of the metastatic or locally advanced Urothelial cancer patients treated by your Trust in the 3 months, December 2017 to February 2018 inclusive, please indicate the number treated with the following therapies.
Cisplatin (mono or combination therapy)
Carboplatin (mono or combination therapy)
Pembrolizumab (Keytruda)
Atezolizumab (Tecentriq)
3. If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust(s) patients are referred:

Download response Urothelial Cell Cancer. 050718

Urothelial Cell Cancer. 151118

You asked:
1. Please indicate the number of metastatic or locally advanced Urothelial cancer patients treated by your Trust in the 3 months, July 2018 to September 2018 inclusive.
If data is not held in a sufficient way within your Trust systems, i.e. if for example you are unable to distinguish between cancer type and/or stage, please indicate accordingly within the tables below.
If unable to provide number of metastatic/locally advanced Urothelial patients, please indicate the level at which data has been provided:
2. Of the metastatic or locally advanced Urothelial cancer patients treated by your Trust in the 3 months, July 2018 to September 2018 inclusive, please indicate the number treated with the following therapies.
If unable to provide number of metastatic/locally advanced Urothelial patients, please indicate the level at which data has been provided:
Cisplatin (mono or combination therapy)
Carboplatin (mono or combination therapy)
Pembrolizumab (Keytruda)
Atezolizumab (Tecentriq)
3. If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust(s) patients are referred:

Download response Urothelial Cell Cancer. 151118

Urothelial Cell Cancer. 301117

1. How many of the following patients (excluding clinical trial patients) are currently being managed by your Health Trust:
All Urothelial cancer (UCC, transitional carcinoma, TCC) patients
Metastatic* or locally advanced* Urothelial cancer (UCC, transitional carcinoma, TCC) patients
2. Of the metastatic* or locally advanced* Urothelial cancer (UCC, transitional carcinoma, TCC) patients, please state the number of patients currently being treated with the following therapies:
Cisplatinum single agent
Cisplatinum in combination with another agent
Carboplatinum single agent
Carboplatinum in combination with another agent
Any other chemo regimen without cisplatinum or carboplatinum
Pembrolizumab (Keytruda)
Atezolizumab (Tecentriq)
3. If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust patients are referred:

Download response Urothelial Cell Cancer. 301117

Vascular and Venous Lead. 180718

You asked:
1. Does the Trust have a vascular and venous lead?
2. If so, what is the name of the lead/s?
3. Please can you provide the email address of the lead/s?

Download response Vascular and Venous Lead. 180718

Venesection Protocols. 180718

You asked:
1. A copy of your clinical protocol(s) for therapeutic venesection

2. The date at which your venesection protocol was most recently reviewed & updated

Download response Venesection Protocols. 180718

Venous Thromboembolism in cancer patients. 241016

Please find attached a set of questions relating to venous thromboembolism in cancer patients.

Venous thromboembolism (VTE) in cancer patients

Part 1: Incidence
Question 1: How many patients has your Trust treated for cancer (of all types) in each of the past four years?
Question 2: Of the patients treated for cancer, how many also had a diagnosis of venous thromboembolism (VTE) {VTE is defined by the following ICD 10 codes: I80.0-I80.3, I80.8-I80.9, I82.9, O22.2 – O22.3, O87.0 – O87.1, I26.0, and I26.9} in each of the past four years?
Question 3: Of the patients treated for cancer who also had a diagnosis of VTE in each of the past four years, how many:
Were receiving chemotherapy?
Had metastatic disease?
Had localised disease?
Were treated for brain cancer?
Were treated for lung cancer?
Were treated for uterine cancer?
Were treated for bladder cancer?
Were treated for pancreatic cancer?
Were treated for stomach cancer?
Were treated for kidney cancer?

Part 2: Mortality
Question 4: In how many patient deaths within your Trust was cancer (of any type) listed as the primary cause of death in each of the past four years:
Question 5: Of the patients who died within your Trust, in how many was VTE as well as cancer listed as a cause of death in each of the past four years:
Question 6: Of the patients who died in your Trust who had both VTE and cancer listed as a cause of death, how many:
Were receiving chemotherapy?
Were treated for brain cancer?
Were treated for lung cancer?
Were treated for uterine cancer?
Were treated for bladder cancer?
Were treated for pancreatic cancer?
Were treated for stomach cancer?
Were treated for kidney cancer?

Part 3: Advice given to patients
Question 7: Are patients who receive chemotherapy provided with written and verbal information about the risk of developing VTE during chemotherapy? Is this information provided to chemotherapy inpatients only, chemotherapy outpatients only, or both in and outpatients?
Question 8: Are patients who receive chemotherapy provided with written and verbal information which outlines the symptoms suggestive of VTE? Is this information provided to chemotherapy inpatients only, chemotherapy outpatients only, or both in and outpatients?
Question 9: Are patients who receive chemotherapy provided with written and verbal information regarding what action they should take if they suspect a Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)? Is this information provided to chemotherapy inpatients only, chemotherapy outpatients only, or both in and outpatients?
Question 10: Does your Trust have a policy or pathway for the management of suspected VTE in patients receiving chemotherapy?

Download response Venous Thromboembolism in cancer patients. 241016

Venous thromboembolism (VTE) in cancer patients 2012,2013 & 2014

Question 1: How many patients has your Trust treated for cancer (of all types) in each of the past three years?

Question 2: Of the patients treated for cancer, how many also had a diagnosis of venous thromboembolism (VTE) {VTE is defined by the following ICD 10 codes: I80.0-I80.3, I80.8-I80.9, I82.9, O22.2 – O22.3, O87.0 – O87.1, I26.0, and I26.9} in each of the past three years?

Question 3: Of the patients treated for cancer who also had a diagnosis of VTE in each of the past three years, how many:
2014 2013 2012
Were receiving chemotherapy?
Had metastatic disease?
Had localised disease?
Were treated for brain cancer?
Were treated for lung cancer?
Were treated for uterine cancer?
Were treated for bladder cancer?
Were treated for pancreatic cancer?
Were treated for stomach cancer?
Were treated for kidney cancer?

Part 2: Mortality
Question 4: In how many patient deaths within your Trust was cancer (of any type) listed as the primary cause of death in each of the past three years:
a) 2014
b) 2013
c) 2012

Question 5: Of the patients who died within your Trust, in how many was VTE as well as cancer listed as a cause of death in each of the past three years:

Question 6: Of the patients who died in your Trust who had both VTE and cancer listed as a cause of death, how many:
2014 2013 2012
Were receiving chemotherapy?
Were treated for brain cancer?
Were treated for lung cancer?
Were treated for uterine cancer?
Were treated for bladder cancer?
Were treated for pancreatic cancer?
Were treated for stomach cancer?
Were treated for kidney cancer?

Part 3: Advice given to patients
Question 7: Are patients who receive chemotherapy provided with written and verbal information about the risk of developing VTE during chemotherapy?

Question 8: Are patients who receive chemotherapy provided with written and verbal information which outlines the symptoms suggestive of VTE?

Question 9: Are patients who receive chemotherapy provided with written and verbal information regarding what action they should take if they suspect a Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)?

Question 10: Does your Trust have a policy or pathway for the management of suspected VTE in patients receiving chemotherapy?

Download response Venous thromboembolism (VTE) in cancer patients 2012,2013 & 2014 311215

 

Car parking

Car Parking Charges

How much money did the trust raise from car parking charges in each of the last four years (state the amount and the years for which figures are available)?
Do you charge for disabled parking? If so, how much of the total amount raised by the trust from car parking charges came from disabled parking?
Do you employ a private firm to run the car park for you? If so, how much of the money generated by parking fees is taken by the private firm?
Please provide a breakdown of your car park charges – per hour/per day/per week.
Do you provide concessions for long-term visitors? What are these?

Download response Car Parking Charges 181115

Hospital Parking Charges

How much money was generated by your hospital trust through parking charges in the hospital car parks during 2013-14 and 2014-15?
How many parking fines were issued for parking infringements in your car parks during 2013-14 and 2014-15?
How many parking fines were written off during 2013-14 and 2014-15?

Download response Hospital Parking Charges 200515

Abandoned motor vehicles

1) How many instances of abandoned motor vehicles were recorded between 2004-15? If the data doesn’t stretch back to 2004, please use the earliest you have.

2) If a 3rd party was called to recover, what was the average cost involved?

Download response Abandoned motor vehicles 181215

Cancer care or treatment 2015-2016. 020317

1. In the years 2015 & 2016 of the patients that became resident for Cancer care/treatment with inside a hospital managed by your trust, please list the annual total for the patients as described?

2. Further to the above please also provide the annual total for those patients’ families who received a pass entitling free parking during the patients stay to reduce the financial burden on the family visiting?

Download response Cancer care or treatment 2015-2016. 020317

Car park management 070317

1. Please could you confirm when your contract for Car Park Management will expire and also when the contract will be re-tendered?

2. Do you currently manage your own car parks or use a Car Park Management company?

3. Which Portal does the trust use when they tender the Car Park Management out?

Download response Car park management 070317

Car parking

1. Please state what the income was to the Trust from parking income in patient car parks in (i) the (14/15) financial year and (ii) the (15/16) financial year?
2. What is the highest hourly rate for parking charged to patients in any of your car parks?

Download response Car parking 090916

Car parking 071116

1. How much revenue did the Trust receive from car parking fees between 1st October 2015 and 1st October 2016?
2. What are the Trusts rates per hour and per day (can you indicate if this varies between hospitals in the Trust)? Is there any way to get a reduction in this rate?
3. Has the Trust increased the parking charge in the last two years and if so by how much?
4. If the Trust car parks are run by an outside firm and can you please say who that is?

Download response letter Car parking 071116

Car parking 071116

1. How much revenue did the Trust receive from car parking fees between 1st October 2015 and 1st October 2016?
2. What are the Trusts rates per hour and per day (can you indicate if this varies between hospitals in the Trust)? Is there any way to get a reduction in this rate?
3. Has the Trust increased the parking charge in the last two years and if so by how much?
4. If the Trust car parks are run by an outside firm and can you please say who that is?

Download response Car parking 071116

Car parking. 190717

1. Hourly Car Parking Charges
2. Daily Car Parking Charges
3. Weekly Car Parking Charges
4. Car Parking Charges for Blue Badge Holders
5. Car Parking Charges for Staff

Download response Car parking. 190717

Car parking 2015-2016 221216

1. Are your carparks managed by a private contractor? If yes, please provide the name of the contractor.
2. How many parking enforcement tickets were issued in your carparks between 1st April 2015 and 31st March 2016?
3. What is the cost of a parking enforcement fine in your carparks?
4. How many parking enforcement ticket appeals did you receive between 1st April 2015 and 31st March 2016?
5. How many parking enforcement ticket appeals were successful between 1st April 2015 and 31st March 2016?

Download response Car parking 2015-2016 221216

Car parking. 210318

1. The income earned from hospital car parking charges for the financial years:
1. 2014-2015
2. 2015-2016
3. 2016-2017
2. The money spent on maintenance for car parking facilities in the financial years:
1. 2014-2015
2. 2015-2016
3. 2016-2017
3. Where the income earned from hospital car parking facilities was spent in the financial years:
1. 2014-2015
2. 2015-2016
3. 2016-2017

Download response Car parking. 210318

Car parking. 240119

Subject to the Freedom of Information Act, I would like to request the following information in the relation to the Trust and associated hospitals.
1. Do you currently manage your car parking in-house or do you contract to a third party?
2. If you do employ a parking operator to manage your parking services, who is your current parking provider?
3. What is the exact date/s your current contract/s terminate?
4. What date do you expect to go to tender?

Download response Car parking. 240119

Car parking at the Trust sites 261015

Under the Freedom of Information Act 2000, I am seeking the following pieces of information in relation to parking at the hospitals covered under your trust.
1. The parking ticket costs at the hospitals under your trust.
2. How much does your trust – or a third party contracted by the trust – charge in fines and/or penalty notices if people are deemed to have breached parking rules?
3. What is the revenue from visitors paying for parking tickets? I would like this broken down for each hospital. I would like this information annually for 2012-2013, 2013-2014, and 2014-2015.
4. What is the revenue received from the payment of fines and/or penalty notices? I would like this broken down for each hospital. I would like this information annually for 2012-2013, 2013-2014, and 2014-2015.

Car parking at the Trust sites 261015

Car parking charges. 011118

1. Do hospitals in your area charge patients/visitors to park in their own car park?
2. If so, how much do they charge?
3. Do the hospitals operate their car park under a PFI contract?

Download response Car parking charges. 011118

Car parking charges 041116

How much money did the trust raise from car parking charges in each of the last four financial years (state the amount and the years for which figures are available)? Include a breakdown of staff and visitor/patient parking if possible.

How much money was raised from parking fines in each of the last four financial years (state the amount and the years for which figures are available)? Include a breakdown of staff and visitor/patient fines if possible.

Do you charge for disabled parking?

Do you employ a private firm to run the car park for you? If so, how much of the money generated by parking fees is taken by the private firm?

Download response Car parking charges 041116

Car parking charges. 111217

1. How much money did the trust raise from car parking charges in each of the last four financial years – up to and including 2016/17 (state the amount and the years for which figures are available)? Include a breakdown of staff and visitor/patient parking if possible.

2. How much money was raised from parking fines in each of the last four financial years (state the amount and the years for which figures are available)? Include a breakdown of staff and visitor/patient fines if possible.

3. Do you charge for disabled parking?

4. Do you employ a private firm to run the car park for you? If so, how much of the money generated by parking fees is taken by the private firm?

Download response Car parking charges. 111217

Car parking charges. 160519

1. How much money did the trust raise from car parking charges in each of the last two financial years – 2017/18 and 2018/19? Include a breakdown of staff and visitor/patient parking if possible.
2. How much money was raised from parking fines in each of the last two financial years – 2017/18 and 2018/19? Include a breakdown of staff and visitor/patient fines if possible.
3. Have you increased the cost of parking in your car parks during the last financial year – between 2017/18 and 2018/19? Please give a breakdown of how much parking has increased by.
4. Do you charge for disabled parking?
5. Is your car park managed by a private firm? If so, what proportion of revenue created by a) parking income and b) parking fines does the firm take?

Download response Car parking charges. 160519

Car parking charges. 181019

1. How much money did the trust raise from car parking charges in each of the last two financial years – 2017/18 and 2018/19? Include a breakdown of staff and visitor/patient parking if possible.
2. How much money was raised from parking fines in each of the last two financial years – 2017/18 and 2018/19? Include a breakdown of staff and visitor/patient fines if possible.
3. Have you increased the cost of parking in your car parks during the last financial year – between 2017/18 and 2018/19? Please give a breakdown of how much parking has increased by.
4. Do you charge for disabled parking?
5. Is your car park managed by a private firm? If so, what proportion of revenue created by a) parking income and b) parking fines does the firm take?

Download response Car parking charges. 181019

Car parking charges 2015/2016 to date.

1. How much money has the trust raised from car parking charges so far this year?
2. How many parking fines were issued for parking infringements in your car parks so far this year?
3. How many parking fines were written off so far this year?

Download response Car parking charges 2015/2016 to date 100516

Car parking charges 2016. 140317

1. Name of your organisation
2. Does your Trust use a private contractor to oversee the car park?
Yes (if yes please provide name of contractor)
No
Parking Charges
3. Parking charges made to general public (patients, visitors, etc.)
4. Parking charges made to staff
5. Agreed exemptions from charges
6. How income from charges is used
Parking Fines (fines issued from 1 January 2016 to date)
7. Number of fines issued to the general public
8. Income from those fines
9. Number of fines issued to staff
Income from those fines
10. How income from fines is used
11. Does the policy for fining staff differ from the fines policy for the general public?
Yes (if yes, please advise how the policy differs) No
12. Please provide details of any policy or agreements covering car parking charges (e.g. collective agreement with NHS Trade Unions)

Download response Car parking charges 2016. 140317

Car parking charges. 280918

1. How much money did the trust raise from car parking charges in each of the last two financial years – 2016/17 and 2017/18? Include a breakdown of staff and visitor/patient parking if possible.

2. How much money was raised from parking fines in each of the last two financial years – 2016/17 and 2017/18? Include a breakdown of staff and visitor/patient fines if possible.

3. Have you increased the cost of parking in your car parks during the last financial year – between 2016/17 and 2017/18? Please give a breakdown of how much parking has increased by.

4. Do you charge for disabled parking?

Download response Car parking charges. 280918

Car parking charges and fines. 070618

1) How much revenue was made by Maidstone and Tunbridge Wells NHS Trust on all car parking charges and fines in 2015, 2016 and 2017. Please break this down by charges and fines.

2) How much profit was made by Maidstone and Tunbridge Wells NHS Trust on all car parking charges and fines in 2015, 2016 and 2017. Please break this down by charges and fines.

Download response Car parking charges and fines. 070618

Car parking contractor

Could you please advise me if you manage the Car Parking facilities on your own or do you employ a contractor to manage the facilities for you? I.e. ANPR, POF’s and PCN’s etc.  If you use a contractor can you please advise me who they are and when their existing contract with yourselves expire?

Download response Car parking contractor 080515

Car parking revenue. 241017

How much revenue the hospital trust made through the charging of hospital car parking in 2016?

Download response Car parking revenue. 241017

Cost and revenue of car parking 2010 – 2016

1. The total amount of revenue generated by in each of the last 5 years by car parking.
2. What was the cost for an hour of car parking in 2010 and 2016?

Download response Cost and revenue of car parking 2010 – 2016 060916

Disabled parking for staff. 030719

1. How many staff members at the trust are declared disabled?
2. How many staff members with a disability use the staff car park?
3. Do the trust charge disabled staff for parking?
4. If yes in Q3 is this charge at a discounted rate compared to a non-disabled staff member?
5. How much is staff car parking for disabled staff and non-disabled staff?

Download response Disabled parking for staff. 030719

Disclosure and Barring checks and staff parking. 221116

1) How many nurses and midwives (from Band 5 upwards) waiting to take up employment with your trust are awaiting completion of Disclosure and Barring Service (DBS) checks?
2) How long is the average wait for DBS approval for new starters at your organisation?
3) How many parking spaces at your hospitals are exclusively for staff use and how much do they pay to use them?
4) What is your FTE nursing and midwifery staff establishment (from Band 5 upwards)?

Download response Disclosure and Barring checks and staff parking. 221116

Electric Vehicle charging points.

1) Does your organisation already offer charging facilities (Electric Vehicle Charging Points EVCP) for electric vehicles and if so, how many charge points?
2) If there is currently no charging provision, what plans do you have to install EVCP and when?
3) Will the charge points be for fleet usage or public charging?
4) Within your organisation, which department is responsible for the selection and installation of EVCP?

Download response Electric Vehicle charging points 060916

Hospital parking. 190719

1. Please state the current fee for parking at the trust for one hour. (If there is no specific fee for one hour, please state the lowest possible time and cost)
2. Please state the fee for parking for one hour in 2018.
3. Please tell me whether the hospital provides free parking for any of the following groups a) cancer patients b) disabled patients c) other patients who are frequent visitors to the trust d) the relatives of patients who are frequent visitors.
4. Please tell me if the hospital provides reduced parking for any of the following groups a) cancer patients b) disabled patients c) patients who are frequent visitors d) the relatives of patients who are frequent visitors 5. If yes to question 4, please provide details.
6. Please state how much the trust collected in parking charges and fines in a) 2018/19 and b) 2017/18.
7. Does the trust hire any private firms to issue parking fines or clamp vehicles?
8. If yes to question 7, please provide the names of these firms

Download response Hospital parking. 190719

Hospital parking 2013-2017. 060617

1. How much money was generated by your hospital trust through parking charges in the hospital car parks during 2013-14, 2014-15, 2015-16 and 2016-17?
2. How many parking fines were issued for parking infringements in your car parks during the years stated above?
3. How many parking fines were written off during the years stated above?

Download response Hospital parking 2013-2017. 060617

Management of car parking facilities

Q: Could you please advise me if you manage the car parking facilties on your own, or do you employ a contractor to manage the facilities for you ie ANPR, POFs and PCNs etc? If you use a contractor can you please advise me who they are and when their existing contract with yourselves expires? Download response car parking contractor 080515

Motorcycle parking. 300419

1) How much do you charge staff members to park a motorcycle on site?
2) Is the motorcycle parking provided for staff in a covered area?
3) Do you provide ground anchors for staff in motorcycle parking areas?

Download response Motorcycle parking. 300419

Ownership of the land the Trust Hospitals stand on and the contractual terms of First Parking LLP’s contract

Details of who owns the land on which both Maidstone and Pembury hospitals are located.
Full details of the contractual terms that allow First Parking LLP to initiate legal action on behalf of the Trust.

Download response Ownership of the land the Trust Hospitals stand on and the contractual terms of First Parking LLP’s contract 021215

Parking. 060717

1. How many car parking sites fall under the remit of the Maidstone and Tunbridge Wells NHS Trust?
2. Roughly how many spaces do they provide in total across all sites?
3. Does the organisation manage their Car Parks directly (go to Q5) or via a Third Party (go to Q4)?
4. If managed by a Third Party:
a. Who is the provider?
b. Dates of the contract duration (from/to)?
c. What is the basis of the contract (build/operate; land lease; management only etc.)?
d. Any pros/cons of this arrangement?
5. How is parking currently controlled, e.g. POF, P&D, Permit, parking officers, barrier control, in/out global counting, bay occupancy?
6. Are you currently able to readily identify any patterns of use of particular zones/bay types/long or short term stays etc. and collate this data to address specific problems areas on certain days/time periods?
7. What existing customer service focused measures are in place, e.g. information provided at entry points, visual guidance to zones/bays with available spaces, on-site support staff?
8. What are the key challenges that the Maidstone and Tunbridge Wells NHS Trust face in regards to the provision of parking for patients/carers/visitors?
9. What are the key challenges that the Maidstone and Tunbridge Wells NHS Trust face in regards to the provision of parking for staff?
10. Do you attend any conferences/events that focus on best practice in the management of parking/land use which you would recommend as good networking opportunities?
11. Who is the person responsible for Car Parks in your organisation (Name, Title, telephone and direct email?)

Download response Parking. 060717

Parking and Security

  1. Who is/are the contractor(s) managing parking at both/either site(s)
  2. How long have they had the contract and when does it/they expire?
  3. What revenue arrangements are in place?I.e where does the money from parking go?
  4. What arrangements are in place for the sharing of parking charge notice revenue?
  5. What input did the trust have in setting the parking charge notice levels and the hourly charges for parking?
  6. Does the parking contract allow for the contractor to initiate and take forward legal action on behalf of the trust in cases where parking charge notices remain unpaid?
  7. I should like to see a full unredacted version of the contract between the trust and any contractor for parking management.
  8. What is the trusts policy regarding intervention at the request of service users after parking charge notices have been issued?
  9. How many times have the trust intervened at the request of a customer and what was the outcome on each occasion?

Download response Parking and Security 111115

Parking charge notices

How much money was generated by your hospital Trust through parking charges in the hospital car parks during 2013/14 and 2014/15? How many parking fines were issued for parking infringements in your car parks during 2013/14 and 2014/15? How many parking fines were written off during 2013/14 and 2014/15? Download response Parking charge notices 200515

Parking charges. 240919

Do the hospitals have any free parking drop-off zones, for example if someone is dropping a patient off at an appointment? Are there any rules around using these drop-off zones (for example, is there a maximum time drivers are able to wait, or is it only for patients with blue badges etc)?

If there are no free drop-off zones (or their use is restricted), what would be the cost to park in each hospital’s car park for 15 minutes in order to drop off a patient?

Download response Parking charges. 240919

Parking charges at Trust controlled or owned car parks 2013 to 2016.

1. What is the hourly parking rate at Trust-controlled or owned car parks?
2. How many spaces are available in Trust-controlled or owned car parks?
3. Who operates the car parks?
4. Please provide details of any discounts/exemptions offered to patients.
5. How much money was raised in each of the last three financial years from parking revenue? Please provide a breakdown for 2013/14, 2014/15, 2015/16.
6. How many parking fines were issued in each of the last three financial years? Please provide a breakdown for 2013/14, 2014/15, 2015/16.
7. How much money was raised from parking fines in each of the last three financial years? Please provide a breakdown for 2013/14, 2014/15, 2015/16.
8. What percentage (if any) of the parking revenue is diverted to the car park operator?
9. What is the remaining money raised from parking and received by the Trust used for?

Download response Parking charges at Trust controlled or owned car parks 2013 to 2016 180516

Parking permits issued between 30 August 2015 to 30 March 2016.

Can you tell me how many NHS staff have applied for a parking permit and issued with a permit between 30th of August last year and 30th of March 2016 and how many Interserve security staff have applied for a parking permit and issued with a permit between 30th of August last year and 30th of March 2016?

Download response Parking permits issued between 30 August 2015 to 30 March 2016 230516

Parking services July 2016

1. How many car parks out of the total number designated for hospital patients/visitors offer free parking, as of your most up-to-date statistics? (Please state how many and out of the total)
2. If you charge fees for hospital patients/visitor designated parking, do you have the same pricing structure at all your parking sites? (Yes/No)
3. What is your most commonly charged minimum rate for patient/visitor parking (excluding any free parking), and for how long does this allow somebody to park?
4. What is your most commonly charged maximum rate for patient/visitor parking (excluding any free parking), and for how long does this allow somebody to park?
5. What percentage of car parks designated for hospital patients/visitors allow payment by debit or credit card? Please approximate if necessary, and state if you do so.
6. What percentage of car parks designated for hospital patients/visitors allow payment on exit? Please approximate if necessary, and state if you do so

Download response Parking services July 2016 010816

Staff car parking spaces and cost 2011-2015.

1) How many staff work at the trust?
2) How many car parking spaces are there?
3) How many staff members use car parking facilities each day?
4) Do staff pay to park?
5) If so, how much to they currently pay if they pay by
a) salary sacrifice
b) daily
(please state if staff on different bands or pay grades pay different amounts to park. Please state what these amounts are)
6) Please state what the charges were for both salary sacrifice and daily parking in 2014/5
7) Please state what the charges were for both salary sacrifice and daily parking in 2013/4
8) Please state what the charges were for both salary sacrifice and daily parking in 2012/3
9) Please state what the charges were for both salary sacrifice and daily parking in 2011/2
10) What is the total amount paid by staff for parking at the trust in 2014/5
11) What is the total amount paid by staff for parking at the trust in 2013/4
12) What is the total amount paid by staff for parking at the trust in 2012/3
13) What is the total amount paid by staff for parking at the trust in 2011/2

Download response Staff car parking spaces and cost 2011-2015 180416

Staff parking. 070618

1. Please can you let me know if you charge your staff for parking at Tunbridge Wells hospital and if so how much?

2. If you have a policy on staff parking at Tunbridge Wells hospital may I please have a copy?

3. Finally can you let me know what ward shift patterns you have for staff nurses. What time do they start the day shift and what time do they finish.
Download response Staff parking. 070618

Staff parking. 160418

How many parking spaces are available for Staff who work for your trust at both hospital sites, and how many parking permits are issued to staff across both sites.

Download response Staff parking. 160418

Staff parking- permits and policy. 311019

Staff parking capacity (please separately count designated disabled spaces and spaces with electric vehicle charging points)
1. What are the names and locations of the acute hospital sites the trust operates from?
2. How many total parking spaces are there at each location and how many of these are reserved for staff?
3. How was the balance between public and staff parking places determined?
4. Do staff have access to other parking spaces at nearby satellite locations?
5. What provision is there to help staff travel from satellite parking locations to the acute site?
6. Is there a trust provided bus service to satellite parking locations?
7. Are there any specifically reserved staff parking spaces and what are these (that is, are these reserved for holders of specific posts or by for those covering operational roles on particular shifts)
Staff parking demand (separate out blue badge holders)
8. Analysed by staff group, what is the established head count of the trust and how many of these use a car to travel to work.
a. Consultant grade doctor and dentists
b. Junior doctors and dentists
c. Nursing and clinical support staff
d. Scientific, technical and therapeutic staff
e. Management and administrative staff, including executive directors.
f. Non-executive directors and trust chair.
Determining access to staff parking
9. How is access to staff parking managed: please provide the current parking policy?
10. If the policy has changed within the last three years what were the specific changes and how were these decided upon. Please provide the papers that accompanied the policy document to the body approving it.
If not specifically covered by the staff parking policy:
11. How is access to staff parking rationed. Please set out by time of day and day of the week if there are differences.
12. Are there criteria for gaining access to staff parking, for example journey time by public transport or home to site distance.
13. How are these criteria assessed. What triggers a need to reconfirm that criteria are being met.
14. How were these criteria set.
If there is a permit system in place and by site:
15. How many permits exist in total and what ratio to the number of places is this.
16. How was this ratio determined.
17. Are there different types of permit. Are different permits allocated for different days of the week?
How are permits allocated:
18. Please provide the application documents and terms and conditions of use of a staff parking permit.
If not covered by these documents:
19. Is there a periodic process of reallocation. How often does this process occur.
20. If there is a waiting list for permits how is this managed.
21. Is there a single trust wide waiting list, or if not what are the different waiting lists.
22. How many staff were on each of the waiting lists as at 1st October 2019.
23. What date was the person at the top of each waiting list added.
24. What is the average wait time (in months) for the lists.
25. Do certain staff groups (as a cohort, for example all junior doctors) automatically get allocated a permit without needing to wait.
26. What is the basis for this policy by each such group.
27. Do certain job related criteria (regardless of staff group) mean certain people advance to the front of the waiting list.
28. What are these criteria.
29. What is the policy when the criteria cease to be met.
30. Does the permit get revoked and the staff member join the waiting list.
31. Where do they join the waiting list in this circumstance.
32. Are there any non-work related criteria that might lead to advancing to the front of the waiting list. What are these criteria.
33. What is the policy when the criteria cease to be met.
34. Does the permit get revoked and the staff member join the waiting list.
35. Where do they join the waiting list in this circumstance.
36. Are there any criteria for temporarily being given a permit.
37. What are these criteria.
38. What is the policy when the criteria cease to be met.
39. Does the permit get revoked and the staff member join the waiting list.
40. Where do they join the waiting list in this circumstance.
41. Are staff that only work bank shifts permitted to apply for a permit.
42. Can staff working less than 37.5 hours per week apply for a permit.
43. How is the system of permits enforced.
44. Are permits vehicle or staff member specific.
45. What controls exist around the misuse of permits.
46. What is the sanction for misusing a permit.
47. If there are more permits than spaces how are spaces allocated.
48. If there is a “first come, first served” system in place what measures are in place to ensure this does not prejudice for example people with caring responsibilities.
Economic and financial aspects
49. What is the charge for one month of access to a staff parking space.
50. Please answer separately for every agenda for change band, for those on VSM contracts, for junior doctors, for consultant grade doctors, for non-executive directors, for trust chair.
51. Is there a different charge for part time permits, if these exist.
52. What are these arrangements.
53. What was the income from staff parking in September 2019.
54. What was the income from staff parking in the year ending 31st March 2019.
55. What is the cost of administering, operating and maintaining staff parking spaces for September 2019 and for the year ending 31st March 2019. Please include capital and revenue expenditure.
56. Are staff permitted to use public car parking spaces. Is there any sanction on this.
Impact on recruitment and retention
57. Has any analysis of the availability of staff parking impacting on recruitment and retention been conducted. If so please provide this.
58. Do staff in hard to recruit roles get pushed to the front of the waiting list for parking permits.

Download response Staff parking- permits and policy. 311019

Wages, staff parking charges and public relations and marketing costs. 200219

1. (if applicable) Please can you provide me with a copy of the current statement of car parking charges for staff? If such a document doesn’t exists, please can you tell me how much you charge (hourly rate) for staff working at your hospital(s)
2. What are the wages and job titles of your five highest paid members of staff?
3. How much money has the trust spent on public relations and marketing (including staff costs) in the past two financial years (15/16 and 16/17). (If this information is easy to obtain please include – if this will take my combined request over the cost/time limit, please do not process this part of the request)

Download response Wages, staff parking charges and public relations and marketing costs. 200219

 

Children's Services

6-in-1 vaccine. 170718

a) The number of 6-in-1 vaccines offered to be given to babies in the financial years 2017/18, 2016/17, and 2015/16.

b)The number of 6-in-1 vaccines that were refused by parents or guardians of the baby in the financial year 2017/18, 2016/17, and 2015/16.

c) The number of children diagnosed with any of the following in 2017/18 alone, who had not received the 6-in-1 vaccine when they were a baby because their parent or guardian had refused it. If a child was diagnosed with more than one of the below, please provide that information: diphtheria, hepatitis B, Hib, polio, tetanus, or whooping cough

Download response 6-in-1 vaccine. 170718

A&E and Outpatient Paediatric attendances. 250419

1- Number of paediatric patient attended A/E in 2018, Tunbridge wells hospital
2- Number of patient attended paediatric OPD (outpatient department) in 2018, Tunbridge wells hospital

Download response A&E and Outpatient Paediatric attendances. 250419

Ankylossia (tongue-tie). 270918

1. How many babies (i.e.) below the age of 1) were diagnosed with issues of Ankylossia (tongue-tie) in each financial year since 2013/14.
2. Of the babies diagnosed with issues of Ankylossia (tongue-tie) in 2017 how many had a surgical procedure carried out by NHS surgeons to resolve these specific issues, and how long did they wait (on average, in calendar days) for the procedure following diagnosis?
3. In 2017, what was the mean age of babies with such issues when the Ankylossia (tongue-tie) procedure was performed?

Download response Ankylossia (tongue-tie). 270918

Anorexia and bulimia in under 14 year olds.

The number of children under the age of 14 your trust has treated for anorexia and bulimia from 1 January 2010 up until the date this request was received.
Please provide the information in yearly breakdowns;
Please break the numbers down by age and, if possible, by gender;
Please keep the data for anorexia and bulimia separate;

Download response Anorexia and bulimia in under 14 year olds 060916

Ante natal screening or diagnostic results for Down syndrome. 100519

Please send me an example of all of the following that are in use:
a) Letter/email reporting low chance combined or quadruple screen results
b) Letter/email reporting high chance combined or quadruple screen results
c) Letter/email reporting low chance NIPT results
d) Letter/email reporting high chance NIPT results
e) Letter/email reporting ‘no result’ NIPT results
f) Letter/email reporting negative QF-PCR/FISH CVS results
g) Letter/email reporting positive QF-PCR/FISH CVS results
h) Letter/email reporting negative full karyotype CVS results
i) Letter/email reporting positive full karyotype CVS results
j) Letter/email reporting negative amniocentesis result
k) Letter/email reporting positive amniocentesis result

Download response Ante natal screening or diagnostic results for Down syndrome. 100519

Audiology services for children and young people.150317

1. Thinking about the 2015/16 financial year, did your service experience longer waiting times for?
2. Were there any changes in policy or practice in what your audiology service provided in 2015/16?
3. If you have ticked yes to any of the above, please tell us what has changed and the reasons for the
Change
4. At what age does your service transfer deaf young people to adult services?
5. Were there any changes to how your audiology service for deaf children is commissioned in 2015/16?
6. Were there any changes in the number and skill-mix of full time equivalent (FTE) staff in your team, including administrative staff, in 2015/16?
7. If you have ticked yes to any of the above, please describe in more detail what has changed (including the number of staff reductions, if any) and the reasons for the change.
8. Was there a training programme in place for audiologists in your service in 2015/16?
9. If yes, were there any changes to the availability of training in 2015/16?
10. Looking ahead to the 2016/17 financial year, are you aware of any planned changes to any of the below?
11. Did your service provide informal family support services such as parent coffee mornings, playgroups, use of voluntary sector, etc. in 2015/16?
12. If yes, were there any reductions in informal family support services in 2015/16?
13. Is anyone from the audiology team involved in the development of Education Health and Care plans?
14. Have you faced any barriers to being involved in developing Education Health and Care plans?
15. If yes, what were the barriers?
16. Did your service provide any assistive listening devices or take any action to ensure they work effectively with the child’s personal amplification in 2015/16?
17. If you have ticked any of the above, were there any reductions in the provision of assistive learning devices or services to ensure they work effectively with the child’s personal amplification in 2015/16
18. Has your service gained accreditation with (Improving Quality in Physiological Diagnostic Services) IQIPS?
19. Has your service registered for the IQIPS process?
20. Has your service started using the Self-Assessment and Improvement Tool (SAIT)?
21. Has your service applied to UKAS to begin the accreditation peer review process?
22. Has your service booked or completed its onsite assessment with UKAS?
23. If you have not registered with the SAIT for IQIPS, what are your reasons for not doing so?
24. What are the most successful aspects of your audiology service at the moment?
25. What are main challenges or problems facing your audiology service at the moment?
26. Is there anything else you would like to tell us about the audiology service and any future plans?
* 27. Your name:
* 28. Your role:
* 29. Name of audiology service (please don’t use abbreviations):
* 30. Name of Trust that provides the paediatric audiology service (please don’t use abbreviations):
* 31. Sites where paediatric audiology is delivered by your service (please don’t use abbreviations):

Download response Audiology services for children and young people.150317

Babies born in 2015 whose birth-weight was 12lbs or 5443g or more.

In the 2015 calendar year were there any babies born at your hospitals where the weight of the baby was 12lbs (5443g) or more? If so please state how many and what their birth-weights were.

Download response Babies born in 2015 whose birth-weight was 12lbs or 5443g or more 280416

Babies born with neonatal abstinence syndrome 2016-2017. 150517

How many babies were born with neonatal abstinence syndrome (showing signs of drug addiction because of their mother taking drugs during pregnancy) at hospitals run by your trust in the past financial year, April 2016 to April 2017? Please break the figures down by hospital.

Download response letter Babies born with neonatal abstinence syndrome 2016-2017. 150517

Babies born to drug dependent mothers. 151118

You asked:
For each year between 2009 and up-to the end of 2017, how many babies born under your trust were born to drug dependent mothers and once born, were transferred to a drug treatment programme to wean them off their addiction?

Download response Babies born to drug dependent mothers. 151118

Babies injured during assisted delivery. 280317

1) Please state the number of babies that were injured during delivery when tools to assist in delivery were used, for example a vacuum extractor or forceps.
Please provide information for each of the following calendar years:
i) 2014
ii) 2015
iii) 2016
iv) 2017 to date
2) Of these babies injured, please provide a breakdown of injuries that they suffered. Please provide a summary of each incident, including the cause of the injury.
Please provide information for each of the following calendar years:
i) 2014
ii) 2015
iii) 2016
iv) 2017 to date
3) Please state the number of babies injured during delivery due to hospital error.
Please provide information for each of the following calendar years:
i) 2014
ii) 2015
iii) 2016
iv) 2017 to date

Download response Babies injured during assisted delivery. 280317

Babies weighing 12lbs (5443g) or more at birth 2016. 250417

In the 2016 calendar year were there any babies born at your hospitals where the weight of the baby was 12lbs (5443g) or more? If so please state how many and what their birthweights were.

Download response Babies weighing 12lbs (5443g) or more at birth 2016. 250417

Baby weights 2015-2016

I would like to know the following regarding live births:
1. The weights of the five heaviest babies that were born in the Trust last year – financial (2015-16) or calendar (2015) year, whichever is easiest.
2. The weights of the five lightest babies that were born in the Trust last year for pregnancies that reached around full term (i.e. that weren’t born prematurely).

Download response Baby weights 2015-2016 090916

Bed shortages and overcrowding. 310117

1. Do you have any strategy or informal policy that allows adults to be treated in beds/wards that are usually used for paediatric care to help with overcrowding?
2. What is that wording of that strategy?
3. When as it first drawn up?
4. How many times since January 2016 year has this been implemented? If applicable, how many times was it implemented between Jan 2015 and Jan 2016?
5. How many individual adult patients since January 2016 have been treated on child wards/bed -with dates if possible? And the same figure Jan 2015-16.
6. Were there any occasions when adults and children were treated on the same ward?
7. How many times has the hospital been on a) black alert and b) red alert for capacity since January 2016? How many times was it put on a and b from January 2015 – 2016?

Download response Bed shortages and overcrowding. 310117

Bereavement of babies

(a) Does your trust have a bereavement suite available for use by parents in the event of limited life expectancy of an anticipated birth of a child?

(b) If the answer to (a) is no, what alternative arrangements are available?

(c) If the answer to (a) is yes, would parents of a baby who turn up at hospital with a sudden infant death be allowed to use the bereavement suite?

(d) If the answer is yes to (a) where in relation to the Labour ward is the suite located?

(e) Do you have bereavement trained midwives? If yes, how many?

(f) Do you have a trained bereavement councillor at the hospital? If yes, what is the average waiting time to be able access support from that councillor?

(g) Do you provide any written information to parents following the loss of a baby? If yes, please name the third sector organisation information is provided from.

(h) Can you list the guidelines around infant death which are implemented by the hospital?

(i) Does the hospital provide support around funeral arrangements for infants or babies who have died at the hospital?

Download response Bereavement of babies 030216

Birthweights. 250419

In the 2018 calendar year were there any babies born at your hospitals where the weight of the baby was 12lbs (5443g) or more? If so please state how many and what their birthweights were.

Download response Birthweights. 250419

Bounty. 110219

In the 12 months to date (23.08.18) please confirm the following:
1) Whether the Trust currently is, or has been in the past 12 months, engaged in a contract or written agreement with Bounty UK Limited. If the Trust is currently engaged in a contract please attach a copy of it, making necessary redactions in order to comply with the Act. Please provide the date that the contract began and/ or ended. Please provide an overview of the terms of payment. (i.e. per mother visited / per photo pack purchased).
2) Please confirm how much money has been paid to the Trust by Bounty UK Limited in the past 12 months and how many new mothers are recorded as having been approached by Bounty representatives (if held).
3) Please provide details of the policies the Trust has in place with regards to protecting new mothers (i.e. are representatives allowed on any ward at any time, or do they have restricted access? Are mothers given the option to opt out of being visited?)
4) Please confirm the number of complaints made to the Trust by new parents. If not time prohibitive, please provide details of the complaints.

Download response Bounty. 110219

Bounty Packs. 110219

Q1) Please provide the name of your Trust
Q2) Do you have a contract with Bounty, whose representatives hand out ‘Bounty Packs’ to new mothers on maternity wards?
Q3) If you answered YES to Question 2, how much money did your trust receive from Bounty in the financial years;
Q4) Please explain how the payment from Bounty is calculated (i.e. a pre-agreed figure, or a set payment per child born in your care).
Q5) How many babies were born in your care during the financial years?

Download response Bounty Packs. 110219

Brain cooling in babies. 011217

1. Please provide the number full term babies at 36 weeks or later who , because of HIE, were transferred for consideration of brain cooling to a tertiary centre for the following calendar years 2014,2015, 2016 and 2017 to date. ( if you are already one of those tertiary centres then please let me know how many babies were considered for brain cooling because of HIE.)
2. For those same babies, and years, please let me know how many were subject to a serious incident report relating to childbirth?

Download response Brain cooling in babies. 011217

CAMHS. 170818

1) How many children received treatment from your local CAMHS in the financial years:
a. 2014/15
b. 2015/16
c. 2016/17
d. 2017/18

2) Please can you breakdown the figures given in answer to Q1a-d by (i) the type of mental health issue that was being treated, and (ii) the ethnicity of the child?

Download response CAMHS. 170818

CAMHS. 270618

How many referrals were made to CAMHS from any possible referrer for the last three financial years (April 1 2015 – March 31 2016, April 1 2016 – March 31 2017, April 1 2017 – March 31 2018)?
How many were accepted for each of the years above?
Of those accepted, how many had any of the below factors known or believed to be evident (if information is available), for each of the years above?
– Previous contact with CAMHS
– Recurrent threats or acts of self-harm
– High levels of risk
– Eating disorders
How many accepted were from each type of referrer (e.g. GP, A&E etc.) for each of the years above?
What was the mean and median waiting time between referral and treatment for each of the years above?
How many were declined for each of the years above?
Of those rejected, how many had any of the below factors known or believed to be evident (if information is available), for each of the years above?
– Previous contact with CAMHS
– Recurrent threats or acts of self-harm
– High levels of risk
– Eating disorders
How many rejected were from each type of referrer (e.g. GP, A&E etc.) for each of the years above?

Download response CAMHS. 270618

Cancelled children’s operations – 01.07.16. 050517

1. How many children’s operations have been cancelled each month since 1st July 2016? Please give additional details as to what the main reasons for the cancellations were, how many were urgent operations or elective operations, and what type of illness did they involve, e.g. cancer, breathing problems, broken limbs etc.

2. How many children’s operations have been cancelled over the last four financial years to date?

Kindly note a child is anyone up to the age of 18.

Download response Cancelled children’s operations – 01.07.16. 050517

Cerebral Palsy (CP). 270618

1. What is the total number of children and young people diagnosed with Cerebral Palsy by your Trust/Health Board in the last five years? (N.B.: this should be recorded as a total figure rather than figures for each year individually.)
2. What is the care pathway for children and young people with cerebral palsy in your Trust/Health Board? Please provide a copy of this if possible.
3. Is there a specific timescale set out in your care pathway for referral to a child development service for diagnosis of cerebral palsy from the point when symptoms are initially identified? If so, please provide this data.
4. What is the total number of:
a. Health visitors employed by your Trust/Health Board?
b. Specialist health visitors for children with special needs employed by your Trust/Health Board?
5. What training is given to healthcare professionals, including health visitors and GP’s, to recognise the risk factors and possible symptoms for Cerebral Palsy?
6. What is the total number of specialist staff employed by your Trust/Health Board, who are trained to work with children and young people with Cerebral Palsy, from the following disciplines:
a. Paediatric speech and language therapy
b. Paediatric physiotherapy
c. Paediatric occupational therapy
7. How many children and young people with Cerebral Palsy are currently on a waiting list to access any of the above services within your Trust/Health Board?

Download response Cerebral Palsy (CP). 270618

Child and Adult Mental Health Services. 260218

How many people under specialist Child and Adolescent Mental Health Services were issued with the ICD-10 code F12. – ‘mental and behavioural disorders due to use of cannabinoids’, during the 2016/17, 2015/2016, 2014/2015, 2013/2014, 2012/2013, 2011/2012, 2010/ 2011, 2009/ 2010, 2008/ 2009, 2007/ 2008, 2006/ 2007 periods?

Download response Child and Adult Mental Health Services. 260218

Child and Adolescent Mental Health Services (CAMHS).

For the purposes of this request we define children and young adults as being between the ages of 0 and 25 years.
1. The information request:
Please can you provide us with the following information?
• The (a) budget and (b) expenditure for all mental health services.
• The (a) budget and (b) expenditure for Child and Adolescent Mental Health (CAMHS) services (total spend) – if you attribute to a CAMHs Tier 1-4 please specify.
• The (a) budget and (b) expenditure for mental health urgent and emergency care (including mental health crisis care) for children and young people – if only total spend is available please approximate proportion that is spent on children and young adults.
• Any additional, discretionary monies (a) budgeted for and (b) spent on child, adolescent or young adult mental health – please specify source.
We are requesting information for the financial years: 2010/11, 2011/12, 2012/13, 2014/15, 2015/16, 2016/17.
And if available – we are also requesting the projected budget (or settlement) for the financial years covering the remainder of Future in Mind and the Five Year Forward View for Mental Health, which includes: 2017/18, 2018/19, 2019/2020, 2020/21.
2. Clarifications:
If the requested information does not relate to your activity, please answer ‘not applicable’ (N/A).
If you share a budget with another organisation, please specify:
a. The name of the other organisation(s) (for example a Clinical Commissioning Group, Local Authority or NHS Trust).
b. Whether the expenditure / budget reported is the total amount of the shared budget, or your organisation’s contribution to the shared budget.

Download response Child and Adolescent Mental Health Services (CAMHS) 270616

Child drug and alcohol related admissions. 241016

This request relates to drug and alcohol related admissions of children. Please include cases where the relevant diagnoses were recorded as both the primary and secondary condition.

I) Broken down by each of the following calendar years a) 2012, b) 2013, c) 2014, d) 2015 and e) 2016 so far, please state the total number of children aged under 13 admitted to hospitals in your trust due to:

1. The toxic effect of alcohol
2. Mental and behavioural disorders due to use of alcohol
3. Poisoning by drugs, medicaments and biological substances
4. Mental and behavioural disorders due to drug and psychoactive substance use
5. Poisoning by antidepressants (subset of question 3)
6. Poisoning by ecstasy (subset of question 3)

II) Broken down by each of the following calendar years a) 2012, b) 2013, c) 2014, d) 2015 and e) 2016 so far, please state the total number of children aged 13-16 admitted to hospitals in your trust due to:

1. The toxic effect of alcohol
2. Mental and behavioural disorders due to use of alcohol
3. Poisoning by drugs, medicaments and biological substances
4. Mental and behavioural disorders due to drug and psychoactive substance use
5. Poisoning by antidepressants (subset of question 3)
6. Poisoning by ecstasy (subset of question 3)

III) Broken down by each of the following calendar years a) 2012, b) 2013, c) 2014, d) 2015 and e) 2016 so far, please state the total number of children aged 16-17 admitted to hospitals in your trust due to:

1. The toxic effect of alcohol
2. Mental and behavioural disorders due to use of alcohol
3. Poisoning by drugs, medicaments and biological substances
4. Mental and behavioural disorders due to drug and psychoactive substance use
5. Poisoning by antidepressants (subset of question 3)
6. Poisoning by ecstasy (subset of question 3)

Download response Child drug and alcohol related admissions. 241016

Child and Mental Health Services. 170817

What was the average waiting time for patients referred to the Child and Mental Health Services at your trust between May 31st 2016 and May 30th 2017?
What was the average waiting time for patients referred to the Child and Mental Health Services at at your trust between May 31st 2015 and May 30th 2016?
What was the longest waiting time for a patient referred to the Child and Mental Health Services at your trust between May 31st 2016 and May 30th 2017?
What was the longest waiting time for a patient referred to the Child and Mental Health Services at your trust between May 31st 2015 and May 30th 2016?
How often did limited capacity mean your trust had to decline access to services for patients referred to the Child and Mental Health Services between May 31st 2016 and May 30th 2017?
How often did limited capacity mean your trust had to decline access to services for patients referred to the Child and Mental Health Services between May 31st 2015 and May 30th 2016?
What’s the furthest distance a patient has had to travel from your trust to find adequate, available care from the Child and Mental Health Services between May 31st 2016 and May 30th 2017, having been turned away due to a lack of resources?
What’s the furthest distance a patient has had to travel from your trust to find adequate, available care from the Child and Mental Health Services between May 31st 2015 and May 30th 2016, having been turned away due to a lack of resources?
What age was the youngest patient dealt with by the Child and Mental Health Services at your trust between May 31st 2016 and May 30th 2017?

Download response Child and Mental Health Services. 170817

Child and Mental Health Services. 200418

1.a. What was the average waiting time for patients referred to the Child and Mental Health Services at your trust during the financial year 2017-2018, and what was their age and gender?
1.b. What was the average waiting time for patients referred to the Child and Mental Health Services at your trust during the financial year 2016-2017, and what was their age and gender?
1.c. What was the average waiting time for patients referred to the Child and Mental Health Services at your trust during the financial year 2015-2016, and what was their age and gender?
2.a. What was the longest waiting time for a patient referred to the Child and Mental Health Services at your trust during the financial year 2017-2018, and what was their age and gender?
2.b. What was the longest waiting time for a patient referred to the Child and Mental Health Services at your trust during the financial year 2016-2017, and what was their age and gender?
2.c. What was the longest waiting time for a patient referred to the Child and Mental Health Services at your trust during the financial year 2015-2016, and what was their age and gender?
3.a. How often did limited capacity mean your trust had to decline access to services for patients referred to the Child and Mental Health Services during the financial year 2017-2018?
3.b. How often did limited capacity mean your trust had to decline access to services for patients referred to the Child and Mental Health Services during the financial year 2016-2017?
3.c. How often did limited capacity mean your trust had to decline access to services for patients referred to the Child and Mental Health Services during the financial year 2015-2016?
4.a. What’s the furthest distance a patient has had to travel from your trust to find adequate, available care from the Child and Mental Health Services during the financial year 2017-2018, having been turned away due to a lack of resources, and what was their age and gender?
4.b. What’s the furthest distance a patient has had to travel from your trust to find adequate, available care from the Child and Mental Health Services during the financial year 2016-2017, having been turned away due to a lack of resources, and what was their age and gender?
4.c. What’s the furthest distance a patient has had to travel from your trust to find adequate, available care from the Child and Mental Health Services during the financial year 2015-2016, having been turned away due to a lack of resources, and what was their age and gender?
5.a. What age was the youngest patient dealt with by the Child and Mental Health Services at your trust during the financial year 2017-2018?
5.b. What age was the youngest patient dealt with by the Child and Mental Health Services at your trust during the financial year 2016-2017?
5.c. What age was the youngest patient dealt with by the Child and Mental Health Services at your trust during the financial year 2015-2016?

Download response Child and Mental Health Services. 200418

Childhood obesity services. 160320

What is the name of your acute trust?
(1) Does your trust provide a weight management service for children living with obesity?
Yes ☐ No ☐
If No, you need not answer further.
If yes, what is the name of the service and where delivered:
Who leads this service?
It is a hospital ☐ or community-based☐ clinic
(2) What if any are the criteria for eligibility to attend (for instance BMI >98th percentile)?
None ☐
Eligible if:
(3) Through what mechanism is the service funded?
CCG ☐
NHS England ☐
Research ☐
Charity ☐
Trust Self-Funding ☐
Other ☐
Please specify
(4) Who are the key personnel providing service? Please tick all who apply:
a. Paediatricians ☐
b. Dieticians ☐
c. Psychologists ☐
d. Trained volunteers ☐
e. Hospital or Community based Nursing staff ☐
f. Exercise specialists ☐
g. Social workers ☐
h. CAHMS ☐
i. Youth workers ☐
(5) How many new cases are seen each year?
(6) Over how many weeks is the clinic intervention delivered?
(7) What is the usual follow up period (entry to discharge?)
(8) What final outcomes are collected: Examples: change in BMI, BMI SDS, Self Esteem, Waist Circumference, recruitment, retention.
Please list all.

Download response Childhood obesity services. 160320

Children treated for alcohol dependency or misuse. 151118

You asked:
Please may you tell me the number of people, under the age of 18, who were treated by the trust for alcohol dependence and/or alcohol misuse in 2012, 2013, 2014, 2015, 2016, 2017, and 2018?

May you please tell me the youngest person you treated for this in 2016, 2017 and 2018?

Download response Children treated for alcohol dependency or misuse. 151118

Children’s Dental Hospital. 250417

1. As of March 31st, 2017, can you tell me how many children were on the waiting list to visit the Trust’s children’s dental hospital?
2. How long is the present waiting list, in terms of months/weeks to be seen?
3. How long is the wait for teeth extractions?
4. How many children are affected by the wait for teeth extractions?
5. Is there a wait for youngsters to be added to the waiting list? if, so how many children are waiting to be placed on to the waiting list?
6. How many dental nurses does the Trust employ at the children’s dental hospital?
7. How many vacancies does it have at present?
8. How many children were on the waiting list to visit the Trust’s children’s dental hospital on?
a) March 31st, 2016?
b) March 31st 2015?
c) March 31st 2014?
d) March 31st 2013?
9. How many children received treatment at the children’s dental hospital between January 1, 2016 and December 31, 2016?

Download response Children’s Dental Hospital. 250417

Children’s Unit. 250919

1. Between 1st April 2018 and 31st March 2019 how many visits to/patients were/are seen at Riverbank Children’s unit? (Volume)
2. Between 1st April 2018 and 31st March 2019 how many individual patients were/are seen at Riverbank Children’s unit? (Reach)
3. How many of these were transferred to Pembury?
4. On a typical day / on average how many patients are transferred from Riverbank to woodlands every day?
5. What are the main reasons for these transfers?
6. On a typical day/ on average many patients transfer each day due to the Riverbank closing time?
7. How often/ on average how many times a week do the staff at Riverbank have to stay past 8.00pm to accommodate patients needs/ transfer to Pembury?
8. Between 1st April 2018 and 31st March 2019 how many visits to/patients were/are seen at Woodlands and hedgehog Children’s unit? (Volume)
9. Between 1st April 2018 and 31st March 2019 how many individual patients were are seen at Woodlands and hedgehog Children’s unit? (Reach)
10. How many of these were transferred from Riverbank?

Download response Children’s Unit. 250919

Cord blood stem cells. 300819

1) Do you allow private stem cell companies to promote their services on your sites, e.g. leaflets?
2) Do you allow representatives from stem cell companies on any of your sites to promote or collect cord blood, e.g. in delivery suites?
3) Does the Trust allow its staff to work for stem cell companies, e.g. collecting umbilical cord blood for private companies?
4) How long (how many minutes) does the Trust consider ‘optimal’ cord clamping?
5) Please supply the following information for each of the individual calendar years: 2015, 2016, 2017, 2018 and 2019 to date:
a) The number of babies born whose umbilical cord blood was collected for banking by a private company.
b) The number of babies born whose umbilical cord blood was collected for banking by the NHS.
c) The income received from stem cell companies.

Download response Cord blood stem cells. 300819

Court intervention. 141119

1. “Since 01 January 2017, please specify the number of individual cases where the Court has had to intervene in the treatment of a critically ill child, when there has been a difference of opinion between parents and doctors, over the course of treatment for that child?”

Download response Court intervention. 141119

Cow’s milk protein Allergy (CMPA) 090916

1) Does your organisation use any guidelines when prescribing specialised infant formula for cow’s milk protein allergy (CMPA)?

2) If yes, please provide a link to, or a copy of the guidelines referenced by your organisation.

3) Please can you confirm whether we are permitted to reuse any information provided under the Open Government Licence?

Download response Cow’s milk protein Allergy (CMPA) 090916

Disorders of Sex Development in the UK. 070818

1. Who provides expert evaluation of gender assignment in newborns with Disorders of Sex Development?

2. Does the trust use a multidisciplinary team that deals with the evaluation and long-term management and needs of patients with Disorders of Sex Development?

3. If yes to question 2, can you provide contact details for the team?

4. What specialties are represented on the multidisciplinary team (e.g. paediatric subspecialists in endocrinology, surgery, and/or urology, psychology/psychiatry, gynaecology, genetics, neonatology, and, if available, social work, nursing, and medical ethics)? Please list them.

5. When dealing with Disorders of Sex Development, what guidelines, if any, do decision makers follow?

6. How many people are referred to this team per year (please give numbers for the last five years)?

Download response Disorders of Sex Development in the UK. 070818

Drug and alcoholism in children aged under 15 2013-2017. 280417

Can I ask for the following information: for each of the last four financial years (including the current one) I request disclosure of data relating to children aged 15 and under who have been diagnosed with alcoholism or drug related conditions.
1. For each year I would like a table containing patients’ ages, from 0 to 15 years old accompanied by a figure for the number of children of that age who were diagnosed as alcoholic, alcohol poisoning, treated for alcoholism or excessive alcohol consumption (for example 2016/17: Age 15– 33 Age 14 – 3). Can you outline the figures for each?
2. For each financial year I would also like a table set out in the same way detailing the numbers of children aged 15 or below who were admitted to A&E suffering alcohol-related illness.
3. For each year I would like a table containing patients’ ages, from 0 to 15 years old accompanied by a figure for the number of children of that age who were diagnosed for drug related illnesses or over-consumption (for example 2016/17: Age 15– 33 Age 14 – 3).
4. For each financial year I would also like a table set out in the same way detailing the numbers of children aged 15 or below who were admitted to A&E suffering drug-related illness. Can you outline the figures for each?
5. For each admission in Q1 and Q3, please tell me a) the sex of the child c) a brief summary of the problem, e.g. child was drunk

Download response Drug and alcoholism in children aged under 15 2013-2017. 280417

Eating disorders. 160119

1) How many admissions of children (under 18’s) presenting with eating disorders your trust has recorded in the past five years?
2) I would like to know how many of these children treated were male/female/transgender.
3) Please present all this information simply and clearly and break it down by year. Please provide as much detail as possible about the nature of their illness (I understand that some children may present with multiple illnesses). I would like this information broken down by type of eating disorder e.g. bulimia, anorexia etc.

Download response Eating disorders. 160119

Eating disorders in paediatric patients 2014-2016.

The number of paediatric patients you have seen between January 1st 2014 and December 31st 2014 for the treatment of eating disorders
The number of paediatric patients you have seen between January 1st 2015 and December 31st 2015 for the treatment of eating disorders
The number of paediatric patients you have seen between January 1st 2016 and December 31st 2016 for the treatment of eating disorders
How many of the paediatric patients were aged 10 and under between January 1st 2014 and December 31st 2014
How many of the paediatric patients were aged 10 and under between January 1st 2015 and December 31st 2015
How many of the paediatric patients were aged 10 and under between January 1st 2016 and December 31st 2016
How many of the paediatric patients were aged 11-16 between January 1st 2014 and December 31st 2014
How many of the paediatric patients were aged 11 -16 between January 1st 2015 and December 31st 2015
How many of the paediatric patients were aged 11 -16 between January 1st 2016 and December 31st 2016

Download response Eating disorders in paediatric patients 2014-2016.

Electronic Patient Records systems in Mental Health, Community Health or Child Health.

1. What are the main Electronic Patient Records systems you operate in Mental Health, Community Health or Child Health?
2. Can you provide a name for these systems?
3. How much are you currently spending on these systems annually for licensing and support fees?
4. What is the date of contract expiry for the systems?
5. How many users? (An estimation if unsure)
6. How are the systems hosted?
7. Who is responsible for your local implementation of the objectives set out by the NHS in the Five Year Forward View?

Download response Electronic Patient Records systems in Mental Health, Community Health or Child Health 270616

FGM C 2013-2016

1) How many females have you treated in connection to/relating to/as a result of FGM/C (female genital mutilation or cutting) practices?
2) Please can you break your answer down by financial years:
– 2015/16
– 2014/15
– 2013/14
3) Can you also break down and categorise the numbers by “reason for treatment”? So for example, i. bleeding ii. infection
4) Can you break down and categorise the numbers by what the treatment was? So for example, i. amputation ii. cosmetic surgery
5) Can you break down and categorise the numbers by the females’ ages? Ideally in these age brackets: i. 0 – 9 ii. 10 – 18 iii. 19 – 27 (and continue by nine-year age brackets)

Download response FGM C 2013-2016

Foetal Alcohol Syndrome 2014-2016. 070417

1. For 2016,
a) How many people were diagnosed as being on the Foetal Alcohol Spectrum. With a breakdown of ages and hospitals.

2. and 3. Same for 2015/2014

Download response Foetal Alcohol Syndrome 2014-2016. 070417

Foetuses that were miscarried, stillborn or aborted and children up to one year old from 1988 to the present day (Nov 2016). 011216

Please supply information for all of the questions below relevant to – foetuses that were miscarried, stillborn or aborted and children up to one year old from 1988 to the present day (Nov 2016).

1. Are you holding organs or tissue samples or bodies of foetuses that were miscarried, stillborn, aborted or of children up to one year old, pending disposal?

2. If yes to Q1, please report how many organs, tissue samples, body parts or bodies of foetuses that were miscarried, stillborn, aborted or of children up to one year old you have retained and still have?

3. In how many of these cases of foetuses that were miscarried, stillborn or aborted or of children up to one year old which have been retained and you still have was consent given by the nearest relatives to take, use and dispose of organs or tissue samples or body parts or bodies?

4. In how many of these cases of foetuses that were miscarried, stillborn or aborted or of children up to one year old which were retained but have since been disposed of was consent given by the nearest relatives to take, use and dispose of organs or tissue samples or body parts or bodies?

Download response Foetuses that were miscarried, stillborn or aborted and children up to one year old from 1988 to the present day (Nov 2016). 011216

Free promotional disposable nappies.260219

1. Do you distribute any free promotional disposable nappies (such as Pampers) or reusable nappies to parents at any services, including (but not exhaustive of) antenatal, maternity, midwife, post-natal and family services?
If the answer is yes to 1, please answer questions 2-7.
2. Which disposable or reusable nappy brand do you allow to distribute their promotional nappies?
3. Which services are they distributed at and how many parents use these facilities annually?
4. How frequently a year have these disposable or reusable nappy brands been able to distribute their promotional material at these services?
5. What is the process for allowing disposable or reusable nappy brands to distribute at your services and who signs it off?
6. Is there any remuneration for the NHS from these disposable or reusable nappy brands for distributing their promotional material?

Download response Free promotional disposable nappies.260219

Infant Formula. 140319

1. Details of the brand(s) of infant formula milk provided in maternity services and the form in which it is provided (e.g. powdered, ready-made bottles, ready-made bottles with teets etc.)

2. Details of your infant formula milk provider, the amount paid and volume received in the last available financial year, and details of whether the infant formula milk is purchased from them at full price, a reduced rate (including details of the reduction if applicable) or received free of charge.

Download response Infant Formula. 140319

Intersex Babies 2012-2017. 170817

• How many intersex babies have you operated on (up until the age of 2) between 2012 and 2017?

• How many of those babies were not operated on (up until the age of 2) between 2012 and 2017?

Download response Intersex Babies 2012-2017. 170817

Juvenile Idiopathic Arthritis. 031219

I would like to understand how patients with juvenile ideopathic arthritis are being treated. So, in the last 6 months, how many patient(s) with juvenile ideopathic arthritis have been treated with:
Humira (adalimumab)
Amgevita (adalimumab)
Imraldi (adalimumab)
Hyrimoz (adalimumab)
Hulio (adalimumab)
Tocilizumab
Abatacept
Enbrel (etanercept)
Erelzi (etanercept)
Benepali (etanercept)
Golimumab
Remicade (infliximab)
Remsima (infliximab)
Inflectra (infliximab)
Flixabi (infliximab)
Canakinumab
Anakinra

Download response Juvenile Idiopathic Arthritis. 031219

Kangawrap or Kangaroo Care and skin to skin. 270918

Could you send me your policy relating to the Kangawrap/kangaroo care and skin to skin please?

Download response Kangawrap or Kangaroo Care and skin to skin. 270918

Kent birth rates. 301117

For the financial years 2017-18 to date, 2016-17, 2015-16, 2014-15, 2013-14, 2012-13

1. What age was the youngest mother to give birth at your trust – and what age was the oldest?

2. What percentage of births were to foreign national or non-British mothers?

Or if that’s not possible – can you please break down the births by the ethnicity of the baby?

Download response Kent birth rates. 301117

Live births and Downs Syndrome. 010618

1. Please could you tell me the total number of live births and separate out the number of live births with Down syndrome in your Trust in the past 7 years?
2010 2011 2012 2013 2014 2015 2016 2017
Number of live births
Number of live births with Down syndrome
2. Also could you tell me if it has, when your hospital started to recommend NIPT (Non Invasive Prenatal Testing) to mothers?
Dates: From – to
a. NIPT offered for free within Trust (also interested to know to what chance level this would be offered i.e. 1:150 or other)
b. NIPT mentioned as an option, but only available outside of Trust, i.e. by private providers not connected with the hospital/Trust
c. NIPT mentioned as an option and available within the Trust if patient willing to pay

Download response Live births and Downs Syndrome. 010618

Neonatal abstinence syndrome. 200617

Q1) How many babies were born with neonatal abstinence syndrome (showing signs of drug addiction because of their mother taking drugs during pregnancy) at hospitals run by your trust in each of the past five financial years?
Q2) Please breakdown the figure from Q1. giving the age of each mother and the substance she was addicted to?
Q3) Please tell me how much it cost to care for these babies as well as the mothers with addictions to illegal drugs in a hospital/other facility your NHS Trust runs in each of the past five financial years?

Download response Neonatal abstinence syndrome. 200617

Neonatal abstinence syndrome 2011-2016.

Can you provide answers for 2011-2012, 2012-2013, 2013-2014, 2014-2015 and 2015-2016 please?

How many babies were born with neonatal abstinence syndrome (showing signs of drug addiction because of their mother taking drugs during pregnancy) at hospitals run by your trust during each financial year?
If you run more than one hospital please breakdown the figures for each hospital.

Download response Neonatal abstinence syndrome 2011-2016 290416

Neonatal drug addiction 2014 – 2016. 070417

1. For 2016,
a) How many babies were born with drug addiction/ drug dependency? With a breakdown of which drugs they were addicted to.

2. and 3. Same for 2015/2014

Download response Neonatal drug addiction 2014 – 2016. 070417

Neonatal services. 121018

For each of the hospitals in your trust that treat newborn babies, please can you provide any information you hold (such as protocol, local guidelines/advice etc), on when a newborn baby would normally receive a lumbar puncture when you are worried about an infection or sepsis. I am particularly interested if there is a local CRP (C-reactive protein) blood level at which a lumbar puncture is usually done.

Download response Neonatal services. 121018

Neonatal Unit 161216

1. The type of neonatal unit you have (NICU, Local Neonatal Unit or SCBU). If you have more than one site, please provide the highest level.
2. The region your hospital is in from this list (trusts will only be identified by region in the analysis):
a. South East
b. London
c. North West
d. East of England
e. West Midlands
f. South West
g. Yorkshire and Humber
h. East Midlands
i. North East
3. Activity (in bed days) for the following Healthcare Resource Groups (HRGs):
a. XA01Z
b. XA02Z
c. XA03Z
d. XA05Z
4. Your 2015/16 and 2016/17 Tariff for the above HRGs. Please provide your full tariff including any MFF enhancements.
5. Current neonatal nursing vacancy rate (% of expected) at
a. Band 5
b. Band 6
c. Band 7

Download response Neonatal Unit 161216

Neonatal withdrawal 2010-2015

Could you let me know how many babies were born to mothers who had abused/ taken drugs during pregnancy each year for the past 5 years including 2014-2015?

How many babies were born showing neo-natal withdrawal symptoms each year for the past five years?

Could you also let me know from the mothers who had taken drugs what was the breakdown for each type of drugs e.g. heroin, cocaine

Download response Neonatal withdrawal 2010-2015 140415

NHS Children’s Workforce 030117

1. How many registered children’s nurses (Whole Time Equivalent) are employed at your organisation? Please list by clinical area.
2. How many support workers (Whole Time Equivalent, bands 1-4) are working in your children’s service? Please list by clinical area.
3. How many nurses (Whole Time Equivalent) deliver your community children’s nursing service? Please list by clinical area.
4. How many clinical specialist children’s nurses do you have in your service? Please list their clinical specialisms, e.g. 1x haematology; 2x epilepsy.
5. How many advanced neonatal nurse practitioners do you have in your service?
6. How many advanced paediatric nurse practitioners do you have in your service?
7. Do you have transition (children’s to adults’ services) nursing roles? If yes, how many? Do any have clinical specialisms? If so, please list their clinical specialisms, e.g. 1x haematology; 2x epilepsy.
8. Do you employ a play specialist?
9. How many inpatient beds are there designated for children and young people? Please provide a number against the following and list by clinical area:
a. Neonates
b. Children’s
c. Adolescents
10. What were the key gaps in knowledge and skills within the children’s nursing workforce identified by your most recent Training Needs Analysis or courses commissioned through Non-Medical Education and Training (NMET)?

Download response NHS Children’s Workforce 030117

Nitrofurantoin antibiotic oral suspension. 070318

1. Nitrofurantoin is the antibiotic 25mg/5ml Oral suspension. Why is it Maidstone hospital pharmacy are not permitted to dispense?
2. On what basis was this decision/policy made?
3. Is there any way in particular clinical cases policy decisions can be challenged or changed?

Download response Nitrofurantoin antibiotic oral suspension. 070318

Overdose of caffeine in under 16 year olds. 220818

1) The number of under 16s who have been admitted in each of the past five years, broken down by year for suspected overdose from high energy drinks/accidental caffeine overdose from high energy drinks?

2) Of those can you tell me, by year how many people were admitted by A&E?

Download response Overdose of caffeine in under 16 year olds. 220818

Paediatric allergy testing. 180718

1. Is your institution involved with providing services for paediatric allergy?
2. With regards to paediatric allergy referrals (tick one or more as appropriate)
a. My hospital doesn’t accept paediatric allergy referrals
b. Allergy referrals are seen in a general paediatric clinic
c. Allergy referrals are seen in a paediatric allergy clinic
d. Children with allergies are seen in Primary Care allergy clinics
e. Children with allergies are seen in adult allergy clinics
f Other (please specify)

Download response Paediatric allergy testing. 180718

Paediatric and neonatal admissions. 100519

1- Number of paediatric ward admission in 2018, if possible by age and diagnosis, Tunbridge Wells Hospital

2- Neonatal admission in 2018, if possible by diagnosis, Tunbridge Wells Hospital (TWH)

Download response Paediatric and neonatal admissions. 100519

Paediatric audiology services. 100519

1. Please provide the following information:
2. We have included below, the locations where previously you, or a CCG for your area, have told us that paediatric audiology services are provided.
3. On average, in the last quarter, (1 January – 31 March 2019) how many days did patients wait for the following?
4. If you are not sure please estimate.
5. What options are included in your current management pathway for temporary conductive hearing loss? Select all that apply:
6. Are there any groups of children that you don’t currently provide hearing instruments for? Select all that apply:
7. Do you currently provide free batteries for children’s hearing aids? Please select one answer:
8. Do you currently provide a choice of coloured moulds to children at no extra charge? Please select one answer:
9. What types of appointments do you offer? Please select all that apply:
10. How many deaf children were on your case load?
11. How many of the children on your caseload were referred to your service from the Newborn Hearing Screen?
12. Have you registered for (Improving Quality in Physiological Services) IQIPS this year? Please select one answer:
13. Which of the below best describes your current status with regard to IQIPS for children’s services? Please select one answer:
14. If you are not registered with IQIPS, what is the main reason?
15. If you are registered with IQIPS but have not progressed in the last year, what is the main reason?
16. Has your service booked its onsite assessment with UKAS? Please select one answer:
17. What colour are you currently at on the UKAS traffic light system?
18. How many full time equivalent staff does your children’s audiology service have at the following levels as on 31 March 2019?
19. If there has been a reduction in the number or skill level of staff compared to last year, what are the reasons for this?
20. Please select all that apply.
21. Are you aware of any planned changes to staffing in 2019/20?
22. Are all staff able to access the CPD necessary for their roles? Select all that apply:
23. Does the Children’s Hearing Services Working Group (CHSWG) in your area include at least one parent representative? Please select one answer:
24. Does the CHSWG in your area produce a publically available annual report? Please select one answer:
25. As of 31 March 2019 which organisation provides the following technology?
26. As of 31 March 2019 do you balance or pair streamers purchased by:
27. Are there any plans to stop the provision of hearing equipment or accessories for hearing equipment in 2019/20? Please select one answer:
28. How do you prepare young people for transition to adult services? Please select all that apply.
29. What was your service’s most recent score in the family and friends test?
30. What was your average ‘Was not Brought (WNB)’ or ‘Did Not Attend (DNA)’ rate across all appointment types for children for the 2018/19 financial year in percent?
31. What was the annual budget for your paediatric hearing aid service for the 2018/19 financial year, from the organisations below?
32. How is your funding provided? Please select all that apply.
33. If you selected tariff per child, how much money do you receive for each service below?
34. If you run a joint paediatric and adult service, are your budgets shared?
35. Was your audiology service for deaf children commissioned differently in the 2018/19 financial year when compared to the 2017/18 financial year?
36. Is your audiology service being commissioned differently or reviewed in 2019/20?

Download response Paediatric audiology services. 100519

Paediatric cancellations. 170818

1. How many children’s operations have been cancelled each month since 1st April 2017? Please give additional details as to what the main reasons for the cancellations were, how many were urgent operations or elective operations and what type of illness did they involve, e.g. cancer, breathing problems, broken limbs etc.

2. How many children’s operations have been cancelled over the past eight financial years (2010/11 through to, and including, 2017/18) and in Year to Date 2018/19? Please break the data down by financial year.

Download response Paediatric cancellations. 170818

Paediatric Cerebral Palsy

1. The total number of children and young people diagnosed with cerebral palsy by Maidstone and Tunbridge Wells NHS Trust within each of the last five years.

2. The total working-time equivalent (WTE) number of specialist staff employed by Maidstone and Tunbridge Wells NHS Trust from the following disciplines, trained to work with children and young people with cerebral palsy:

a. Paediatric speech and language therapists
b. Paediatric physiotherapists
c. Paediatric occupational therapists

3. The total working-time equivalent (WTE) number of:

a. Health visitors
b. Specialist health visitors for children with special needs employed by Maidstone and Tunbridge Wells NHS Trust.

4. A copy of your care pathway for children and young people with cerebral palsy.

5. A copy of your service framework for children and young people with cerebral palsy.

6. Whether there is a specific timescale set out in your care pathway for referral for diagnosis of cerebral palsy, from the point of the formal identification of symptoms.

7. An overview of training and advice provided by Maidstone and Tunbridge Wells NHS Trust for health professionals on identifying and referring children with cerebral palsy.

Download response Paediatric Cerebral Palsy 250516

Paediatric department complaints. 050719

Please provide me with number of complaint raised against paediatric department (nurses, doctors) from patient in 2018, and if possible to clarify each complaint nature and what action taken.

Download response Paediatric department complaints. 050719

Paediatric mortality rates. 100519

1- Number of mortalities in paediatric age group in 2018. If possible breakdown the information by age and cause of death.
2 – Number of paediatric cases which transferred from Tunbridge Wells Hospital (TWH) to other hospitals for further managements. If possible breakdown the information by age of the patient, name of hospital transferred to and the cause of transfer.

Download response Paediatric mortality rates. 100519

Paediatric policies and procedures. 260218

I wondered if you could please send me copies of your paediatric day case surgery policies and procedures?
I am doing some research into this field. I am a nurse.

Polices such as:
Starvation times
Transfer policy
Medications

Download response Paediatric policies and procedures. 260218

Paediatric scrotal pain. 190219

1.) Please provide the following general hospital information:
Name of hospital
Name of Trust
What is the population size of your hospital’s catchment area?
What is the specialty of the individual advising upon the majority of the clinical information of this form?
Does your hospital have a casualty/emergency department?
Does your hospital have a separate paediatric casualty/emergency department on site?
Is there a ‘scrotal pain’ or ‘suspected testicular torsion’ pathway or Standard Operating Procedure (SOP) relating to this issue for paediatric patients in place at your site?
2.) At your hospital, which speciality and grade of doctor or surgeon most commonly makes the initial assessment of a paediatric patient with a suspected testicular torsion, other than A&E staff? Please provide an answer for each of the following time slots provided.
3.) If a paediatric suspected testicular torsion required emergency scrotal exploration, would the operation take place at your site? Please answer the appropriate column of questions according to whether your answer is A, B or C.
3.A.) Table A
Which grade and specialty of surgeon most commonly operates during normal working hours?
Which grade and specialty surgeon most commonly operates outside of normal working hours on weekdays?
Which grade and specialty surgeon most commonly operates on the weekend?
3.B.) Table B
Which grade and specialty surgeon most commonly operates during normal working hours?
On weekdays outside of normal working hours, do emergency scrotal explorations take place at your hospital? If yes please specify the grade and speciality of the surgeon that most commonly operates.
On weekends, do emergency scrotal explorations take place at your hospital?
Do any surgeons travel from a separate hospital to any of the sites in your Trust to undertake emergency paediatric scrotal exploration surgery rather than transfer the patient?
3.C.) Table C
To which hospital(s) do you transfer patients, for emergency scrotal exploration?
4.) Please answer the following questions, with separate answers for the years 2013, 2014 and 2015.
How many emergency scrotal explorations on paediatric patients to exclude testicular torsion were carried out at your site?
How many emergency scrotal explorations on paediatric patients resulted in finding an unsalvageable or infarcted testis, resulting in orchidectomy?
5.) Please provide the following information about audits into paediatric testicular torsions.
At your hospital, has there been an audit or review conducted into the length of time taken, for a paediatric patient with a suspected testicular torsion, to arrive in the operating theatre from initial triage in the emergency department?
6.) How many cases presenting as paediatric scrotal pain or paediatric suspected testicular torsion resulted in incident reports, serious untoward incidents or legal proceedings in 2013, 2014, 2015?
Please attach an anonymised copy of all incident reports, and root cause analysis reports with outcomes identified in this question.
7.) In your organisation, who will be the most senior clinician to review this FOI request before submission?

Download response Paediatric scrotal pain. 190219

Portable Bilirubin (jaundice) meters. 111019

• What (if any) portable bilirubin meters they currently use to assess possible jaundice in babies?
• When were they purchased?
• When will they be renewed or when does the current contract expire?

Would it also be possible to obtain the contact details of the person dealing with managing the Bilirubin Meters (Jaundice meters) that the community midwife use?

Download response Portable Bilirubin (jaundice) meters. 111019

Portable Bilirubin (jaundice) meters. 260319

• What (if any) portable bilirubin meters they currently use to assess possible jaundice in babies?
• When were they purchased?
• When will they be renewed or when does the current contract expire?

Download response Portable Bilirubin (jaundice) meters. 260319

Premature birth survival 2012-2016. 280317

For each of the last five calendar years, could you please provide information on the following births at your trust?
How many babies were born live at 21 weeks gestation and how many survived to discharge
How many babies were born live at 22 weeks gestation and how many survived to discharge
How many babies were born live at 23 weeks gestation and how many survived to discharge
How many babies were born live at 24 weeks gestation and how many survived to discharge
How many babies were born live at 25 weeks gestation and how many survived to discharge

Download response Premature birth survival 2012-2016. 280317

Provision of services for Attention Deficit Hyperactivity Disorder (ADHD) 101116

  • What proportion of children and young people with symptoms of ADHD have been referred to an ADHD specialist for assessment in the past 12 months (Quality Statement 1)
  • What proportion of adults with symptoms of ADHD without a childhood diagnosis of ADHD have been referred to an ADHD specialist for assessment in the past 12 months (Quality Statement 2)
  • What proportion of adults who were diagnosed with ADHD as children or young people and present with symptoms of continuing ADHD have been referred to general adult psychiatric services in the past 12 months (Quality Statement 3)
  • What proportion of parents or carers of children with symptoms of ADHD who meet the NICE eligibility criteria have been offered a referral to a parent training programme in the past 12 months (Quality Statement 4)
  • What proportion of children and young people with moderate ADHD have been offered a referral to a psychological group treatment programme in the past 12 months (Quality Statement 5)
  • In the past 24 months, what proportion of eligible patients with ADHD who are starting drug treatment go on to have their initial drug dose adjusted and response assessed by an ADHD specialist (Quality Statement 6)
  • In the past 24 months, what proportion of eligible patients with ADHD who are taking drug treatment have a specialist review at least annually to assess their need for continued treatment (Quality Statement 7)

In addition, can you please provide information on?

  • The number of people with symptoms of ADHD who have come into contact with your service in the past 12 months:

O Children and young people

O adults

  • The number of people referred with symptoms of ADHD who are currently waiting for their first outpatients’ appointment:

O Children and young people

O adults

  • The average waiting time from referral to first outpatients’ appointment in the past 12 months for

O Children and young people presenting with symptoms of ADHD

O Adults presenting for the first time with symptoms of ADHD

  • The range of waiting times (i.e. shortest to longest) for patients from referral to first outpatient appointment in the past 12 months for

O Children and young people presenting with symptoms of ADHD

O Adults presenting for the first time with symptoms of ADHD

  • What specialist services are available for referral for adults presenting with symptoms of ADHD
  • Does your organisation provide a transition to an adult service for adolescents with ADHD?
  • The age at which your organisation transitions a young person diagnosed with ADHD to general adult psychiatric services
  • Does your organisation receive out of area referrals for specialist ADHD services?

Download response letter Provision of services for Attention Deficit Hyperactivity Disorder (ADHD) 101116

Reported extravasation injury within the Neonatal Unit (NNU).

I would like to be provided with the following information.

1. The latest total annual figures for reported extravasation injury within your NNU/NICU/SCBU

2. Model of the large volume infusion pump used on the unit

3. Model of the syringe pump used on the unit

Download response Reported extravasation injury within the Neonatal Unit (NNU) 060416

Retinopathy of Prematurity (ROP) screening. 140319

Can you please provide me with your protocol for ROP screening protocol, as we are updating our department protocol?

Download response Retinopathy of Prematurity (ROP) screening. 140319

Self-harming. 260218

1. How many children aged under-18 were admitted to hospital through each of your accident and emergency departments between 1 April 2016 and 31 March 2017 due to self-harming?

2. Can you provide an age breakdown of admittance’s for this period?

Download response Self-harming. 260218

Self-harming in under 18 year olds.

1. How many children aged under 18 were admitted to each of your accident & emergency departments in the below years due to self-harming?
• 2015-16
• 2014-15
• 2013-14

2. Can you provide an age breakdown of admittances for each of these years?

3. Can you provide an injury breakdown for each of these years?

Download response Self-harming in under 18 year olds 060916

Sexually transmitted diseases in the under 16 year olds 2012-2016. 250417

1.) How many children (aged 15 and under) have attended services at your trust to get tested for sexually transmitted diseases? Please provide the total number for each year – and in addition, break down by age (age band is adequate if the numbers are small).
2.) Please provide the total number of STD tests that came back positive in children under 16 over the last five years – and again, please break down by year, age, – as well as the type of STDs that were diagnosed.
3.) If this has not been made clear in the above response – what is the specific age of the youngest child to be diagnosed with an STD over the last five years – and what was the STD?
4.) Within these figures, please also include the numbers of children who were found to have an STD when using hospital services for other services.
5.) Please separately provide the total number of children under 16 who were a) tested b) diagnosed with HIV over the last five years – with a breakdown of people and ages for each year. This includes children who were found to have HIV when attending hospital for another matter.
If you believe any of the questions this to be exempt information in line with Section 40 (2)(a)(b)(3)(a)(i) Can you please, then, instead, provide an age bracket and the total number for the 5 years as a total.

Download response Sexually transmitted diseases in the under 16 year olds 2012-2016. 250417

Self-harm and suicidality in 14-25 year olds.

How many people aged 14-25 have presented to your services with self-harm and suicidality (ICD-10 term/code: ‘Intentional Self-Harm’ (X60-X84))? I would like the figures for the past 5 years (either calendar of financial).

Download response Self-harm and suicidality in 14-25 year olds 060916

Transition from child to adult services. 010818

You asked:
I would be grateful if you could provide me with any policy that the Trust has published or any other formal guidance that staff follow concerning transition from child to adult health services within your hospitals, in particular concerning complex and life-limiting health conditions.

Download response Transition from child to adult services. 010818

Under 16’s and sexually transmitted diseases (STD).

Q1.) How many children (aged 15 and under) have attended services at your trust to get tested for sexually transmitted diseases?

Please provide the total number for each year – and in addition, break down by age (age band is adequate if the numbers are small).

Q2.) Please provide the total number of STD tests that came back positive in children under 16 over the last five years – and again, please break down by year, age, – as well as the type of STDs that were diagnosed.

Q3.) If this has not been made clear in the above response – what is the specific age of the youngest child to be diagnosed with an STD over the last five years – and what was the STD?

Q4.) Please separately provide the total number of children under 16 who were diagnosed with HIV over the last five years – with a breakdown of ages for each year. This includes children who were found to have HIV when attending hospital for another matter.

Q5.) Within these figures, please also include the numbers of children who were found to have an STD when using hospital services for other services.

Download response Under 16’s and sexually transmitted diseases (STD) 060416

Weight of new born babies. 140618

In the 2017 calendar year were there any babies born at your hospitals where the weight of the baby was 12lbs (5443g) or more? If so please state how many and what their birthweights were.

Download response Weight of new born babies. 140618

 

Complaints, PALS and Legal Services

Allegations of misconduct. 081117

For each of the past five financial years (12/13 – 16/17) please tell me the following:

The total number of allegations of misconduct made by employees of your trust against another employee, broken down by:
• The job category of the complainant, for example doctor, nurse, porter, receptionist.
• The nature of the alleged misconduct. For example sexual harassment, sexual assault, physical assault, theft, bullying, racism.
• The outcome of the complaint. For example, unsubstantiated, written warning, dismissed, training requirement, police informed.

Download response Allegations of misconduct. 081117

Allegations of sexual assault or sexual harassment. 081117

1- How many allegations of a) sexual assault and b) sexual harassment has your trust received against staff members in each of the past four years?
2- In how many of the cases were any of the alleged victims aged 18 or under at the time of the alleged offence?
3- In how many of the cases were any of the alleged victims current or former patients?
4- For each case, did it lead to i) internal disciplinary proceedings, ii) external disciplinary proceedings (i.e. through a regulator) and/or iii) a financial settlement.
5- For each case, please provide a broad description of the allegations involved, including the number of alleged victims / alleged perpetrators; their age (within a 10-year band); the date of the alleged offence and whether the alleged perpetrator occupied a managerial position.
6- For each case, please list the gender of the alleged perpetrator and the alleged victim. Alternatively, provide totals for the genders of the alleged perpetrators and alleged victims across all of your cases.
7- For each case which was dealt with by disciplinary proceedings, how many alleged offenders were i) fired; ii) suspended, iii) received written or verbal warnings.
8- Please provide the value of any financial settlement in each case.
9- Did any settlements (financial or otherwise) include clauses placing any restriction on the ability of the alleged victim to discuss the events involved or the institution? If so, how many?

Download response Allegations of sexual assault or sexual harassment. 081117

Amputation operations. 201119

1. A list of every amputation operation at your hospital over the past ten years.
2. The amount of cases of the above that have resulted in claims of medical negligence.
3. The amount of cases of the above that have resulted in your informing your insurers of a possible claim for medical negligence.
4. The details of each incident.

Download response Amputation operations. 201119

Breaches of the Data Protection Act.

1a.Approximately how many members of staff do you have?
1b.Approximately how many contractors have routine access to your information?

2a.Do you have an information security incident/event reporting policy/guidance/management document(s) that includes categorisation/classification of such incidents?
2b.Can you provide me with the information or document(s) referred to in 2a? (This can be an email attachment of the document(s), a link to the document(s) on your publicly facing web site or a ‘cut and paste’ of the relevant section of these document(s))

3a.Do you know how many data protection incidents your organisation has had since April 2011? (Incidents reported to the Information Commissioners Office (ICO) as a Data Protection Act (DPA) breach)
Answer: Yes, No, Only since (date):
3b.How many breaches occurred for each Financial Year the figures are available for?
Answer FY11-12: FY12-13: FY13-14: FY14-15:

4a.Do you know how many other information security incidents your organisation has had since April 2011? (A breach resulting in the loss of organisational information other than an incident reported to the ICO, eg compromise of sensitive contracts or encryption by malware. )
Answer: Yes, No, Only since (date):
4b.How many incidents occurred for each Financial Year the figures are available for?
Answer FY11-12: FY12-13: FY13-14: FY14-15:

5a.Do you know how many information security events/anomaly your organisation has had since April 2011? (Events where information loss did not occur but resources were assigned to investigate or recover, eg nuisance malware or locating misfiled documents.)
Answer: Yes, No, Only since (date):
5b.How many events occurred for each Financial Year the figures are available for?
Answer FY11-12: FY12-13: FY13-14: FY14-15:

6a.Do you know how many information security near misses your organisation has had since April 2011? (Problems reported to the information security teams that indicate a possible technical, administrative or procedural issue.)
Answer: Yes, No, Only since (date):
6b.How many near-misses occurred for each Financial Year the figures are available for?
Answer FY11-12: FY12-13: FY13-14: FY14-15:

Download response Breaches of the Data Protection Act 230516

Breast augmentation claims. 010319

1. How much money has been paid out in compensation for botched breast augmentation or botched breast enlargements? Please provide information for the last three years.
2. How many people have made successful compensation claims for botched breast augmentation or botched breast enlargements? Please provide information for the last three years.
3. How many unsuccessful claims for compensation for botched breast augmentation or botched breast enlargements has there been in the last three years?
By last three years I mean 2015, 2016 and 2017. Please provide information for each calendar year.

Download response Breast augmentation claims. 010319

Claims relating to deep vein thrombosis (DVT) and pulmonary embolism (PE). 010319

1. How many hospital negligence claims have been made against the Trust relating to deep vein thrombosis and pulmonary embolism (blood clots) in the last five financial years?
2. Of the legal claims referred to in question 1, how much money has been paid to those who have brought claims against the Trust?
3. Please break down the data to questions 1 and 2 by hospital.

Download response Claims relating to deep vein thrombosis (DVT) and pulmonary embolism (PE). 010319

Communication and consent. 031117

1. In the past 5 years how many complaints have you had regarding communication with or supplying information to patients (written and oral)?
2. In the past 5 years how many complaints have you had regarding the inappropriate or incorrect taking of consent?
3. If the level of detail in questions 1 and 2 is unknown then please say how many complaints have you had in the past 5 years categorised as communication complaints?
4. In the past 5 years how many claims for compensation have you had involving the inappropriate or incorrect taking of consent?
5. If the level of detail in question 4 is unknown please say how many claims for compensation have you had categorised as communication claims?
6. How much did you pay the NHSLA for insurance last year?
7. Can I have a copy of your Consent to Examination or Treatment Policy?
8. If no Consent to Examination or Treatment Policy exists then can you supply me with your approved documented process for obtaining consent, as specified in the NHSLA Risk Management Standards 2013-14?
9. Can you tell me how information is provided to patients to support their decision making, including risks, benefits and alternatives where appropriate?
10. Can you tell me how the discussion and provision of information to patients is recorded?
11. Can you tell me the process for recording that consent has been given?
12. Can you tell me how your organisation monitors compliance with points 9 to 11?
13. Who has overall responsibility for your Consent to Examination or Treatment Policy? (There name would helpful)?

Download response Communication and consent. 031117

Compensation claims by staff. 070417

I would like information on the number and nature of compensation claims brought against your organisation by members of staff who have sustained an injury or contracted a disease while employed your organisation in the past five years.
I would like a year by year breakdown, preferably on an excel document via email, detailing:
Details of the injury (i.e. moving and handling injury, slips/trips/falls and so on)
Staff role if known (i.e. staff nurse, doctor)
Whether compensation was paid
The total amount of compensation paid
If information available, any action taking following the incident (i.e. additional training, non-slip flooring and so on)

Download response Compensation claims by staff. 070417

Complaints. 090719

1) How many compliments did your trust receive in 2017?
2) Do you have a procedure for handling compliments?
3) Do you respond to the authors?
4) Do you pass the compliments onto to the complimentees?
5) Do management see copies of compliments?
6) Do you analyse the content of compliments?

Download response Complaints. 090719

Complaints. 280119

1. Does the Trust routinely publish the complaints data it reports to NHS Digital (KO41a) via any other public channel, i.e. on your website (please indicate YES or NO in the box below)? If YES, please provide details of where and how frequently you publish this data.
Further information on publication:
2. Does the Trust routinely publish, make public or evidence the outcomes and/or learning taken from complaints received (please indicate YES or NO in the box below)? If YES, please provide details of where and how frequently you publish this data.
Further information on publication:
3. Do you record complaints made by third parties who don’t have the expressed consent of the patient(s)? I.e. members of the public, people visiting other patients and/or external non-medical contractors who have concerns about the way patients are being treated or cared for.
4. If you record complaints made by third parties, please could you provide the numbers of complaints received by your NHS Trust for the following financial years?
5. Do you record complaints made by third parties in your official complaints figures as reported to NHS Digital (KO41a)?

Download response Complaints. 280119

Complaints about noise for 2013 – 2016.

How many noise-related complaints the organisation has received in the past three years? For each year, I would like to know:
The department/ward the noise-related complaint refers to
Who made the complaint (patient/relative/staff member etc.)
The nature of the complaint – i.e. if it is noise from staff, noise from another patient, equipment, building work etc.
I would also to know if your organisation has a noise policy or any noise-reduction measures in place – for example soft-closing doors, not transferring patients at night, ‘sleep kits’ for patients and so on.

Download response Complaints about noise for 2013 – 2016 270616

Complaints data for 2018-19. 151119

1. How many complaints were upheld by the Ombudsman?
2. How many complaints were partly upheld by the Ombudsman?
3. What was your complaints (3 working days) performance as a percentage?
4. What was your complaints (final response) performance target in days?
5. What was your performance as a percentage in response to this target? (e.g. 75% of complaints are answered within 25 working days or as agreed with the complainant)
6.How many days does it take on average for you to respond to a complaint?

Download response Complaints data for 2018-19. 151119

Complaints for patients admitted to A&E.241219

1. For each of the last three calendar years (2019, 2018, 2017), please provide a monthly list of the chief complaints for patients admitted to A&E, broken down by:
• The name of the chief complaint.
• The number of patients admitted to A&E for each chief complaint.
• The number of male patients admitted for each chief complaint.
• The number of female patients admitted for each chief complaint.
Please note that the Chief Complaint is the presenting symptom rather than the primary diagnosis.
2. For each of the last three calendar years (2019, 2018, 2017) please disclose the total number of patients that were admitted to A and E.
3. For each of the last three calendar years (2019, 2018, 2017) please disclose the total number of patients admitted to A and E that were not GP registered.

Download response Complaints for patients admitted to A&E.241219

Complaints made to the End of Life Care Strategy Group. 070219

Please detail the number and type of complaints made to your End of Life Care Strategy Group in the last four years. Please break the information down into complaints per month (where possible) and whether the complaint was to do with, for example poor communication, issues to do with consent or the care itself etc. Where recorded, please also detail the outcome of the complaint.

Download response Complaints made to the End of Life Care Strategy Group. 070219

Complaints or concerns raised by staff members

1) Name of:
a) Your trust
b) The hospitals in your trust
2) Between April and October 2015, how many complaints/concerns were raised by Trust staff members regarding?
a) Staffing levels/staffing shortages
b) Shifts being filled by under-qualified staff/staff “acting up”/agency staff/locums
c) Staff overwork/unpaid overtime
d) Staff not being able to take breaks
3) What is the longest time (in days) one patient has remained in a bed at your NHS Trust due to delays in transfer of care (DTOC) from September 2014 to September 2015?
4) What was the age of the patient (from question 3) and the reason for delay?
5) What is the longest time (in days) one patient has remained in a bed at your NHS Trust due to delays in transfer of care (DTOC) from September 2013 to September 2015?
6) What was the age of the patient (from question 5) and the reason for delay?

Download response Complaints or concerns raised by staff members 270516

Counter Fraud. 030619

1. How many people does your organisation employ?
2. What is the total annual expenditure budget of your organisation?
3. How many full-time employment staff does your organisation employ dedicated to counter fraud activities?
4. If you employ such staff, how many full-time employment staff are directly employed by your organisation?
5. If any of your counter fraud staff are supplied by another organisation, could you identify the name of the organisation(s) which supplies them?
6. Approximately how much did you spend on counter fraud activities in the last reporting year?
7. How many referrals for fraud investigation has your counter fraud team received in the last reporting year?
8. How many fraud cases has your counter fraud team successfully investigated? I.e. leading to sanction and/or recovery of monies in the last reporting year.

Download response Counter Fraud. 030619

Court intervention. 141119

1. “Since 01 January 2017, please specify the number of individual cases where the Court has had to intervene in the treatment of a critically ill child, when there has been a difference of opinion between parents and doctors, over the course of treatment for that child?”

Download response Court intervention. 141119

Delayed discharge and court action. 070317

1. Since 1.1.15 how many times have you taken court action to evict a patient from a hospital in your trust because you believe they are fit for discharge but they have failed to leave their hospital bed? For each occurrence please state how many days they had occupied a hospital day for while considered fit for discharge?
2. Of those patients discharged from your hospital in either 2014/15 or 2015/16 please state how many patients had been considered fit to discharge but remained in hospital in excess of one full calendar year before they were discharged? For each patient please state how many days they occupied a hospital bed while considered fit to discharge?
3. Using the most recent convenient date do you have any patients in your hospital who are considered fit to discharge but have been in hospital and been fit to discharge in excess of one full calendar year? For each patient please state how many days they have occupied a hospital bed while considered fit to discharge?

Download response Delayed discharge and court action. 070317

Employees who have left the Trust as a result of judicial mediation 2011 – 2016

1. For each of the past five financial years, what was the total number of employees that left your trust through judicial mediation?
2. For each of the last five financial years how much was paid to departing employees through judicial mediation? Again, I am looking for annual breakdowns of the data.
The annual breakdown should include the following three elements;
A – The statutory amount the employee received (i.e. the sum to which they were legally entitled for redundancy).
B – The amount paid in special severance payments.
C – The overall total of statutory and special severance payments.
3. For each of the past five financial years, how many of the employees who left through judicial mediation signed a settlement agreement (formerly known as a compromise agreement)?
4. For each of the past five financial years, how many employees who left through judicial mediation agreed a confidentiality clause?
5. Taking the definition of confidentiality clauses used in Question 4, for each of the past five financial years, how many fell under the definition 1? 2? 3? Other?
6. For each of the past five financial years, how many staff who left via judicial mediation received an agreed reference?
7. For each of the past five financial years, how many of the judicial mediation cases were referred to the Department for Health/Treasury for sign off?

Download response Employees who have left the Trust as a result of judicial mediation 2011 – 2016

Enforced DNR. 300317

The number of patients who have been taken to the Royal Courts of Justice Court of Protection, to have a DNR placed upon their lives by your hospital. I would like to know if the patient had a Lasting Power of Attorney and the sex, age, ethnicity of the patients and the length of time each case took & outcomes of each case. From when the hospital opened to the present day.

Download response Enforced DNR. 300317

External legal advice

1. How many members of staff are directly employed at the Trust at present as of 24 August 2015?
2. What was your external legal advice expenditure from 01/04/2014 to 31/03/2015?
3. What is your budget for external legal advice for the current financial year?
4. Please provide the list of the solicitors instructed for external legal advice from 01/04/2014 to 31/03/2015.
5. Please provide the full structure of your legal services team (titles of the positions- no names are required).
6. Please provide your Trust’s policy which relates to the process of provision of internal legal advice to the members of staff within your Trust.
7. Please provide the name of the software or system which you use for the claims management.
8. Please provide the annual cost of your claims management system.
9. Please provide the name of the software or system which you use for the complaints management.
10. Please provide the annual cost of your claims management system.
11. How many active Coroner’s Inquest cases are you managing at your Trust as of 24 August 2015?
12. How many active clinical negligence claims against your Trust as of 24 August 2015 (claims reported to the NHSLA)?
13. How many active clinical negligence claims against your Trust as of 24 August 2015 (claims not reported to the NHSLA)?
14. How many active Employer’s Liability claims against your Trust as of 24 August 2015 (claims reported to the NHSLA)?
15. How many active Employer’s Liability claims against your Trust as of 24 August 2015 (claims not reported to the NHSLA)?
16. How many active Public Liability claims against your Trust as of 24 August 2015 (claims reported to the NHSLA)?
17. How many active Public Liability claims against your Trust as of 24 August 2015 (claims not reported to the NHSLA)?
18. Please attach a relevant policy and a flowchart which describe the process of how your legal services team communicates the lessons learned from the claims and coroner’s inquests to the relevant teams across the Trust, to ensure the effective risk management and prevention of similar incidents and to improve care provided.
19. Please provide two, most recent, monthly claims management/ legal services reports. If you do not have monthly reports please provide two most recent quarterly reports.

Download response External legal advice 280716

External legal spend

1. What does your organisation spend on legal fees e.g. external legal advice and what is the breakdown of fees and expenses.
2. What is the breakdown of spend e.g. what percentage of work is completed on an hourly rate basis, capped fee, fixed fee etc. We do not break it down in these terms.
3. Who in your organisation is responsible for managing external legal spend-
4. What controls do you have in place to manage external legal counsel spend?
5. Do you use any of the eBilling (also known as Enterprise Legal Management or Legal Spend Management) tools (e.g. Serengetti, Mitratech, CT Tymetrix, Datacert etc.) available in the market to manage your legal spend – if yes what are you currently paying for this system and does the vendor charge your firms to use the same
6. Do you use a matter management system and if yes how much do you pay for the system.
7. How do you decide if work is completed internally or by external counsel?
8. What performance management do you complete with your external legal counsel to ensure you are receiving value for money?
9. What is the breakdown of spend e.g. % of time billed by partner, by senior associate, junior associate, trainee and paralegals etc.
10. What is the breakdown of your legal spend by location e.g. how much work is performed in London, Manchester, Birmingham, Edinburgh, Glasgow, Cardiff, Belfast etc.
11. How do you measure what value added services law firms provide to you (e.g. free advice, free training, free secondees etc.)
12. Do you use external consultants to advice on how to manage your legal spend more effectively. If yes, who and what have you spent with them in the last 12 months

Download response External legal spend 180216

Fat-shaming complaints. 210519

Could you please tell me for each of the years 2016, 2017 and 2018

How many complaints through the patient advice and liaison system (PALS) your trust received from patients alleging they had been discriminated against or badly treated by a member of staff because of their being overweight or obese.

Please do this by searching for complaints containing any of the words “weight”, “fat”, “obese”, “overweight” and “bariatric” and filtering these to find those that refer to fat-shaming comments made by a member of staff.

Can you select the first five such complaints from 2018 and provide me with the following details:

1. What type of staff member was the complaint levelled against? E.g. healthcare assistant, junior doctor, consultant, cleaner, kitchen staff

2. Please quote the words allegedly used by the hospital staff or summarise the offending action

3. Please tell me what, if any, action was taken by your trust in response to these five sample complaints from the beginning of 2018

Download response Fat-shaming complaints. 210519

Food poisoning. 020819

1. How many inpatients developed food poisoning (relating to E.coli, listeria, campylobacter, salmonella or other) during a stay at the hospitals in your trust between the end of May 2018 and the end of May 2019?
2. How many inpatients developed food poisoning (relating to E. coli, listeria, campylobacter, salmonella or other) during a stay at the hospitals in your trust between the end of May 2013 and the end of May 2014?
3. Are meals prepared on site or off the premises by an outside provider?
4. How many complaints did you receive about hospital food between the end of May 2019 and the end of May 2018?
5. How many complaints did you receive about hospital food between the end of May 2013 and the end of May 2014?

Download response Food poisoning. 020819

Grievance complaints in the last five years.

1. The number of all the Grievance complaint cases dealt with by MTW Trust in the last five years?
2. The outcome of these cases:
a. Numbers and percentage of Grievance cases accepted
b. Numbers and percentage of Grievance cases upheld
c. Number of staff members suspended, demoted or sacked within a year of making a grievance complaint.
3. Numbers and percentage of cases made by BME members of staff.
4. Outcome of BME grievance complaints in numbers and percentage as successful or upheld
5. Number of BME staff members suspended, demoted or sacked within a year of making a grievance complaint.

Download response Grievance complaints in the last five years 270616

Legal fees. 010719

1. How much was spent on legal fees by your Trust on defending employment tribunal cases relating to (a) discrimination; (b) unfair dismissal and (c) public interest disclosure in each year since 2016?

Download response Legal fees. 010719

Legal proceedings issued to patients refusing to leave the Trust hospitals.

1. The number of letters issued by your Trust threatening legal proceedings if a patient does not leave. Please include specific details of any laws referred to in each.

2. How many letters has your Trust issued threatening legal proceedings if a patient does not vacate a hospital bed/ward on 2013/14, 2014/15, 2015/16. Please include specific details of any laws referred to in each if different from Question 1.

3. Number of cases an eviction notice or court order for possession of a bed been served by your trust in 2013/14, 2014/15, 2015/16. Please include specific details of any laws referred to in each if different from Questions 1 and 2.

Download response Legal proceedings issued to patients refusing to leave the Trust hospitals 060916

Legal spend in Government

1. How much did your organisation spend on legal fees in the financial year 2015?
2. Do you have a panel of preferred legal providers? If yes, what year was this panel appointed?

Download response Legal spend in Government 270616

Letters of complaint 2013. 310517

We request the first 25 type-written letters of complaint that your Trust received after 1st October 2013. If your Trust contains more than one unit, we request that the letters are from across the units.

Anonymity of patient letters: The letters will contain personally identifying information, and we request that all personally identifying information be redacted from the letters (i.e., information about addresses, dates, units attended, sexuality, religion, ethnicity, age etc.). We only request information about the patient’s experience of the NHS. We understand that the resultant letters may be heavily redacted.

Why we have selected your Trust: Your trust has been randomly selected. We want a national sample of letters of complaint received by NHS Acute Trusts, and your Trust is an Acute Trust.

Anonymity of your Trust: The name of your trust will not appear in any of our research. The letters which you provide will be aggregated with letters from other Trusts, and will in no way be traceable back to your trust. We are not interested in the identity of any particular Trust.

Download response Letters of complaint 2013. 310517

Ligature points. 280119

• Number of serious incidents involving ligature points, occurring within the trust grounds, in the following years; 2018-19 (to date) 2017-18, 2016-17, 2015-16
• Number of patient deaths involving ligature points, occurring within the trust grounds, in the following years; 2018-19 (to date) 2017-18, 2016-17, 2015-16
• Of the serious incidents listed above how many of the patients involved were under 18?
• Of the patient deaths listed above how many of the patients involved were under 18?
• How much has the trust spent on specific programmes to tackle ligatures points in each of the following years; 2018-19 (to date) 2017-18, 2016-17, 2015-16

Download response Ligature points. 280119

Listeria and hospital sandwiches. 140819

1) A copy of any correspondence sent and received by the trust about listeria from hospital sandwiches since 1 January 2016.
2) A copy of any reports prepared by the trust about listeria and hospital sandwiches from 1 January 2016.
3) The number of patients found or suspected to have contracted listeria from hospital sandwiches in each calendar year from 1 January 2016, including the current calendar year.
4) Any correspondence with The Good Food Chain about listeria since 1 January 2016.

Download response Listeria and hospital sandwiches. 140819

Litigation cases bought against the Trust since 2010.

1. How many litigation cases have been brought against the trust since 2010? (Please provide a breakdown per year)
2. For each litigation case brought against the trust, please provide a brief outline of the nature of the case
3. For each litigation case brought against the trust, how many did the trust admit liability for?
4. For each litigation case brought against the trust, how much money did the trust pay out to the other party?
5. For each litigation case brought against the trust, how much money was spent on legal fees?

Download response Litigation cases bought against the Trust since 2010 070416

Losses and special payments 2014-2015

In your financial accounts for the financial year 2014/15 did you have a section for “losses and special payments?
1. If so how much money was accounted for in the 2014/2015 financial year as being “losses and special payments”? (Please note l am aware that the loss may have occurred many years earlier but I am interested in items which were accounted for in the last financial year, irrespective or when the loss took place.)
Please detail the three largest single amounts within this total, giving a cost for each loss and a detailed description of the claim and the reason for the loss.
2. What was the total paid on claims for property lost by patients and how much related to (i) Dentures, (ii) Spectacles, (iii) jewellery and (iv) hearing aids?

Download response Losses and special payments 2014-2015 080216

Lost property. 261119

I’d like to know the number of electronic items reported missing at your trust over the last three calendar years broken down by year, 2018, 2017, 2016.
• Mobile phones
• Laptops
• Tablet computers
If possible, please list the make of the devices e.g. ‘Apple’, no worries if this is not possible.

Download response Lost property. 261119

Managing personal injury claims. 280917

1. What policies does the Trust have in place to identify, investigate and report potential cases of clinical negligence?
2. In the financial year 2015/16, how much did the Trust spend in-house on managing clinical negligence claims?
3. In the financial year 2015/16, how much did the Trust spend in-house on managing all personal injury claims (e.g. clinical, employer’s /public liability etc.)?
4. How many full-time equivalent staff within the Trust’s employment are responsible for managing clinical negligence claims? What is the total annual pay bill for these members of staff?
5. How many full-time equivalent staff within the Trust’s employment are responsible for managing all types of personal injury claim? What is the total annual pay bill for these members of staff?
6. In total, how much did the Trust spend in 2015/16 on contracting outside providers (e.g. solicitors), other than the NHS LA, to deal with clinical negligence claims.

Download response Managing personal injury claims. 280917

Medication errors 2014 and 2015.

I would be grateful if you could let me have the following information, for two separate years: 2014 and 2015.
1) The number of medication errors recorded by the Trust for each of these two years.
2) The number of these incidents for each of these two years that were recorded as causing:
– no harm
– low harm
– moderate harm
– severe harm
– death
3) The number of errors for each of these two years attributed to:
– prescribing error
– dispensing error or
– any other cause
4) The number of errors for each of these two years attributed to:
– the prescribing or dispensing of the wrong dose, or
– the prescribing or dispensing of the wrong medicine.

5) The number of incidents for each of these two years in which the Trust has paid financial compensation to patients or relatives of patients in respect of medication errors, and the total paid in compensation for each of these two years in respect of medication errors.
6) Finally, does the Trust have a named medication safety officer, and when was this post established and filled?

Download response Medication errors 2014 and 2015 030516

NHS Injury Costs Recovery Scheme 2015-2016 171016

Please can you provide me with information about the total amounts collected by the Trust/Hospital in relation to the NHS Injury Costs Recovery Scheme (was RTA) for the year 2015/16.

Download response NHS Injury Costs Recovery Scheme 2015-2016 171016

Number and costs of court cases launched to prevent patients being identified in media reports.

1) How much money has your Trust spent in total during the three financial years between April 2012 and April 2015 to prevent patients being identified in media reports? Please enter the answer into the supplied MS Excel template file in the cells under the column labelled “Q1”.

2) How much money has your Trust spent in each financial year between April 2012 and April 2015 to prevent patients being identified in media reports? Please enter the answer into the supplied MS Excel template file in the cells under the columns labelled: “Q2 – 12/13”; “Q2 – 13/14”; “Q2 – 14/15”.

3) How many separate court cases has your Trust launched in each financial year between April 2012 and April 2015 to prevent patients being identified in media reports? Please enter the answer into the supplied MS Excel template file in the cells under the columns labelled: “Q3 – 12/13”; “Q3 – 13/14”; “Q3 – 14/15”.

4) How many Reporting Restriction Orders has your Trust obtained in each financial year between April 2012 and April 2015 to prevent patients being identified in media reports? Please enter the answer into the supplied MS Excel template file in the cells under the columns labelled: “Q4 – 12/13”; “Q3 – 13/14”; “Q3 – 14/15”.

5) How many other privacy injunctions has your Trust obtained in each financial year between April 2012 and April 2015 to prevent patients being identified in media reports? Please enter the answer into the supplied MS Excel template file in the cells under the columns labelled: “Q5 – 12/13”; “Q3 – 13/14”; “Q3 – 14/15”.

6) How many separate court cases has your trust launched in each financial year between April 2012 and April 2015 to prevent patients being identified in media reports where the mental capacity of the patient was an issue? Please enter the answer into the supplied MS Excel template file in the cells under the columns labelled: “Q6 – 12/13”; “Q4 – 13/14”; “Q4 – 14/15”.

7) How many separate cases has your trust launched in each financial year between April 2012 and April 2015 to prevent patients being identified in media reports where the Trust acted with the family of the patient? Please enter the answer into the supplied MS Excel template file in the cells under the columns labelled: “Q7 – 12/13”; “Q4 – 13/14”; “Q4 – 14/15”.

8) How many separate cases has your Trust launched in each financial year between April 2012 and April 2015 to prevent patients being identified in media reports where the Trust acted without the family of the patient? Please enter the answer into the supplied MS Excel template file in the cells under the columns labelled: “Q8 – 12/13”; “Q4 – 13/14”; “Q4 – 14/15”.

9) Please enter any additional notes, caveats or general points into the supplied MS Excel template file in the cell under the column labelled “Additional notes”.

Download response Number and costs of court cases launched to prevent patients being identified in media reports 250216

Paediatric department complaints. 050719

Please provide me with number of complaint raised against paediatric department (nurses, doctors) from patient in 2018, and if possible to clarify each complaint nature and what action taken.

Download response Paediatric department complaints. 050719

Penalties and fines 2014-2015.

1) Name of a) your trust b) the hospitals in your trust
2) Does the hospital trust have a Major A&E Unit?
3) We would like to request the income retained by the commissioner (the CCG) as a result of funds withheld or ‘defunded’ from your Trust under the application of the 30% marginal emergency tariff in the following financial year of 2014/15?
4) How much money has the Trust been fined or had withdrawn/withheld for not meeting the percentage target for referral to treatment time of 18 weeks for patients in the following financial year of 2014/15?
5) How much money has the Trust been fined or had withdrawn/withheld for not meeting the percentage target for A&E waiting time (4 hours) in the following financial year of 2014/15?
6) How much money has the Trust been fined or had withdrawn/withheld for emergency readmissions of patients within 30 days of discharge in the following financial year of 2014/15?

Download response Penalties and fines 2014-2015 181115

Physical attacks on Trust premises 2011 to 2016. 040118

1) How many physical attacks have there been on premises owned by your Trust in each of the last five financial years by patients on
a) patients
b) staff
c) visitors?
2) How many physical attacks have there been on premises owned by your Trust in each of the last five financial years by staff on
a) patients
b) staff
c) visitors?
3) How many physical attacks have there been on premises owned by your Trust in each of the last five financial years by visitors on
a) patients
b) staff
c) visitors?
By ‘physical attacks’ I mean any physical attack by one person on another person reported to or collected by your trust, or reported by your trust to the police or any other law enforcement agency.

Download response Physical attacks on Trust premises 2011 to 2016. 040118

Sexual assaults. 040118

Please clarify whether you hold data on the number of patient-on-patient sexual assaults in your Accident and Emergency department, as well as patient-on-staff sexual assaults?

If so, could you please release the number of reported assaults to me, divided by year and by category (patient-on-patient and patient-on-staff) in an Excel spreadsheet to send to this email, along with the number of resulting arrests or convictions (if you have this information), for the past five years.

Download response Sexual assaults. 040118

Use of technology. 070219

I would like to request access to the following information, including any data from the past five years:
1. Any complaints or escalations from each trust across the UK relating to technology. Including new technology being introduced (iPads etc.) as well as complaints about the internal computer systems. I would like this information broken down by hospital or other location (e.g. ambulance dispatch centre or community area), and would like the details of each the complaint.
2. If the above has an impact on the A&E department, I would like that detailed separately.
3. Any information that is submitted internally relating to complaints about technology
4. Information about any tech trials your trust has been a part of, including smart watches, iPads etc. and any feedback you have had on these.
5. Any instances of periods of time where hospitals are unable to function normally because of issues with the IT systems. Including details of the trust and time it took to fix the issue
6. Results of the employee survey for the past 2 years, including any mentions of frustrations around technology.

Download response Use of technology. 070219

Violations of patient privacy. 020919

1. How many (a) medical staff and (b) non-medical staff were disciplined in the last two calendar years (2017 and 2018) for improper/illegal or inappropriate use of patient records?

2. Please provide for the five most recent incidents a brief description, which should include

(i) The nature of the offence or breach of Trust policy (e.g. looked at health records of neighbour/celebrity/family member without professional purpose)

(ii) The person’s job title (e.g. nurse, admin staff, physio, consultant)

(iii) How the matter was resolved, i.e. written warning, sacked etc.

Download response Violations of patient privacy. 020919

Violent incidents. 081117

1. Following the changes to NHS Protect in April 2017 do you still have access to an accredited local security management specialist? Yes / No
a. If yes, are they directly employed or support accessed as part of a contract?
b. If no, how is your board assured of maintaining security standards?

2. Please provide in the table below information about aggression and violence incidents for the financial years April 2014 – March 2015, April 2015 – March 2016, April 2016 – March 2017. Please note all non-physical assaults would include all incidents of aggression and violence that did not result in physical contact i.e. verbal, racial abuse etc.

3. For the physical assault numbers above please break down by the actual impact recorded for each incident in the table below. If your grading of actual impact is different to that defined below, please match to the nearest descriptor from your risk management system.

4. For the physical assaults number above, please indicate in the table below how many incidents were classified as serious and investigated in line with the NHS England Serious Incident Framework.

5. For the physical assaults numbers detailed in table 2, please break down the number in the table below by the staff group.

Download response Violent incidents. 081117

 

Coronavirus COVID-19

Coronavirus outreach working. 310320

Due to recent concerns and government changes in advice related to working (regarding the Coronavirus), we are putting together our plan for our staff that are working from outreach locations.

We are getting in touch with all outreach locations our staff work from to ask for their plans/policies in light of the Coronavirus. Are we able to get your plan also?

Download response Coronavirus outreach working. 310320

Isolation pods. 070420

I was in desperate need to gain information on the “Testing and Isolation Pods” and as much detail as practically possible on how to build them please!?

Download response Isolation pods. 070420

 

Critical Care

Agency spend for locum doctors in Acute Medicine. 240317

Can you please assist me with retrieving the total Agency spend for Medical Locum Doctors within Acute medicine over the following months, within your Trust or Health Board?
August 2016
September 2016
October 2016
November 2016
December 2016
January 2017

Download response Agency spend for locum doctors in Acute Medicine. 240317

Anchors. 050418

Name of your Trust
Hospitals within Trust (select multiples as needed)
The number of anchors used between Jan 2017-Dec 2017
The supplier name(s) of knotless anchors (select multiple suppliers as needed)
The supplier name(s) of knot tying anchors (select multiple suppliers as needed)
Procurement Route
Procurement agreement end date (DD/MM/YY)
Estimated annual value, Jan 2017-Dec 2017 (£s)
Number of Rotator Cuff repairs completed between Jan 2017-Dec 2017
Number of instability/stability repairs completed between Jan 2017-Dec 2017

Download response Anchors. 050418

Cardiology digital systems.241219

1) Regarding echocardiograms:
a) Which digital system is used by healthcare professionals in your trust to request echocardiograms?
b) On what digital system(s) are echocardiogram images stored?
c) On what system are echocardiograms reported?
d) On what system(s) are the reports for echocardiograms available for review?

2) Regarding coronary angiograms:
a) Which digital system is used by healthcare professionals in your trust to request coronary angiograms?
b) On what digital system(s) are images from coronary angiograms stored?
c) On what system are coronary angiograms reported?
d) On what system(s) are the reports from coronary angiograms available for review?

3) Regarding cardiac pacemakers:
a) Which digital system is used by healthcare professionals in your trust to request pacemaker insertion?
b) On what system are pacemaker procedure reports written?
c) On what system(s) are pacemaker procedure reports available for review?
d) On what system(s) are cardiac pacemaker routine outpatient checks available for review?

4) Regarding cardiology patient documentation:
a) On what system(s) are outpatient letters available for review?
b) On what system(s) are discharge letters available for review?
c) Are copies of ECGs stored electronically? If so, on what system(s) are they available?

5) Regarding CT coronary angiograms:
a) Which digital system is used by healthcare professionals in your trust to request CT coronary angiograms?
b) On what digital system(s) are images from CT coronary angiograms stored?
c) On what system are CT coronary angiograms reported?
d) On what system(s) are the reports from CT coronary angiograms available for review?

6) What RIS system does your hospital use?
7) What PACS system does your hospital use?

Download response Cardiology digital systems.241219

Clinically Artificial Nutrition and Hydration (CANH). 170120

• In your Trust is there any formal register kept of deaths occurring as a result of withdrawal of Clinically Artificial Nutrition and Hydration (CANH) that occur under the provisions of the Mental Capacity Act 2005 and BMA/RCP/GMC Guidelines 2018?
• If such a register is kept can you advise if there is any independent internal or external audit made of such deaths and the degree to which there Is compliance with the BMA/RCP/GMC Guidelines, 2018 when such deaths occur?
• Where deaths due to withdrawal of CANH are recorded and an audit is made of these, can you give an indication of the number such deaths in 2018 and in 2019 and the percentage of cases where the BMA/RCP/GMC Guideline Checklist has been used and fully completed?

Download response Clinically Artificial Nutrition and Hydration (CANH). 170120

Complaints regarding end of life care.

1. How many complaints in the following years has the Trust received relating to the end of life care/palliative care of a patient? Please answer each year by breaking down month by month e.g. January: 9, February 10…
a) In 2015
b) So far in 2016 (up to 16/5/2016)
2. Of the number of complaints above what numbers were related to:
a) Communication that the patient is actually dying
b) The patient or relatives was unaware that lifesaving drugs had been withdrawn
c) Care, including dignity, respect and privacy
d) Lack of pain relief
e) Access to specialised support and information
f) Lack of access to care through the night, at weekends and over holiday’s periods

Download response Complaints regarding end of life care 060616

Continuous renal replacement therapy (CRRT). 010217

1. How many machines do you have for continual renal replacement (CRRT) in the intensive care unit/critical care unit?
1. a. Can you split these by manufacturer and age of machine please?
2. Are you in a contract for your machines, if so when does the contract expire?
3. How many CRRT treatments were carried out in 2016 (or the latest 12 month period you have data for)?
4. How many bags of fluid did you use for CRRT in 2016 (or the latest 12 month period you have data for)?
5. Who is your current manufacturer of fluids for CRRT? And for Vascular access? (Double Lumen catheters)
6. Are you in a contract for fluids, if so, when does this expire and is it linked in with the machine contract?
7. What was your total spend on CRRT fluids in 2016 (or the latest 12 month period you have data for)?
8. What was your total spend on CRRT consumables (e.g. consumable sets for the machines) in 2016 (or the latest 12 month period you have data for)?
9. What is the typical renal dose you prescribe to the patients? (In ml/kg/h)
10. Are your units using Citrate Anticoagulation? If yes how frequent (in % vs. Heparin).

Download response Continuous renal replacement therapy (CRRT). 010217

Covered stents. 030118

What is the total number of Covered stents deployed in Arterio venous (AV) fistula/graft access procedures in 2016-17?

Download response Covered stents. 030118

Critical care. 200718

The hospitals under your trust?
Number and types of operating theatres.
Number of beds within the critical/intensive care unit(s).
Number of endoscopy treatment rooms/theatres.
If possible I would like to know the make, model and age of the following equipment if applicable:
1.0 Ultra clean ventilation systems
2.0 General Theatres
3.0 Ceiling mounted medical service pendants
4.0 Operating lights
5.0 Theatre control panels
6.0 AHU Units
7.0 Class 1,2 & 3 Cabinets

Download response Critical care. 200718

Critical care bed capacity. 090617

Question 1: What is the total number of critical care beds (Level 2 and Level 3) per 100,000 of the population your trust serves?
1. If you cover both secondary and tertiary care, please provide your TOTAL bed:population ratio for the whole trust, AND a figure for both types of service
Question 2: How many critically ill patients were transferred from your hospital to another hospital’s critical care unit for non-clinical reasons in 2016-17?
Question 3: How many days in 2016-17 was the occupancy of your critical care beds over 85% at least one point during those 24 hours?
Question 4: How many patients had an elective operation cancelled due to lack of a critical care bed capacity in 2016-17?
Question 5: How many days in 2016-17 was at least one critical care bed closed due to lack of staff for at least part of the day?

Download response Critical care bed capacity. 090617

Domiciliary services for medicines review and palliative care. 281116

I am currently setting up (1) domiciliary visiting medicines review (focussing on both medicines optimisation and medicines adherence) and (2) palliative care services (to ensure the timely and appropriate availability of end of life medicines) within Norfolk using the community pharmacy network and GP practice based pharmacy network, working in conjunction with our NHS community services teams.  I am therefore writing to ask if you could send me any reports (service specifications, audit reports, service evaluations etc.) which you may have relating to any services of a similar nature delivered in your area.

Download response Domiciliary services for medicines review and palliative care. 281116

Emergency admissions for Asthma, Epilepsy and Diabetes 2014 – 2016. 270317

1. For the last 4 quarters from January 2016 – December 2016, please provide a breakdown of the number of emergency admissions by age group, broken down by quarter, for the following conditions: (a) asthma (b) epilepsy (c) diabetes type 1 & type 2.
2. For the last 4 quarters from January 2016 – December 2016, please could you provide a breakdown of the number of emergency attendances by age group, broken down by quarter, for the following conditions: (a) asthma (b) epilepsy (c) diabetes type 1 & type 2.
3. For the 4 quarters January 2015 – December 2015, please could you provide a breakdown of the number of emergency admissions by age group, broken down by quarter, for the following conditions: (a) asthma (b) epilepsy (c) diabetes type 1 & type 2.
4. For the 4 quarters January 2015 – December 2015, please could you provide a breakdown of the number of emergency attendances by age group, broken down by quarter, for the following conditions: (a) asthma (b) epilepsy (c) diabetes type 1 & type 2.
5. For the 4 quarters January 2014 – December 2014, please could you provide a breakdown of the number of emergency admissions by age group, broken down by quarter, for the following conditions: (a) asthma (b) epilepsy (c) diabetes type 1 & type 2.

6. For the 4 quarters January 2014 – December 2014, please could you provide a breakdown of the number of emergency attendances by age group, broken down by quarter, for the following conditions: (a) asthma (b) epilepsy (c) diabetes type 1 & type 2?

Download response Emergency admissions for Asthma, Epilepsy and Diabetes 2014 – 2016. 270317

Escalation procedures for ITU/ICU/HDU.

This is FOI request, please tell me what happens if you get patients for ITU / ICU / HDU but they are full with other patients, what do you do?

Download response Escalation procedures for ITU/ICU/HDU 190416

Follow-up of Critical Care patients.

Please could you send me any policies relating to intensive care/ critical care follow up of patients?

Download response Follow-up of Critical Care patients 130116

Laparoscopic instruments. 110219

Please could you forward the following information in regards to laparoscopic monopolar scissors, laparoscopic Maryland dissector and laparoscopic graspers?
• Your current supplier?
• Annual usage in the following years: 2015-2016, 2016-2017, 2017-2018, 2018 year to date
• Annual spend in the following years: 2015-2016, 2016-2017, 2017-2018, 2018 year to date
• Current contract details?
• Contract manager’s name and email address?

Download response Laparoscopic instruments. 110219

No Resus Orders (DNR) in 2011 – 2016. 200417

1. How many No Resus Orders were issued by your hospital in last 5 years?
2. How many of these patients survived and were thus discharged from your hospital in same above period?
3. Have you a pro forma No Resus Order checklist which you use to see whether patient should be given No Resus Order, please send me a copy?
4. What percentage of your SpR or Specialist Registrars are on the General Medical Council’s Specialist Register?

Download response No Resus Orders (DNR) in 2011 – 2016. 200417

OHCA and IHCA. 180320

1.
a. The care bundle was due for review October 2019 – could you please provide any details of an update?
b. Also, please could you describe what guidelines are currently referenced in the management of OHCA?

2. Could you please confirm if you have access to the data on the proportion of OHCA that arrive at Maidstone and Tunbridge Wells NHS Trust that receive TTM?

3. I have looked through the care bundle attached but I’m unable to find any reference to whether the TTM is part of the training curriculum for the resuscitation and advanced life support team or the critical health team, or any training materials?

Download response OHCA and IHCA. 180320

OHCA and IHCA. 190220

I would like to obtain information related to the management of out-of-hospital cardiac arrest (OHCA) and in-hospital cardiac arrest (IHCA) and the approach to targeted temperature management (TTM) in patients admitted to Maidstone and Tunbridge Wells NHS Trust following sudden cardiac arrest.

1) Can you please describe what guidelines are currently used in NHS Acute Trust Name for the management of OHCA and IHCA? Please attach a copy of Trust’s protocols for the management of OHCA.

2) Has Maidstone and Tunbridge Wells NHS Trust incorporated the European Resuscitation Council Guidelines for Resuscitation 2015 into Trust’s post cardiac arrest care protocols?

3) Can you please confirm if TTM is incorporated as part of the OHCA management in Maidstone and Tunbridge Wells NHS Trust? If yes, can you please confirm:

a. what is the target temperature?
b. what method or equipment is currently used to ensure that the target temperature is achieved and maintained?
c. which staff members are currently responsible for delivering TTM as part of OHCA management?
d. What proportion of OHCA that arrive at Maidstone and Tunbridge Wells NHS Trust that receive TTM

4) Can you confirm whether TTM is part of the OHCA training curriculum for the members of the resuscitation and advanced life support team and critical care team at Maidstone and Tunbridge Wells NHS Trust? Please include any relevant training materials and checklist currently in use.

5) Please provide data on outcomes for patients who had suffered OHCA and have been treated in Maidstone and Tunbridge Wells NHS Trust. Can you please tell us the number of patients who suffered OHCA and were admitted to Maidstone and Tunbridge Wells NHS Trust for the period from 2014 to 2019 (please include yearly breakdown where available) that:

a. have resulted in a poor outcome, such as severe neurological disability, persistent vegetative state or death (CPC scores 3, 4, or 5);
b. have been discharged with a good neurological outcome (CPC 1 or 2).

Download response OHCA and IHCA. 190220

Operating theatre fire incidents. 020518

1) What is the number of operating theatre fire incidents reported in Maidstone and Tunbridge Wells NHS Trust for the period 2010-2018? Please provide a breakdown for each year.
2) Can you please include a breakdown of the type of operating theatre fire incidents for the period 2010-2018, broken down by each year and characterised as follows:
a. chemical ignition
b. chemical related
c. diathermy related
d. equipment related
e. other reported in Maidstone and Tunbridge Wells NHS Trust? Please provide a breakdown for each year.
3) What is the number of operating theatre fire incidents related to alcoholic skin preparation agents specifically reported in Maidstone and Tunbridge Wells NHS Trust’s for the period 2010-2018? Please provide a breakdown for each year.
4) Can you please include additional details on the number of operating theatre fire incidents that resulted in an injury for the patient, i.e. burn reported in Maidstone and Tunbridge Wells NHS Trust for the period 2010-2018? Please provide a breakdown for each year.
5) Can you please describe what prevention protocols are in place to avoid operating theatre fire accidents in Maidstone and Tunbridge Wells NHS Trust? Please attach a copy of any protocols.
6) Does Maidstone and Tunbridge Wells NHS Trust provide any prevention training courses for operating theatre healthcare professionals on operating theatre fire incidents? If so please provide details.

Download response Operating theatre fire incidents. 020518

Operating theatres and intensive care units.

1. How many operating theatres do you have per hospital?
2. How many intensive care units (ICU) do you have per hospital for each of the following?
a. Neonatal
b. Pediatrics
c. Adults

Download response Operating theatres and intensive care units 060916

Service suspensions. 300317

1) In the past 12 months, have you suspended any acute services because of a shortage of doctors or nurses to staff the service?
If yes:
a) Which services were suspended?
b) How many suspensions have there been?
c) What was the longest period a service was suspended for?
2.) Intensive care services: Are any ITU beds closed?
If yes:
a) How many times in the past 12 months have ITU beds had to be closed?

Download response Service suspensions. 300317

Spinal cord stimulation consent and procedures. 070219

Q1. Does your trust use a standard pre-designed consent form (or set of consent forms) for any of the spinal cord stimulation (SCS) procedures listed in the table below? Please specify for which of these procedures such a consent form exists.
Q2. If your trust does use standard consent forms, please provide me with digital copies of the relevant forms and make clear what procedures each consent form is used for.
Q3. Please provide digital copies of any patient information leaflets or guidance about SCS that is given to patients by your trust.
Q4. With reference to your trust’s coding database, please tell me how many of each of the following SCS procedures were performed by your trust in each of the years 2016 and 2017 – the relevant OPCS 4.x codes are:
Q5. Which OPCS coding version (or version of whatever other coding system) is used by your trust (e.g., OPCS 4.5)?

Download response Spinal cord stimulation consent and procedures. 070219

Surgical and general specialist tables. 010420

1. Number of in beds in each hospital
2. Number of ICU Beds specifically
3. Overall Theatre Numbers
4. Number of spinal theatres
5. Number of Spinal Consultants
6. Number of Neuro Theatres
7. Number of Neuro Consultants

Download response Surgical and general specialist tables. 010420

Theatres.241219

1. Number of theatres
2. Vital Signs System supplier name
3. Date of Installation
4. Preferred purchase route i.e. Direct
5. Theatre System supplier name i.e. Mindray, GE, Philips
6. Date of installation
7. Planned replacement date
8. ICU System supplier name
9. Date of installation
10. Preferred purchase route i.e. Direct
11. Defibrillation Supplier name
12. Date of installation
13. Planned replacement date
14. Number of manual defib devices
15. Number of Automatic AED defib devices
16. Spo2 Pulse Oximetry technology supplier name

Download response Theatres. 241219

Therapeutic Hypothermia (cooling) system in ITU. 060319

Please forward me the following information regarding your Intensive Care Units?
1. What Therapeutic Hypothermia (patient cooling) system they currently use?
2. When it was purchased?
3. When will it be renewed or when does the contract expire?
Would it also be possible to obtain the contact details of the person dealing with managing the Therapeutic Hypothermia (patient cooling) system in your ITU?

Download response Therapeutic Hypothermia (cooling) system in ITU. 060319

Upper and Lower GI Procedures for Endoscopy. 240919

1). Has the trust performed Upper and Lower GI Procedures for Endoscopy within the time period noted in the table below?
2). Please could you kindly mention the number of Upper and Lower GI Endoscopy Procedures; as per the table format below.

Download response Upper and Lower GI Procedures for Endoscopy. 240919

Uscomm BP+. 270917

Please tell me if you have bought, stock it and use this product:

It is called Uscomm BP+, previously it was called Pulsecor.

It is used by cardiologists or doctors and consultants who have interest in heart related things.

Download response Uscomm BP+. 270917

Vaginal mesh surgeries. 240919

1. The number of surgeries performed using vaginal mesh to treat pelvic organ prolapse or urinary incontinence for the last available fiscal year and previous years (up to 10 years in the past)
2. The total number of pelvic organ prolapse surgeries that were performed on women and men (separate statistics) between 01 April 2018 and 01 April 2019
3. The total number of patients who were recommended pelvic floor muscle training as treatment for their pelvic organ prolapse between 01 April 2018 and 01 April 2019
In terms of pelvic organs, I refer to the pelvic organs such as the bladder, uterus, vagina, bowel, and rectum.

Download response Vaginal mesh surgeries. 240919

Withdrawing life-sustaining treatment. 300120

(i) The number of registered medical practitioners who conscientiously objected and opted out of withdrawing life-sustaining treatment between 1 January 2015 and 31 December 2019.

Download response Withdrawing life-sustaining treatment. 300120

 

Delayed transfer of care

12 hour trolley waits. 141217

a) How many patients spent longer than 12 hours from decision to admit to admission at your Trust between October 2016 and October 2017?
b) Of those patients waiting longer than 12 hours from decision to admit to admission, what was the longest wait over 12 hours between October 2016 and October 2017?
c) If possible, please provide a reason for the delay.

Download response 12 hour trolley waits. 141217

Delayed discharge. 160119

1) How many delayed discharges from inpatient wards were recorded by your trust during the following date ranges (please break down the data into the date ranges specified below):
a. 1st November 2017 to October 31st 2018
b. 1st November 2016 to October 31st 2017
c. 1st November 2015 to October 31st 2016
2) What was the total amount of time spent by delayed discharge patients in hospital wards managed by your trust between patients being ready for transfer and the patients being fully discharged from hospital during the following date ranges (please break down the data into the date ranges specified below. Please use whichever time measurement is used by default by your trust):
a. 1st November 2017 to October 31st 2018
b. 1st November 2016 to October 31st 2017
c. 1st November 2015 to October 31st 2016
3) What is the average cost per day to your trust of a patient staying in hospital to your trust, excluding costs specific to their medical condition (i.e. the basic cost of providing a bed, food and care but excluding condition specific drugs, care or medical procedures)
4) Does your trust currently have a plan in place to reduce the delayed discharge of patients in the future?

Download response Delayed discharge. 160119

Delayed discharge 2013-2017 150217

What is the longest continual stretch of days that have been lost to delayed discharge by one patient in?
a) 2013/14
b) 2014/15
c) 2015/16
d) 2016/17 (YTD)

Download response Delayed discharge 2013-2017 150217

Delayed discharge and court action. 070317

1. Since 1.1.15 how many times have you taken court action to evict a patient from a hospital in your trust because you believe they are fit for discharge but they have failed to leave their hospital bed? For each occurrence please state how many days they had occupied a hospital day for while considered fit for discharge?
2. Of those patients discharged from your hospital in either 2014/15 or 2015/16 please state how many patients had been considered fit to discharge but remained in hospital in excess of one full calendar year before they were discharged? For each patient please state how many days they occupied a hospital bed while considered fit to discharge?
3. Using the most recent convenient date do you have any patients in your hospital who are considered fit to discharge but have been in hospital and been fit to discharge in excess of one full calendar year? For each patient please state how many days they have occupied a hospital bed while considered fit to discharge?

Download response Delayed discharge and court action. 070317

Delayed discharge from the stroke rehabilitation unit at Tunbridge Wells Hospital at Pembury. 011216

1. Please could you provide details of the current number of patients whose discharge from the stroke rehabilitation unit at Pembury Hospital is being delayed while social services arrange personal care packages?
2. Please could you provide details of the number of patients whose discharge has been delayed for more than 7, 14, 21 and 28 days for the same reasons for each month of 2016?
3. Please state the longest number of days for which an individual patient had to wait for a discharge from the stroke rehabilitation unit at Pembury hospital due to a lack of social services capacity to provide personal care 2016?

Download response Delayed discharge from the stroke rehabilitation unit at Tunbridge Wells Hospital at Pembury. 011216

Delayed discharges. 080517

1 – Number of adult patients who are medically fit to leave hospital but are currently unable to be safely discharged. Most recent figures are preferential however the latest on record would also be of use.

2 – Please provide the number of packages of care that are currently delayed due to lack of staffing resources within the community.

3 – Data on agency spend between March 2016 to present date for nursing services within the community.

Download response Delayed discharges. 080517

Delayed discharges. 091117

For the financial year 16/17 how many people were classed as bed-blocking; who was responsible for delayed discharges and over the length of time they were bed blocking by weeks. A simple table showing councils/relevant body holding up the discharge down the side and weeks along the top and number of patients in the data will suffice.

Download response Delayed discharges. 091117

Delayed discharges 2014-2017 111116

In two of the questions we ask for information collected on 28th September, 2016. This date has been chosen because it is the most recent data collection day for NHS England.

When giving reasons for the delay in discharging a patient, please chose one of the ten categories used by NHS England – awaiting completion of assessment, awaiting public funding, awaiting further non-acute NHS care, awaiting residential home placement or availability, awaiting care package in own home, awaiting community equipment and adaptations, patient or family choice, disputes or housing.
If you record it differently please supply information using the official categories for your nation.

1) Please state the five longest delays (in days) which patients who were ready for discharge, have had before they were able to leave the hospital during the period 1st April 2014 to 31st September 2016.
For each of these delayed discharges, please state:
i) The age of the person concerned.
ii) The original reason for admission to hospital.
iii) The reason for the delayed discharge.
iv) The date on which the patient was ready for discharge.
v) The date on which they were in fact discharged.
2) Please state how many patients, who were ready for discharge, had to wait 28 days or more to leave the hospital.
Please break these figures down by the cause of the delay.
Please provide this information for the following financial years:
i) 2014/15
ii) 2015/16
iii) 2016/17 to date
3) On the day of the 28th September 2016, please state:
i) The five longest waits in days that patients ready for discharge had had as of this date.
ii) For each of these waits, please state the age of the person concerned and the reason for their admission.
iii) For each of these waits, please state the reason for the delay.
4) Please state how much your trust spent on delayed discharges in each of the following financial years.
i) 2011/12
ii) 2012/13
iii) 2013/14
iv) 2014/15
v) 2015/16
vi) 2016/17 to date.
5)
i) On the 28th September 2016, how many of your acute beds were occupied by people who were ready for discharge?
ii) What proportion of your overall number of acute beds were being used by people who were ready for discharge?
iii) Have you had to open extra transitional, reablement or similar beds to meet the additional demand caused by delayed discharges?
iv) If yes, please state how many beds and the cost of providing these.

Download response Delayed discharges 2014-2017 111116

Delayed discharges. 210218

1. Between 1.2.16 and 31.1.17 how many times have you written to a patient, or the family members of a patient, or the legal guardians of a patient, stating that in the Trust’s view they are fit for discharge and should vacate their hospital bed? For each occurrence please state how many days they had occupied a hospital day for while considered fit for discharge prior to the date of the letter being sent to them or their representatives? For the most recent occasion that a letter was sent please provide me with a copy of the letter accepting that any details that might identify the patient will be redacted to comply with S.40.
2. Of those patients discharged from your hospital in either 2014/15 or 2015/16 please state how many patients had been considered fit to discharge but remained in hospital in excess of one full calendar year before they were discharged? For each patient please state how many days they occupied a hospital bed while considered fit to discharge?
3. Using the most recent convenient date do you have any patients in your hospital who are considered fit to discharge but have been in hospital and been fit to discharge in excess of one full calendar year? For each patient please state how many days they have occupied a hospital bed while considered fit to discharge?

Download response Delayed discharges. 210218

Delayed discharges. 300519

Are you able to let me know the number of bed days lost because medically fit patients are waiting for placements in care homes? If you have this data for the most current reporting period that would be useful.

I’m not sure if the data includes the number of patients who are medically fit but need accommodation due to dementia. Would that data include the average length of delay for dementia patients or just all patients?

Download response Delayed discharges. 300519

Delayed transfer of care 2013-2016. 070317

1. Over the last 3 years (2013-2016) how many patients have been involved in long-term delayed transfer of care (broken down into a delay of over six months; over one year; over two years etc.)
2. Over the last three years (2013-2016) what is the longest someone has been medically fit to be discharged but is still in the hospital?
3. Currently, what is the longest duration a patient has occupied a hospital bed because they are refusing to leave/disputing/family or patient not accepting the care package available?
4. How many times has the Trust applied for court orders to evict a patient over the last three years?
5. (If this figure is available) How much a year does delayed transfer for care cost the Trust?

Download response Delayed transfer of care 2013-2016. 070317

Delayed transfer of care. 190320

1. The number of patients stuck in hospital due to delayed transfers of care, also known as bed blocking. Please tell me the reasons for their delayed transfer and be as specific as possible.
2. The length of time these patients were stuck in hospital.
3. The number of patients stuck in hospital due to delayed transfers of care (bed blocking) because they have hoarding disorder.
4. The length of time these patients were stuck in hospital.

I request the information for the following years:
2015-16
2016-17
2017-18
2018-19
2019-20
2020-present

Download response Delayed transfer of care. 190320

Delayed transfers of care 060317

1. The number of patients who have died in hospital while experiencing a delayed transfer of care. Please could I have these figures for the years 2014, 2015 and 2016, broken down by year?

Download response Delayed transfers of care 060317

Delayed transfers of care 2016-2017. 150517

What is the longest amount of time in days a patient had been kept in hospital due to delayed transfer in the past 12 months?

Could you give me details for the three longest delayed transfer stays, the name of the hospital concerned and if possible the age and gender of the patients concerned and the department they were in (i.e. elderly care/general surgery, paediatrics etc.)?

Are you also able to give a brief reason for the delay in each instance (i.e. lack of beds in care facility/delay equipping home etc.)?

Download response Delayed transfers of care 2016-2017. 150517

Delays in transfer of care (DTOC) in 2013-14, 2014-15, 2015-16.

1. What is the longest time (in days) one patient has remained in a bed at your NHS Trust due to delays in transfer of care (DTOC) in 2013/14, 2014/15, 2015/16;

2. In each case, please provide the age of the patient and reason for delay.

Download response Delays in transfer of care (DTOC) in 2013-14, 2014-15, 2015-16.

Delays in transfer of care (DTOC) in 2013-14, 2014-15, 2015-16. 190417

1. What is the longest time (in days) one patient has remained in a bed at your NHS Trust due to delays in transfer of care (DTOC) in 2013/14, 2014/15, 2015/16;

2. In each case, please provide the age of the patient and reason for delay.

Download response Delays in transfer of care (DTOC) in 2013-14, 2014-15, 2015-16. 190417

Delays in transfer of care (DTOC) in 2013/14, 2014/15, 2015/16.190416

1. What is the longest time (in days) one patient has remained in a bed at your NHS Trust due to delays in transfer of care (DTOC) in 2013/14, 2014/15, 2015/16;

2. In each case, please provide the age of the patient and reason for delay.

Download response Delays in transfer of care (DTOC) in 2013/14, 2014/15, 2015/16.190416

DTOC and missed target fines. 280119

1) What is the name of?
a) Your trust
b) The hospitals run by your trust
2) What is the longest time (in days) one patient has remained in a bed at your trust due to delays in transfer of care (DTOC) from October 2016 to October 2018?
3) What was the age of the patient (from question 2) and the reason for delay?
4) How much money has your trust been fined or had withdrawn/withheld for not meeting the percentage target for A&E waiting time (4 hours) in the following financial years: (If possible please breakdown by quarters, if not just give the whole sum for that period)
a) 2017/2018
b) so far 2018
5) How much money has your trust been fined or had withdrawn/withheld for not meeting the percentage target for referral to treatment time of 18 weeks for patients in the following financial years: (If possible please breakdown by quarters, if not just give the whole sum for that period)
a) 2017/2018
b) so far 2018
6) How much money has your trust been fined or had withdrawn/withheld for not meeting the 15 minute target of handing over a patient from an ambulance to your hospital in the following financial years: (If possible please breakdown by quarters, if not just give the whole sum for that period)
a) 2017/2018
b) so far 2018

Download response DTOC and missed target fines. 280119

DTOC patients. 300819

1. Could the authority state how they use agencies and/or software to expedite the discharge of DTOC patients?
2. How much did they spend with agencies to arrange placements with care homes or home care for DTOC patients in each of the last three financial years?
3. Do they use Capacity Tracker or any other software of services to identify care homes or home care packages? Please state which software or services are used.

Download response DTOC patients. 300819

DTOC and self-funding patients. 240817

DTOC and Self-Funding Patients
1. How many self-funding adult social care patients waiting for placements causing DTOCs in 2015-16, 2016-17 and 2017 to date?
2. Are there currently any care home placements and / or care package brokerage services being offered to the self-funders at the moment?
MH / Alcohol Related A&E Admissions
3. How many Alcohol and Mental Health A&E admissions and related occupied bed days? And total cost for this?
4. Is there an Alcohol Nurse Liaison service available at the hospital?
Acute Bed Days DTOCs
5. What is the average cost of an acute hospital bed in your NHS Trust
6. The gross cost to the Trust due to delayed transfers of care (DTOC) (before taking into account reimbursements from local authorities).
7. The gross cost to the Trust due to delayed transfers of care where Social Care was responsible for the delay (before taking into account reimbursements from local authorities).
8. The total sum received from local authorities in reimbursements for delayed transfers of care.
9. How many bed days were lost as a result of delayed transfers of care in your NHS Trust for the years 2014/2015 , 2015/2016 & 2016 /2017
10. What is the longest time (in days) one patient has been a delayed transfer of care (DTOC) in your NHS Trust for the years 2014/2015 2015/2016 2016/2017
11. In each case, please provide the age of the patient and reason for the delay and responsible CCG/local authority.
12. What is the longest time in (in days) one patient has been a delayed transfer of care awaiting further assessment in your NHS Trust for the years 2014/2015 2015/2016 2016/2017.
13. In each case, please provide the age of the patient and responsible CCG/ Local authority
14. Has the Trust ever taken legal action to remove a patient whose transfer of care was delayed? a) If so please provide details of when and the reason for delay in transfer of care and responsible CCG/local authority
Contact Details
15. Discharge and DTOC lead within the Trust
16. Alcohol Liaison Service

Download response DTOC and self-funding patients. 240817

Elderly patients delayed transfer of care (DTOC). 040117

I would like some information on the number of elderly patients who have been kept in hospital when they are well enough to be discharged due to a lack of suitable social care provision in the last 5 years.

Download response Elderly patients delayed transfer of care (DTOC). 040117

Patient discharges 2011 – 2016. 081116

(a) Total number of patients discharged by the Trust between 11pm and 6am in each of the last six financial years
(b) Total number of patients discharged by the Trust in each of the last six years

Download response Patient discharges 2011 – 2016. 081116

Patients who have died in hospital while waiting for the start of a social care package 2016

Q1: How many people in all the hospitals within your Trust have died in hospital awaiting the start of a package of local authority social care?
Q2: How many people in all the hospitals within your Trust have died in hospital awaiting the start of a package of continuing healthcare broken down by:

· Those that have been identified as meeting the fast track criteria
· Those that have not been identified as meeting the fast track criteria

Q3: What is the average time period in your Trust in hours/days from the point at which a fast-track CHC application is made to the care package being provided for the 12 month period to the end of September 2016?

What is the average time period in hours/days from the point at which a fast-track CHC application is approved to the care package being provided for the 12 month period to the end of September 2016?

Download response Patients who have died in hospital while waiting for the start of a social care package 2016

Section 5 under the Community Care (Delayed Discharges) Act in the year to March 31 2015

Please could you provide the number of patients whose discharge has
delayed by 28 days or more after the serving of a Section 5 under
the Community Care (Delayed Discharges) Act in the year to March 31
2015, with any available monthly breakdowns?

Please including the longest number of days for which an individual
patient had to wait for a discharge after a Section 5 was served, and any available breakdown by length of wait for a discharge after a Section 5 was served.

Would you please state on November 15 2015, how many beds were occupied in your trust by patients who had been served a Section 5 at least 24
hours previously?

Download response Section 5 under the Community Care (Delayed Discharges) Act in the year to March 31 2015 010216

 

Diagnostics, Therapies, Pathology & Pharmacy

Pain relief prescriptions 031016

For each of the questions, please can you provide answers for each of the financial years 2013/14, 2014/15 and 2015/16:

1. PARACETAMOL

a. Which suppliers did you buy paracetamol from?
b. How many packets of paracetamol did you buy from each supplier? Please disclose how many tablets were in the packets.
c. How many packets of paracetamol did you buy in total? Please disclose how many tablets were in the packets.
d. How much did you pay each supplier for paracetamol?
e. How much did you spend on paracetamol in total?
f. How many prescriptions in total did you make for paracetamol?
g. How many of these prescriptions were free for the patient?
h. How much money were you paid by patients for paracetamol?

2. IBRUPROFEN

a. Which suppliers did you buy ibuprofen from?
b. How many packets of ibuprofen did you buy from each supplier? Please disclose how many tablets were in the packets.
c. How many packets of ibuprofen did you buy in total? Please disclose how many tablets were in the packets.
d. How much did you pay each supplier for ibuprofen?
e. How much did you spend on ibuprofen in total?
f. How many prescriptions in total did you make for ibuprofen?
g. How many of these prescriptions were free for the patient?
h. How much money were you paid by patients for ibuprofen?

3. ASPIRIN

a. Which suppliers did you buy aspirin from?
b. How many packets of aspirin did you buy from each supplier? Please disclose how many tablets were in the packets.
c. How many packets of aspirin did you buy in total? Please disclose how many tablets were in the packets.
d. How much did you pay each supplier for aspirin?
e. How much did you spend on aspirin in total?
f. How many prescriptions in total did you make for aspirin?
g. How many of these prescriptions were free for the patient?
h. How much money were you paid by patients for aspirin?

4. CODEINE PHOSPHATE

a. Which suppliers did you buy codeine phosphate from?
b. How many packets of codeine phosphate did you buy from each supplier? Please disclose how many tablets were in the packets.
c. How many packets of codeine phosphate did you buy in total? Please disclose how many tablets were in the packets.
d. How much did you pay each supplier for codeine phosphate?
e. How much did you spend on codeine phosphate in total?
f. How many prescriptions in total did you make for codeine phosphate?
g. How many of these prescriptions were free for the patient?
h. How much money were you paid by patients for codeine phosphate?

Download response Pain relief prescriptions 031016

Acromegaly. 070918

1. Does your trust treat patients for Acromegaly
2. Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs;
• Ocreotide
• Lanreotide
• Pasireotide
• Pegvisomant

Download response Acromegaly. 070918

Acupuncture treatments 2010 to 2015

Please provide the following for the years 2010 to 2015 inclusive:
1. The names of the hospitals, clinics or other settings in which you provided acupuncture treatments.
2. The number of acupuncture treatments provided and the number of patients treated at each of these locations.
3. The types of clinicians who provided these treatments, e.g. physiotherapists, doctors, acupuncturists.
4. The total cost of providing acupuncture treatments at each of these locations.
5. The cost of acupuncture needles purchased included in the total cost.

Download response Acupuncture treatments 2010 to 2015 241016

Adult formulary

We would like to request the following information regarding the prescribing of growth hormones within Maidstone and Tunbridge Wells NHS Trust

1. We have the following formularies listed as used by your organisation. Please confirm if they are correct and if not, please provide a link/copy of relevant formularies.

West Kent Interface Adult Formulary

2. Please provide a copy or link to any supporting guidelines containing growth hormone product prescribing recommendations that are in addition to the published formulary. If none are available, please confirm if they are currently being developed/drafted.

3. Where guidelines are held in addition to the published formulary, please confirm which has dominance when prescribing growth hormones.

Download response Adult formulary 170815

AeroChamber with and without mask January – December 2015. 290617

I am writing to request the prescribed annual units (for the period January 2015 – December 2015) of the below:

• AeroChamber with Mask
• AeroChamber without Mask

Download response AeroChamber with and without mask January – December 2015. 290617

Agency Pharmacists and Pharmacy Technicians. 240119

I would like you to send me the locum agency spend in the AHP/HSS division of the hospital for Pharmacists and Pharmacy Technicians. I would like to know the spend for 2018 with each agency- if this is not possible then I’d like to know overall spend for the year for both Pharmacists and Pharmacy Technicians.

Download response Agency Pharmacists and Pharmacy Technicians. 240119

Agency spend in Radiology August 2016 – January 2017. 240317

Can you please assist me with retrieving the total Agency spend for Medical Locum Doctors within Radiology over the following months, within your Trust or Health Board?
August 2016
September 2016
October 2016
November 2016
December 2016
January 2017

Download response Agency spend in Radiology August 2016 – January 2017. 240317

Aimovig (Erenumab). 130619

Does your trust treat patients with Aimovig [Erenumab]?
If yes, how many patients have been treated in the past 12 months?

Download response Aimovig (Erenumab). 130619

Alternative medicine

1. Do you offer complementary therapies within the trust?
2. If yes, do you offer Reiki therapy?
3. Which types of services or departments offer Reiki therapy?
4. Have you conducted a formal evaluation of the Reiki service? If so, please provide brief details.

Download response Alternative medicine 060916

Anaemia and blood transfusions. 290118

1. Number of RBC units utilised by ward and/ or department in a) 2015 and b) 2016
2. Number of elective surgical procedures cancelled in 2016 due to the patient being identified as anaemic
3. Number of elective surgical procedures occurring for patients who were anaemic on the day of surgery
4. Of the above, the number of these procedures that required a blood transfusion
5. Following the NICE Quality Standards published in December 2016 on blood transfusion, is able to meet Quality Standard 1? Please see Quality Standard Review form attached. We are partially compliant with Standard 1. The Pre-Assessment Teams are referring patients for IV iron if they are found to be anaemic at Clinic, if there is time pre-operatively. Post-op iron therapy does not appear to be standard practice as yet.

Download response Anaemia and blood transfusions. 290118

Anti-microbial resistance. 230817

Please could you provide me with the number of cases between 2010-2017?

– In which patients were unable to be treated with anti-biotics due to anti-microbial resistance.
– In which patients had to undergo an operation to remove the site of resistance due to anti-microbial resistance.
– In which patients had amputations due to anti-microbial resistance.

Download response Anti-microbial resistance. 230817

Antibiotic guidelines. 040117

1) Please provide, in full, the antibiotic guidelines used by your trust.
2) Is antibiotic prophylaxis routinely given for urinary catheter removal after any joint replacement? : yes/no
3) If yes, which is given and how?
4) If yes, what proportion of patients with urinary catheters receive it?

Download response Antibiotic guidelines. 040117

Antibiotic prescribing. 220118

Could you please supply me with the number of each antibiotic prescribed in hospital for the past 10 years?
Could you please break this information down by the name of the drug (eg vancomycin) for each year in the past 10 years? For 2016 could you please give the number of each antibiotic prescribed so far?
Could you also provide me with the cost of each drug for each year?
Please note I am not seeking antibiotics dispensed in the community, but antibiotics prescribed in hospitals.
Download response Antibiotic prescribing. 220118

Antibiotic resistant NDM 2014-2016. 280217

Can you please send details of any cases of antibiotic resistant NDM (New Delhi metallo-ß-lactamase) “superbugs” you have reported to Public Health England in 2014, 2015 and 2016.

We are particularly interested in NDM-1, but would appreciate details of any other NDM incidents if available.

Please break the information down into the three years listed.

Download response Antibiotic resistant NDM 2014-2016. 280217

Antibiotics. 270617

Please could you provide me with a list of all companies currently supplying antibiotics – or that have supplied antibiotics in the last three years – to Maidstone & Tunbridge Wells NHS Trust.

Plus:

– The details, where possible, of the antibiotic products these companies supply or have supplied.

Download response Antibiotics. 270617

Aseptic drug compounding or preparation. 290617

1. How much does your aseptic unit cost to run annually?
2. How many aseptically prepared doses does your unit produce per annum?
3. What types of aseptically prepared products does your aseptic unit produce? E.g Parenteral nutrition, antibiotics, cancer chemotherapy?
4. What IT systems does your Aseptic unit currently use to manage the compounding process or help with your prescribing?
5. How many staff do you employ in your aseptic department?
6. How many members of staff are full time equivalents?
7. How many clean rooms do you have in your department?
8. How many isolators do you have in your department?
9. Do you do any outsourcing? Or is all of your compounding carried out in house?
10. Are you a licensed unit? If so, do you compound for any other customers? If yes, who and for how long?
11. What is your unit’s annual drug spend?

Download response Aseptic drug compounding or preparation. 290617

Autopsies. 080519

For each of the years 2017 and 2018 please may you provide me with-

1. The total number of adult (aged 17 and above) deaths within your Trust (on Trust sites) between 1st January and 31st December of each year.
2. The number of Hospital (consent) autopsies carried out on adult (aged 17 and above) deaths which occurred between 1st January and 31st December of each year.

Download response Autopsies. 080519

Benzodiazepines. 270617

Prescription of Benzodiazepines (class of psychoactive drugs)
How many patients were given any form of benzodiazepines during treatment in hospital?
Please provide broken-down figures (if possible) for up to the past five years and at least for the past 3 years

Download response Benzodiazepines. 270617

Biological and Biosimilar medicines. 070818

1 – In your Trust, how much did you spend on Biological and biosimilar medicines, in the past financial year ending April 2018?
2 – Have you developed a policy on how prescribers can switch their patients to biosimilars and support them in making informed choices to save resources?
If yes, please provide details
3 – Do you have any specific plans in place for the launch of biosimilar Adalimumab later in 2018?
4 – Are there any agreements in place between you the Provider and CCG that would enable savings in drug costs to be made? (For example, Gainshare agreements where the benefits associated with more efficient use of medicines not reimbursed through national prices is shared between the Provider and the Clinical Commissioning Group party to the agreement. This included agreements for the switch to biosimilar products)
If “Yes”, then please provide the following details:
5 – Are there any other agreements with a CCG, not included in the above, for the following services?
If “Yes”, then please provide the following details:

Download response Biological and Biosimilar medicines. 070818

Biologics 101016

We would like to request from Maidstone and Tunbridge Wells NHS Trust (MTW) the numbers of patients treated in the last 12 months with the following drugs for the conditions listed below:

Download response Biologics 101016

Biologics and Biosimilar

1. Does your trust run a dedicated Gastroenterology infusion clinic for the treatment of patients with Infliximab [or Vedolizumab] If Yes, how frequently are they run?
2. Could you please provide me with the following numbers of patients treated in the last six months with the following drugs for the conditions listed below?

Rheumatology [Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis] Dermatology [Psoriasis] Hidradenitis suppurativa (sometimes known as acne inversa) L73.2 Gastroenterology
[Crohns / Ulcerative Colitis]
Abatacept (Orencia)
Adalimumab (Humira)
Apremilast (Otezla)
Certolizumab Pegol (Cimzia)
Etanercept (Enbrel)
Golimumab (Simponi)
Infliximab (Remicade)
Infliximab biosimilar (Inflectra)
Infliximab biosimilar (Remsima)
Rituximab (MabThera)
Secukinumab (Cosentyx)
Tocilizumab (RoActemra)
Tofacitinib [Xeljanz]
Ustekinumab (Stelara)
Vedolizumab (Entyvio)

Download response Biologics and Biosimilar 120116

Biologics and Biosimilar. 120919

I have a Freedom of Information request regarding biologics and biosimilar prescribing. Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs regardless of diagnosis?

Download response Biologics and Biosimilar. 120919

Biologics and biosimilar prescribing 01.06.2015 – 31.05.2016

Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs for the conditions listed below?

• Psoriasis
• Hidradenitis Suppurativa
• Crohn’s disease
• Ulcerative Colitis

Download response Biologics and biosimilar prescribing 01.06.2015 – 31.05.2016 250716

Biologics and Biosimilar prescribing. 031219

Could you please provide me with following numbers of patients treated in the last 12 months (latest) 12 months possible) with the following drugs for either Rheumatology, Dermatology and Gastroenterology departments:
Abatacept (Orencia)
Adalimumab biosimilar (Amgevita)
Adalimumab biosimilar (Hulio)
Adalimumab (Humira)
Adalimumab biosimilar (Hyrimoz)
Adalimumab biosimilar (Imraldi)
Apremilast (Otezla)
Baricitinib (Olumiant)
Brodalumab (Kyntheum)
Certolizumab (Cimzia)
Dimethyl Fumarate (Skilarence)
Etanercept (Enbrel)
Etanercept Biosimilar (Benepali)
Etanercept Biosimilar (Erelzi)
Golimuab (Simponi)
Guselkumab (Tremfya)
Infliximab (Flixabi)
Infliximab (Inflectra)
Infliximab (Remicade)
Infliximab (Remsima)
Ixekizumab (Taltz)
Rituximab (Mabthera)
Rituximab Biosimilar (Rixathon)
Rituximab Biosimilar (Truxima)
Sarilumab (Kevzara)
Secukinumab (Cosentyx)
Tildrakizumab (Ilumetri)
Tocilizumab (Ro Actemra)
Tofacitinib (Xeljanz)
Ustekinumab (Stelara)
Vedolizumab (Entyvio)

Download response Biologics and Biosimilar prescribing. 031219

Biologics and Biosimilar prescribing. 170119

Could you please provide me with the following numbers of patients treated for Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis, Crohn’s Disease, Ulcerative Colitis in the last 12 months (latest 12 months possible) with the following drugs;
Abatacept (Orencia)
Adalimumab (Biosimilar)
Adalimumab (Humira)
Apremilast (Otezla)
Baricitinib (Olumiant)
Brodalumab (Kyntheum)
Certolizumab (Cimzia)
Dimethyl Fumarate (Skilarence)
Etanercept (Enbrel)
Etanercept Biosimilar (Benepali or Erelzi)
Golimumab (Simponi)
Guselkumab (Tremfya)
Infliximab (Remicade)
Infliximab Biosimilar (Inflectra, Remsima or Flixabi)
Ixekizumab (Taltz)
Rituximab (Mabthera)
Rituximab Biosimilar (Rixathon or Truxima)
Sarilumab (Kevzara)
Secukinumab (Cosentyx)
Tildrakizumab (Ilumetri)
Tocilizumab (Ro Actemra)
Tofacitinib (Xeljanz)
Ustekinumab (Stelara)
Vedolizumab (Entyvio)

Download response Biologics and Biosimilar prescribing. 170119

Biologics and biosimilar prescribing in Rheumatology. 020320

Could you please provide me with the following numbers of patients treated in the last 12 months with the following drugs.
· Abatacept [Orencia]
· Adalimumab [Amgevita]
· Adalimumab [Hulio]
· Adalimumab [Humira]
· Adalimumab [Hyrimoz]
· Adalimumab [Imraldi]
· Apremilast [Otezla]
· Baricitinib [Olumiant]
· Brodalumab [Kyntheum]
· Certolizumab [Cimzia]
· Dimethyl fumarate [Skilarence]
· Etanercept [Benepali]
· Etanercept [Enbrel]
· Etanercept [Erelzi]
· Golimumab [Simponi]
· Guselkumab [Tremfya]
· Infliximab [Flixabi]
· Infliximab [Inflectra]
· Infliximab [Remicade]
· Infliximab [Remsima]
· Ixekizumab [Taltz]
· Risankizumab [Skyrizi]
· Rituximab [MabThera]
· Rituximab [Rixathon]
· Rituximab [Truxima]
· Sarilumab [Kevzara]
· Secukinumab [Cosentyx]
· Tildrakizumab [Ilumetri]
· Tocilizumab [Ro Actemra]
· Tofacitinib [Xeljanz]
· Upadacitinib [Rinvoq]
· Ustekinumab [Stelara]

Download response Biologics and biosimilar prescribing in Rheumatology. 020320

Biologics and Biosimilar prescribing. 050718

Could you please provide me with the following numbers of patients treated in the last 12 months (latest 12 months possible) with the following drugs for either Rheumatology, Dermatology or Gastroenterology departments.

Download response Biologics and Biosimilar prescribing. 050718

Biologics and Biosimilar prescribing. 210917

Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs for the conditions listed below?

• Psoriasis
• Hidradenitis Suppurativa
• Crohn’s disease
• Ulcerative Colitis

Download response Biologics and Biosimilar prescribing. 210917

Biologics and Biosimilar prescribing. 250517

Could you please provide me with the following numbers of patients treated in the last six months (to date) with the following drugs for the conditions listed below?

Rheumatoid arthritis Ankylosing spondylitis Psoriatic arthritis
Abatacept (Orencia)
Adalimumab (Humira)
Apremilast (Otezla)
Certolizumab Pegol (Cimzia)
Etanercept (Enbrel)
Etanercept biosimilar (Benepali)
Golimumab (Simponi)
Infliximab (Remicade)
Infliximab biosimilar (Inflectra)
Infliximab biosimilar (Remsima)
Rituximab (MabThera)
Secukinumab (Cosentyx)
Ixekizumab (Taltz)
Tocilizumab (RoActemra)
Ustekinumab (Stelara)
Vedolizumab (Entyvio)

Download response Biologics and Biosimilar prescribing. 250517

Biologics and biosimilar prescribing. 290617

Could you please provide me with the numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs within the dermatology or gastroenterology departments?
Abatacept (Orencia)
Adalimumab (Humira)
Apremilast (Otezla)
Certolizumab Pegol (Cimzia)
Etanercept (Enbrel)
Etanercept biosimilar (Benepali)
Fumaric Acid Esters N/A
Golimumab (Simponi)
Infliximab (Remicade)
Infliximab biosimilar (Inflectra)
Infliximab biosimilar (Remsima)
Rituximab (MabThera)
Secukinumab (Cosentyx)
Ixekizumab (Taltz)
Tocilizumab (RoActemra)
Ustekinumab (Stelara)
Vedolizumab (Entyvio)

Download response Biologics and biosimilar prescribing. 290617

Biologics and Homecare. 290118

1. What is the Trust’s annual spend on anti-TNF drugs (most recent year available)?
2. How many patients has the Trust treated with anti-TNF drugs in the last 12 months?
3. What is the % split of anti-TNF patients by the following channels?
4. How many patients has the Trust treated with the following conditions in last 12 months?
5. Are there any gain share agreements in place between the Trust and CCGs for anti-TNF biosimilars?
If yes, please provide:

Biologics and Homecare. 290118

Biomarker testing. 270318

1. Do you currently offer a biomarker testing for the following, as of the beginning of 2018?
PD-L1 in NSCLC
ALK in NSCLC
BRAF in Melanoma
2. Is predictive biomarker testing conducted at the same lab (or similar location such as in same building) as the initial cytological and histological (H&E stain) assessment, or is this done at a different site?
IHC
FISH /ISH/ NGS / PCR
3. Is biomarker testing performed reflexively or upon request for the following biomarkers?
PD-L1 in NSCLC
ALK for NSCLC
BRAF in Melanoma
4. Which of the following biomarkers are assessed in lung cancer patients in your laboratory? (please select all that apply)
5. Which of the following testing platforms are used at this this laboratory?
6. What IHC staining platform(s) are used in the laboratory for biomarker testing? (please select all that apply)
7. What type of test does the institution prefer to use for biomarker-predictive IHCs?
What is the main factor in this decision?
8. Does your lab / trust seek separate reimbursement from NHS under the “high-cost medicines and tests” provision for biomarker tests that have been excluded from tariff?
9. What is the number of samples being tested (or sent-out) are tested for the following biomarkers?
ALK
EGFR
PD-L1
BRAF
10. Where are archived tissues from lung cancer patients stored?
11. If on-site; how long are tissues stored on site until transferred to other storage facility?
12. What is the typical turn-around time from tissue/specimen extraction to the report of biomarker testing results in lung cancer patients?
13. How are the following biomarker testing funded at your lab?

Download response Biomarker testing. 270318

Blood cultures. 090617

1. Who is the policy or clinical lead for blood culture best practice at your trust? Please provide a name, job title, postal address, email address and phone number.
2. Does your Trust follow the Public Health England SMI guidelines for blood cultures?
3. How many blood culture sets are taken for each suspected case of (a) sepsis and (b) other bacterial infection, and where there is more than one blood culture set taken are these taken from different sites – please provide an answer for both (a) and (b).
4. How many individual blood cultures were taken at your trust in the following years: (a) 2012/13 (b) 2013/14 (c) 2014/15 (d) 2015/16 (e) 2016/17?
5. How many individual blood cultures were identified as being contaminated in the following years: (a) 2012/13 (b) 2013/14 (c) 2014/15 (d) 2015/16 (e) 2016/17?

Download response Blood cultures. 090617

Blood grouping analyser. 291118

You asked:
Question 1: Does your Trust have a blood transfusion service?
If yes, please answer the following questions about your blood group analysers:
Question 2: Who is the analyser manufacturer?
Question 3: What is the make and model type of analyser?
Question 4: What percentage of false positive results do you see with this analyser for blood grouping and antibody screening? (Only include false positives caused by external contaminants or analyser failures)
Question 5: How many group and screen samples do you test per year?
Question 6: Do you provide electronic issue of red cells?
Question 7: Do you provide automated crossmatching using your analysers?
Question 8: Do you have an agreed blood ordering schedule?

Download response Blood grouping analyser. 291118

Blood pressure monitors

1. Total number of all types of blood pressure monitors in your institution (e.g. 1000 blood pressure monitors overall)
2. Can you please list all the types of blood pressure monitors and its quantities (e.g. NIBP – x20, SpO2 – x20), its brands (e.g. Omron – x20, Criticare – x20, Datascope – x20), and models (e.g. Criticare 506DXN – x10, Criticare 507DXN – x10, Datascope Accutorr + x20). We would like to ask you kindly if you can state this information in a separate spreadsheet document.
3. In which departments do you use blood pressure monitors? (e.g. 20 Omron in wards, 20 Criticare in ITU, 20 Datascope in outpatient surgery).
4. Types of devices acquired in period of 2014 – 2016 (e.g. 100 Omron monitors in 2014, 150 Criticare monitors in 2015.) if none please state when was the last purchase.
5. Minimum and maximum price of blood pressure monitors. If you can not provide this information, please give us an average price of a single blood pressure monitor
6. Please provide a full contract with supplier of blood pressure equipment
7. Which quality tests or quality standards a blood pressure device must pass in order for you to consider it as a good quality blood pressure monitor (e.g. CE Marked)
8. Can you please provide regulations and guidelines that your institution follow (we would like to know about national, local and your own guidelines + regulations (if it also possible can you please attach medical device management action card + medical equipment pre-registration form))
9. What creates extra costs for the usage of monitors on a yearly basis? Please break it down and relate the expenditure associated to it (e.g. cuffs = £2.000, hoses = £3.000, maintenance = £5.500)
10. Do you provide maintenance in-house or out?
11. How do you provide training to medical staff when a new blood pressure monitor is introduced in your hospital? (e.g. manual handbook, training sessions from suppliers)
12. How the supply chain is established in your organisation when you order new blood pressure monitors? (e.g. supplier delivers the products, currier or take out?)
13. Do you provide feedback to your suppliers? If “yes” how? (e.g. emailing, calling, submitting a form)
14. What is the average useful life of a single blood pressure monitor?

Download response Blood pressure monitors 090916

Blood and Transfusion Service. 160818

In order to assess the savings to the taxpayer, could you please provide the number of overnight (19:00-07:00) pick-ups or deliveries, by the below mentioned services, to or from your hospital’s Transfusion Lab/Blood Bank on the date(s) below.

Please include a schedule of documents where possible.
Download response Blood and Transfusion Service. 160818

Bowel Cleansers. 031019

Information request – 1
Has the pharmacy of your hospital dispensed any bowel cleansing preparations from January 1, 2018 till December 31, 2018?

Information request – 2
If the answer is ‘yes’ to request 1, could you please send me below details:
• Name of dispensed brand(s) and number of packs dispensed in the 12 month period (January 1, 2018 till December 31, 2018).

Download response Bowel Cleansers. 031019

Bronchial challenge testing 040117

Can you please advise if the trust performs Bronchial challenge testing? If the trust does perform these tests could you also advise?
1) The number of tests performed in the last 12 months?
2) Which products are used to perform the test?
3) Contact details for the sites performing the test?

Download response Bronchial challenge testing 040117

Candida Auris. 250419

1. Which hospitals within your Trust have reported Candida Auris cases since 2009?
2. How many patients have been infected with Candida Auris within your Trust since 2009?
3. How many patients have died after being infected with Candida Auris whilst being under the care of your Trust since 2009?

Download response Candida Auris. 250419

Candida Auris. 250817

I am attempting to discover whether the fungus ‘Candida Auris’ has been found in the Tunbridge Wells hospital.

Is it possible for you to give me any information regarding this matter?

Download response Candida Auris. 250817

Carboxyhaemoglobin levels

Under the Freedom of Information Act 2000 I request that the NHS Trust provides me with the following information:

• What methods of measuring carboxyhaemoglobin levels do each hospital covered by the Trust use
• Whether or not each hospital covered by the Trust has a Masimo Rad-57 Oximeter in its accident and emergency department.

Download response Carboxyhaemoglobin levels 181215

Caspofungin (Generic) and Cancidas (May 2016-April 2017). 070917

I am writing to request details of the quantity of vials prescribed for below products by your Trust.

The period for which data is being requested is May 2016 – April 2017.

Data Requested for below products:
• Caspofungin 50mg powder for concentrate for solution for infusion
• Cancidas 50mg powder for concentrate for solution for infusion
• Caspofungin 70mg powder for concentrate for solution for infusion
• Cancidas 70mg powder for concentrate for solution for infusion

Download response Caspofungin (Generic) and Cancidas (May 2016-April 2017). 070917

Charges for ultrasound baby scan pictures for 2011, 2012, 2013, 2014 and 2015. 160617

1) The charges for ultrasound baby scan pictures for the years 2011, 2012, 2013, 2014 and 2015 until now (how much you charge expectant mums/dads).
2) The figures for how much profit has been made from the ultrasound charges for each year from 2011 to now.
3) An explanation for why the charges increased (if they did so).

Download response Charges for ultrasound baby scan pictures for 2011, 2012, 2013, 2014 and 2015. 160617

Chronic Myeloid Leukaemia (CML) 2015 (follow up)

Following your reply, please could you provide the information requested in sections 2, 3 and 5 regardless of indication.

1. In your organisation, how many patients diagnosed with Chronic Myeloid Leukaemia (CML) have been treated in calendar year 2015?

2. Of these patients, how many are currently being treated with each of the following tyrosine kinase inhibitors (TKIs)?
· Dasatinib (Sprycel)
· Imatinib (Glivec)
· Nilotinib (Tasigna)
· Ponatinib (Iclusig)
· Bosutinib (Bosulif)

3. If possible, of these patients on a TKI, how many have had treatment with a previous TKI?

4. In your organisation, how many patients diagnosed with Philadelphia positive (Ph+) Acute Lymphoblastic Leukaemia (ALL) have been treated in calendar year 2015?

5. Of these patients how many are currently being treated with each of the following TKIs?
· Dasatinib (Sprycel)
· Imatinib (Glivec)
· Nilotinib (Tasigna)
· Ponatinib (Iclusig)
· Bosutinib (Bosulif)
· Other (i.e. not on a TKI)

Download response Chronic Myeloid Leukaemia (CML) 2015 (follow up) 230516

Chronic pain service 031016

1. The definition of calculation used for new to follow up ratios for chronic pain referrals.
2. The data for new to follow up for chronic pain referrals for your trust for the years April 2010 to April 2015
3. Is the calculation used for new and follow-up in Chronic Pain a local or national definition?
4. Can you provide the wording of the definition used?
5. Does the New to follow up ratio calculation that is used by your organisation for Chronic Pain also apply to other specialties?
6. If no – please explain the differences in the calculations.

Download response Chronic pain service 031016

Collection of prescription charges. 120320

1. Do you directly supply pre-labelled medication from stock against a PGD or FP10REC for patients who present at urgent care services?

2. Do you take a prescription charge for medicines directly supplied from stock against a PGD or FP10REC?

3. If the answer to question 2 is YES please provide a brief description of how you collect the prescription charge.

4. Please feel free to add any comments that you think would be useful or if you would like to discuss please do so using the contact details below.

Download response Collection of prescription charges. 120320

Complementary therapy. 240418

1. Do you have a staff Health and Wellbeing Strategy for the Trust? If yes, can you supply an electronic copy?
2. As part of your strategy or through Occupational Health Department, do you or have you considered using Complementary Therapies to support staff? For example, holistic therapeutic massage for staff mental wellbeing and workplace stress, reflexology, sports massage for rehab and recovery or any others
3. If you do use complementary therapy – do you find it useful in reducing sickness absence, reducing stress related absences and expediting return to work?
4. If you don’t currently use complementary therapy, would you consider using them if they could help reduce sickness absence days, help manage workplace stress and help rehab/recovery from MSK related sickness?
5. Would you consider offering complementary therapy as a staff benefit at discounted rates or donations towards your hospital charity?
6. Would you consider employing a Complementary Therapist as part of your Occupational Health Team? If no, would you reconsider this if their qualification was gained via the NHS natural health school which is supported by NHS England?

Download response Complementary therapy. 240418

Complicated skin and soft tissue infections (cSSTI). 151019

1. How many patients have you treated for complicated skin and soft tissue infections (cSSTI ) in the last 12 months with the following:
Ceftaroline (Zinforo)
Flucloxacillin
Meropenem (Meronem)
Teicoplanin (Targocid)
Tigecycline
Vancomycin
2. How many patients have you treated for community acquired pneumonia in the last 12 months with the following:
Ceftaroline (Zinforo)
Ceftriaxone
Ceftobiprole (Zevtera)
Co-Amoxiclav
Isavuconazole (Cresemba)
Meropenem (Meronem)
3. How many patients have you treated mucormycosis with the following in the last 12 months
Amphotericin B/amphotericin liposomal (AmBisome )
Isavuconazole (Cresemba)
Posaconazole (Noxafil)
4. How many patients with Gram negative infections, have you treated in the last 12 months with:
Amoxicillin/clauvanate
Piperacillin/tazobactam
Ceftazidime/avibactam
Ceftolozane/tazobactam
Carbapenems (e.g. Ertapenem, Imipenem, Meropenem etc)
Aminoglycosides (e.g. Gentamicin, Amikacin, Tobramycin)
Cephalosporins (e.g. Cefotaxime, Ceftazidime, Ceftriaxone)
Quinolones (e.g.Ciprofloxacin, Levofloxacin, Ofloxacin)

Download response Complicated skin and soft tissue infections (cSSTI). 151019

Continence Product Formulary 011216

1) Does the Trust have a Continence Product Formulary?
2) If yes to Q1, please provide a copy
3) How often is the Continence Product Formulary reviewed?
4) What date was the Continence Product Formulary last reviewed?
5) What date will Continence Product Formulary be next reviewed?

Download response Continence Product Formulary 011216

CRE infections. 181116

1. How many patients have been?
-colonised
-infected
With CRE infections for each of the past 10 years in your trust?
2. Does your trust have universal screening of patients for CRE when they are admitted, screening of patients with high risk factors or no formal screening policy?
3. How many patients were screened for CRE when they were admitted and deemed high risk for a CRE infection?
4. How many isolation rooms does your hospital have for isolating CRE patients?
5. How many isolation rooms have en suite bathrooms?
6. What is your policy if there is no side room available for isolating patients with CRE?

Download response CRE infections. 181116

CT scanner. 301117

Q1. Does your trust have a 64-slice (or above) CT scanner?
Q2. Does your trust perform Coronary CT angiography?
Q3. How many Coronary CT Angiography scans have you performed in the past financial year? (2016-2017)
Q4. Does your Trust have access to Coronary CT Angiography with non-invasive FFR analysis or HeartFlow technology?
Q5. If so how many CT FFR scans have been performed in total in the past financial year (2016-2017)?

Download response  CT scanner. 301117

CT scanner information – June 2016

• How many CT scanners are in your hospitals?

• Who is the manufacturer of them and what is their model?

• Who has the service maintenance contract for the scanners – is it the supplier or an external service company?

Download response CT scanner information – June 2016 060616

Cyanide antidotes, Levothyroxine and Primidone. 210218

1) Does your trust hold stocks of the following Cyanide poisoning antidotes: Cyanokit (hydroxocobalamin), Sodium Nitrite, Sodium Thiosulfate and Dicobalt Edetate?
• If yes, what is your stock volume and total expenditure by financial year from FY11-12 to present day for each individual medication?
• If yes, what is the price paid per unit for each medication type?

2) Does your trust hold stocks of Levothyroxine in the following forms: Tablets (25mcg, 50mcg & 100mcg), Oral solution (25mcg/5ml, 50mcg/5ml, 100mcg/5ml) and Levothyroxine solution for injection (IV or IM)
• If yes, what is your stock volume and total expenditure by financial year from FY11-12 to present day for each individual medication?
• If yes, what is the price paid per unit for each medication type?

3) Does your trust hold stocks of Primidone in the following forms: tablets (50mg & 250mg?)
• If yes, what is your stock volume and total expenditure by financial year from FY11-12 to present day for each individual medication?
• If yes, what is the price paid per unit for each medication type?

Download response Cyanide antidotes, Levothyroxine and Primidone. 210218

Cyclotron 221116

This FOI is about the use of Cyclotrons, used for the manufacture of radiopharmaceuticals in PET-CT scanning
Pertains to four main radiopharmaceuticals isotopes (radio-isotopes) used for PET-CT scanning:
18F-Fluorodeoxyglucose = FDG
18F-Choline = FEC for the diagnosis of prostate cancer
18F-Sodium Fluoride = NAF for the diagnosis of skeletal cancers
18F-Florbetaben = FBB for the diagnosis of Alzheimer’s

Download response Cyclotron 221116

Dermatology and Atopic Dermatitis. 010917

Funding pre-NICE;
For the attention of (FAO): Pharmacy / Dermatology Department Clinical Director
1. Is it your Trust/CCG policy to wait until 90 days post NICE guidance to fund new drugs or do they fund earlier?
2. What is your Trust/CCG policy re use of Zero Risk (ZR)/Early Use Schemes (EUS), i.e. where a medicine is made available free of charge or at a reduced price to the NHS whilst awaiting NICE/SMC approval, in lieu of NICE?
3. What is the process for getting such ZR/EUS schemes implemented/approved/signed off within your Trust/hospital? Who needs to sign the contracts for such schemes?
IFR/Cohort Funding;
FOA: Dermatology Lead Pharmacist / Dermatology Department Clinical Director
4. What is your Trust’s policy re Individual Funding Request and/or Cohort Funding policy? Ref: IFR/Cohort Funding
https://www.engage.england.nhs.uk/consultation/af642939/supporting_documents/genericcommissioningpolicies.pdf
5. Do you have a pathway/preferential prescribing list, illustrating sequential use of Biologics in Dermatology? What does this recommend?
6. How many lines/trials of biologics are allowed/funded for the management of psoriasis within your trust/CCG? What happens if a clinician needs to exceed this?
7. If there is a biologics psoriasis pathway – how often is it updated to reflect changes to NICE status of new therapies?
8. If there is no formulary/pathway – what do the Trust/CCG utilise in order to guide use of biologics in the management of psoriasis?
Atopic Dermatitis
FAO: Dermatology Service Manager
9. How many patients attended for a new outpatient appointment in dermatology Utilising ICD-10 classification – L20 Atopic Dermatitis (Eczema) – from April 2015 – March 2016?
10. The number of paediatric attendances of patients utilising ICD-10 classification – L20 for Atopic Dermatitis (Eczema) – from April 2015 – March 2016?
11. Does your Trust have a paediatric dermatologist? Does your Trust have a paediatrician with a dermatology interest/specialism?

Download response Dermatology and Atopic Dermatitis. 010917

Dermatology Biologics. 130220

I have a Freedom of Information request regarding biologics and biosimilar prescribing in dermatology.
Could you please provide me with the following numbers of patients treated in the last 12 months with the following drugs.
Adalimumab [Amgevita]
Adalimumab [Hulio]
Adalimumab [Humira]
Adalimumab [Hyrimoz]
Adalimumab [Imraldi]
Apremilast [Otezla]
Brodalumab [Kyntheum]
Certolizumab [Cimzia]
Dimethyl fumarate [Skilarence]
Dupilumab [Dupixient]
Etanercept [Benepali]
Etanercept [Enbrel]
Etanercept [Erelzi]
Golimumab [Simponi]
Guselkumab [Tremfya]
Infliximab [Flixabi]
Infliximab [Inflectra]
Infliximab [Remicade]
Infliximab [Remsima]
Ixekizumab [Taltz]
Risankizumab [Skyrizi]
Secukinumab [Cosentyx]
Tildrakizumab [Ilumetri]
Tocilizumab [Ro Actemra]
Upadacitinib [Rinvoq]
Ustekinumab [Stelara]
If you are unable to provide the information above with specific reference to dermatology then please provide me with the numbers of patients treated in the last 12 months with the above drugs, regardless of disease/indication.

Download response Dermatology Biologics. 130220

Diabetes. 091117

1. The number of patients with Type 1 diabetes that are currently treated as an outpatient in the hospitals in Maidstone and Tunbridge Wells NHS Trust.
2. The number of patients with Type 2 diabetes that are currently treated as an outpatient in the hospitals in Maidstone and Tunbridge Wells NHS Trust.
3. The number of patients with Type 1 diabetes in the hospitals in Maidstone and Tunbridge Wells NHS Trust with an Insulin Infusion Pump.
4. The number of patients with Type 2 diabetes in the hospitals in Maidstone and Tunbridge Wells NHS Trust with an Insulin Infusion Pump.
5. The number of Diabetes Specialist Nurses that are employed in Maidstone and Tunbridge Wells NHS Trust as of the 1st October 2017. Please break down the response to this question by pay band e.g. band 6, band 7.
6. Is structured education for patients with Type 1 diabetes offered within Maidstone and Tunbridge Wells NHS Trust?
7. The number of patients with Type 1 diabetes that have received structured education within Maidstone and Tunbridge Wells NHS Trust between the period October 1st 2016 to October 1st 2017.

Download response Diabetes. 091117

Diagnosis of heart failure in 2015.

1. What was the size of the patient population covered by your Trust in 2015?
2. How many patients were diagnosed with heart failure by your Trust in 2015?
3. Does your Trust follow NICE guidelines to support the diagnosis of suspected heart failure? If not, what guidance does your Trust follow? Please provide a copy
4. Please provide the details – including the manufacturer and brand name – of those tests used to support the diagnosis of heart failure
5. Does your Trust follow NICE guidelines to support the management of chronic heart failure? If not, what guidance does your Trust follow? Please provide a copy
6. Please provide the details – including the manufacturer and brand name – of those tests used to support the management of chronic heart failure
7. Does your Trust use NTproBNP or BNP testing to support the diagnosis of heart failure in patients presenting through A&E?
8. How many NTproBNP tests were performed by your Trust in 2015? Please provide the manufacturer and brand name of the test used
9. Are there any restrictions for using NTproBNP or BNP tests? If yes, please explain
10. How many echocardiographs were performed at your Trust in 2015?
11. What was the average waiting time for an echocardiogram at your Trust in 2015?

Download response Diagnosis of heart failure in 2015 290416

Diagnostic data on an MRI technique for men with suspected prostate cancer.270318

1. Please tell us which Trust, Health Board or Health and Social Care Trust you are responding on behalf of?
2. What percentage of men receive mpMRI before biopsy as part of the initial diagnostic process using T2-weighted, diffusion-weighted (multi-b ADC and high/long b) and dynamic contrast enhanced (DCE) sequences?
3. What are your eligibility criteria/exclusion criteria for men to receive pre-biopsy mpMRI?
4. Are you using mpMRI before biopsy to rule some men out of biopsy as part of the initial diagnostic process?
5. What mpMRI scores and/or other clinical factors are used to rule men out of biopsy?
6. Do you intend to use mpMRI to rule men out of biopsy in the future?
7. How many men annually are referred?
8. If you are unable to provide numbers for question 6, please estimate the percentage of all men referred for b, c and d.
9. Do you carry out targeted biopsies in men with mpMRI lesions in addition to systematic biopsies?
(Please indicate with a X below)
If No, what are the reasons for not carrying this out? (e.g. expertise, equipment, don’t believe it makes a difference)
10. If you do not currently carry out targeted biopsies, but wish to in the future, what are the current barriers to doing so?
(Please indicate with a X below)
11. Please indicate the number of uroradiologists undertaking prostate MRI
12. How many scanners do you have available for mpMRI before biopsy?
Has this increased in the last 12 months?
13. What percentage of scanner time is dedicated to mpMRI before biopsy?

Download response Diagnostic data on an MRI technique for men with suspected prostate cancer.270318

Diagnostic imaging 150217

1. What is the approximate local population catchment your hospital trust provides services for?
2. For each MRI, CT, and PET-CT, please set out the location for each scanner located on Trust property using one line per machine:
3. For each scanner listed in Question 2 as per index, please set out the type of ownership and both the year of manufacture and the year of installation in your trust for each machine:
4. For each scanner listed in Question 3 that is not owned by the trust and as per index, please list the name of the company providing the service:
5. For each scanner listed in Question 2 as per index, please set out the current ‘normal opening hours’ of the service per week and indicate whether this includes a non-emergency weekend service or not:
6. Please set out the total number of MRI, CT, and PET/CT scans that were carried out on scanners within your trust in the financial years (April to March) 2012/13, 2013/14, 2014/15, and 2015/16:
7. Please set out the total number of MRI, CT, and PET/CT scans referred by clinicians from your trust, regardless of whether they were carried out at your trust or at another trust or provider, in the financial years (April to March) 2012/13, 2013/14, 2014/15, and 2015/16:
8. Please list the providers outside your trust below that carried out MRI, CT, and PET/CT scans on your trust’s patients trust during the financial year 2015/16:
9. For each of the hospital providers listed in Question 8 as per index, please set out the total number of MRI, CT, or PET/CT scans that were carried there on your behalf in the financial years (April to March) 2012/13, 2013/14, 2014/15, 2015/16:
10. Does your trust currently hold plans to extend its MRI, CT, or PET/CT capacity (e.g. increase number of scanners)?
11. If yes, what is the likely procurement method your trust is likely to take?
12. Does your trust currently hold plans to invest into high value (>£500k) capital diagnostic equipment (both radiological and non-radiological) over the next five years?
13. If your trust has done any assessment/forecasting of the evolution of demand for MRI, CT, and/or PET-CT scanning, either historic or future, please provide a copy.

Download response Diagnostic imaging 150217

Diagnostic Imaging (DI) for 2014/2015.

Please provide the information set out below in respect of Diagnostic Imaging (DI) at your Trust for the FY 2014/15:

For each of the key Points of Delivery categories (just EL, SSEL, NEL, SSNEL, DC and OP), the numbers and types (e.g. CT/MR/PET-CT/endoscopy) of DIs performed per Primary Diagnosis (ICD) and the number of patients so investigated in that ICD category.

We would only need the first three characters of the Primary Diagnosis code (e.g. C00 to D49 for Neoplasms).

Download response Diagnostic Imaging (DI) for 2014/2015 270516

Diagnostic and procedure codes. 160518

1) Any diagnosis from the category Z38 (i.e. Z38.0 – Z38.8, I believe obtained by searching for Z38.X, but local procedures may vary). This diagnosis could be in any position, principle or secondary.
Explanation: This is looking at the number of live births in the time period in your trust.

2) The number of episodes from the results of part 1) that has also given the diagnosis code P39.9. This diagnosis could be in any position, principle or secondary.
Explanation: This is looking at the number of the above patients who were screened and treated for sepsis, without diagnosed bacteraemia.

3) The number of episodes from the results of part 1) that has also given a diagnosis from the category P36 (i.e. P36.0 – P36.9, I believe this is searched for by P36.X). This diagnosis could be in any position, principle or secondary.
Explanation: This is looking at the number of patients from part 1) that had a bacterial sepsis.

4) The number of episodes from the results of part 1), which also has the procedure code A55.8 or A55.9
Explanation: This is looking at the number of patients from parts 1) that have had a lumbar puncture, an investigation for meningitis.

5) The number of episodes from the results of part 1), which also has any diagnosis from the category G00, G01, G02, or G03. These diagnoses could be in any position, principle or secondary
Explanation: This is looking at the number of patients from parts 1) that actually were diagnosed with meningitis.

Notes to help complete request:

For each of 1) 2) 3) 4) and 5), you only need to provide one number for the number of episodes for each; they do not need to be broken down in to subcategories. If any of the answers is zero, please state as such (or state you do not hold any information on it). Kindly note this information is not publicly available from other sources, including NHS Digital.

Download response Diagnostic and procedure codes. 160518

Diagnostic services provided by external providers outside the UK. 260717

Does your trust have any diagnostic services provided by external providers outside the UK (e.g. radiology)?

If yes –

– What services?
– Which provider(s) have been chosen to provide these services?
– How much is each contract worth?
– For what time period will the contract run?
– When did you first enter into these arrangements?

Download response Diagnostic services provided by external providers outside the UK. 260717

Discharge Summaries. 250419

1) How many digital discharge summaries from 1st November 2017 to 1st November 2018 included any of the following terms?
• GHB
• GBL
• gamma-hydroxybutyrate
• gamma-Hydroxybutyric acid
• 4-hydroxybutanoic acid
• 1,4-butanediol
• 1,4-BD

Download response Discharge Summaries. 250419

Dispensed drugs. 160119

1. Can I ask although the Trust is not commissioned to provide Dermatology services would it be possible to provide data for the number of drugs dispensed regardless of indication / condition in the last three months?
Drug Name
Acitretin
Alitretinoin
Pimecrolimus
Tacrolimus
Dupixent (Dupilumab)
Phototherapy including with ultraviolet (UVB) radiation or psoralen ultraviolet A (PUVA)
Potent Topical Corticosteroids (creams or ointments) total
Amcinonide 0.05% (Cyclocort)
Betamethasone diproprionate 0.05% (Diprosone)
Betamethasone valerate
Clobetasol proionate
Desoximetasone 0.25% (Topicort)
Diflucortolone valerate
Fluocinonide 0.05% (Lidex)
Fluticasone proprionate 0.005% (Cutivate)
Halcinonide 0.05% (Halog)
Mometasone furoate 0.1% (Elocon ointment)
Triamcinalone acetonide 0.5% (Kenalog, Aristocrt cream)
Betamethasone dipropionate 0.25% (Diprolene)
Clobetasol dipropionate 0.05% (Temovate)
Diflorasone diacetate 0.05% (Psorcon)
Halbetasol proprionate 0.05% (Ultravate)
Immunosppressive therapies total
Azathioprine
Ciclosporin
Methotrexate
2. The number of drugs dispensed regardless of indication / condition in the past 3 months?
Drug Name
Etanercept
Infliximab
Adalimumab
Ustekinumab

Download response Dispensed drugs. 160119

Disposal of drugs. 070818

1. Please can you provide me information on the quantity of prescription medications, drugs and any other dispensed medical substances (“Drugs”) disposed of during the summer heat wave (from the start of June 2018 until the most recent possible date when the search is made.
2. If you have a register of Drugs being disposed of including dates of the disposal, type and name of Drug, quantities involved, and value of each batch to be disposed of, please provide me with such a register for the given period.
3. Otherwise, please provide information as to the overall quantity and value of Drugs to be disposed, and provide as much of a breakdown into the fields given previously as is possible.
4. Please can you tell me whether (i) all, (ii) some, or (iii) which of the hospitals or medical centres that come under the Trust, have the appropriate facilities to refrigerate Drugs.

Download response Disposal of drugs. 070818

Drug resistant infections. 250419

– How many cases of drug resistant infections (both bacterial and fungal) have there been at your NHS trust in each of the past five years (2018, 2017, 2016, 2015, 2014)?
– What were those infections?
– How many of those infections resulted in deaths?

Please could you break the results down by year, rather than providing them as one number?

The Trust requested clarification and received the following response:

The point of this question is to determine whether, in the wake of stories about so-called superbugs and drug-resistant fungi such as Candida Auris, there is any truth to speculation that drug-resistant infections are on the rise, and if so, to what extent.

So, of course I am interested to know about the number of cases of so-called superbugs but I am also looking for trends of other, less well-documented, cases of antimicrobial drug resistance.

Therefore, ideally I would like data on all such cases.
However, if this is impossible, then I would like the data as requested on cases of drug resistance in the following:
1. Acinetobacter baumannii
2. Pseudomonas aeruginosa
3. Enterobacteriaceae
4. Enterococcus faecium
5. Staphylococcus aureus
6. Helicobacter pylori
7. Campylobacter spp.
8. Salmonellae
9. Neisseria gonorrhoeae
10. Candida auris

Download response Drug resistant infections. 250419

Drug spend 2014-15 and 2015-16. 081117

a) Total drug spend for financial years 2014-15, and 2015-16
b) Total Off-tariff drug spend for financial years 2014-15, and 2015-16
c) Total Homecare drug spend for financial years 2014-15, and 2015-16

Download response Drug spend 2014-15 and 2015-16. 081117

Drug stock. 300518

1. Has your trust accepted or is it currently accepting manufacturer provision of free of charge drug stock between licensing and NICE funding? [Yes/No]
2. Has your trust accepted or is it currently accepting the following list of drugs in psoriasis:
Brodalumab [Kyntheum] [Yes/No]
Guselkumab [Tremfya] [Yes/No]
Ixekizumab [Taltz] [Yes/No]
Secukinumab [Cosentyx] [Yes/No]
3. Has your trust accepted or is it currently accepting the following list of drugs in Rheumatoid Arthritis:
Tofacitinib [Xeljanz] [Yes/No]
Baricitinib [Olumiant] [Yes/No]
Golimumab [Simponi] [Yes/No]
Certolizumab [Cimzia] [Yes/No]
Apremilast [Otezla] [Yes/No]
Tocilizumab [Ro Actemra] [Yes/No]
4. Has your trust accepted or is it currently accepting the following list of drugs in Ankylosing Spondylitis or Psoriatic Arthritis:
Secukinumab [Cosentyx] [Yes/No]
5. Has your trust accepted or is it currently accepting the following list of drugs in Ulcerative Colitis:
Golimumab [Simponi] [Yes/No]
6. If your trust has not accepted manufacturer provision of free of charge drug stock, what have been the reasons for this?
7. In future, will your trust be able to accept manufacturer provision of free of charge drug stock? [Yes/No]
8. What is the preferred distribution channel for the provision of free of charge drug stock?
Homecare [Yes/No]
Delivered directly to hospital/Trust [Yes/No]
Other (please provide details)
9. For how long is free of charge drug stock typically provided for each patient?
First dose [Yes/No]
First month [Yes/No]
First 3 months [Yes/No]
Other

Download response Drug stock. 300518

Drug usage. 051119

How many patients have been treated with these drugs in the past 6 months, regardless of diagnosis:
a. Aubagio (teriflunomide)
b. Avonex (interferon beta-1a)
c. Betaferon (interferon beta-1b)
d. Brabio (glatiramer acetate)
e. Copaxone (glatiramer acetate)
f. Extavia (beta interferon-1b)
g. Gilenya (fingolimod)
h. Lemtrada (alemtuzumab)
i. Mavenclad (cladribine)
j. Ocrevus (Ocrelizumab)
k. Plegridy (Peginterferon beta-1a)
l. Rebif (beta interferon-1a)
m. Tecfidera (dimethyl fumarate)
n. Tysabri (natalizumab)
o. Zinbryta (daclizumab)
p. Ampyra (Fampyra)
q. Ozanimod

Download response Drug usage. 051119

Drug usage. 130619

Within your health trust how many patients are, within the past 6 months that you have data available, being treated with the following treatments? This is regardless for the disease being treated.

Disodium pamidronate (Aredia)
Ibandronic acid or ibandronate (Bondronat)
Sodium clodronate (Bonefos, Clasteon, Loron)
Zoledronic acid or zoledronate (Zometa)
Denosumab (Xgeva)
Omalizumab [Xolair]
Mepolizumab [Nucala]
Reslizumab [Cinqaero]
Benralizumab [Fasenra]
How many paediatric patients have been treated in the last 6 months with Xolair/omalizumab?

Download response Drug usage. 130619

Drug usage. 151118

You asked:
This is a Freedom of Information request regarding usage of certain products in all NHS Trusts, these products are:
• Glycopyrronium bromide 1 mg tablets
• Glycopyrronium bromide 2 mg tablets
• Glycopyrronium bromide 1 mg/5 ml oral solution
• Glycopyrronium bromide 5 mg/5 ml oral solution
• Sialanar 320 mcg/ ml glycopyrronium (400 mcg/ml glycopyrronium bromide) oral solution
• Scopoderm (hyoscine) 1.5 mg patch
• Glycopyrronium bromide 200 micrograms/ml ampoule (for injection)
1. How many units* of these products were dispensed quarterly in 2016 – present?
*tablets: units as number of TABLETS or PACKS
• If packs, please specify pack size e.g. 14 tablets
*oral solution: units as number of bottles
• Please specify bottle size e.g. 60 ml
*patch: units as packs
• Please specify pack size e.g. 5 patches
*ampoule: units as number of AMPOULES or PACKS
• If packs, please specify pack size e.g. pack of 10

Download response Drug usage. 151118

Drug usage. 2 151118

You asked:
1. How many patients have been treated in the past 6 months [latest 6 months available] with the following, If possible please split by paediatric (less than 18 years) and adult 18+years;
• Genotropin
• Humatrope
• Norditropin
• NutropinAq
• Omnitrope
• Saizen
• Valtropin
• Zomacton

Download response Drug usage. 2 151118

Drugs usage. 061119

In the past 12 months, how many patients were treated with:
Avelumab + Axitinib
Axinitib
Bevacizumab
Cabozantinib
Doxorubicin
Everolimus
Lapatinib
Lenvantinib
Lenvantinib + Everolimus
Nivolumab
Nivolumab + Ipilimumab
Pazopanib
Pembrolizumab + Axitinib
Regorafenib
Sorafenib
Sunitinib
Temsirolimus
Tivozanib
Vandetanib

Download response Drugs usage. 061119

Drugs usage. 070318

This is a Freedom of Information request regarding usage of certain products in all NHS Trusts, these products are:
• Iloprost 0.5mg/0.5ml Ampoules
• Melatonin 1mg/ml oral solution,
• Melatonin 2mg Capsules,
• Melatonin 3mg Capsules,
• Melatonin 5mg Capsules,
• Melatonin 3mg Tablets
• Mexiletine 200mg capsules
• Diazoxide 50mg/ml oral suspension
1. How many packs of these products were dispensed quarterly in 2015?
2. How many packs of these products were dispensed quarterly in 2016?
3. How many packs of these products were dispensed quarterly in 2017?
4. What was the annual spend for each product between 2015 and 2017?
5. What was the cost per unit of each product between 2015 and 2017 to your organisation?

Download response Drugs usage. 070318

Drugs usage. 210218

This is a Freedom of Information request regarding usage of certain products in all NHS Trusts, these products are:
Iloprost 0.5mg/0.5ml Ampoules
Melatonin 1mg/ml oral solution,
Melatonin 2mg Capsules,
Melatonin 3mg Capsules,
Melatonin 5mg Capsules,
Melatonin 3mg Tablets
Mexiletine 200mg capsules
Diazoxide 50mg/ml oral suspension

1. How many packs of these products were dispensed quarterly in 2015?
2. How many packs of these products were dispensed quarterly in 2016?
3. How many packs of these products were dispensed quarterly in 2017?
4. What was the annual spend for each product between 2015 and 2017?
5. What was the cost per unit of each product between 2015 and 2017 to your organisation?

Download response Drugs usage. 210218

Drugs usage. 271119

Within your trust how many of the following intra-vitreal vials/implants have been used in the latest 4 months, if possible between May to August 2019;
Ranibizuma, Bevacizumab, Aflibercept, Fluocinolone & Dexamethasone

Download response Drugs usage. 271119

Drugs usage. 2711191

Within your health trust how many patients are currently [within the past 12 months] being treated with the following treatments, regardless of reason.
Amphotericin B/amphotericin liposomal (AmBisome )
Ceftaroline (Zinforo)
Ceftobiprole (Zevtera)
Ceftriaxone
Co-Amoxiclav
Flucloxacillin
Isavuconazole (Cresemba)
Meropenem (Meronem)
Posaconazole (Noxafil)
Teicoplanin (Targocid)
Tigecycline
Vancomycin
Amoxicillin/clauvanate
Piperacillin/tazobactam
Ceftazidime/avibactam
Ceftolozane/tazobactam
Carbapenems (e.g. Ertapenem, Imipenem, Meropenem etc)
Aminoglycosides (e.g. Gentamicin, Amikacin, Tobramycin)
Cephalosporins (e.g. Cefotaxime, Ceftazidime, Ceftriaxone)
Quinolones (e.g.Ciprofloxacin, Levofloxacin, Ofloxacin)

Download response Drugs usage. 2711191

Eating Disorders. 130619

1. Please provide the number of women who were treated by the NHS for INPATIENT (TIER 4) and COMMUNITY (TIER 1, 2, 3) Eating Disorder services in your region in the last 3 years. Where possible, please provide separate sub-totals for those placed in-area and those placed out-of-area.
2. Please provide the number of men who were treated by the NHS for INPATIENT (TIER 4) and COMMUNITY (TIER 1, 2, 3) Eating Disorder services in your region in the last 3 years. Where possible, please provide separate sub-totals for those placed in-area and those placed out-of-area.
3. Please provide the average waiting time in weeks (time from referral to treatment) for ADULT INPATIENT (TIER 4) and ADULT COMMUNITY (TIER 1, 2, 3) Eating Disorder services in your region in the last 3 years.
4. Please provide a copy of your threshold criteria for access to ADULT INPATIENT (TIER 4) and ADULT COMMUNITY (TIER 1, 2, 3) Eating Disorder services.
5. Please provide the percentage of referrals to ADULT INPATIENT (TIER 4) and ADULT COMMUNITY (TIER 1, 2, 3) Eating Disorder services have been refused in your region in the last 3 years.
6. Please provide the total number of NHS beds in your region that are usable for ADULT INPATIENT (TIER 4) Eating Disorder patients. This does not refer to current occupancy levels, but rather the total capacity of beds.
7. Please provide the total amount spent by your organisation on treating ADULT Eating Disorder patients? Of this spend please can you advise the proportion allocated to ADULT INPATIENT (TIER 4) Eating Disorder services? Of this spend please can you advise the proportion allocated to ADULT COMMUNITY (TIER 1, 2, 3) Eating Disorder services?
8. For the last 3 years of which you have full accounts, please can you name the organisations that you have commissioned to provide ADULT Eating Disorder services?

Download response Eating Disorders. 130619

ECG equipment. 260418

1. The name or your current ECG equipment manufacturer and product name, the year of purchase and installation date?
Do you have plans and timescales to replace?

2. The name of your current Stress Exercise ECG equipment manufacturer and product name, the year of purchase and installation date?
Do you have plans and timescales to replace?

Download response ECG equipment. 260418

Elastomeric Infusion Devices (E.I.D) 020320

Information request in respect to Elastomeric Infusion Devices

Please could you kindly advise which departments and healthcare professionals within your Trust use elastomeric infusion devices?

Information request in respect of Elastomeric Infusion Devices

1. Please could you also advise if you purchase E.I.D and if so:
a. What brand(s) do you purchase?
b. What quantities do you purchase on an annual basis?
c. Who are the main clinicians responsible within your Trust for the prescribing and administration of elastomeric devices?
d. What medicines do you fill the devices with?
e. Do you fill elastomeric devices in your pharmacy aseptic unit if you have one?
2. Please could you also advise if you purchase pre-filled elastomeric devices from a commercial compounder and if so:
a. What drugs are provided pre-filled?
b. What quantities do you purchase on an annual basis?

Download response Elastomeric Infusion Devices (E.I.D) 020320

Electronic prescribing and medicines administration. 230419

1. Who is the Trust’s current supplier for their Electronic prescribing and medicines administration?
2. What is the contract start and end date for the Electronic prescribing and medicines administration?
3. What is the annual cost for the Electronic prescribing and medicines administration?

Download response Electronic prescribing and medicines administration. 230419

Electrophysiology equipment. 300317

1. Does your Trust have an Electrophysiology Lab or perform Electrophysiology Procedures?
2. How many 3D Mapping Systems are installed in your Trust?
3. How many Electrophysiology Recording Systems are installed in your Trust?
On average, what is the lifespan of these EP Recording systems?
What brands are they?
Were there any EP Recording systems purchased in the last 12 months?
If yes, how many?
Were these to replace old machines or new purchases?
4. How many Intracardiac Echocardiography (ICE) Systems are installed in your Trust?
5. How many Radiofrequency (RF) Ablation Generators are installed in your Trust?
6. How many cardiac stimulators are installed in your Trust?
7. How many Remote Navigation Systems (from Stereotaxis) are installed in your Trust?

Download response Electrophysiology equipment. 300317

ESBL and CPE infections. 181116

Can you please tell me how many people in your hospital trust:

1. Were admitted to hospital with an ESBL infection
2. Acquired an ESBL infection while in hospital
3. Were admitted to hospital with a CPE infection
4. Acquired a CPE infection while in hospital

Please provide the information for the past 10 years.

Download response ESBL and CPE infections. 181116

EU staff and medicines from the EEA. 151118

You asked:
1. How much does it cost in pounds sterling to recruit one doctor from an EEA country, as of October 2018?
2. How much does it cost in pounds sterling to recruit one nurse from an EEA country, as of October 2018?
3. How much did it cost in pounds sterling to recruit one doctor from an EEA country in October 2015?
4. How much did it cost in pounds sterling to recruit one nurse from an EEA country in October 2015?
5. How much of the overall budget is dedicated to recruitment?
6. How much did you spend on medicines from the EEA in 2015?
7. How much are you projecting to spend on medicines from the EEA in 2018?
8. What percentage of medication came from the EEA in 2015?
9. What percentage of medication came from the EEA in 2018?

Download response EU staff and medicines from the EEA. 151118

Foot protection team. 020617

1. Does your trust operate a foot protection service, as recommended by NICE guideline NG19 on ‘Diabetic foot problems: prevention and management’?

2. If the answer to Q1 is yes, please state the number of podiatrists and orthotists employed within this service.

3. If the answer to Q1 is yes, is this service led by a podiatrist with specialist training in diabetic foot problems, as recommended by NICE guideline NG19 on ‘Diabetic foot problems: prevention and management’?

4. If the answer to Q1 is no, please provide a reason for this.

Download response Foot protection team. 020617

Formaldehyde and Formalin

1. How many reported incidents involving formaldehyde and/or Formalin have occurred in the last 3 years at your trust? Please provide numbers of staff and patients involved in such incidents
2. How many reported illnesses or injury due to formaldehyde and/or formalin has your trust had?
3. Has your trust ever been subject to legal proceedings due to exposure to formaldehyde and and/or formalin? Please supply numbers of incidents
4. Does your trust have a policy or procedure in place to reduce exposure to formaldehyde and/or formalin in the treatment room setting whilst harvesting biopsy samples? If so please supply
5. Does your trust have a policy to purchase the safest practicable solution to reduce harmful exposure to Formaldehyde and/or formalin? If so please supply details

Download response Formaldehyde and Formalin 260216

Formularies and committees.241218

1) We understand the CCG/Trust has representation on the following medicines management / prescribing / formulary committees:
a. Maidstone and Tunbridge Wells NHS Trust Drugs and Therapeutic Committee
b. West Kent CCG Prescribing Interface Group
Please confirm if this is correct.
2) Does the CCG/Trust have representation on any other medicines management / prescribing / formulary committees? If so, please advise which.
3) We have the following formularies listed as used by the CCG/Trust:
a. West Kent Interface Adult Formulary
Please confirm if this is correct and if not, please provide a link/copy of relevant formularies.
4) Are any of the above formularies dominant when making prescribing decisions or does this depend on therapy area?

Download response Formularies and committees.241218

Gaseous anaesthetic agents.011118

In particular, I would like to know the total volume and total amount spent in the last financial year on sevoflurane, Desflurane and isoflurane.
To avoid any commercial sensitivity, I do not want to know who the manufacturer or supplier is, simply the total volume and cost as shown below:
• Total volume purchased in 2017-2018, last 12 months (ml or litres if possible)
• Total amount spent on agent in 2017-2108
Regarding the volume of agent used, millilitres or litres would be preferred. If it is easier to provide another unit of measure, please provide details so that I can calculate the volume.
Also, could you please state whether the total amount spent includes or excludes VAT.

Download response Gaseous anaesthetic agents.011118

Gout and Bowel Cleanser products. 031219

Information request 1

Has your hospital dispensed the products listed below from January 1 2018 till December 31 2018? If the answer is ‘yes’, could you confirm the number of tablets dispensed?
1. Colchicine 500mcg tablets
2. Allopurinol 100mg tablets
3. Allopurinol 300mg tablets
4. Adenuric 80mg tablets (Febuxostat)
5. Adenuric 120mg tablets (Febuxostat)

Information request 2
Has your hospital dispensed the products listed below from January 1 2018 till December 31 2018? If the answer is ‘yes’, could you confirm the number of sachets dispensed?
1. Moviprep powder for oral solution
2. Moviprep Orange powder for oral solution
3. Klean-Prep 69g sachet powder for oral solution
4. Picolax powder for oral solution

Download response Gout and Bowel Cleanser products. 031219

Growth Hormone Treatments. 111219

In your trust, in the past 12 months [latest 12 months available], how many patients have been treated with the following medications?
• Genotropin
• Humatrope
• Norditropin
• Nutropin
• Omnitrope
• Saizen
• Zomacton

Download response Growth Hormone Treatments. 111219

Haemochromatosis. 261016

A. the number of patients treated with Haemochromatosis in 2015 who are in maintenance phase of the treatment (*)
B. the number of patients treated with Haemochromatosis in 2015 who are in PRE-maintenance phase of the treatment (+)
C. a copy of the clinical protocol(s) used to treat haemochromatosis
D. a copy of the clinical protocol(s) for therapeutic venesection

(*) “Maintenance phase” relates to patients whose ferritin is <=50 ug/L
(+) “PRE-maintenance phase” relates to patients whose ferritin is in excess of 50 ug/L

Download response Haemochromatosis. 261016

HCV testing 151216

1. Do you currently offer a clinical testing service for HCV?
o Yes, In-house service
o Yes, Send-out to another laboratory
o No
If you have selected send-out testing above, to which laboratory do you send samples for HCV testing?
2. What type of clinical HCV testing do you offer?
o HCV Antibody testing
o HCV RNA testing
o HCV Genotyping
o HCV Drug resistance testing
o Other. Please Specify:
3. If you are offering HCV antibody testing as well as HCV RNA testing, what is the laboratory algorithm used for testing?
o RNA testing is automatically performed as a reflex test dependant on the Antibody result
o The HCV antibody result is reported to the clinician and RNA testing is only performed when specifically requested by the clinician
4. HCV antibody testing details:
Is HCV antibody testing performed using a kit or laboratory developed technique?
If appropriate, please specify kit details:
What platform is used for HCV antibody testing?
What is the laboratory turnaround time for HCV antibody testing?
How frequently is HCV antibody testing performed
(on sample receipt, daily, twice a week, monthly)?
5. HCV RNA testing details:
Is HCV RNA testing performed using a kit or laboratory developed technique?
If appropriate, please specify kit details:
What platform is used for HCV RNA testing?
What is the laboratory turnaround time for HCV RNA testing?
How frequently is HCV RNA testing performed
(on sample receipt, daily, twice a week, monthly)?
6. HCV sample volume:
Annual Sample Volume
1st Nov 2015- 1st Nov 2016 Positivity Rate
1st Nov 2015- 1st Nov 2016
HCV
Antibody testing
HCV
RNA testing
HCV
Genotyping
(If applicable)
HCV
Drug resistance testing
(If applicable)

Download response HCV testing 151216

Hepatitis C. 151217

Please could you supply the following information, for patients with hepatitis C, for the latest month available? Please use the tables to enter by genotype if possible thank you.

Treatment Regimens in last month by Genotype

Download response Hepatitis C. 151217

Hepatitis C. 270918

1. Does your trust treat Hepatitis C? [Yes/No]
2. If YES, please could you supply the following information, for patients with hepatitis C, for the latest month available? Please use the tables to enter by genotype if possible thank you.

Download response Hepatitis C. 270918

Hepatitis C. 280417

1. Does your trust treat Hepatitis C? [Yes/No]
2. How many patients with Hepatitis C are registered, or recorded as under you care? [Number]
3. Please could you supply the following information, for patients with hepatitis C, for the last month if possible? Please use the tables to enter by genotype as possible thank you.
By genotype as follows
Interferon Free Treatment
Epclusa
Harvoni
Sovaldi
Sovaldi/Olysio
Sovaldi/Daklinza
Viekirax
Viekirax/Exviera
Zepatier
If your systems do not support the ability to split by treatment, please supply total treated by the genotype split. Similarly, if you are unable to split by genotype, please just split by treatment type.

Download response Hepatitis C. 280417

Hepatitis C Patients 221216

For Hepatitis C patients:
1. How many patients in total are under the institution’s care, but not under any treatment (i.e. no drugs being given for this virus)?
If possible please split by Genotype.

2. For Hepatitis C patients, how many were treated in the month (last month’s available data) with interferon containing therapy and interferon free therapy as listed below. Please use the tables to enter by genotype if possible, thank you.

Download response Hepatitis C Patients 221216

Heroin and cocaine prescriptions. 250117

Under the FOI Act, can you please tell me how many times your trust has prescribed either heroin/diamorphine and/or cocaine to patients in the 2015 and 2016 calendar years.

Download response Heroin and cocaine prescriptions. 250117

Hidradenitis Suppurativa 230117

In your trust, how many patients with a diagnosis of Hidradenitis Suppurativa* (HS) have been treated in the last 12 months [latest available]?

Of these patients how many have been treated with the following;
Adalimumab
Etanercept
Infliximab
Infliximab Biosimilar
Ustekinumab

Download response Hidradenitis Suppurativa 230117

Histology. 170320

For the financial year 2018/19 please provide information relating to histology requests reported for patients of the trust.

How much was paid (to the nearest £) in 2018/19 with each of the following in relation to the reporting of histology cases:

A. Consultants employed by the trust being paid for additional sessions
B. Consultants employed by the trust being paid an amount per slide or case for activity outside their contracted programmed activities
C. Consultants employed by other trusts, where the trust contracts with these consultants or their trust
D. Locum agencies (please specify which)
E. Backlogs Limited
F. Unilabs
G. Source Bioscience
H. Cellular Pathology Services Limited
I. LD Path Limited
J. Pathognomics Limited
K. Other private histology providers (please specify which)

Download response Histology. 170320

Histology Reporting. 240817

For the financial year 2016/17 please provide information relating to histology slides/ cases reported for patients of the trust.

1. How many histology slides and or cases (please state whether the number given is slides or cases or both) were reported by consultant histopathologists for patients treated by the trust. If exact numbers are not available, an estimate to within 5% is acceptable, but please state whether exact numbers or estimates are given. (Cytology should be excluded)

2.Of these slides/ cases how many were reported by: a.Consultants employed by the trust working in their normal NHS programmed activity sessions b.Consultants employed by the trust being paid for additional sessions c.Consultants employed by the trust being paid an amount per slide or case for activity outside their contracted programmed activities d.Consultants employed by other trusts, where the trust contracts with these consultants or their trust e.Backlogs Limited f.Unilabs g.Source Bioscience h.Cellular Pathology Services Limited i.Other private histology providers (please specify which)

3.How much was spent in 2016/17 with each of the following in relation to the reporting of histology slides/ cases a.Consultants employed by the trust being paid for additional sessions b.Consultants employed by the trust being paid an amount per slide or case for activity outside their contracted programmed activities c.Consultants employed by other trusts, where the trust contracts with these consultants or their trust d. Backlogs Limited e.Unilabs f.Source Bioscience g.Cellular Pathology Services Limited h. Other private histology providers (please specify which)

Download response Histology Reporting. 240817

Histopathology Speciality Registrars July 2015

Under the Freedom of Information Act I am requesting the following

Monitoring results for the full time Histopathology Specialty Registrars who undertook a monitoring exercise July 2015
Monitoring results for the Less Than Full Time Histopathology Speciality Registrars who undertook monitoring July 2015

Download response Histopathology Speciality Registrars July 2015 211215

HIV patients treated with antiretroviral therapy (ART). 170817

1. Within your Trust for HIV patients treated between August 2016 – May 2017’ and August 2016 – July 2017, the total numbers treated with antiretroviral therapy (ART)

2. For HIV patients treated between August 2016 – May 2017 and August 2016 – July 2017, the total numbers treated with the following drugs.

Download response HIV patients treated with antiretroviral therapy (ART). 170817 

Homecare medicine delivery service. 151118

You asked:
1. Which homecare provider(s) do you as a Trust commission and fund for medicines where there is no ‘free of charge’ homecare provision?
2. Which homecare provider(s) do you as an organisation utilise,
2a. Which is pharmaceutical manufacturer-commissioned?
3. Does your organisation commission homecare services for any medicines as an alternative to the pharmaceutical manufacturer’s homecare provision?
4. Are there any homecare providers you have a policy not to work with? If yes, please select/name them
5. In your organisation, which group has the overall responsibility for any homecare provision for your patients?
6. In your organisation, which named individuals have the overall responsibility for any homecare provision for your patients?
7. What are your minimum requirements for accepting a homecare provider?
8. Do you currently have in post an operational lead for homecare services in your organisation – If so, what is their name/role?
9. If you have an outsourced outpatient pharmacy, are they able to provide training for patients on how to self-inject for medicines administered by sub-cutaneous injection as part of their contract?
10. Is it your policy to accept new homecare service level agreements (SLAs) with homecare providers whom you do not currently have an SLA in place with?
11. Any additional comments?

Download response Homecare medicine delivery service. 151118

Hospital Laboratories. 190919

1. How many laboratories (please include breakdown of sites/disciplines if possible) are there in your Trust?
2. What is the headcount of laboratory staff (please include breakdown of sites/departments/roles if possible) in your Trust?
3. How many patient samples or ‘reportable laboratory activities’ are processed (please include breakdown of sites/departments if possible) by your Trust’s laboratories each year (please include the three most recent available years’ numbers)?
4. What number (and percentage) of your Trust’s patients have a sample processed in a laboratory as part of their treatment?
5. How many patient samples are taken by your Trust but not processed/analysed by your Trust’s laboratory staff? (IE: outsourced)
6. If any, where are outsourced patient samples sent? (please include company names/addresses and number of samples sent each year)

Download response Hospital Laboratories. 190919

Hospital pharmacy provision. 220817

1. Please can you inform me whether your inpatient pharmacy (Discharge Medication not ward-level dispensing) is:
a. A department of the hospital?
b. A wholly owned outsourced subsidiary of the hospital?
c. Contracted-out to a private provider?

2. Please can you inform me whether your out-patient pharmacy is:
a. A department of the hospital?
b. A wholly owned outsourced subsidiary of the hospital?
c. Contracted-out to a private provider?

3. Please can you inform me whether your home care dispensing service is:
a. Provided by the pharmacy as a department of the hospital?
b. Provided by the pharmacy as a wholly owned outsourced subsidiary of the hospital?
c. Contracted-out to a private provider?

Download response Hospital pharmacy provision. 220817

Hydrotherapy pools. 011217

– What was the total cost of maintaining the hydrotherapy pools in your NHS trust between October 2016 and October 2017 and how many pools do you have? [Can you specify which hospitals these are at?]
– If possible, can I also have a breakdown of the maintenance cost per pool during the same time period?
– If this total cost include staff costs could you give the total amount relating to staff costs separately for this period?
– How much revenue did you raise between October 2016 and October 2017 from charging people to use the hydrotherapy pools in the hospitals within your NHS trust?
– Have any hydrotherapy pools been closed down in your NHS trust in the time period October 2014- October 2017? If yes, which hospitals had their hydrotherapy pools closed down?
– What were the reasons for the hydrotherapy pool closures at hospitals within your NHS trust?

Download response Hydrotherapy pools. 011217

Imaging services. 070317

1. Total number of and the manufacturer and model number(s) of each individual:
o MRI scanner
o CT scanner
o PET scanner
o SPECT scanner
o Ultrasound scanner
o Flexible Endoscope [An estimate of the number and predominant manufacturer brand will suffice]
o Catheter Lab X-ray machines
2. The year each individual scanner was purchased, the purchase method**, cost and the scheduled replacement year for each individual:
o MRI scanner
o CT scanner
o PET scanner
o SPECT scanner
Please state the total cost for trust purchases and annual payments if lease or MES.
Please indicate if equipment was purchased through a group purchasing organisation
3. How each of the following equipment has been purchased (e.g. contract with OEM, NHS Supply Chain catalogue) and how often they are replaced on average:
o Ultrasound scanner
o Sets of Flexible Endoscopes
o Catheter Lab CT machines
An estimate of how often the trust aims to replace the listed equipment would be useful (e.g. once every 2 years).
4. The maintenance provider (e.g. the OEM or a third party) and the annual maintenance cost (if applicable) for each individual:
o MRI scanner
o CT scanner
o PET scanner
o SPECT scanner
o Ultrasound scanner
o Catheter Lab CT machines
Might be done by the Original Equipment Manufacturer (OEM) (e.g. Siemens maintenance for a Siemens MRI machine) or a third party. If so, please state the provider name.
If no listed maintenance provider, please state – possibly the case for ultrasound.
5. Staffed hours for each individual: (Please note which of the individual scanners are available 24/7 for A&E purposes.)
o MRI scanner
o CT scanner
o PET scanner
o SPECT scanner
Please state hours each scanner is manned. (e.g. 9am – 6pm, Mon-Fri). Scanners used by A&E departments presumably must be 24/7, so please indicate these where relevant.
6. Number of scans/procedures performed annually in period financial year 2005/06 – 2015/16 for the following: [See the attachment for the relevant OPCS and modality ID codes].
o MRI scans*
o CT scans*
o PET scans*
o SPECT scans*
o Ultrasound scans
o Endoscopy procedures (Upper GI, Lower GI and Urological)
o Cardiac Angiography and Angioplasty procedures
o Cardiac Electrophysiology procedures
*For MRI, CT, PET and SPECT these may be covered by submissions to HSICIC for the Diagnostic Imaging Dataset (DID) (http://www.hscic.gov.uk/did), but we are looking for more granular data by individual machine if possible.
7. Number of scans/procedures performed by external providers on behalf of the trust in this same period. How much was paid per scan/procedures on average? Please list by external provider name. For the following:
o MRI scans
o CT scans
o PET scans
o SPECT scans
o Ultrasound scans
o Endoscopy procedures (Upper GI, Lower GI and Urological)
o Cardiac Angiography and Angioplasty procedures
o Cardiac Electrophysiology procedures
Number of activities performed by an external provider (NHS or Non-NHS), data may be collected by CCGs.
8. Average cost per scan from by year for the period 2005/06 – 2015/16 for the following:
o MRI scans
o CT scans
o PET scans
o SPECT scans
9. The provider of tracers for PET (e.g. FDG) and annual spend on tracers.

Download response Imaging services. 070317

Infected blood enquiry. 280119

a) Copies of all correspondence to/from the Infected Blood Inquiry during the period 1st April 2018 to 7th January 2019.

b) Please advise whether or not you have received any notice or instruction regarding the retention and/or request of documents relevant to the Infected Blood Inquiry?

c) If a request for documentation and/or its retention has been received from the Infected Blood Inquiry, please supply a copy of any such notices or requests.

Download response Infected blood enquiry. 280119

Infected Blood Inquiry. 310719

a) Copies of all correspondence to/from the Infected Blood Inquiry during the period 1st January 2019 to 17th July 2019.

b) Have you received any notice or instruction regarding the retention and/or request of documents relevant to the Infected Blood Inquiry?

c) If a request for documentation and/or its retention has been received from the Infected Blood Inquiry, please supply a copy of any such notices or requests and copies of any replies to such a request and internal correspondence relating to such.

Download response Infected Blood Inquiry. 310719

Instrument sterilisation service February 2016

1, Is the core instrument sterilisation service
A) Run in house
B) Onsite
C) Out sourced to a separate trust
D) Outsourced to a private company

2, How many instruments have been processed by the sterile services facility mentioned in question one.
A) In 2014 (or that financial year)
B) In 2015 (or that financial year)
C) How many surgical instruments are anticipated to require sterilising in 2016?

3, How much has the trust spent annually on sterilising surgical instruments for the following years?
A) Financial year 2013/14
B) Financial year 2014/15
C) How much has been budgeted or anticipated to be spent for the Financial year 2015/2016

4, How many staff are employed by the sterile service facility mention in question on, for the purposes of instrument sterilisation only, (i.e. exclude porters)
A) Management/admin
B) Team Leaders, supervisors, technicians

5, Does the trust provide decontamination and sterilisation services for re-usable surgical instruments to other customers who are not part of the trust? If so who?

6, In relation to surgical cancellations due to sterilisation failures.
A) How many operations were cancelled in 2014 due to issues with sterilisation of the equipment?
B) How many operations have been cancelled in 2015 due to issues with sterilisation of the equipment?

7, What where the costs associated with these cancellations
A) 2014
B) 2015

8, Of the instruments sterilised, approximately how many would be from dental/oral departments?
A) In 2014 (or that financial year)
B) In 2015 (or that financial year)

9, What Would the costs be for these instruments to dental/oral departments (Please state if approximate costs or not)
A) In 2014 (or that financial year)
B) In 2015 (or that financial year)

10, Does the trust use single use instruments?

Download response Instrument sterilisation service February 2016 250216

Insulin pump and UFE NICE compliance. 070318

1. Please enter the name of your Trust.
2. Does your Trust have a policy to ensure that all staff fully and objectively inform all patients of all their treatment options and offer them a choice of treatment? Please tick the appropriate box below
Yes
No
Don’t know
3. How do your monitor your staff to ensure that all patients are properly and objectively informed? [Please tick all answers that apply]
Carry out patient surveys to ensure they have been given all the information about all their treatment options?
We have patient information leaflets available all treatments on our web site
We send patient information leaflets about all treatments options before their outpatient clinic so they can discuss them with their doctor
We include questions on patient information and treatment options in all patient surveys
We have a policy and expect all staff to comply
We do not have a policy and do not think this important
It is up to the individual clinician
Other (please specify)
4. How many complaints has your Trust received in the last 2 years about lack of patient information and choice of treatment?
5. NICE Clinical and Diagnostic Guidelines set minimum standards that patients would expect for the quality of their healthcare. Does your Trust have a policy to ensure that all your staff comply with all NICE Clinical and Diagnostic Guidelines? Please tick appropriate box
Please provide us with a copy of your Trust’s policy on NICE Guideline compliance.
6. How do you monitor each of your clinical departments and clinicians to ensure their compliance with all NICE Guidelines? [Please tick all that apply]
Each department is required to update all care pathways to include the latest NICE Guidelines and this is reviewed by a Director
Every care pathway is reviewed by their clinical lead to ensure compliance with all NICE Guidelines
Audits are carried out in each clinical department to ensure NICE Guideline compliance and reported to the Board
Audit and patient surveys are carried out to ensure compliance
We trust our clinicians to comply with NICE Guidelines but do not monitor this
7. How many complaints has your Trust received in the past 2 years about lack of compliance with NICE Guidelines?
8. NICE Technology Appraisal Guidance 151 (TAG 151 Jul 08) states that continuous subcutaneous insulin infusion (CSII or insulin pump) therapy is a treatment option for adults and children with type 1 diabetes who meet certain criteria. How does your Trust ensure that all patients who meet the criteria are given the option of insulin pump therapy? [Please tick all that apply]
9. Which brands of insulin pump are offered at your Trust? [Please tick the appropriate box below]
10. What is the number of people with Type 1 diabetes registered with this Trust?
11. What is the number of patients using insulin pumps attending clinic at this Trust?
12. NICE Clinical Guidelines on Heavy Menstrual Bleeding (CG44 Jan ’07), which includes uterine fibroids, states that all women with fibroids >3cm requiring hospital treatment must be offered hysterectomy, uterine artery embolisation and myomectomy. How does your Trust ensure that all women are given the choice of all 3 treatments and that there is no age discrimination in treatment choices given to women? [Please tick all that apply]
13. NICE Guidelines on Heavy Menstrual Bleeding state that “1.3.1 A woman with HMB referred to specialist care should be given information before her outpatient appointment.” How does the Trust ensure compliance? [Please tick all that apply]
14. NICE Interventional Procedures Guidance on Uterine Artery Embolisation (IPG 367 Nov ‘10) states that – 1.3 Patient selection should be carried out by a multidisciplinary team, including a gynaecologist and an interventional radiologist.
How does your Trust ensure multidisciplinary team working between gynaecologists and interventional radiologists to ensure women have access to all fibroid treatment recommended by NICE? [Please tick all that apply]
15. NICE Guidelines on Heavy Menstrual Bleeding (HMB) states that –
1.10.1 All those involved in undertaking surgical or radiological procedures to diagnose and treat HMB should demonstrate competence (including both technical and consultation skills) either during their training or in their subsequent practice.
How does the Trust ensure all gynaecologists receive adequate training on UAE?
16. How is the training of gynaecologists about UAE monitored and recorded?
17. How many patients referred to your Trust in the last 2 years had a primary main diagnosis of heavy menstrual bleeding – Diagnostic Code N92?
18. How many patients referred to your Trust in the last 2 years in total (i.e. both primary and secondary main diagnosis) had a diagnosis of heavy menstrual bleeding Diagnostic Code N92?
19. How many patients had a primary main diagnosis of uterine leiomyoma/fibroids in the last two years Diagnostic Code D25.0 – 25.02 and D25.9?
20. How many patients in total (i.e. both primary and secondary main diagnosis) had a diagnosis of uterine leiomyoma/fibroids in the last two years Diagnostic Code D25.0 – 25.02 and 25.9?
21. How many patients with a diagnosis of heavy menstrual bleeding or fibroids (N92 and D25.0- 25.02 and 25.9) had a hysterectomy in the last 2 years Code Q07.1- Q08.9?
22. What were the ages of these women who had hysterectomy in the last 2 years Code Q07.1- Q08.9? (Please indicate the numbers for each age range below)
23. Does your Trust provide myomectomy – surgical removal of the fibroid(s) alone?
24. If ‘Yes’ how many myomectomies did your Trust perform in the last 2 years – open myomectomy code Q09.2, a endoscopic myomectomy in the last 2 years Code Q17.1?
25. What were the ages of the women who underwent myomectomy in the last 2 years (codes Q09.2 -9.3 + Q16.1 + Q17.1 and 17.4)? [Please indicate the numbers in each age range below]
26. Does your Trust provide uterine artery/fibroid embolisation? [Please tick the appropriate box below]
27. If ‘No’ where are patients wanting UAE referred?
28. If ‘Yes’ had uterine artery/fibroid embolisation in the last 2 years Code RC41Z?
29. Does your Trust provide beds for UAE patients on a regular basis – say once a week, as are provided for hysterectomy patients?
30. Do your interventional radiologists have admitting rights and named consultant status?
31. What were the age ranges of the women who had uterine artery/fibroid embolisation in the last 2 years Code RC41Z?

Download response Insulin pump and UFE NICE compliance. 070318

Intra-vitreal injections and implants. 070618

Within your trust how many intra-vitreal injections/implants have been used in the latest 4 months, if possible between January to April 2018
If your trust is able to identify injections/implants by eye conditions please split by the drug used [ranibizumab, bevacizumab, aflibercept, Fluocinolone and Dexamethasone].

Download response Intra-vitreal injections and implants. 070618

Intra-vitreal injections or implants. 061119

Within your trust how many intra-vitreal injections/implants have been used in the latest 4 months, if possible between January and April 2019
If your trust is able to identify injections/implants by eye conditions please split by the drug used [ranibizumab, bevacizumab, aflibercept, Fluocinolone and Dexamethasone].

Download response Intra-vitreal injections or implants. 061119

Intra-vitreal vials or implants. 210917

Within your trust how many intra-vitreal vials/implants have been used in the latest 4 months, if possible between May and August 2017?
Please state the number of vials dispensed from your pharmacy in this period, if the number for wet AMD is not known, then regardless of reason for use.

Download response Intra-vitreal vials or implants. 210917

Intra-vitreal vials or implants September – December 2016.100217

1. Within your trust how many intra-vitreal vials/implants have been used in the latest 4 months, if possible between September and December 2016
Please state the number of vials dispensed from your pharmacy in this period, if the number for wet AMD is not known, then regardless of reason for use.

2. Does your trust record the time taken from referral of a patient for treatment to the time for an injection or implant to be complete?
If so what is the average waiting time for treatment with an injection of implant?

Download response Intra-vitreal vials or implants September – December 2016.100217

Intra-vitreal vials/implants January 2016 – April 2016.

Within your trust how many intra-vitreal vials/implants have been used in the latest 4 months, if possible between January to April 2016
Please state the number of vials dispensed from your pharmacy in this period, if the number for wet AMD is not known, then regardless of reason for use.

Download response Intra-vitreal vials/implants January 2016 – April 2016 270616

Intra-vitreal vials/implants May – August 2016.

Within your trust how many intra-vitreal vials/implants have been used in the latest 4 months, if possible between May and August 2016

Please state the number of vials dispensed from your pharmacy in this period, if the number for wet AMD is not known, then regardless of reason for use.

Download response Intra-vitreal vials/implants May – August 2016 101016

Intravenous voriconazole injection. 290819

For the period 1st April 2018 to 31st March 2019:
1. The total number of individual doses of intravenous voriconazole administered to patients in the above organisation during the above period.
a) Please note, this request does not relate to the number of dose units of voriconazole injection used (as one dose may use more than one vial).
b) Please note, this request does not relate to the number of patients given intravenous voriconazole (as one patient will usually receive multiple doses).
c) I appreciate that this information will probably only be available if the above organisation uses an electronic prescribing and medicines administration system.
d) If this information is only available for part(s) of the above organisation, please provide this partial information and state to which parts of the organisation it applies (see also point 2a below)
2. The total number of dose units of voriconazole intravenous injection supplied for use within the above organisation during the above period.
a) If for request 1 you are only able to provide information for part of your organisation (see point 1d), please also state the number of dose units of voriconazole injection supplied for use within these same areas.
b) Please exclude voriconazole injection supplied by the above organisation for use within a different organisation.
3. In the above organisation, is the NHS Injectable Medicines Guide (commonly known as “Medusa” – http://medusa.wales.nhs.uk/) used at ward level by staff preparing intravenous medicines for administration to patients?
a) If the NHS Injectable Medicines Guide is only used in this way in parts of the above organisation, please state these areas.

Download response Intravenous voriconazole injection. 290819

Intravitreal injections or implants. 130619

I have a Freedom of Information request regarding Ophthalmology. Within your Trust how many Intra-vitreal Injections / Implants have been used in the latest 4 months, if possible between September and December 2018.
If your Trust is able to identify Injections / Implants by eye conditions please split by the drug used (Ranibizumab, Bevacizumab, Aflibercept, Fluocinolone and Dexamethasone)

Download response Intravitreal injections or implants. 130619

Intravitreal injections or implants 2. 130619

I have a Freedom of Information request regarding Ophthalmology. Within your Trust how many Intra-vitreal Injections / Implants have been used in the latest 4 months, if possible between May and August 2018?
If your Trust is able to identify Injections / Implants by eye conditions please split by the drug used (Ranibizumab, Bevacizumab, Aflibercept, Fluocinolone and Dexamethasone)

Download response Intravitreal injections or implants 2. 130619

Iron Infusions and Patient Product breakdown. 110320

1. How many patients have received an iron infusion in the last 12 months?
2. How many patients have been treated with Monofer and how many with Ferinject?
3. What was the average weight of these patients?
4. How many patients required more than 1 gram of iron?
5. How many nurses and for what days and hours are your Iron infusion clinics available?

Download response Iron Infusions and Patient Product breakdown. 110320

Ketamine and fentanyl. 160119

1. How many prescriptions were given out to patients under the age of 18 for Ketamine or Fentanyl in 2018?
2. How many prescriptions were given out to patients under the age of 18 for Ketamine or Fentanyl in 2017?
3. How many prescriptions were given out to patients under the age of 18 for Ketamine or Fentanyl in 2016?
4. If these drugs are not prescribed please could I have the details for the number of children administered with the drugs by hospital staff in the years; 2018, 2017, 2016?

Download response Ketamine and fentanyl. 160119

Klebsiella Pneumoniae 090617

In the 12 months ending 31 October 2016, what was:
1. The number of patients who had a blood culture positive for Klebsiella pneumoniae (Group A)
2. In Group A, the number of patients who had a blood culture positive for Klebsiella pneumoniae, with the organism found to be resistant to meropenem, resistant to ertapenem, OR reported positive for a carbapenemase (Group “CRKPb”).
3. In Group A, the number of patients who had a blood culture positive for Klebsiella pneumoniae, with the organism NEITHER found to be resistant to meropenem, NOR resistant to ertapenem, NOR reported positive for a carbapenemase (Group “CSKPb”).
4. Within Group CRKPb, the percentage of patients who had died in the period between the specimen date of the first blood culture that became positive for Klebsiella pneumoniae found to be resistant to meropenem, resistant to ertapenem, OR reported positive for a carbapenemase, and 6 days after the specimen date.
5. Within Group CRKPb, the percentage of patients who had died in the period between the specimen date of the first blood culture that became positive for Klebsiella pneumoniae found to be resistant to meropenem, resistant to ertapenem, OR reported positive for a carbapenemase, and 30 days after the specimen date.
6. Within Group CSKPb, the percentage of patients who had died in the period between the specimen date of the first blood culture that became positive for Klebsiella pneumoniae NEITHER found to be resistant to meropenem, NOR resistant to ertapenem, NOR reported positive for a carbapenemase, and 6 days after the specimen date.
7. Within Group CSKPb, the percentage of patients who had died in the period between the specimen date of the first blood culture that became positive for Klebsiella pneumoniae NEITHER found to be resistant to meropenem, NOR resistant to ertapenem, NOR reported positive for a carbapenemase, and 30 days after the specimen date.”
Please provide answers on the same questions for the 12 months period ending 31 October 2015.

Download response Klebsiella Pneumoniae 090617

Laboratory Information Management System (LIMS). 010319

1) What LIMS does your Trust currently use in the Cellular Pathology Department?
1a) Is this LIMS an all in one solution across all disciplines in Pathology?
1b) Can you please indicate the name of the supplier of the LIMS system for Cellular Pathology and the wider disciplines within Pathology. Can you also detail the contract expiry date?
1c) Can you indicate if the LIMS is something you may consider procuring in the next 2 years? If there are intentions of procuring a LIMS system in the next two years how much funding does the trust have to implement this?
1d) If not- is there a reason why the Trust is not procuring a LIMS in this timeframe (be this new or a replacement)?
2) What Digital Pathology Solution do you currently use in the Cellular Pathology Department?
2a) Does the Digital Pathology Solution encompass other disciplines throughout Pathology or the wider diagnostic disciplines such as Radiology MRI CT PET?
2b) Can you please indicate the name of the supplier of the Digital Pathology Solution for the Cellular Pathology Department, in particular the manufacturer of the Digital Slide Scanner? Can you also detail the contract expiry dates?
2c) Can you indicate if you are looking to procure a Digital Pathology Solution in the next two years if not already procured? If there are intentions of procuring a Digital Pathology system in the next two years how much funding does the trust have to implement this?
2d) If not- is there a reason why the Trust is not looking to procure a Digital pathology Solution in this timeframe (be this new or a replacement)?
3) Could you please give me the name/ title/email/telephone details of the Trust employee(s) who are responsible for your LIMS?
4) Could you please give me the name/ title/email/telephone details of the Trust employee(s) who is responsible for your Digital Pathology system?
5) Which Cancer Alliance does the Trust belong too? Who is in charge of this alliance? Please can you provide their title/email/telephone if you have these details?

Download response Laboratory Information Management System (LIMS). 010319

Laboratory medicine services. 210318

I would like to request the following information applicable for year 2016-2017:
1. Regarding the following diagnostic procedures/tests:
a. Complete (Full) blood cell count (FBC)
b. C-Reactive Protein (CRP)
c. Procalcitonin (PCT)
d. Chemistry panel/Serum electrolytes
e. Blood gas
f. Blood culture
g. Urine culture
h. Sputum culture
i. Stool (faeces) culture
j. Multiplexed PCR panels for pathogen identification
k. Viral serology (Antibody ID panel)
l. Lumbar puncture (Cerebro Spinal Fluid cytology)
m. Urine stick/Rapid urine test (Urine dipstix)
n. Chest x-ray
o. Rapid viral (RSV/FLU) diagnostic test
2. The total number of diagnostic procedures/tests performed in Maidstone and Tunbridge Wells NHS Trust as given in the table below.
3. The unit cost for said diagnostic procedures/tests for the requested year.
4. The total cost for said diagnostic procedures/tests for the requested year.

Download response Laboratory medicine services. 210318

LIMS (Laboratory Information Management System). 100419

1. Do you have a full User Requirement Specification (URS) within your LIMS service?
2. Do you have a full (requirements) traceability matrix (RTM) to drive validation for LIMS?
3. Do you have full validation evidence ready for review and fully referenced on your local QMS for LIMS?
4. Which LIMS is in use?
5. When was it last upgraded?
6. When was the URS last reviewed?
7. When did the MHRA last inspect the lab?
8. How much notice did MHRA provide before this inspection?
9. Would you benefit from a review of evidence to assess the transfusion labs “readiness for inspection”?

Download response LIMS (Laboratory Information Management System). 100419

Lord Carters Pathology Report

Following on from Lord Carters Pathology Report and in turn Efficiency report, please can you provide information on the following questions?
1. Does your pathology service currently meet the 1.6% cost of service to Trust operating expenditure target as set out by the 2016 report?
2. Do you currently have a managed service arrangement within Pathology (entire disciplines or pan pathology, not individual analysers)?
3. If yes, please can you provide the Suppliers name, expiry date, and average annual cost?
4. Are you planning on collaborating with another NHS entity to provide pathology services?

Download response Lord Carters Pathology Report 100616

Lost or stolen controlled drugs. 240419

I wanted to get a list of controlled drugs that have been reported lost/stolen from your NHS Trust in the last five years (2014, 2015, 2016, 2017, 2018)?

Please provide the answers in an excel spreadsheet or google spreadsheet with the following headings: date, whether drug was stolen/lost, whether the drug was recovered/found, the name of the controlled drug, the approximate value.

Download response Lost or stolen controlled drugs. 240419

Lymphoma Subtyping. 051017

1. Do you provide a lymphoma testing service?
2. Do you participate in an EQA program for lymphoma testing?
3. Approximately how many lymphoma cases are tested? (per month or per year, whichever is easier to determine)?
4. Approximately how many of these samples are B-cell lymphomas? (per month or per year or as a percentage of lymphoma samples above, whichever is easier to determine)?
5. Do you perform DLBCL subtyping?
6. Approximately how many samples are DLBCL positive? (per month or per year, whichever is easier to determine)?
7. Which DLBCL algorithm do you use to classify subtypes?
8. Which IHC antibodies are used for DLBCL subtyping?
9. Which IHC platform/autostainer do you use for DLBCL subtyping?
10. Is Gene Expression Profiling (GEP) used for DLBCL subtyping?
11. Approximately how many DLBCL samples are tested using GEP? (per month or per year, whichever is easier to determine)?
12. If GEP is used to test for DLBCL which platform is used in your lab?
13. What is the laboratory turnaround time for DLBCL subtyping using IHC?
14. What is the laboratory turnaround time for DLBCL subtyping using GEP?
15. Are any additional tests performed to help confirm a diagnosis of DLBCL?
16. If multiple tests are performed to confirm DLBCL, how are the reports issued?
17. Who pays for DLBCL testing?

Download response Lymphoma Subtyping. 051017

Managed Service agreements. 070318

1. Do you currently have Managed Service agreement in place, either in Cardiology, Radiology, Ultrasound or for Patient Monitoring?
2. If any such agreements are in place, who is your existing provider?
3. What is the scope of the agreement by department and by services offered?
4. When was the contract start date? When is the contract end date?
5. Have there been any measurable financial or operational benefits from the agreement and what are they?
By Managed Service we understand any contract with a private provider which:
– Spans multiple years
– Includes provision of technology and services
– Includes Service Level Agreements and KPIs
– Has an element of risk transfer for pricing and service delivery
– There is an element of performance risk transfer to the contracting party

Download response Managed Service agreements. 070318

Mass Spectrometry. 190919

1) Does your Trust routinely offer Mass Spectrometry testing for Diagnostic purposes? (please answer either yes or no to this question).

2) If you answered yes to question 1, can you please provide a list of which assays / tests are routinely run on the Mass Spectrometry system in your Trust.

3) Does your Trust send away samples (to locations outside of your trust) for Mass Spectrometry testing? (please answer either yes or no to this question).

4) If you answered yes to question 3, can you please list the assays / tests which are run on the samples you send away?

Download response Mass Spectrometry. 190919

Medical refrigeration.260219

1. How many medical fridges are used throughout the Trust for the storage of vaccines and other temperature-sensitive items?
2. Over the last 12 months approximately how much stock has the Trust had to dispose of due to refrigeration malfunctions or failures? How are staff alerted to potential problems, particularly when the fridges are unattended?
3. Please describe the process in place to log temperatures and deal with any fluctuations in temperature (on a daily basis). How are the records stored and data retrieved when required?
4. When is the Trust due to test the market regarding acquiring new, state of the art medical refrigeration units – next 6 months, next 12 months, 24 months?

Download response Medical refrigeration.260219

Medicines Formulary

Does the Trust have its own formulary? If so could you please provide me with a copy or a link to the most recent version?

Download response Medicines Formulary 280716

Medicines shortage cost. 121119

1) The total number of medicines that your trust considered to be facing a shortage throughout:
a. 2016/17
b. 2017/18
c. 2018/19 to date
2) A list of the medicines your trust considered to be in short supply for each year:
a. 2016/17
b. 2017/18
c. 2018/19 to date
3) The total amount of money your trust spent in response to these medicines shortages to find and procure alternative medicines – including the cost of “off-contract claims” from suppliers against NHS England/CMU contracts – in:
a. 2016/17
b. 2017/18
c. 2018/19 to date
4) A breakdown of what this cost includes, if it includes costs other than that of finding and procuring alternative medicines, for each year listed above.

Download response Medicines shortage cost. 121119

Micafungin (Generic) and Mycamine Vials (May 2016-April 2017). 070917

I am writing to request details of the quantity of vials prescribed for below products by your Trust.

The period for which data is being requested is May 2016 – April 2017.

Data Requested for below products:
Micafungin 50mg vials
Mycamine 50mg vials
Micafungin 100mg vials
Mycamine 100mg vials

Download response Micafungin (Generic) and Mycamine Vials (May 2016-April 2017). 070917

Microbiological techniques 281116

1. Clostridium difficile
2. Penicillin resistant Streptococcus pneumonia
3. Macrolide-resistant Group A Streptococcus
4. Clindamycin-resistant Group B Streptococcus
5. Meticillin resistant Staphylococcus aureus (MRSA
6. Vancomycin resistant / intermediate Staphyloccocus aureus
7. Glycopeptide-resistant
8. Multi-drug resistant Pseudomonas aeruginosa
9. Multi-drug resistant Acinetobacter
10. Drug resistant campylobacter
11. Fluconazole-resistant Candida albicans
12. Carbapenemase-Producing Enterobacteriaceae (CPE
13. ESBL-Producing Enterobacteriaceae
14. AmpC-Producing Enterobacteriaceae
15. Drug resistant non-typhoidal Salmonella
16. Drug resistant Salmonella typhi / paratyphi
17. Drug resistant Shigella
18. Drug resistant TB (MRDTB, XDRTB, Pan-DRTB)

Download response Microbiological techniques 281116

Missing or stolen drugs. 180319

1) In each individual calendar year: 2013, 2014, 2015, 2016 and 2017 how many incidents of missing or stolen drugs were reported to your Trust in relation to each of the individual items listed below.
Tramadol
Morphine
Diamorphine
Oxycodone
Fentanyl
Methadone
Buprenorphine

2) Where one of the following drugs was listed as being missing or stolen to your trust: tramadol, morphine, diamorphine, oxycodone, fentanyl, methadone, buprenorphine. Please provide detail of the quantity of the drug that was reported missing for each individual incident.

Download response Missing or stolen drugs. 180319

Missing or unaccounted for drugs. 301117

1/ Please state the quantity of controlled drugs that has gone missing or unaccounted for from Trust hospitals in each of the last three calendar years, 2014-15, 2015-16, 2016-17?
• Please include a breakdown of types of drugs and locations from which they have gone missing
2/ Please state the quantity of prescription drugs that has gone missing or unaccounted for from Trust hospitals in each of the last three calendar years, 2014-15, 2015-16, 2016-17?
• Please include a breakdown of types of drugs and locations from which they have gone missing
3/ Please state the monetary value of the missing or unaccounted for drugs, broken down by each of the last three calendar years 2014-15, 2015-16, 2016-17?
4/ Please state the number of cases referred to police and relevant professional regulators
5/ Please describe auditing procedures that take place relating to controlled and non-controlled medicines

Download response Missing or unaccounted for drugs. 301117

Mobility related products. 110917

Formally request a breakdown of your suppliers of mobility-related products (wheelchairs, hoists etc.), including names, goods/services supplied and funds paid out to each supplier.

Download response Mobility related products. 110917

Modalities computed radiography. 050418

This is in relation to the computed radiography portfolio within your trust.

Please answer the ‘Computed Radiography Questions FOI’ and submit the responses in the ‘Modalities Computed Radiography FOI Form’.
Download response Modalities computed radiography. 050418

Molecular pathology BRAF testing

1. Do you currently offer a clinical testing service for BRAF mutation in solid tissue, specifically melanoma? (Yes, No, currently in development)

2. Which methodology(ies) do you use for BRAF testing in melanoma? e.g. Real time PCR (QPCR), High resolution melting curve analysis (HRMCA), Sanger sequencing, Next Generation Sequencing (NGS), Pyrosequencing, Immunohistochemistry (IHC), Fluorescence In Situ Hybridisation (FISH), Other (please specify). If you use a specific kit I would be grateful if you could provide the name of the kit you use.

3. Which BRAF mutations does your methodology(ies) cover? E.g. V600E, V600K, V600D, V600R etc.

4. What is your current laboratory turnaround time for BRAF testing in melanoma?

5. What is the level of sensitivity of your BRAF methodology(ies)?

6. I understand that molecular testing in FFPE tissue can be difficult due to tissue quality and/or quantity. What would you estimate is your current failure rate for BRAF testing for melanoma?

7. Approximately how many BRAF tests for melanoma would you conduct per month or year (whichever time period is most convenient for you to estimate)?

8. Of the BRAF tests performed for melanoma, please estimate how many (or what percentage) are found to be positive for a mutation?

9. Of the positive tests, please estimate how many (or what percentage of the positives) are V600E? How many (or what percentage of the positives) are V600K? How many (or what percentage of the positives) are V600 all other mutations?

Download response Molecular pathology BRAF testing 250216

Mortuaries. 210918

1. Please can you tell me how many pathologists the trust has employed in each year for the last 6 years?

2. Also, for each year over the past 6 years please can you provide me with:
• The date a body arrived at the mortuary
• The date a post mortem was started on this body
• The date release papers were signed to allow this body to be removed from the mortuary following the completion of the post mortem

Download response Mortuaries. 210918

Mortuary numbers. 270618

1. How many deceased bodies do you have at today’s date 14.06.2018 in your mortuary?
2. In any of your hospitals of that number how many are unidentified?
3. Or identified but no one has stepped forward to arrange a funeral service?
4. Or identified or unidentified but are being stored for some other reason?
5. Please provide details of how long they have been in the mortuary and the sex male or female.

Download response Mortuary numbers. 270618

Mortuary storage

1. How many fridge spaces does the trust/council have for deceased on each site?
2. How many freezer spaces does the trust/council have for deceased on each site?
3. How many deceased are sent out to external overflow storage per year for normal refrigeration (2016, 2015 + 2014)?
4. How many deceased are sent out to external overflow storage per year for deep freeze refrigeration (2016, 2015 + 2014)?
5. How much does the trust/council pay for transfer of deceased to external overflow storage?
6. How much does the trust/council pay per day for external overflow storage of deceased per day?
7. How many deceased per year do the trust/council transfer between sites (non-coroner cases e.g. hospital post-mortems?
8. How much does the trust/council pay to transfer deceased between sites (non-coroner cases) e.g. hospital post-mortems?
9. If the hospital does not have any mortuary storage what is the procedure for dealing with deceased?

Download response Mortuary storage 060916

Mouthwash product for oral mucositis treatment or prevention. 270317

1. Please advise the estimated number of beds at your hospital(s)
2. Please advise the estimated number of patients treated annually at your hospital(s)
3. Please advise the estimated number of patients receiving chemotherapy at your hospital(s) each year
4. What is the preferred mouthwash product prescribed to patients for oral mucositis treatment or prevention?
5. What is the estimated annual spend on mouthwash?
6. What is the estimated annual number units of mouthwash prescribed?

Download response Mouthwash product for oral mucositis treatment or prevention. 270317

MRI equipment and activity 070317

Please provide the total number of, the manufacturer, the model number(s), and the emplacement type of each individual MRI scanner used in the last year by your trust.
For each of the individual MRI scanner above, in which year was it purchased (or contracted), what was the purchase method, and the scheduled replacement year.
For each of the individual MRI scanner above, please provide the maintenance provider (if applicable).
Please provide the total number of MRI scanners in your trust (static sites only, excluding any mobile scanners), as well as the total number of days during which a MRI Mobile Scanner was used / contracted in your trust annually, for the period from financial year 2005/06 until 2015/16.
Where the number of static MRI scanners changed during a financial year, please list the number of static scanners in operation on 31st March for the year in question.
Please provide the number of MRI scans/procedures performed by external providers (3rd party providers, such as Alliance Medical, InHealth, etc.) on behalf of the trust over the same period.
How much was paid per scan/procedures on average, every year over the same period? Please list by external provider name.
Please detail the normal staffed hours of operation for each individual MRI scanner. In addition, please note which (if any) of the MRI scanners is available for emergency and urgent scanner (e.g. referrals from A&E or medical assessment unit).
Please provide the number of staff employed in your Imaging Department (FTEs = Full Time Equivalent), for each site you may operate, and whether the operation of the scanner(s) and the reporting are done in-house, partly outsourced to a third party provider (supplementing in-house staff) or fully outsourced to a third party provider.
Please describe the availability of free space you currently have within the radiology / imaging sites of your trust, and whether it would be sufficient to add an additional MRI scanner (assuming an increase in demand would require one additional scanner).
Please provide the list of activities (clinical and non-clinical areas) for which your trust (partly) relies on the use of third party providers, and whether those activities have been outsourced to a third party provider outside the hospital ground or within the existing premises.

Download response MRI equipment and activity 070317

MRI scanners. 200417

1. What make/model are your existing MRI scanners?
2. When were they installed?
3. When are they due for renewal?

Download response MRI scanners. 200417

MRI scanners. 310118

For each scanner operated anywhere by your Trust
1. Manufacturer?
2. Model?
3. Software version?
4. Do your scanners have fast T1 mapping capacity?
5. Located in which hospital within Trust?
6. Acquisition year?
7. How it was financed (owned by Trust, leased or held under Managed Equipment Service (‘MES’) arrangements)?
8. If MES, which provider do you use?
9. What year will the equipment be replaced?
10. Is maintenance done by the Trust, by the Manufacturer or by 3rd party provider?
11. If 3rd party provider which provider do you use?
12. What are the operational hours of the equipment?

Download response MRI scanners. 310118

MRI scans. 090519

1. Please tell me how many patients in the trust who had an MRI scan in 2018 had waited a) six months or longer b) a year or longer?
2. Please tell me how many patients in the trust who had an MRI scan in 2017 had waited a) six months or longer b) a year or longer?
3. Please tell me how many patients in the trust who had a CT scan in 2018 had waited a) six months or longer b) a year or longer?
4. Please tell me how many patients in the trust who had a CT scan in 2017 had waited a) six months or longer b) a year or longer?
5. Please tell me how many a) MRI scanners b) CT scanners there are in the trust?
6. Please tell me the approximate age of a) the MRI scanner and b) the CT scanner?

Download response MRI scans. 090519

MRI scans. 090519

1. Please tell me how many patients in the trust who had an MRI scan in 2018 had waited a) six months or longer b) a year or longer?
2. Please tell me how many patients in the trust who had an MRI scan in 2017 had waited a) six months or longer b) a year or longer?
3. Please tell me how many patients in the trust who had a CT scan in 2018 had waited a) six months or longer b) a year or longer?
4. Please tell me how many patients in the trust who had a CT scan in 2017 had waited a) six months or longer b) a year or longer?
5. Please tell me how many a) MRI scanners b) CT scanners there are in the trust?
6. Please tell me the approximate age of a) the MRI scanner and b) the CT scanner?

Download response MRI scans. 090519

MRI scans 111116

1. What is the current waiting time (in weeks) for a routine MRI scan? What is the current trust waiting time (in weeks) targets for a routine MRI scan?

2. Does the trust hire in any private mobile MRI scanners to meet the existing workload? Or do they send any NHS patients to private centres for their scans?

Download response MRI scans 111116

MRI scans 2016. 070417

A- What is the total number of MRI scans performed by your trust between 1st Jan 2016 and 31st Dec 2016?

B- Of these scans please can I have a breakdown on how many are scans of the brain, IAMS, Cervical spine, Lumbar spine, Hip, Knee, Ankle, Foot, Shoulder, Wrist, Elbow, Hand, Thumb and Finger.

Download response MRI scans 2016. 070417

MRI scans under general anaesthetic. 070417

1. How many patients each year have required an MRI under general anaesthetic in the following years?
a. 2016/17
b. 2015/16
c. 2014/15

2. What is the total approximate cost of these scans in each of the above years?

download response MRI scans under general anaesthetic. 070417

MSK Physiotherapy Services. 170919

1: Please provide details of the number of referrals received by the Trust for patients to all MSK physiotherapy services for the following financial years: i) 2016/17, ii) 2017/18 and iii) 2018/2019
2: Please confirm or deny whether the Trust provides Musculoskeletal (MSK) services that include first contact physiotherapists in General Practice
3: Please confirm or deny whether patients can self-refer to physiotherapy services within the MSK services provided by the Trust
4: The amount of time taken between a referral (regardless of its source) to physiotherapist being made and the patient’s first appointment with the physiotherapist for both routine and urgent cases
Please provide details of the average time taken for the following financial years:
i) 2016/17 Routine: Urgent:
ii) 2017/18 Routine: Urgent:
iii) 2018/2019 Routine: Urgent:
c) If this is not available, please confirm if another entity, and if so which, holds this information for patients in the locality.
d) If this information is not held by you or another health body in your area, please confirm if referral to treatment times for physiotherapist appointments used to be recorded and if so, when did this cease to be measured?
Definitions of terms used in questions 2 and 3:
First contact physiotherapists in General Practice* = When a patient has an appointment with a physiotherapist instead of a GP at a GP practice

Patient self-referral**= Patients can refer themselves to physio without seeing a GP or having a referral from anyone else.

Download response MSK Physiotherapy Services. 170919

Multiparametric MRI. 070317

Please find attached a copy of your letter in response to a “freedom of information” request. Please can you explain the answer at point 1 in your letter which, at best seems factually incorrect and at worse, deliberately misleading.

Your letter clearly states at point 1 that the Trust does provide multi-parametric MRI scans prior to biopsies but, I have been told by the consultant at Maidstone Hospital that only larger tumours will be detected thereby. I have been advised that there are no machines suitable for mpMRI scans at either Maidstone or Tunbridge Wells hospitals.

The web-site here seems to be clearly relying on the information provided in your letter – https://public.tableau.com/profile/ali.cooper#!/vizhome/mpMRIFOIpublicdashboard-ProstateCancerUK_0/FullresultsStory as shown by the map excerpt below.

Download response Multiparametric MRI. 070317

Multiparametric MRI usage data.

1. Do you conduct multi-parametric MRI (mpMRI) scans (using T2-weighted, diffusion-weighted and dynamically enhanced sequences) before prostate biopsies?
If no, it would be helpful to know what the main reasons are:
If yes, it would be helpful if you can you provide an estimate of the percentage of men who receive an mpMRI scan before prostate biopsy:
2. How many scanners do you have available to use for mpMRI scans before prostate biopsy?
3. For each individual scanner used for mpMRI scans before prostate biopsy, please provide the following:
• Make
• Model
• Magnetic field strength
• Age
• When the scanner is due to be replaced
4. How many mpMRI scans before prostate biopsy do you estimate you carry out per year?
• 0
• Up to 50
• 50 -100
• 100 – 250
• 250 – 500
• 500 – 750
• 750 – 1000
• More than 1000
5. i. Do you intend to increase the number of mpMRI scans before prostate biopsy following the first results from the large clinical trial PROMIS?
The ASCO 2016 abstract has shown mpMRI as a triage test can identify one quarter of men (27%) who might safely avoid unnecessary biopsy, without impairing the detection of clinically significant cancer (http://abstract.asco.org/176/AbstView_17…).
5. ii If yes, do you currently have sufficient resources and capacity to cope with this increase?

Download response Multiparametric MRI usage data 270616

Multiple Sclerosis 031016

In your trust how many patients with Multiple Sclerosis have been treated with MS disease modifying drugs in the past 6 months, latest 6 months that you can provide?
Please provide the number of patients by treatment for the following disease modifying drugs.
Aubagio (Teriflunomide)
Avonex (interferon beta-1a)
Betaferon (interferon beta-1b)
Copaxone (Glatiramer acetate)
Extavia (beta interferon-1b)
Gilenya (Fingolimod)
Lemtrada (Alemtuzumab)
Rebif (beta interferon-1a)
Tecfidera (dimethyl fumarate)
Tysabri (Natalizumab)
Ampyra (Fampyra)
Peginterferon beta-1a (Plegridy)
Daclizumab (Zinbryta)
Others

Download response Multiple Sclerosis 031016

Multiple Sclerosis. 270918

1. In your trust how many patients with Multiple Sclerosis have been treated with MS disease modifying drugs in the past 6 months, latest 6 months that you can provide. Please provide the number of patients by treatment for the following disease modifying drugs.
Aubagio (teriflunomide)
Avonex (interferon beta-1a)
Betaferon (interferon beta-1b)
Cladribine (Mavenclad)
Copaxone (glatiramer acetate)
Daclizumab (Zinbryta)
Extavia (beta interferon-1b)
Gilenya (fingolimod)
Glatiramer acetate generic [eg Brabio]
Lemtrada (alemtuzumab)
Ocrevus (Ocrelizumab)
Peginterferon beta-1a (Plegridy)
Rebif (beta interferon-1a)
Tecfidera (dimethyl fumarate)
Tysabri (natalizumab)
Others
Ampyra (Fampyra)
2. For patients receiving Tysabri (natalizumab) what is the average waiting times to treatment (i.e. once diagnosed and natalizumab selected as DMT of choice, how long do patients wait for their treatment to start)?

Download response Multiple Sclerosis. 270918

Multiple Sclerosis and MRI

Number of patients with an annual review in the last 12 months and number of patients with an MRI in the last 12 months being treated with the following products:
· Tysabri
· Gilenya
· Interferon beta 1a
· Interferon beta 1b
· Copaxone
· Lemtrada
· Tecfidera
· Aubagio
· Plegridy
I would also like to request the following information on patient numbers:
· Number of new MS diagnoses
· Number of patients who have had a relapse in the above month
· Number of relapse events in the above month
I would like this information for the period March 2015 to February 2016, broken down by month

Download response Multiple Sclerosis and MRI 270516

Multiple Sclerosis patients 160916

Please see attached for form to fill in to respond to an FOI request regarding the number of patients treated in your trust for the names drugs. I am also interested in knowing the number of new MS diagnoses, MRI scans and the total catchment population of the trust.

Download response Multiple Sclerosis patients 160916

NHS Imaging Infrastructure

For each scanner operated anywhere by your Trust
Q1. Equipment type (CT or MRI)?
Q2. Manufacturer?
Q3. Model?
Q4. Located in which hospital within Trust?
Q5. Acquisition year?
Q6. How was it financed (owned by Trust, leased or held under Managed Equipment Service (‘MES’) arrangements)?
Q7. If MES, which provider do you use?
Q8. What year will the equipment be replaced?
Q9. Is maintenance done by the Trust, by the Manufacturer or by 3rd party provider?
Q10. If 3rd party provider which provider do you use?
Q11. What is the annual maintenance cost for the relevant scanner?
Q12. What are the operational hours of the equipment?

Download response NHS Imaging Infrastructure 230516

Occupational Therapists 2011-2017. 310317

1. How many occupational therapists were/are employed within your Trust in each of the following financial years, in working time equivalent format: 1) 2011/12; 2) 2012/13; 3) 2013/14; 4) 2014/15; and 5) 2016/17 budgeted?

2. What was the total amount spent on occupational therapy services within your Trust in each of the following financial years: 1) 2011/12; 2) 2012/13; 3) 2013/14; 4) 2014/15; and 5) 2016/17 budgeted?

3. Of these, how many occupational therapists were/are working on acute medical wards in each of the following financial years, in working time equivalent format: 1) 2011/12; 2) 2012/13; 3) 2013/14; 4) 2014/15; and 5) 2016/17 budgeted?

4. Of these, how many occupational therapists were/are working in Accident & Emergency departments in each of the following financial years, in working time equivalent format: 1) 2011/12; 2) 2012/13; 3) 2013/14; 4) 2014/15; and 5) 2016/17 budgeted?

Download response Occupational Therapists 2011-2017. 310317

Occupational Therapy Lead 150217

Do you have an occupational therapy lead for the Trust? If so, please provide their name, job title and contact information (including email address, postal address and contact phone number).

Download response Occupational Therapy Lead 150217

Ocriplasmin (Jetrea) treatment. 110717

We are trying to understand the cost effectiveness of Ocriplasmin (Jetrea) treatment for vitreo-macular traction.

We would like to obtain data regarding the number of injections performed, and possibly cost, of this treatment in your Trust, should you have ever provided it.

The time frame would be 01/01/2016 to 31/05/2017, if possible divided by month, otherwise just a total number will suffice.

Download response Ocriplasmin (Jetrea) treatment. 110717

Omnicell Medicine Cabinet. 270618

1. Can you please tell me if your hospital/trust uses Omnicell Medicine cabinets?
2. Have you taken disciplinary measures against any staff (or agency staff) resulting from the use, or the reports generated, of the Omnicell System.

Download response Omnicell Medicine Cabinet. 270618

Ophthalmology injectors. 020320

1. Within your trust how many trained and active staff do you have that can administer the anti-VEGF injection [Ranibizumab, Bevacizumab or Aflibercept]?
2. Within your trust how many intra-vitreal injections/implants have been used in the latest 4 months, if possible between September to December 2019
If your trust is able to identify injections/implants by eye conditions please split by the drug used [Ranibizumab, bevacizumab, Aflibercept, Fluocinolone and Dexamethasone],
If you are unable to split by condition then please just indicate the number of times a drug has been used (regardless of condition)

Download response Ophthalmology injectors. 020320

Outbreaks of resistant organisms 2012-2016. 280217

In the last five years, please list each outbreak the trust has declared due to the following organisms:
– Vancomycin-resistant enterococci
– Methicillin-Resistant Staphylococcus aureus (MRSA)
– Extended-spectrum β-lactamase (ESBLs) producing Gram-negative bacteria
-Carbapenem resistant enterobacteriaceae
-Carbapenemase producing organism
-Drug resistant Acinetobacter
-Drug resistant pseudomonas

For each case please specify
-The organism causing the outbreak (eg for carbapenemase producing organisms specify Klebsiella pneumoniae carbapenemase)
-Date the outbreak was declared and date it was declared over
-Number of confirmed cases and number of probable cases
-Description of control measures, eg whether wards were closed, patients put in isolation rooms, hydrogen peroxide vapour used to clean rooms etc. For ward closures please give details of ward type and size (eg 30-bed renal ward)
-Whether the outbreak was reported to Public Health England, and if so, the date it was reported
-Date audit report, outbreak investigation, infection control committee report (or equivalent report) was published
-Number of bed days lost
-Number of patient deaths

Download response Outbreaks of resistant organisms 2012-2016. 280217

Ozudex (Dexamethasone) Implants. 040917

In relation to Ozudex (Dexamethasone) Implants, in your response you indicate that you cannot break their use down by indication. As such I was wondering if the total used for any indication could be given instead for this implant.

Download response Ozudex (Dexamethasone) Implants. 040917

PACS and medical monitors. 301117

1. Which company is the current PACS system provider for the trust?
2. When will the current PACS contract end?
3. Roughly how many reporting workstations the X-Ray department currently have?
4. When the current medical monitors are due to refresh?
5. The contact details of the PACS manager.

Download response PACS and medical monitors. 301117

Pathology. 160818

1. Does the Pathology Laboratory in your organisation use Demand Management to manage Pathology requests?
2. If the Pathology Laboratory does not make use of Demand Management, why not?
3. If the Pathology Laboratory does make use of Demand Management, what methods do you use?
EG. Is it carried out at time of request, using a function of electronic requesting software or are unnecessary requests screened out once the sample reaches the laboratory?
4. Which Pathology disciplines use demand management the most?
5. What tests is demand management most frequently used for?
6. How many samples / requests did the Pathology Laboratory in your organisation process last year (April 17-March 18)?
7. How many samples / requests were not tested due to being screened out by using demand management techniques? How is this measured?
8. Does your organisation promote demand management to clinical staff who request pathology tests? How is it promoted?

Download response Pathology. 160818

Pathology. 300518

1. The name and email address of your Clinical Director of Pathology
2. The name and email address of your Service manager of Pathology
3. The name and email address of your Lead Pathologist

Download response Pathology. 300518

Pathology integration projects. 300518

1. Can you please tell us whether your Pathology department is currently working on any integrated care projects, such as:
a) Creating a single, integrated pathology service with partnering organisations, or;
b) Creating bi-directional interfaces between systems e.g. sharing Pathology data with A&E or GP systems
2. If you answer yes to any of the above, please can you provide the name of the contact who is leading on this project and their contact email address?
3. If you answered yes to Q1, will your Organisation be procuring for external integration services to assist with these projects?

Download response Pathology integration projects. 300518

Pathology IT systems. 260619

1. Does your Trust have a single EPR system currently in use (as of 20/06/2019)?
– If ‘Yes’, what system is this, and is there a Pathology module actively in use or does the LIMS have an automated information feed into the EPR?
– If ‘No’, are there agreed plans to begin implementation of an EPR in your Trust within the next 3 years?
2. What LIMS (Supplier/Vendor, version number) is currently (as of 20/06/2019) in-use across all disciplines managed within Pathology (such as but not limited to Microbiology, Blood Sciences, Cellular Pathology, Mortuary)?
3. When was the hardware for the server of this LIMS last refreshed?
4. When was a disaster recovery exercise of the LIMS/EPR last performed (month/year)?
5. Does your current LIMS have inbuilt business intelligence software tools, such as a SQL reporting?
– If ‘Yes’, what is this tool and is it made available Trust/network wide or access limited to dedicated Pathology users?
6. Is your Trust currently part of a Pathology network?
– If ‘Yes’, what LIMS are currently (as of 20/06/2019) in use within the networked laboratory sites? Has a formal process begun of selecting a single LIMS provider for your network? If this process has reached tender award stage / implementation, which LIMS has been chosen and what year is currently targeted for the ‘go-live’ of the system?
– If ‘No’, has a process begun of selecting a new LIMS provider for your Trust? If this process has reached tender award stage / implementation, which LIMS has been chosen and what year is currently targeted for the ‘go-live’ of the system?
7. Does your Trust use electronic requesting and reporting in secondary care?
– If ‘Yes’, what systems (as of 20/06/2019) is currently in use?
8. Does your Trust use electronic requesting and reporting in primary/tertiary care?
– If ‘Yes’, what systems (as of 20/06/2019) is currently in use?
9. Do you currently use nPex or other 3rd party software for exporting results and requests between either network partners or external reference laboratories?
– If ‘Yes’, could you provide details of which Pathology disciplines use this software, and who their primary reference / network laboratory is for this communication link.
10. Does administration of Pathology specific software (such as LIMS, document control, stock databases, middleware) lie within a dedicated Pathology IT team or a Trust-wide IT team?
11. Does administration of Pathology specific hardware lie (such as shared network storage, report printers, dedicated servers) within a dedicated Pathology IT team or a Trust-wide IT team?
12. Does your Pathology department have a formal service level agreement of equivalent with your Trust/Network IT department with stated roles and responsibilities for IT maintenance and project development?
13. If your Pathology department has a dedicated team, how many WTE are assigned to this team?

Download response Pathology IT systems. 260619

Pathology out of hours service. 011018

You asked:
1. Does the Pathology Department in the Trust offer a 24/7 service?
2. If so, in which pathology disciplines (e.g. Haematology, Blood Transfusion, Chemical Pathology, Cytology, Histology, and Microbiology)?
3. Does the Trust pay any enhancements (over and above Agenda for Changes terms and conditions) for out of hours working (5.30pm – 8.00am) in Pathology?
4. If so, in which pathology disciplines?
5. How are those enhancements structured (please specify by discipline and by grade of staff if there are differences between disciplines and grades)?
6. What is the remuneration for working out of hours in the relevant pathology disciplines (please specify by discipline if there are differences between disciplines)?

Download response Pathology out of hours service. 011018

Pathology R&R payment. 151118

You asked:
Please can you provide a summary of the number of pathology staff currently receiving the recruitment and retention payment? Please could this be categorised by their respective departments and pay bands (no personal/sensitive information required).

Download response Pathology R&R payment. 151118

Pathology Services

We are carrying out a short survey to understand the impact of Lord Carter’s reviews and the HSCA 2012 on pathology services across England and the potential role of private providers.
For pathology services, we are considering the following laboratory diagnostic specialties: Chemical pathology/Clinical biochemistry, Haematology, Medical Microbiology and Virology, Histopathology.
Under the Freedom of Information Act 2000 we seek the following information within your NHS Trust/NHS Foundation Trust:

Download response Pathology Services 040216

Pathology Services – Follow up request

6. What is your current total budget for pathology services (in GBP) including laboratory staff?
________________________________________
7. In the year 2010, what was your total budget for pathology services (in GBP) including laboratory staff?

Download response Pathology Services – Follow up request 270516

Patient group directives. 040320

1. Does your trust have any patient group directives in use?
2. Which drugs currently have active patient group directives?
3. Which healthcare professionals utilise patient group directives and for which drug?
4. Are patient group directives being audited within your trust, by who and how often?

Download response Patient group directives. 040320

PCS2 Plasma Collection System by Haemonetics.241219

Please can you tell me how many of the following device – PCS2 Plasma Collection System from a company called Haemonetics – the trust has used over the last 10 years and how many of these devices are currently in operation.

Please provide a figure for each year over the last 10 years. If possible, please also state how many patients have had this device used on them.

Download response PCS2 Plasma Collection System by Haemonetics.241219

PD-L1 testing

I would like to access information with regard to PD-L1 testing offered by your institution as detailed in the document attached; this testing will likely be performed in pathology/histopathology laboratories. If your institution does not currently offer PD-L1 testing in-house then I would please ask that the request is still sent to the relevant laboratory as there are questions included regarding whether they send samples for this testing to be conducted in other laboratories and also whether they have any plans to introduce this testing in-house in the future. If your institution does not in fact have any testing laboratories then do please let me know.

Download response PD-L1 testing 290616

PDL1 testing. 070417

1. Do you currently offer a clinical testing service for PD-L1 in non-small cell lung carcinoma (NSCLC) as off the beginning of 2017?
2. How is PD-L1 testing in NSCLC normally requested by the clinician? (please select all that apply)
3. If requested as part of a NSCLC panel of tests, how is PD-L1 testing performed in the lab
4. What sample types are processed by the lab for NSCLC testing (EGFR/ALK/PD-L1)? (please select all that apply)
5. What is the number of NSCLC samples being tested (or sent-out) are tested for:?
6. What proportion of PD-L1 NSCLC samples tested are cytology/ cytological cell block samples? (per month or per year or as a percentage of PD-L1 samples tested, whichever is easier to determine)
7. What proportion of PD-L1 NSCLC samples are NOT tested because the samples are EBUS/cytology samples? (per month or per year or as a percentage of PD-L1 samples tested, whichever is easier to determine)
8. What methods are used for PD-L1 testing in NSCLC and their associated clinical cut-off? (please select all that apply)
9. What is the clinical cut offs are used in relation to the antibodies selected above?
10. What IHC staining platform(s) are used in the laboratory that performs the PD-L1 testing e.g. Ventana, Dako, Leica, Menarini, Shandon, Labvision, etc? (If possible, please supply the model of the platform)
11. What percentage of samples tested have ≥1% PD-L1 expression?
12. What percentage of samples tested have ≥50% PD-L1 expression?
13. What is the average turnaround time from sample receipt to report being issued?
14. Are there bottlenecks that prevent this turnaround time from being quicker?
15. Who pays for DLBCL testing?

Download response PDL1 testing. 070417

PET CT services – Alliance Medical.

For the purposes of the questions below, ‘Provider’ = Alliance Medical.
In respect of each of your Trust locations, please advise as follows. For ease of completion I have provided a table to populate with your answers:-
1. Has a services agreement between the Provider and your NHS Trust been executed covering all of the services to be provided by the Trust to the Provider and/or otherwise governing the terms of the Provider’s occupation or use of the site?
2. Has a final agreement been reached and executed between the Provider and the Trust for the provision of new PET CT scanning facilities, whether by way of construction on the acute Trust site or refurbishment of existing facilities?
3. Where the Provider plans to occupy facilities constructed or refurbished since contract commencement on 1 April 2015, what is the actual or proposed term of the lease/licence permitting that occupation?
4. Does the lease contain any break clause and if so, at what periods is it exercisable?
5. Is there any residual value payment associated with the expiry or earlier termination of such lease or licence?
6. On what date are services expected to commence from purpose built new facilities at each site (as envisaged by the press release for this contract)
7. Is implementation of the PET CT service at your Trust in line with your expectations (in terms of timing, responsibilities or otherwise) of the overarching contract entered into for PET CT Services by NHS England?

Download response PET CT services – Alliance Medical 180516

Pet Therapy

1) Has the Trust ever used any form of pet therapy or animal assisted therapy in your hospitals?

2) If your Trust has used such services how have they been provided to the Trust i.e. Voluntary or funded by the Trust and has this remained the same or changed between voluntary and funded?

3) What do you estimate the cost to be to the Trust of using animal assisted therapy by year for the last 5 years (if applicable?)

4) Who is responsible within the Trust for organising Pet Therapy Services?

5) What policies and procedures have been put in place as safeguards for using animals in hospitals?

6) What qualifications / certifications does the Trust expect therapy animals to hold to guarantee patient safety?

Download response Pet Therapy 060916

PET/CT scanner and ancillary facilities.

I write to request an up to date list of contractors, subcontractors, suppliers and consultants & their telephone numbers involved with the Single storey hospital building to house PET/CT scanner and ancillary facilities.

Maidstone Hospital, Hermitage Lane, Maidstone, Kent, ME16 9QQ

Download response PET/CT scanner and ancillary facilities 010816

Pharmaceutical samples. 180319

1) Please confirm if the Institution accepts pharmaceutical samples of licensed medicines (i.e. sample packs provided free of charge)?
2) If it does, please confirm whether the Institution also accepts “cold chain” samples? If it does, is there any restriction on pack size?
3) Does the Institution have a formal policy relating to the receipt of samples in either of the above cases? If yes, please can you provide an electronic copy of this policy?
4) Excluding samples, are there any other circumstances or criteria under which the Institution would accept free of charge licensed medicines?

Download response Pharmaceutical samples. 180319

Pharmacy department 150217

1. How many permanent staff are employed by the pharmacy department?
2. How many permanent vacancies are currently open/unfilled within the pharmacy department?
3. How many agency staff/locums are currently being used across the pharmacy department?
4. How many bank temps are being used across the pharmacy department?
5. During the 2015-2016 financial year, how much did the pharmacy department spend on temporary agency staff?
6. During the 2015-2016 financial year, how much did the pharmacy department spend on temporary bank staff?
7. During the 2015-2016 financial year, how much did the pharmacy department spend on permanent finders/introduction fees through recruitment agencies
8. Does the pharmacy department utilise frameworks for temporary staffing? If so, which framework is of choice?
9. Does the pharmacy department book agency staff direct with agencies or do all bookings run through a centralised temporary staffing team?
10. Does the pharmacy department work within a master vendor agreement or managed service agreement?
11. Which agencies does the pharmacy department use for temporary/locum staff?
12. Please provide me with the following contact names within the authority:
a) The name of the senior manager (Chief Pharmacist/Director of Pharmacy) with overall responsibility for the pharmacy department.
b) The name of the head of temporary staffing.

Download response Pharmacy department 150217

Pharmacy Management and staff structure. 010318

1. Copy of pharmacy management structure
2. Total WTE of pharmacists and pharmacy technicians
3. Total WTE consultant pharmacist posts, and their areas of speciality
4. Copy of Job Description for:
a. each Consultant Pharmacist post
b. Chief Pharmacist / Director of Pharmacy Name

Download response Pharmacy Management and staff structure. 010318

Pharmacy services. 061119

1. Are the pharmacy services in-house or outsourced? (proceed to Section I if in-house and Section II if outsourced). If part of the services are in-house (tendered through the Department of Health / NHS frameworks) and part outsourced (for example for outpatients), please answer both parts.
2. Who are your suppliers for:
2.1. Clozapine (antipsychotic)
2.2. Fluoxetine (antidepressant)
2.3. Lithium carbonate (anticonvulsant)
Section I – in-house pharmacy
1. Did the trust tender through the Department of Health’s Commercial Medicines Unit (CMU)?
a. If not, tendered through CMU:
i. How did the trust / hospital tender?
ii. Who applied to fill the tender?
iii. What were the tender criteria?
iv. Why was the chosen supplier awarded the contract?
v. Is the chosen supplier the trust’s de-facto supplier?
vi. What is the annual cost of the contract?
b. If tendered through CMU:
i. How many suppliers are engaged with the hospitals to provide pharmaceuticals?
ii. On average, what discounts does the supplier offer vs. the retail price?
2. Delivery of pharmaceuticals:
a. How often do you get deliveries from pharmaceutical suppliers?
b. Is the delivery a fixed amount of each contracted drug or is it based on the hospital’s stock of the drug i.e. more frequently used drugs are delivered in larger quantities and more frequently by the supplier?
c. Is the stock of each drug monitored manually on an Excel sheet or electronically via a specialised software?
i. If monitored by specialist software, who is the provider of said software?
3. Current provider:
a. Has / have the current providers always been the suppliers of pharmaceuticals for the hospital for more than 3 years?
i. If not, who was the previous supplier?
ii. Why were the old supplier’s contract not renewed?
Section II – Outsourced pharmacy
1. Current provider:
a. Who is the current provider of your outsourced pharmacy services?
b. Are they the de-facto provider for all pharmaceutical needs? If not, could you list the other providers?
c. How did the hospital contract the current provider?
i. What is the duration of the contract?
ii. What were the key terms of the contract that the supplier had to meet?
iii. How many suppliers applied for the contract?
iv. Has / have the current providers always been the suppliers of pharmaceuticals for the hospital for more than 3 years?
1. If not, who was the previous supplier?
2. Why were the old supplier’s contract not renewed?
d. On average, what discounts does the supplier offer vs. the retail price?
e. How often do you get deliveries from pharmaceutical suppliers?
f. Is the delivery a fixed amount of each contracted drug or is it based on the hospital’s stock of the drug i.e. more frequently used drugs are delivered in larger quantities and more frequently by the supplier?
g. Is the stock of each drug monitored manually on an Excel sheet or electronically via a specialised software?
i. If monitored by specialist software, who is the provider of said software?

Download response Pharmacy services. 061119

Pharmacy staffing structure

I would like to make a freedom of information request for the following information:-

– A detailed breakdown of current locum staff at each hospital by job title in the pharmacy department (for example At —— Hospital we have – Locum pharmacists, — Locum technicians and — Locum ATOs.)

– Management structure and contact names within the pharmacy department

Download response Pharmacy staffing structure 271115

Physiotherapy appointments. 31.01.17

1 How many physiotherapy appointments are made each Year with the Hospital/Trust?
a. How many of these are postponed/re-appointed for a later date
b. How many are cancelled
c. How many are DNA
2 How much is the Trust paid for each Physiotherapy appointment by the CCG (please indicate if there are different tariffs with different CCGs)
a. For the initial appointment
b. For the follow-up appointments
c. Is the Trust paid for cancellations?
3 How many referrals are from Acute Medicine (ED/Fracture/Ortho) to the Physiotherapy department are there per Year and how many from Primary Care.
4 Does the Trust work with any none NHS rehabilitation partners?
a. Please identify which speciality for rehabilitation
b. Please indicate the organisation
5 What is the mean and modal average waiting time (in days) for a physiotherapy appointment from initial referral from an NHS service (GP/Acute/other) to receipt on initial treatment at the physiotherapy department?
a. How are changes of appointment communicated?
6 For those attending a timed/scheduled/booked appointment at the physiotherapy department
a. how many are treated at that time stated on the appointment
b. For those not treated at the booked time, what is the average waiting time discrepancy from scheduled appointment to actual appointment
c. How long is the mean and modal average scheduled appointment time (in minutes)
i. How long is the actual mean and modal appointment (in minutes)
d. How many patients’ appointments re-scheduled after turning up at the booked time, but are unable to be seen due to delays
7 Does the Trust face any penalties for cancelations/re-scheduling appointments from Government/NHS/CCG?
8 What is the Trusts official stance on referrals to Private Physiotherapy services?
9 Does the Trust offer any private/paid for physiotherapy/rehabilitation service?

Download response Physiotherapy appointments. 31.01.17

Physiotherapy Services. 280917

VACANCIES
Request 1
a) Please confirm how many whole time equivalent physiotherapist and physiotherapy support worker vacancies were held in Maidstone and Tunbridge Wells NHS Trust as at 31 March 2017.
b) Please confirm how many of the posts in Request 1a had been vacant for 3 months or more as at 31 March 2017.

POSTS
Request 2:
Please confirm how many whole time equivalent (WTE) physiotherapists and physiotherapy support workers were employed by Maidstone and Tunbridge Wells NHS Trust on the 31 March 2017. (This should include any generic assistant or technical instructor posts that support physiotherapy service provision).

PATIENT DEMAND
Request 3:
Please confirm the number of new referrals (including patient self-referral) to physiotherapy services in Maidstone and Tunbridge Wells NHS Trust, in the following financial years:
• 1 April 2016 to end of 31 March 2017
• 1 April 2015 to end of 31 March 2016
• 1 April 2014 to end of 31 March 2015

SPENDING
Request 4:
Please confirm how much was spent on physiotherapy agency/locum/temp staff in Maidstone and Tunbridge Wells NHS Trust, in the following financial years:
• 1 April 2016 to end of 31 March 2017
• 1 April 2015 to end of 31 March 2016
• 1 April 2014 to end of 31 March 2015

PRACTICE BASED LEARNING
Request 5:
Please identify the clinical areas within your physiotherapy services that provide placements for physiotherapy undergraduates in the last financial year (1 April 2016 to end of 31 March 2017).

MUSCULOSKELETAL (MSK) PATHWAY
Request 6:
a) Please confirm/deny whether Maidstone and Tunbridge Wells NHS Trust provides MSK services that include first contact physiotherapists in General Practice
b) Please confirm/deny whether patients can self-refer to physiotherapy services within the MSK services provided by Maidstone and Tunbridge Wells NHS Trust

Download response Physiotherapy Services. 280917

Pitolisant. 180319

1. Is pitolisant (Wakix) an approved therapy on the trust formulary for patients with narcolepsy?
2. If yes, has pitolisant (Wakix), been used in the last 12 months for an adult patient? If so, in how many patients has it been used?
3. Is pitolisant therapy reimbursed?
4. If yes, by whom?

Download response Pitolisant. 180319

Podiatry services 2013-2017. 200417

1. The services of how many podiatrists across all podiatry services were engaged by your trust in each of the following fiscal years 1) 2013-14; 2) 2014-15; 3) 2015-16; 4) Budgeted for 2016-17; all in (i) Working Time Equivalent and (ii) Headcount format

2. How many referrals were made from NHS services at your trust to private podiatric services in each of the following fiscal years 1) 2013-14; 2) 2014-15; 3) 2015-16; 4) Budgeted for 2016-17, and how much did these referrals cost the trust in each such year?

Download response Podiatry services 2013-2017. 200417

Policies and Procedures – Prescribed Drugs

I am writing to you to request the provision of several documents from the Trust approved document management database which relate to the main policies and procedures in place.

If at all possible, please could you provide the following documents (unique ID in brackets):

1. Critical Medicines where Timeliness of Administration is Crucial (RWF-OWP-APP299);
2. Critical Medicines Loading Doses (RWF-OWP-APP300);
3. Standard Operating Procedure for Prescribing, Preparing and Administering Injectable Medicines in Clinical Areas (RWF-OPPM-CSS2);
4. Standard Operating Procedures for the Management of Controlled Drugs in Operating Theatres (RWF-OPG-CSS4);
5. Standard Operating Procedures for the Management of Controlled Drugs in Wards and Departments (RWF-OPG-CSS5); AND
6. All of the above policies as in place on February and March 2014, if different from the above.

Download response Policies and Procedures – Prescribed Drugs 311215

Post CCT doctors in Radiology.130417

Please provide details of all the current filled training fellowship posts (or other similar training programmes for post CCT doctors) within your Radiology departments.
Please provide:
1. Start dates of current posts
2. End date of current posts
3. The sub-specialist interest under ophthalmology the training post is within (example: MSK, Breast Imaging, Paediatric Radiology…)

Download response Post CCT doctors in Radiology.130417

Post mortems. 101018

You asked:
1. What is the most amount of post mortem cases that you are willing to carry out in a single post mortem session?
2. How many hospital post mortem examinations did you undertake between 1st April 2017 – 1st April 2018?
3. How many coronial post mortem examinations did you undertaker between 1st April 2017 – 1st April 2018?
4. What is the average number of hospital post mortem examinations that you have undertaken over the past 3 financial years?
5. What is the average number of coronial post mortem examinations that you have undertaken over the past 3 financial years?
6. How many brain & spinal cord donations have you carried out over within the mortuary over the past 3 financial years?
7. How many members of staff do you employ within the mortuary? (This includes administration staff)
8. What qualifications (In relation to mortuary activity) do your employees currently hold?
9. What NHS pay bands are your employees in?
10. What is your capacity for the storage of deceased?
11. Does your mortuary charge undertakers/service users for storage of deceased? (Assuming that the deceased would remain in your care for an extended period of time once they have been released to go.)
12. Do you store deceased patients’ offsite with non NHS service users?
13. If the answer to question 11 is yes, are the premises risk assessed and do they coincide with HTA regulations?
14. Do you actively undertake increased risk post mortem work? (Blood borne)
15. Do you actively undertake increased risk post mortem work? (Air borne)

Download response Post mortems. 101018

Prescriptions issued. 140120

1. The number of prescriptions issued within the Trust, per month, for the period November 2018 – September 2019, for the following items:
a. Sativex;
b. Nabilone;
c. Epidiolex/Epydiolex;
d. Unlicensed cannabis-based products for medicinal use (CBPMs).
2. Total costs to the Trust associated with prescriptions of unlicensed cannabis-based products for medicinal use over the same time period.

Download response Prescriptions issued. 140120

Proficiency testing. 180718

Is it possible you send me your schedule or list with all PT tests opened in 2018?

Please send me your scope and certification in ISO 17043 too.

Download response Proficiency testing. 180718

Prolia Treatments. 011119

1. How many patients were started on treatment with Prolia (denosumab 60mg) in the period 1st July 2017 – 31st December 2017?
2. Of the above patients, how many were subsequently treated with Prolia (denosumab 60mg) in the period of 1st January 2018 – 30th June 2018?
3. Of these patients, how many were treated again with Prolia (denosumab 60mg) in the period 31st July 2018 – 31st December 2018?

Download response Prolia Treatments. 011119

Propofol. 130619

I would like to know the total volume of Propofol used/issued PER YEAR between 2006 and 2018 by intensive care unit (ICU) and operating theatre (OT) as shown below:
– Total (annual) volume of Propofol used/issued in ICU units PER YEAR for 2006-2018 (in millilitres or litres).
– Total (annual) volume of Propofol used/issued in OT units PER YEAR for 2006-2018 (in millilitres or litres).
If it is easier to provide another unit of measure (for example, vial), please provide details of the products (incl. pack size and mL per vial) so that I can calculate the volume in millilitres/litres.

Download response Propofol. 130619

Provision of Physiotherapy services 031016

1. The number of patients on the waiting list for an appointment with a physiotherapist at the year-end 31st March in each year between 2006 and 2016.
2. The average waiting time for a physiotherapist appointment in each financial year from 2006 to 2016.
3. Annual expenditure on physiotherapy in the trust each year from 2006 to 2016.

Download response Provision of Physiotherapy services 031016

Psoriasis. 070918

1. How many patients with plaque psoriasis in your Trust are currently being treated with unlicensed Fumaderm?
2. How many patients with plaque psoriasis in your trust are currently being treated with Skilarence?
3. Is the Trust starting patients with plaque psoriasis on Skilarence?
a. If yes to Q3, how many patients in the last 6 months?
4. Is the Trust starting patients with psoriasis on unlicensed Fumaderm?
a. If yes to Q4, how many patients in the last 6 months?
5. Does the Trust intend to review all patients with plaque psoriasis taking unlicensed Fumaderm in order to move them to a licensed formulation where appropriate?
6. Please describe the process in place to achieve Q5 and the anticipated completion date.
7. If the Trust does not intend to initiate Skilarence or review all patients with plaque psoriasis taking unlicensed Fumaderm, please provide an explanation why the Trust intends to continue with its current practice.

Download response Psoriasis. 070918

Radio Frequency Identification (RFID) technology. 111116

1. How many beds are in your trust?
2. How many Medical Devices are managed by your trust?
3. How many Clinical Technicians/Engineers are in your Trust?
4. Do you use RFID tracking technology, if yes, Please answer the below questions.
a. For what purpose do you use RFID? (i.e. Records, Patients, Medical Devices, Security etc.)
b. What were the initial setup costs of the supplier? (0-10k, 10-20k, etc.)
c. How many medical devices are tagged?
d. Do you use Passive or Active Tagging?
e. Approximately how long does it take to perform a ward audit using RFID?
f. What are the main medical device types tagged?
5. How long does it take your EBME department to perform a ward audit (for Non-RFID users)?

Download response Radio Frequency Identification (RFID) technology. 111116

Radiology. 210218

1. The name and email address of the Clinical Director responsible for Radiology
2. The name and email address of your Radiology Manager
3. The name and email address of your Imaging/Radiology Directorate Manager

Download response Radiology. 210218 

Radiology extravasation threshold rates. 100519

Do you have a threshold number and/or criteria regarding extravasations during administration of IV contract media to trigger an internal investigation?

Download response Radiology extravasation threshold rates. 100519

 

Radiopharmaceuticals. 270617

Pertains to four main radiopharmaceutical isotopes (radio-isotopes) used for PET-CT scanning:
18F-Fluorodeoxyglucose = FDG
18F-Choline = FEC for the diagnosis of prostate cancer
18F-Sodium Fluoride = NAF for the diagnosis of skeletal cancers
18F-Florbetaben = FBB for the diagnosis of Alzheimer’s
* includes academia and commercial

Question Set 1
Please provide information for the questions below
SUPPLIER INFORMATION
Who is your Radiopharmaceuticals supplier?*
Postcode of supplier
Annual order size (£/year)

Question Set 2
Please provide information for the questions below
CURRENT PURCHASED VOLUMES
18F-Fluorodeoxyglucose (FDG) (kg/month)
18F-Choline (FEC) (kg/month)
18F Florbetaben (FBB) (kg/month)
18F-Sodium Fluoride (NAF) (kg/month)
CURRENT AVERAGE PURCHASE PRICE
18F-Fluorodeoxyglucose (FDG) (kg/month)
18F-Choline (FEC) (kg/month)
18F Florbetaben (FBB) (kg/month)
18F-Sodium Fluoride (NAF) (kg/month)

Question Set 3
Please describe the procurement structure of your radiopharmaceuticals (ie, procurement buying-groups; tenders?)

Question Set 4
Please describe the tariff structure for radiopharmaceuticals (i.e., how do prices of radiopharmaceuticals change with the quantity bought?)

Question Set 5
When assessing the supply of FDG 18
What drives your choice of supplier? Please state your purchase criteria
When assessing the supply of FBB
What drives your choice of supplier? Please state your purchase criteria

Download response Radiopharmaceuticals. 270617

Rheumatoid Arthritis. 291118

You asked:
1. Within your trust how many patients do you have diagnosed with Rheumatoid Arthritis?

2. How many Rheumatoid Arthritis patients have had an IFR [Individual Funding Request] put in for them to have an advanced treatment (i.e. biologic or JAK inhibitor) in the past 12 months?

3. How many patients do you have diagnosed with moderate Rheumatoid Arthritis? [moderate is defined within the guidelines as patients with a DAS score of between 3.2 and 5.1]

4. How many moderate Rheumatoid Arthritis patients have had an IFR [Individual Funding Request] put in for them to have an advanced treatment (i.e. biologic or JAK inhibitor) in the past 12 months?

5. How many moderate Rheumatoid Arthritis patients have been granted an IFR request for an advanced treatment (i.e. biologic or JAK inhibitor) in the past 12 months?

6. If possible, please state the number of patients and the name of an advanced treatment (i.e. biologic or JAK inhibitor) provided

Download response Rheumatoid Arthritis. 291118

Ribavirin 200mg, 400mg and 600mg. 270617

I am writing to request hospital prescribing data for Ribavirin 200mg, 400mg and 600mg (Tablets and Capsules). The data is required for all generic and branded prescriptions and should have the below information:

Coverage period: January 1, 2015 to December 31, 2015
BNF Code
BNF Presentation Name
Net Ingredient Cost in £s.
Quantity Prescribed.

Download response Ribavirin 200mg, 400mg and 600mg. 270617

Rituximab. 180718

1. Do you have local clinical pathways or standard operating procedures (SOPs) for the use of MabThera? If so are you able to share these? For instance, is one cycle of MabThera intravenous (IV) always used before initiating the patients on MabThera subcutaneous (SC) in oncology indications?
2. Number of patients treated* using MabThera subcutaneous versus MabThera intravenous in oncology indications between 2016-2018, if only partial data is available please indicate the timeframe the data refers to.
3. Total number of patients treated* with MabThera (intravenous and subcutaneous) vs Rixathon vs Truxima in oncology and rheumatology indications between 2016-2018, if only partial data is available please indicate the timeframe the data refers to.
4. Do you have local clinical pathways or standard operating procedures (SOPs) for the initiation of new patient treatment regimens? If so are you able to share these?
5. Specifically, are new patients directly prescribed biosimilar rituximab (i.e. Truxima or Rixathon) instead of MabThera?
6. Are existing patients being switched from MabThera intravenous to biosimilar rituximab (i.e. Truxima or Rixathon)? If so is there a set point in their treatment pathway when patients are switched and how is this managed?
7. Are any existing patients being switched from MabThera subcutaneous to biosimilar rituximab (i.e. Truxima or Rixathon)? If so is there a set point in their treatment pathway when patients are switched and how is this managed?
8. Number of patients treated* using rituximab biosimilars (Truxima and Rixathon) instead of MabThera (intravenous and subcutaneous) between 2016-2018, if only partial data is available please indicate the timeframe the data refers to.
9. As an organisation, are you aware of any financial savings made by using biosimilar rituximab (i.e. Truxima or Rixathon) vs MabThera between 2017-2018, if only partial data is available please indicate the timeframe the data refers to and the methods used to calculate the financial savings.
10. Please provide information for the current contracts for Truxima, Rixathon, MabThera intravenous (IV) or subcutaneous (SC).
11. Related to question 10, if contracts are tiered by volume, could you please provide the thresholds for each tier and what is the price percentage difference between tiers?

Download response Rituximab. 180718

Rosuvastatin (Generic) and Crestor Tablets (April 2016 – March 2017).

I am writing to request details of the number of tablets prescribed for below products by your Trust. The period for which data is being requested is April 2016 – March 2017:
• Rosuvastatin Tablets 5mg
• Rosuvastatin Tablets 10mg
• Rosuvastatin Tablets 20mg
• Rosuvastatin Tablets 40mg
• Crestor Tablets 5mg
• Crestor Tablets 10mg
• Crestor Tablets 20mg
• Crestor Tablets 40mg

Download response Rosuvastatin (Generic) and Crestor Tablets (April 2016 – March 2017).

Scanners 150217

Question 1
How many of the following scanners do you operate in your Trust?
Question 2
For each scanner, could you please fill in the table below with the requested information?
Question 3
Have you used a mobile MRI or CT scanner in the last 12 months? If yes, approximately how many scans were undertaken on a mobile scanner in the last 12 months, and which provider was used?
Question 4
If so, what was the primary reason for using mobile services? (Please allocate an approximate % if multiple reasons)
Question 5
If a mobile scanner has been used in the last 12 months:
– What is the main reason why a new static scanner has not been installed to serve this volume? (Please allocate an approximate % if multiple reasons)
Question 6
Is your Trust planning on installing a new scanner, a new mobile scanner or adding third-party operated scanners, in the next 12 months? If so, is this as a replacement for a scanner already in your Trust?
Question 7
How much do you spend on outsourced radiology reporting, by hospital (or across Trust if not broken down at hospital level)?

Download response Scanners 150217

Secondary Care medicines. 310118

Please provide the medicine usage information according to Freedom of Information act for the below mentioned Anti Biotics during the past 5 years 2011/12, 2012/13, 2013/14, 2014/15, 2015/16.
It would be much appreciable if you can provide the pack size information of the usage if possible
1. *Cefuroxime powder for injection or infusion*
*250/750/1500 mg vials.*
2. *Ceftriaxone powder for injection or infusion 1gram and 2 gram vials.*
3. *Ceftazidime powder for injection or infusion*
*500/1000/2000 gram vials*
4. *Cefotaxime powder for injection or infusion*
5. *Meropenem powder for injection or infusion*
*500/1000 gram vials*
6. *Imipenem Cilastatin powder for injection or infusion*
*250/250 mg and 500/500 mg vials*
7. *Piperacillin Tazobactam powder for injection and infusion
4gram/500mg vials.*”

Download response Secondary Care medicines. 310118

Self-funding drug and medications 220818

Freedom of information questions (time parameters 1st January 2017 to date:
1. What is the policy of the Maidstone and Tunbridge Wells Trust in terms of supporting NHS patients who have had drug and medication recommended to them which is not funded by the NHS, and who have privately paid for the drugs. The NHS support amounting to Consultation and/or/drug administration and/or blood tests and/or aftercare by NHS staff.
2. Within the Oncology Department, how many patients who have privately paid for a drug which is not funded by the NHS are receiving support as described above by the NHS and its staff.
3. Within the Oncology Department, how many NHS second line patients who have privately paid for the drug Palbociclib, as it is not funded by the NHS are receiving support and care as outlined above.
4. How many other Departments adopt this policy of NHS support for NHS patients who have had to privately pay for their medication, as it is not funded by the NHS.
5. Does the Maidstone and Tunbridge Wells NHS Trust support any NHS patients who have had to pay privately for the drug Rituximab as it is not NHS funded?
6. In the event of a positive answer to 5. above, which department provides the support and for the treatment of which disease?

Download response Self-funding drug and medications 220818

Sepsis. 200220

1. What percentage of patients with suspected sepsis were treated with antibiotics within one hour in a) 2019 and b) 2018?
2. Please provide the above figure as a raw number – what was the total number of patients with suspected sepsis who were treated with antibiotics within one hour in a) 2019 and b) 2018?
3. What was the total number of patients with suspected sepsis who waited longer than an hour for antibiotics in a) 2019 and b) 2018?
4. If possible, please state the longest delay for a patient with suspected sepsis before receiving antibiotics in a) 2019 and b) 2018?

Download response Sepsis. 200220

Severe Asthma patients. 311017

1.) How many adult severe asthma patients have been seen via both in-patient visits and outpatient clinics in the last 3 months?
2.) How many adult severe asthma patients have you treated with a biologic in the last 3 months?
3.) Of these patients treated, can you provide which drugs they were treated with, as follows:
• Omalizumab (Xolair)
• Mepolizumab (Nucala)
• Resilizumab (Cinqaero)

Download response letter Severe Asthma patients. 311017

Smoking cessation services. 270619

1: Please confirm or deny if you are currently, or have been in any year since 2015-16, commissioned to provide stop smoking services
a. If confirm, please provide your allocated budget for a) this financial year (2019-20) and b) each of the previous years to 2015-16 that you have been commissioned to deliver the service
b. If deny, please confirm or deny if you have access to an on-site stop smoking service
2: Please confirm or deny if you have a) pharmacotherapies and b) licensed nicotine-replacement therapies on your hospital formularies
a. If confirm, please list (i) the relevant therapies included on your formularies, (ii) the first-line therapy recommended and (iii) the main form of treatment received by patients
3: Please confirm or deny if you have on-site shops selling
a) Licensed nicotine-replacement therapies,
b) Unlicensed quitting aids
c) e-cigarettes
4: Please confirm or deny if you have policies in place to implement NICE guideline PH48, Smoking: acute, maternity and mental health services, with regards to recommendations for:
a. Ensuring immediate access to stop smoking pharmacotherapies and a range of licensed nicotine-replacement therapies for patients who smoke
b. Ensuring the sale of stop smoking pharmacotherapies and licensed nicotine-replacement therapies in hospital shops
c. Ensuring care pathways deliver continuity between hospital and primary care stop smoking services (including any referral pathways)
d. Encouraging patients using unlicensed quitting aids to switch to licensed quitting aids
If confirm for any of the above, please share the current policy
5: Please provide your annual budget for stop smoking support
a) in total,
b) on stop smoking services
c) on licensed quitting aids for (i) 2015/16, (ii) 2016/17, (iii) 2017/18, (iv) 2018/19 and (v) 2019/20
6: Please confirm or deny if there are any requirements from your local CCG to ration treatment options for people who smoke; if confirm, please provide details

Download response Smoking cessation services. 270619

Sodium Chloride. 130220

1. What is your usage of sodium chloride 5% (10ml) units in the last 12 months?
2. How many units of ODM5 have you used in the last 12 months?
3. Who have been your suppliers of sodium chloride 5% (10ml) units during the past 12 months?
4. What price does your trust pay for Sodium Chloride 5% (10ml units)?

Download response Sodium Chloride. 130220

Sodium Hyaluronate eye drop.270218

1. How much did your organisation spend on Sodium Hyaluronate eye drop formulations between the period of 01/01/2017 to 31/12/2017?
2. Between the period 01/01/2017 to 31/12/2017, which brand(s) of Sodium Hyaluronate eye drop formulations did you use?
3. How many units of each brand did you use?

Download response Sodium Hyaluronate eye drop.270218

Speech therapy for patients with Parkinson’s Disease.

– How much of your budget in monetary and percentage terms is allocated to support for Parkinson’s?
– Do you provide speech therapy within your Parkinson’s services?
– If so, how much of your budget in monetary and percentage terms was allocated to speech therapy services in 2010, 2011, 2012, 2013, 2014, and 2015?
– How regularly do Parkinson’s patients have access to NHS funded speech therapy?
– How many Parkinson’s patients have you treated on average over the past five years?
– How many speech therapists do you provide funding for? Has this number increased or decreased in the past five years?

Download response Speech therapy for patients with Parkinson’s Disease 280416

Staff details and structure chart for Pharmacy department March 2016

Please provide me with:
1. The name of your Head/Director of Pharmacy (or Chief Pharmacist)
2. Structure chart of your pharmacy department
3. Total number of pharmacists, pharmacy technicians, pharmacy assistants and administrative staff in the dept.

Download response Staff details and structure chart for Pharmacy department March 2016 300316

Sterile Services. 170718

You asked:
Would your organisation be able to provide information or data for the following questions below?
• Period from 1st January 2017 – 31st December 2017, Activity for Sterile Services Department, either broken down monthly or annually, i.e. how many trays and bagged/supplementary items processed?
• Period from 1st January 2017 – 31st December 2017, Total Count of Instruments processed, i.e. total count of instruments processed in the make-up of trays or bagged/supplementary items broken down into totals either monthly or annually? For example 100 trays processed containing 25 instruments would total 2,500 instruments processed.
• Current Sterile Service Department Staffing/Personnel Organisation Structure?
• Current Sterile Services Job Titles and Pay Banding?
• Current WTE / FTE employed for each job title?
• Current Sterile Services shifts operated and staffing numbers / grades associated with each shift?

Download response Sterile Services. 170718

Sterile Services 281116

Name of your Trust
Number of hospitals you provide sterile services to
Number of instruments processed each year?
Number of trays processed each year?
What is the sterilisation cost (in £’s) per instrument? Please provide breakdown if dependent upon tray size
Which specialty has the highest instrument sterilisation requirement?
Are your sterile services, on site or off site?
Are you sterile services in house or out sourced?
What is the isolated cost of sterilising loan trays/instruments in 2015?
If in house
total annual cost 2015 excluding staff
total annual cost 2015 including staff
Number of staff?
Total number of hours over-time paid 2015?
If off site
What is the distance to the off site?
What is the carriage cost incurred? Please provide breakdown if needed.
If outsourced
What is the total annual cost to fast track instrument trays?

Download response Sterile Services 281116

Sterilisation equipment

1. Please enter the name of your Hospital or Trust
2. Does your Trust sterilize your own surgical instruments and packs?
3. How many floor & pit mounted steam sterilizers are installed in your Trust?
4. How many tabletop steam sterilizers are installed in your Trust?
5. How many ethylene oxide sterilizers are installed in your Trust?
6. How many hydrogen peroxide plasma sterilizers are installed in your Trust?
7. Do you have any other types of sterilizers? If you do, could you please indicate the type and installation number?

Download response Sterilisation equipment 270616

Sterilisation unit for sterilisation of surgical instruments and implants November 2015

1. Is the current sterilisation unit for sterilisation of surgical instruments and implants used by the trust an in-house facility or do you currently pay a privately owned sterilisation unit to sterilise the trusts surgical equipment?

2. What is the cost to the trust for sterilisation per surgical tray?

3. Is this cost dependent on number of instruments per tray and what is the costing per banding for each quantity of instruments per tray?

Download response Sterilisation unit for sterilisation of surgical instruments and implants November 2015 201115

Stockpiled any medication to prepare for a Brexit ‘no-deal’.241218

Has your NHS Foundation Trust stockpiled any medication to prepare for a Brexit ‘no-deal’?
If yes, which types of medication have been stockpiled?
If yes, how many weeks worth of medication has been stockpiled?

Download response Stockpiled any medication to prepare for a Brexit ‘no-deal’.241218

Stool antigen tests for Helicobacter pylori testing. 280819

Has your hospital performed any stool antigen tests for helicobacter pylori testing from January 1, 2018 till December 31, 2018? If the answer is ‘yes’, could you provide me the number of stool antigen tests performed during this period.

Download response Stool antigen tests for Helicobacter pylori testing. 280819

Stress echocardiograms. 291118

You asked:
1) How many Stress echocardiograms (Dobutamine or exercise) were performed in the trust in the financial year 2011-12?
2) How many Stress echocardiograms (Dobutamine or exercise) were performed in the trust in the financial year 2012-13?
3) How many Stress echocardiograms (Dobutamine or exercise) were performed in the trust in the financial year 2013-14?
4) How many Stress echocardiograms (Dobutamine or exercise) were performed in the trust in the financial year 2014-15?
5) How many Stress echocardiograms (Dobutamine or exercise) were performed in the trust in the financial year 2015-16?
6) How many Stress echocardiograms (Dobutamine or exercise)were performed in the trust in the financial year 2016-17?

Download response Stress echocardiograms. 291118

Sugammadex. 270218

• Do you buy a reversal drug in anaesthesia called Sugammadex.
• Can you advise quantities brought annually per year for the last 3 years.
• Can you advise of total spend annually per year for the last 3 years.

Download response Sugammadex. 270218 

Synacthen 250mcg-1ml. 151018

How many vials of Synacthen 250mcg/ml injection have been used in hospitals in UK?
Would you happen to have this kind of data for the Synacthen 250mcg/1ml injection for the last 5 to 10 years please?

Download response Synacthen 250mcg-1ml. 151018

Synagis. 240919

1. Please complete the number of patients treated with Synagis (palivizumab) in the grid below. Please note that the total number of patients (A to E) in each column must add to total patients in the last row in the corresponding column.
2. Please advise which OPCS codes are used within your Trust to code respiratory syncytial virus (RSV) prophylaxis treatment.
3. If your Trust does not provide RSV prophylaxis treatment and you refer your patients to another Trust, please state to which Trust(s) patients are referred.

Download response Synagis. 240919

TARGeted Intraoperative Radiotherapy

For Maidstone and Tunbridge Wells NHS Trust (and any previous iterations of it) the number of early breast cancer cases treated at the Trust with TARGeted Intraoperative Radiotherapy (also known as Intrabeam or TARGIT IORT) for each year from January 2000 to the date of this request. Please identify the number of cases in each year which were delivered as part of a clinical trial and the number which were delivered as treatment which was not part of a clinical trial.

For the Trust, the date at which the Trust or Clinical Commissioning Group purchased equipment able to deliver TARGeted Intraoperative Radiotherapy, the price paid for that equipment and the name of the organisation from whom it was purchased.

Download response TARGeted Intraoperative Radiotherapy 220216

Testing services for cancer indications and therapies.

Do you currently offer a companion diagnostic (stratified medicine) testing services for the following cancer indications and therapies? If so I would be grateful if you could please indicate which tests are offered, the charge per patient test (ideally a comment on what the overhead/kit breakdown of the test cost) and the number performed per year January-December (or month if easier – please specify in comments). The brand name of the test used or any information regarding commercial partnerships would also be appreciated to be included in the comments.

Test Types: IHC = Immunohistochemistry, FISH = Fluorescent In-Situ Hybridization, PCR = Polymerase Chain Reaction, Pyro= Pyrosequencing, NGS = Next Generation Sequencing. If the lab performs another test type or the test is linked to another oncological therapy not listed please check “Other” and include it in the comments section.

Download response Testing services for cancer indications and therapies 270616

The Patient Access Schemes Liaison Unit (PASLU). 011216

In order to assist the PASLU in finding new members, I would be extremely grateful if you could supply the contact details of your chief pharmacist or equivalent role within the trust so that the offer to join the NRG can be extended to them. More information regarding the PASLU and the NRG will then be sent to them directly.

Download response The Patient Access Schemes Liaison Unit (PASLU). 011216

The use of immunotherapy products

Please can you supply the total number of items purchased by product for immunotherapy in an allergy indication. E.g. GRAZAX 75,000 SQ-T oral lyophilisate. Please supply a full list of products used and the number of items for the last 12 months within your trust.

Download response The use of immunotherapy products 021215

Theranos’ Edison blood-testing machines 150916

I would like to know how much the trust has spent on Theranos’ Edison blood-testing machines since the beginning of 2012. I would also like to know if there were any planned investments on the products or any investigations into the results they produced.

Download response Theranos’ Edison blood-testing machines 150916

Total spend on sterilisation in 2014

What was the trusts total spend on sterilisation in 2014?

What was the trusts spend on sterilisation of Orthopaedic equipment in 2014?

How many instruments sets in 2014 had to be fast tracked, i.e. sterilized at a higher cost to be returned to theatres in a shorter time frame than usual?

How long is the current sterilization service contracted until?

How many trays in 2014 were returned to the account non-compliant? What were the reasons for the sterilised trays being classed as non-compliant?

Download response Total spend on sterilisation in 2014 130116

Trust imaging infrastructure.

Equipment type (CT or MRI):
Manufacturer:
Model:
Located in which hospital within Trust:
Acquisition year:
How it was financed (owned by Trust or leased via MES):
If MES which provider do you use:
What year will the equipment be replaced?
Is maintenance done in-house or by 3rd party provider?
If 3rd party provider which provider do you use?
What is the annual maintenance cost?
What are the operational hours of the equipment?

Download response Trust imaging infrastructure 180516

Unlicensed cannabis based medical products. 031019

1. Please list the unlicensed cannabis based medical products you have approved for prescription by consultants (on the General Medical Council’s specialist register), in your NHS Acute (Hospital) Trust’s area on an NHS prescription to their patients. (‘Unlicensed’ refers to the medicine not having received Market Approval in the UK by the Medicines and Healthcare products Regulatory Agency and it not being listed in Schedule 4 of the Misuse of Drugs Regulations 2001).
2. Please state the number of prescriptions that have been issued within your NHS Trust’s area for the following cannabis based medical products since 01/11/2018:
– Nabiximols (Sativex). Product code: PL 18024/0009.
– Cannabidiol (Epidiolex). Product code: N/A.

Download response Unlicensed cannabis based medical products. 031019

Unlicensed medicines. 270220

Please could you supply us with the following information for the period of December 2018 to December 2019 with the purchases of Unlicensed Medicines and UK bespoke special formulations by the Trust.
1. Name and pack size of medicine (generic and propitiatory name if applicable)
2. The number of packs procured broken down by month as above
3. The total cost of the 12 month period for each medicine to the Trust.
For the purchasing of Unlicensed Medicines and UK Unlicensed Specials:
Please could you advise if you plan to publish any contract, tender or Framework during 2020 and 2021?
If this is the case, please could you also advise where we should register to take part in this process?

Download response Unlicensed medicines. 270220

Urine cultures January to December 2015

• How many urine samples were tested for Culture and Sensitivity in the last full year that the Trust has records for
• How many of these samples showed signs of mixed growth

Download response Urine cultures January to December 2015 220216

Ursodeoxycholic Acid 250mg capsules. 16.10.19

1. Has the pharmacy of your hospital(s) dispensed Ursodeoxycholic Acid 250mg capsules between the following periods?
a. From September 1, 2017 till August 31, 2018
b. From September 1, 2018 till August 31, 2019
2. If the answer is ‘yes’ to request 1, could you please send me details in below requested format:
No. of Ursodeoxycholic Acid 250mg capsules dispensed by pharmacy
a. From September 1, 2017 till August 31, 2018
b. From September 1, 2018 till August 31, 2019

Download response Ursodeoxycholic Acid 250mg capsules. 16.10.19

Ursodeoxycholic Acid Capsules.201218

Information request – 1
Has the pharmacy of your hospital (since 1st Nov 2017) prescribed any Ursodeoxycholic Acid Capsules?
Information request – 2
If the answer is ‘yes’ to request 1, could you send me details of the number of capsules and brand(s) dispensed in the 12 month period (1st Nov 2017 to 31st Oct 2018).

Download response Ursodeoxycholic Acid Capsules.201218

Uveitis with a biologic treatment, including those on a Patient Access Scheme.

In your Trust please supply the number of patients currently treated for Uveitis with a biologic treatment, including those on a Patient Access Scheme.

Please state the number of Uveitis patients treated, and where possible by each biologic drug:
· Adalimumab
· Etanercept
· Infliximab
· Rituximab
· Other biologics

How many Psoriasis patients have been treated in the last 6 months with Fumaric acid esters (Fumaderm), If your trust can’t supply patients, please supply the number of packs of tabs

Download response Uveitis with a biologic treatment, including those on a Patient Access Scheme 270516

Vial sharing across the Trust. 180319

1. Please can you provide a copy of your medicines management policies for the Trust which includes the policy of sharing medicines in vials and how the policy fulfils the requirements of the Nursing & Midwifery Council (NMC) with regards to vial sharing?
2. As part of the Trust’s medicines management policy for vial-sharing. Please can you provide the names of the injectable monoclonal antibody medicines which are being vial shared?
3. Can you please provide the reasons for vial sharing, for each of the medicines you have listed in Q2, i.e. gain share, cost savings etc?
4. If gain share is one of the reasons in Q3, please provide the details relating to the gain share for each medicine you have listed in Q2.
5. If a cost saving is one of the reasons given in Q3 then please clarify what these cost savings are and the recipient of the cost saving.
6. For each of the medicines you have outlined in Q2, please list the medicines that are vial shared and prepared in Aseptic Units under a sterile laboratory environment fulfilling the requirements of NHS Quality Control North West?
7. Which hospitals in the Trust are vial sharing in this way.
8. What were the individual annual Service costs associated with preparing the medicines you have identified in Q2 via Aseptic preparation & were internal departments recharged these amounts? Please provide a list of the hospitals and departments that were recharged.
9. For the medicines you have identified in Q6 prepared in Aseptic Units, please provide the Service costs for aseptic unit preparation for the following financial years: 15/16, 16/17 and current financial year 17/18, per hospital within the Trust.
10. How do the drug acquisition costs of each of the medicines being prepared in Aseptic Units listed in Q6 compare to the Service Costs relating to Aseptic preparations for each of these medicines
11. Of the medicines you have outlined in Q2 including those which you may not have mentioned so far, which monoclonal antibodies are being administered to patients via vial sharing practices not prepared in Aseptic Unit sterile conditions?
12. If vial sharing practice is taking place outside Aseptic Unit conditions, please can you provide reasons as to why this practice is taking place?
Patient Safety
13. According to the Centre for Disease Control and Prevention (CDCP):
https://www.cdc.gov/injectionsafety/cdcposition-singleusevial.html
Protect Patients Against Preventable Harm from Improper Use of Single–Dose/Single–Use Vials
It states that medications labelled as “single-dose” or “single-use” should be used for only one Patient
14. Please provide a list which of the medicines that are being vial shared not using Aseptic Lab conditions which include within their Summary of Product Characteristics (SPC), the following:
· That the solution for injection does not contain a preservative and
· Is for single use and should be administered immediately after drawing the dose into the syringe
15. For medicines you have listed in Q14, can you explain why the recommendations of the CDCP and the SPC are not adhered to or implemented and thus patient safety is being compromised.
16. For those medicines you have identified in Q14, which types of health care professionals (HCPs) are administering the medicines to patients?
17. How does the Trust communicate with these HCPs the recommendations of the CDCP regarding medicines labelled for ‘single-dose’ or ‘single use?’
18. Please provide a copy of this communication
19. What is the Trust’s Vial sharing policy for medicines labelled for ‘single-dose’ or ‘single use’ and those medicines that don’t contain a preservative.

Download response Vial sharing across the Trust. 180319

Vials/Implants for Wet Age Related Macular Degeneration (wAMD)

Within your organisation how many intra-vitreal vials/implants have been used in the latest 4 months, if possible between September and December 2015?

Please state the number of vials dispensed from your pharmacy in this period, if the number for wet AMD is not known, then regardless of reason for use.

Avastin (bevacizumab) Injections Eylea (aflibercept) Injections Illuvien (Fluocinolone) Implants Lucentis (ranibizumab) Injections Ozurdex (Dexamethasone) Implants
Total Vials/Implants
Vials/Implants for Wet Age Related Macular Degeneration (wAMD)

Download response Vials/Implants for Wet Age Related Macular Degeneration (wAMD) 030216

Viscosupplementation. 210318

1. Does your organisation use/perform Viscosupplementation injections?
2. If so, how much did your organisation spend on Viscosupplementation injections between the period of 01/01/2017 to 31/12/2017?
3. If your organisation used Viscosupplementation between the period 01/01/2017 to 31/12/2017, which brand(s) Viscosupplement did you use?

Download response Viscosupplementation. 210318

Viscosupplementation injections. 181019

1. Does your organisation use/perform Viscosupplementation injections?
2. If so, how much did your organisation spend on Viscosupplementation injections between the period of 01/01/2018 to 31/12/2018?
3. If your organisation used Viscosupplementation between the period 01/01/2018 to 31/12/2018, which brand(s) Viscosupplement did you use?
To make your research easier, I have listed all commonly used Viscosupplements that you can cross reference:
· Arthrum H
· Orthovisc
· Crespine Gel
· Durolane
· Euflexxa
· Fermathron
· Ostenil
· Ostenil Plus
· RenehaVis
· Suplasyn
· Synocrom
· Synocrom Mini
· Synolis
· Monovisc
· Synopsis
· Synvisc (Hylan GF-20)
· Synvisc One (Hylan GF-20)
4. How many units of each brand of Viscosupplement injections did you use?

Download response Viscosupplementation injections. 181019

Viscosupplementation Injections 2015 – 2017.

1) Does your organisation use/perform Viscosupplementation injections?

2) How much has your organisation spent in the financial year 2015/16 and 2016/17, on Viscosupplementation?

3) Which (brands) Viscosupplements have been use in the financial year 2016/17?

Download response Viscosupplementation Injections 2015 – 2017.

Viscosupplementation injections. 240717

1. Does your organisation use/perform Viscosupplementation injections?
2. If so, how much did your organisation spend on Viscosupplementation injections between the period of 01/01/2016 to 31/12/2016?
3. If your organisation used Viscosupplementation between the period 01/01/2016 to 31/12/2016, which brand(s) Viscosupplement did you use?

Download response Viscosupplementation injections. 240717

Vivomixx Sachets 2015. 300617

Can you please provide me with the usage statistics (number of sachets prescribed) of Vivomixx during the period January 2015 – December 2015.

Download response Vivomixx Sachets 2015. 300617

Walking frames. 090418

1. In the last 5 years, how many walking frames (including zimmer frames, wheeled walkers, rollators and pick-up walkers) and how many walking sticks have been issued to patients by your Trust? Please include separate numbers for each category of walking aid.
2. What was the total spend by your Trust on the above for each of the last 5 years? (If possible, please break this down by year and item type).
3. How many of the above have been returned to your Trust by patients over the last 5 years? (if possible, please break this down by year and item type).
4. Of those returned how many were deemed fit for re-use and how many were classed as unfit for re-issue?

Download response  Walking frames. 090418

X-ray equipment. 301117

1. Please can you provide the following information for each piece of mobile X-ray equipment within the Trust or associated sites? (Please complete the attached spreadsheet)
a. Manufacturer
b. Model
c. Location – Hospital Name or Site Name
d. Department equipment is primarily used in
e. Method of Finance at Procurement (Trust/Lease/MES/Charity/PFI)
f. Initial cost of Equipment
g. Annual Maintenance cost
h. Acquisition Date
i. Planned Replacement Date

2. Please can you provide the following information for each X-ray room within the Trust or associated sites? (Please complete the attached spreadsheet)
a. Manufacturer
b. Model
c. Location – Hospital Name or Site Name
d. Department equipment is primarily used in
e. Method of Finance at Procurement (Trust/Lease/MES/Charity/PFI)
f. Initial cost of Equipment
g. Annual Maintenance cost
h. Acquisition Date
i. Planned Replacement Date

Download response X-ray equipment. 301117

Zoledronic Acid. 291118

You asked:
Question 1
What is the OPCS code in your Trust for the delivery of Zoledronic acid 5 mg for the treatment of osteoporosis in post-menopausal women and adult men at increased risk of fracture?
Question 2
What is the corresponding HRG code that would relate to the OPCS code from Information request 1 for the outpatient delivery of Zoledronic acid 5 mg for the treatment of osteoporosis in post-menopausal women and adult men at increased risk of fracture in your Trust?
Question 3
What is the OPCS code in your Trust for the delivery of Zoledronic acid 4 mg for the prevention of skeletal related events in adult patients with advanced malignancies involving bone or tumour-induced hypercalcaemia?
Question 4
What is the corresponding HRG code that would relate to the OPCS code from Information request 3 for the outpatient delivery of Zoledronic acid 4 mg for patients with advanced malignancies involving bone in your Trust?

Download response Zoledronic Acid. 291118

 

Emergency and Medical Services

Pain relief prescriptions 031016

For each of the questions, please can you provide answers for each of the financial years 2013/14, 2014/15 and 2015/16:

1. PARACETAMOL

a. Which suppliers did you buy paracetamol from?
b. How many packets of paracetamol did you buy from each supplier? Please disclose how many tablets were in the packets.
c. How many packets of paracetamol did you buy in total? Please disclose how many tablets were in the packets.
d. How much did you pay each supplier for paracetamol?
e. How much did you spend on paracetamol in total?
f. How many prescriptions in total did you make for paracetamol?
g. How many of these prescriptions were free for the patient?
h. How much money were you paid by patients for paracetamol?

2. IBRUPROFEN

a. Which suppliers did you buy ibuprofen from?
b. How many packets of ibuprofen did you buy from each supplier? Please disclose how many tablets were in the packets.
c. How many packets of ibuprofen did you buy in total? Please disclose how many tablets were in the packets.
d. How much did you pay each supplier for ibuprofen?
e. How much did you spend on ibuprofen in total?
f. How many prescriptions in total did you make for ibuprofen?
g. How many of these prescriptions were free for the patient?
h. How much money were you paid by patients for ibuprofen?

3. ASPIRIN

a. Which suppliers did you buy aspirin from?
b. How many packets of aspirin did you buy from each supplier? Please disclose how many tablets were in the packets.
c. How many packets of aspirin did you buy in total? Please disclose how many tablets were in the packets.
d. How much did you pay each supplier for aspirin?
e. How much did you spend on aspirin in total?
f. How many prescriptions in total did you make for aspirin?
g. How many of these prescriptions were free for the patient?
h. How much money were you paid by patients for aspirin?

4. CODEINE PHOSPHATE

a. Which suppliers did you buy codeine phosphate from?
b. How many packets of codeine phosphate did you buy from each supplier? Please disclose how many tablets were in the packets.
c. How many packets of codeine phosphate did you buy in total? Please disclose how many tablets were in the packets.
d. How much did you pay each supplier for codeine phosphate?
e. How much did you spend on codeine phosphate in total?
f. How many prescriptions in total did you make for codeine phosphate?
g. How many of these prescriptions were free for the patient?
h. How much money were you paid by patients for codeine phosphate?

Download response Pain relief prescriptions 031016

Abdominal aortic aneurysms. 160518

Are you able to provide me with a copy of the protocols the Trust use in terms of monitoring Abdominal Aortic Aneurysms (AAAs)?

Download response Abdominal aortic aneurysms. 160518

Acanthamoeba Keratitis (AK).241218

How many cases of acanthamoeba keratitis (AK) have been diagnosed within your trust over the past five years?

Download response Acanthamoeba Keratitis (AK).241218

Accident and Emergency Quality Indicators.

The indicators published by HSCIC’s report include:
Left department before being seen for treatment (Data quality)
– Total number of attendances in A&E HES (excluding planned follow-up attendances and attendances where the attendance category was unknown)
– Attendances with an unknown attendance disposal category
– % of attendances with unknown attendance disposal categories
– % of attendances with an attendance disposal category of “Other”
Left department before being seen for treatment (Performance)
– Total number of attendances in A&E HES (excluding planned follow-up attendances, attendances where the attendance category was unknown, and attendances where the attendance disposal category was unknown)
– Number of attendances with an attendance disposal of “Left Department before being seen for treatment”
– Left department before being seen for treatment
Re-attendance (Data quality)
– Total number of applicable attendances for this indicator (1st A&E attendance, unplanned follow up attendance and unknown attendance)
– Attendances with unknown attendance category
– % of attendances with an unknown attendance category
Re-attendance (Performance)
– Total number of attendances in A&E HES (excluding planned follow-up attendances and attendances where the attendance category was unknown)
– Number of re-attendances within 7 days of a previous attendance at A&E
– Re-attendance rate
Time to initial assessment [emergency ambulance cases only] (Data quality)
– Total number of attendances in A&E HES that were brought in by ambulance (excluding planned follow-up attendances and attendances where the attendance category was unknown)
– Attendances with an unknown duration to initial assessment
– % of attendances with unknown duration to assessment times
Time to initial assessment [emergency ambulance cases only] (Performance; minutes)
– Median
– 95th Percentile
– Longest wait
Time to Treatment (Data quality)
– Total number of attendances in A&E HES (excluding planned follow-up attendances, attendances where the attendance category was unknown, and attendances where the attendance disposal category was: Left Before Treatment, Left Refusing Treatment, or Unknown)”
– Attendances with unknown duration to treatment
– % of attendances with unknown duration to treatment times
Time to Treatment (Performance; minutes)
– Median
– 95th Percentile
– Longest wait
Total Time in A&E (minutes) [Admitted patients only]
– Median
– 95th Percentile
– Longest wait
Total Time in A&E (minutes) [Non-admitted patients only]
– Median
– 95th Percentile
– Longest wait
Total Time in A&E (Data quality) [All patients]
– Total number of attendances in A&E HES (excluding planned follow-up attendances and attendances where the attendance category was unknown)
– Attendances with unknown duration to departure
– % of attendances with unknown duration to departure times
Total Time in A&E (Performance; minutes) [All patients]
– Median
– 95th Percentile
– Longest wait

Download response Accident and Emergency Quality Indicators 290616

Accidents in the home. 071217

1. A: How many people have died in the past year (Oct 2016 – Oct 2017) due to an accident in the home?”
1. B: How many children aged 0-18 have died in the past year (Oct 2016 – Oct 2017) due to an accident in the home?”
1. C: How many people aged 65+ have died in the past year (Oct 2016 – Oct 2017) due to an accident in the home?”
2. A: How many people have attended A&E in the past year (Oct 2016 – Oct 2017) due to an accident in the home?”
2. B: How many children aged 0-18 have attended A&E in the past year (Oct 2016 – Oct 2017) due to an accident in the home?”
2. C: How many people aged 65+ have attended A&E in the past year (Oct 2016 – Oct 2017) due to an accident in the home?”
3. A: How many people have been treated in A&E in the past year (Oct 2016 – Oct 2017) due to an accident in the home?”
3. B: How many children aged 0-18 have been treated in A&E in the past year (Oct 2016 – Oct 2017) due to an accident in the home?”
3. C: How many people over 65 years have been treated in A&E in the past year (Oct 2016 – Oct 2017) due to an accident in the home?”
4. A: How many people have been treated in A&E in the past year (Oct 2016 – Oct 2017) due to leisure activities?”
4. B: How many people have been treated in A&E in the past year (Oct 2016 – Oct 2017) due to an accident in education settings?”
4. C: How many people have been treated in A&E in the past year (Oct 2016 – Oct 2017) due to an accident on the road?”
4. D: How many people have been treated in A&E in the past year (Oct 2016 – Oct 2017) due to an accident at work?”
5. A: How many people have been treated in A&E in the past year (Oct 2016 – Oct 2017) due to a fall in the home?”
5. B: How many adults over 65 have attended A&E in the past year (Oct 2016 – Oct 2017) due to a fall in the home?”
5. C: How many people have died in the past year (Oct 2016 – Oct 2017) due to a fall in the home? ”
6. A: How many cases have attended A&E in the past year (Oct 2016 – Oct 2017) with suspected carbon monoxide poisoning?”
6. B: How many cases of carbon monoxide poisoning have been treated in A&E the past year (Oct 2016 – Oct 2017)?”
6. C: How many cases have been admitted from A&E in the past year (Oct 2016 – Oct 2017) for carbon monoxide poisoning treatment?”
6. D: How many people have died in the past year (Oct 2016 – Oct 2017) due to carbon monoxide poisoning?”
7. A: How many cases of asthma have been treated in A&E the past year (Oct 2016 – Oct 2017)?”
7. B: How many cases have been admitted from A&E in the past year (Oct 2016 – Oct 2017) for asthma? ”
7. C: How many people have died in the past year (Oct 2016 – Oct 2017) due to asthma?”
8. A: How many people have been treated in A&E in the past year (Oct 2016 – Oct 2017) due to an electrical accident in the home?”
9. A: How many people have been treated in A&E in the past year (Oct 2016 – Oct 2017) due to a burn or scalding accident in the home?
10. A: How many people have been treated in A&E in the past year (Oct 2016 – Oct 2017) due to an injury caused while gardening?
10. B: How many people have been treated in A&E in the past year (Oct 2016 – Oct 2017) due to an accident with the lawn mower?
10. C: How many people have been treated in A&E in the past year (Oct 2016 – Oct 2017) due to an injury caused by a BBQ?

Download response Accidents in the home. 071217

Acopia and-or social admission or ICD 10 code z73. 250417

With regard to A&E statistics pertaining to presenting complaints can you please provide the number of times ‘acopia’ and/or ‘social admission’ or ICD 10 code z73 were recorded as causes for
a. Admission
b. Noted in the discharge summary
c. Recorded as a diagnosis for the periods of
January 2017- March 2017
2016
2015

Download response Acopia and-or social admission or ICD 10 code z73. 250417

Acute Myocardial Infarction (AMI).

Which test(s) does the Trust use to diagnose patients who present with suspected acute myocardial infarction (AMI)? Please give details of tests used – including the brand and name of the test(s).

What, if any, guidelines or protocols does the Trust follow to support the diagnosis of suspected AMI? Please give details.

Does your Trust use early rule-out protocols to diagnose AMI? If so, please give details.

What is the average waiting time for a diagnosis following a suspected AMI at the Trust?

What is the target turn-around-time for tests used in the diagnosis of AMI in the Trust? What percentage of tests are performed within this target turn-around-time?

How long has the Trust and/or hospitals within the Trust been using their current troponin test(s)?

Download response Acute Myocardial Infarction (AMI) 211215 (AMI)

Admissions and Discharge policies and Venous Thromboembolism (VTE) policy.

Under the Freedom of Information Act, please may you send me a copy of your Admissions Policy and Discharge Policy?

If held, please may you send me your policy on preventing and treating venous thromboembolism (VTE’s).

Download response Admissions and Discharge policies and Venous Thromboembolism (VTE) policy 010216

Admissions of patients over the age of 65. 020518

1. How many people in the following categories had a fall as their primary reason for emergency admission in 2011/2012, 2015/2016, 2016/2017?
People over 65:
People over 65 and with dementia:
2. How many people in the following categories had a urinary tract infection as their primary reason for emergency admission in 2011/2012, 2015/2016 and 2016/2017?
People over 65:
People over 65 and with dementia:
3. How many people in the following categories had delirium as their primary reason for emergency admission in 2011/2012, 2015/2016 and 2016/2017?
People over 65:
People over 65 and with dementia:
4. How many people in the following categories had dehydration or gastroenteritis as their primary reason for emergency admission in 2011/2012, 2015/2016 and 2016/2017?
People over 65:
People over 65 and with dementia:
5. How many people in the following categories had a chest infection or pneumonia as their primary reason for emergency admission in 2011/2012, 2015/2016 and 2016/2017?
People over 65:
People over 65 and with dementia:

Download response Admissions of patients over the age of 65. 020518

Admissions via A&E. 210218

1. How many patients visiting A&E each week who required admission were admitted within four hours? Please also provide the total number of patients attending A&E, for context.
2. What percentage of patients who required admission were admitted within four hours?
3. What was the average (mean) length of time between arrival and admission for patients who required admission each week?
4. How many patients who required admission were in A&E for more than 12 hours? Please note, I would like the number of patients who were in the department for more than 12 hours from the time they arrived, not those who waited more than 12 hours from decision to admit to admission.
5. Each week, what was the longest amount of time a patient spent in A&E between arrival and admission? I would like to know their age and sex.
6. I would appreciate it if you could provide the same information for the financial year 2016/17, 2015/16 and so on, back as far as records allow.

Download response Admissions via A&E. 210218

A&E admissions on 8 and 9 December 2016. 080517

How many admissions happened on 8 and 9 December and at what times and how many cubicles are available in A&E.

Download response A&E admissions on 8 and 9 December 2016. 080517 

A&E admissions for people in the last year of life. 270618

1. During the financial year 2016/2017 or last full year figures, what:
a. Was the total number of emergency admissions for people in the last year of life?
b. Was the total number of emergency bed days for people in the last year of life?
2. During the financial year 2016/2017 or last full year figures, what was the total number of people in the last year of life admitted from a care home setting as an emergency?

Download response  A&E admissions for people in the last year of life. 270618

A&E agency staff 2016. 290317

1. The amount spent on employing agency/temporary/locum doctors in A&E departments in each month in 2016.
2. The number of FTE roles covered by agency/temporary/locum doctors in each month in 2016
3. The total number of FTE doctors working in the A&E department in each month in 2016.

Download response A&E agency staff 2016. 290317

A&E attendances for assault in 2016. 091216

The data we require are as follows (for period 1st January 2016 and 31st December 2016) in an electronic format that allows us to read the data into a database. Many hospitals respond to our survey and provide data in the form we require. Preferably this format is in an excel file or comma separated text file.

We require the gender of the patient (M or F), the date that they attended due to assault (dd/mm/yyyy) and their age. Age can either be numerical to the nearest year (preferred) or in age bands (“0-10”, “11-17”, “18-30”, “31-50”, “51+”), we can also accept date of birth.

To calculate the level of assault-related injury in England and Wales we also require the total number of attendances for any reason in the year of interest, i.e. 2016.

Download response A&E attendances for assault in 2016. 091216

A&E attendances for assault in 2015.

The data we require are as follows (for period 1st January 2015 and 31st December 2015)

ED attendance date
Age or date of birth
Gender
Reason for ED attendance

We also require the total ED attendances for 2015.

Download response A&E attendances for assault in 2015 080216  

A&E attendances with mental health issues. 070120

1. For each financial year in the period 2014-15 to 2018-19, please provide figures for:
a. The number of adults (aged 18 and over) attending your A&E department for mental health related issues.
Please breakdown the above figure according to:
i.) How many were treated/seen by a doctor within 4 hours;
ii.) How many waited longer than 4 hours to be treated.
b. For the people in (a.ii.), please provide a breakdown for how long those people were waiting by hour e.g. five hours, six hours etc.
2. Please detail the longest period of time an adult attending your A&E department for mental health related issues waited to be treated/seen by a doctor in
a. Each individual financial year from 2014-15 to 2018-19 inclusive;
b. 2019-2020 to date.

Download response A&E attendances with mental health issues. 070120

A&E attendees with no fixed abode 220818

1. The number of patients presenting at your A&E/urgent care centres whose address is recorded as no fixed abode or any other similar indicator the trust uses to categorise those who do not have a fixed address/are homeless.
2. The number of patients admitted into your hospital/s whose address is recorded as above.

Please provide these figures for each financial year from 2010/11 to the 2017-18.

Download response A&E attendees with no fixed abode 220818

A&E beds and upfront charging. 250417

Accident and Emergency

1. As of April 2010, the total number of Accident and Emergency beds within the Trust (including predecessor Trusts)
2. As of March 2011, the total number of Accident and Emergency beds within the Trust (including predecessor Trusts)
3. As of April 2017, the total number of Accident and Emergency beds within the Trust
Please split the figures for questions 1-3 into overnight beds and day-only beds. This request includes beds that were temporarily unavailable.
4. Please list any Accident and Emergency wards or units that have been permanently closed since April 2010. Please state how many A&E beds they included at point of closure.
5. Please provide the business case or management report/review underpinning each closure listed in response to question 4
6. Please list any Accident and Emergency wards or units that have been permanently opened since April 2010. Please state how many A&E beds they include.

In this request, Accident and Emergency beds, wards and units are those whose primary usage is for Accident and Emergency cases.

Upfront charging of non-residents

7. What is the Trust’s policy on treating overseas patients who are eligible to be charged upfront for care but are not able or willing to pay upfront?
8. What is the Trust’s policy on upfront charging for overseas patients where it is not possible to establish the cost of care upfront?
9. What is the Trust’s policy towards clinical staff who refuse to enforce upfront payment?
10. What is the Trust’s policy on identifying which patients need to be asked for proof of residency in relation to upfront charging, and what form does that proof take?

Download response A&E beds and upfront charging. 250417

A&E by people suffering with mental health related issues 2012-2016. 091216

How many attendances have there been at A&E by people suffering with mental health related issues (for example, categories including, psychiatric conditions, social problems, self-harm) over the last five calendar years (2012/2013/2014/2015/ January 1st – September 30th 2016)?

Please give the breakdown for under 18s and over 18s attendances (and if possible a further breakdown of ages for under 18s).

If possible, for each year, please state how many people waited longer than the four hour waiting target?

If the trust is in charge of more than one hospital, please give separate information per hospital please.

Download response A&E by people suffering with mental health related issues 2012-2016. 091216

A&E Department.241218

I would like to request the following information under the Freedom of Information Act.
In the week starting at 00.1am Sunday 7 August through to 11.59pm Saturday 13 August for how many hours was the most senior doctor present in your A&E department
*a consultant;
*a specialty registrar or other middle grade (please specify job title);
*a foundation year one or two doctor;
*a GP; or
*no doctor present.

Download response A&E Department.241218

A&E repeat attendees. 071217

For each of the following financial years – how many patients turned up repeatedly in A&E 2015-16, 2016-17 and 2017-18 to date?

1. How many patients turned up more than 10 times within a year?
2. How many patients turned up 20 times within a year?
3. How many patients turned up 50 times within a year?
4. How many patients turned up more than 100 times within a year?
5. What was the most number of occasions that a patient turned up within a year?

Download response A&E repeat attendees. 071217

A&E staffing. 080519

1. The amount spent on employing agency, temporary and/or locum doctors in A&E departments in each month in 2017 and 2018
2. The number of FTE roles in A&E departments covered by agency, temporary and/or locum doctors in each month in 2017 and 2018
3. The total number of FTE doctors (including agency, temporary and/or locum and permanent staff) working in A&E departments in each month in 2017 and 2018

Download response A&E staffing. 080519

A&E statistics

1. How many minors/see & treat patients are seen in the A&E per day? If no statistics available please provide an approximate amount estimated by the Clinical Lead of the department.
2. How many haematology blood test requests are sent from the A&E?
3. How many patients arrive to the A&E by ambulance?
4. How many ENPs/ANPs does the A&E employ?
5. Is the A&E paid by the CCG per patient according to the national tariff for type 1 A&Es? Are there any modifications to the tariff?
6. How big is the activity with regards to particular HRG codes in minors area? For example how many patients with VB08Z code are seen annually? Please provide figures for all A&E HRG codes.

Download response A&E statistics 010816

A&E Urgent Care and Technology. 200917

1. TOTAL Number of Attenders to A&E for the year 2015/2016
a. Of these attenders – how may attended Majors?
b. Of these attenders – how many attended Minors?
c. Of these attenders – how many attended Children’s Paed A&E?
d. Of the TOTAL attenders, how may were conveyed by ambulance?
e. Of the TOTAL attenders, how many self-presented (made their own way to A&E)
f. Of the TOTAL attenders, how many were discharged with advice only/self-discharged without being seen (metrics can be added together)
g. How many 12 hour breaches did you have?
h. How many 4 hour breaches did you have?
i. What was the primary cause of the breaches?
2. TOTAL Number of Attenders to A&E for the year 2016/2017
a. Of these attenders – how may attended Majors?
b. Of these attenders – how many attended Minors?
c. Of these attenders – how many attended Children’s Paed A&E?
d. Of the TOTAL attenders, how may were conveyed by ambulance?
e. Of the TOTAL attenders, how many self-presented (made their own way to A&E)
f. Of the TOTAL attenders, how many were discharged with advice only/self-discharged without being seen (metrics can be added together)
g. How many 12 hour breaches did you have?
h. How many 4 hour breaches did you have?
i. What was the primary cause of the breaches? Was this reason different from 2015/16?
3. TOTAL Number of Attenders to A&E for year 2017/18 – to-date
4. Please describe how your patients are triaged, what is their typical journey? Is there a streaming model? If yes, how effective is it and who streams e.g. GP or Nurse?
5. What would you like to see implemented in your health economy to deter avoidable admissions? I.e. those who have attended A&E but could have been seen and treated in a walk-in centre/MIU, Pharmacy or GP etc.
6. Do you have Self Check-in Kiosks in your A&E area?
7. Do you have publicly available WiFi in your A&E waiting areas?
a. What is the bandwidth?
b. If you don’t have publicly available WiFi in your A&E waiting area, is there a plan to install this? If yes, when? Is it on trajectory for delivery and what is the planned bandwidth? Please comment
8. Do you think technology has a role to play in preventing avoidable admissions?
If yes, please comment on what the value of technology would be.

Download response A&E Urgent Care and Technology. 200917

A&E visits by postcode. 040118

You asked for a breakdown of the 10 most and 10 fewest A&E visits by postcode and hospital in 2017.

Download response A&E visits by postcode. 040118

A&E wait times. 270317

1. What was the date the live A&E wait time information went live on the trust website?
2. For the year before the live A&E wait time information was live on the trust website how many ambulance diverts were requested?
3. For the year before the live A&E wait time information was live on the trust website how many ambulance diverts were granted?
4. For the year after the live A&E wait time information was live on the trust website how many ambulance diverts were requested?
5. For the year after the live A&E wait time information was live on the trust website how many ambulance diverts were granted?
6. How many occasions has the hospital breached 12 hour trolley waiting times, in the last calendar year, for patients that require a inpatient bed.
7. What specialism (directorate/division) were patients who required a inpatient bed if they breached 12 hour trolley waiting times within the last year. Example medical/surgical/ maternity etc. To clarify 12 hour breach time refers specifically to 12 hour trolley wait decision to admit to admission.
8. How many outlying patients were placed in areas due to lack of available beds in the correct specialty/area for the year before the live A&E wait time information was live on the trust website. An example of a outlier is a patient requiring a medical bed being placed in another specialist area such as surgery due to no available medical beds.
9. How many outlying patients were placed in areas due to lack of available beds in the correct specialty/area for the year After the live A&E wait time information was live on the trust website. An example of a outlier is a patient requiring a medical bed being placed in another specialist area such as surgery due to no available medical beds.
10. What system is used to collate the information for the A&E live wait times?
11. How often is this updated on the trust website?

Download response A&E wait times. 270317

A&E waiting times 2013,2014 and 2015

1. How many patients have waited more than 12 hours in your A and E department in the last 3 years. Please break this down per month.
To be clear, this is since the patient arrived in A and E, not since decision to admit.

2. How many 12 hour decisions to admit patient did you report to NHS England in the last 3 years, please break this down per month.

This time frame is where you had to report a 12 hour breech to NHS England (it is typically taken after the patient has been in A and E more than 12 hours after decision to admit)

3. How many people came to A and E in the last 3 years, please break this down per month.
3a.Of these total number of patients, how many people were admitted to hospital for an inpatient stay – again please can you give me three years data, broken down per month.

4. Of those people that were admitted, in question 3 how many people breeched the 4 hour A and E target, per month for the last 3 years.

5. What was your percentage recorded rate of getting patients seen and out of the department in 4 hours, each month for the last 3 years? i.e. percentage of people who meet the 4 hour target.

Download response A&E waiting times 2013,2014 and 2015 160216

A&E waiting times. 301117

1) For all patients who are admitted from A&E, what is the average time from arrival in A&E to getting a bed on a ward? I would like this data from the period of September 2011 to September 2012 and the period of September 2016 to September 2017
(i) How many of these admitted patients went from arrival to a bed in under 4 hours?
(ii) How many went from arrival to a bed in under 12 hours?
(iii) How many went from arrival to a bed in over 12 hours?

Download response A&E waiting times. 301117

Agency spend for locum doctors in Acute Medicine. 240317

Can you please assist me with retrieving the total Agency spend for Medical Locum Doctors within Acute medicine over the following months, within your Trust or Health Board?
August 2016
September 2016
October 2016
November 2016
December 2016
January 2017

Download response Agency spend for locum doctors in Acute Medicine. 240317

Alcohol-related attendances and admissions. 121119

1. Within your Trust, how many alcohol-related A&E attendances (where alcohol is the primary attendance reason) per site between;
a) 1st November 2013 and 2nd January 2014
b) 1st November 2018 and 2nd January 2019
2. Within your Trust, how many alcohol-related A&E admissions (where alcohol is the primary admittance reason) per site between;
a) 1st November 2013 and 2nd January 2014
b) 1st November 2018 and 2nd January 2019

Download response Alcohol-related attendances and admissions. 121119

Alcohol related illness in the under 14 year olds.

1. How many people under the age of 14 have been treated for alcohol related illness at your hospitals in 2014 and (as a separate figure) so far this year?

2. What was the youngest person treated for alcohol related illness in those periods (separate figures)?

3. How many people under the age of 14 have been treated for drug related illness at your hospitals in 2014 and (as a separate figure) so far this year?

4. What was the youngest person treated in those periods (separate figures)?

Download response Alcohol related illness in the under 14 years olds 311215

Aluminium Composite Material (ACM) cladding. 020818

Please can you tell me if any of your buildings are clad in Aluminium Composite Material, and if so how many?
If any buildings have ACM please can you tell me whether the trust will be removing the cladding and if you have estimated how much this will cost?

Download response Aluminium Composite Material (ACM) cladding. 020818

Alzheimer Disease 2012-2016

For the years between 2012 and 2016
1. How many people has your trust/hospital diagnosed with Alzheimer Disease for each of the years mentioned above? If possible could this be broken down by gender?
2. How many people are seen within 12 weeks of being referred by a GP?

Download response Alzheimer Disease 2012-2016 150317

Ambulatory ECG’s 2015-2016. 090217

1. Total number of Ambulatory ECG’s (aka Holter tests, R-Tests, etc) performed in 2015 and to date in 2016 calendar year.
2. If possible, please indicate how many were for ≤24-hour duration; 24-72 hour durat